form10-q_063011.htm

0000704415-11-000025.txt : 20110808 0000704415-11-000025.hdr.sgml : 20110808 20110808170049 ACCESSION NUMBER: 0000704415-11-000025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110808 DATE AS OF CHANGE: 20110808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHWAYS, INC CENTRAL INDEX KEY: 0000704415 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 621117144 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19364 FILM NUMBER: 111017873 BUSINESS ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 BUSINESS PHONE: 6156144929 MAIL ADDRESS: STREET 1: 701 COOL SPRINGS BOULEVARD CITY: FRANKLIN STATE: TN ZIP: 37067 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN HEALTHWAYS INC DATE OF NAME CHANGE: 20000322 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN HEALTHCORP INC /DE DATE OF NAME CHANGE: 19940211 10-Q 1 form10-q_063011.htm HEALTHWAYS, INC. FORM 10-Q form10-q_063011.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended June 30, 2011

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number 000-19364

HEALTHWAYS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware		62-1117144
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

701 Cool Springs Boulevard, Franklin, TN 37067

(Address of Principal Executive Offices) (Zip Code)

615-614-4929

(Registrant’s Telephone Number, Including Area Code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨ Accelerated filer x

Non-accelerated filer ¨

(Do not check if a smaller reporting company)

Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No x

As of August 4, 2011 there were outstanding 33,702,609 shares of the Registrant’s common stock, par value $.001 per share.

Healthways, Inc.

Form 10-Q

Table of Contents

			Page
Part I
	Item 1.	Financial Statements	4
	Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	32
	Item 4.	Controls and Procedures	33
Part II
	Item 1.	Legal Proceedings	34
	Item 1A.	Risk Factors	35
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	35
	Item 3.	Defaults Upon Senior Securities	35
	Item 4.	Removed and Reserved	36
	Item 5.	Other Information	36
	Item 6.	Exhibits	36

Part I

Item 1.

Financial Statements

HEALTHWAYS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

ASSETS

	June 30,			December 31,
	2011			2010
Current assets:
Cash and cash equivalents	$	955		$	1,064
Accounts receivable, net		82,210			89,108
Prepaid expenses		10,393			12,577
Other current assets		2,802			3,064
Income taxes receivable		1,885			8,695
Deferred tax asset		13,657			11,272
Total current assets		111,902			125,780

Property and equipment:
Leasehold improvements		41,147			40,662
Computer equipment and related software		222,005			207,077
Furniture and office equipment		27,437			27,328
Capital projects in process		15,302			10,117
		305,891			285,184
Less accumulated depreciation		(172,860	)		(154,528	)
		133,031			130,656

Other assets		12,888			14,733

Intangible assets, net		91,297			94,255
Goodwill, net		496,265			496,265

Total assets	$	845,383		$	861,689

See accompanying notes to the consolidated financial statements.

HEALTHWAYS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

LIABILITIES AND STOCKHOLDERS’ EQUITY

		June 30,			December 31,
		2011			2010
Current liabilities:
Accounts payable	$	24,296		$	22,555
Accrued salaries and benefits		31,905			39,157
Accrued liabilities		29,896			31,532
Deferred revenue		6,275			5,931
Contract billings in excess of earned revenue		23,441			18,814
Current portion of long-term debt		4,178			3,935
Current portion of long-term liabilities		4,080			3,309
Total current liabilities		124,071			125,233

Long-term debt		223,200			243,425
Long-term deferred tax liability		24,621			23,050
Other long-term liabilities		34,166			39,140

Stockholders’ equity:
Preferred stock
$.001 par value, 5,000,000 shares
authorized, none outstanding		—			—
Common stock
$.001 par value, 120,000,000 shares authorized,
33,808,298 and 34,018,706 shares outstanding		34			34
Additional paid-in capital		239,796			232,524
Retained earnings		216,124			206,210
Treasury stock, at cost, 1,101,765 and 429,654 shares in treasury		(13,950	)		(4,494	)
Accumulated other comprehensive loss		(2,679	)		(3,433	)
Total stockholders’ equity		439,325			430,841

Total liabilities and stockholders’ equity	$	845,383		$	861,689

See accompanying notes to the consolidated financial statements.

HEALTHWAYS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except earnings per share data)

(Unaudited)

	Three Months Ended								Six Months Ended
	June 30,								June 30,
		2011			2010			2011			2010

Revenues		$	169,596	$		175,523		$		332,565	$	354,522
Cost of services (exclusive of depreciation and amortization of $8,970, $9,928, $17,994, and $20,161, respectively, included below)			126,009			121,985				247,917		250,852
Selling, general and administrative expenses			17,706			18,703				35,547		35,938
Depreciation and amortization			12,443			13,341				24,876		26,895

Operating income			13,438			21,494				24,225		40,837
Gain on sale of investment			—			(1,163	)			—		(1,163	)
Interest expense			3,170			3,612				6,588		7,034

Income before income taxes			10,268			19,045				17,637		34,966
Income tax expense			4,490			7,207				7,723		13,714

Net income		$	5,778	$		11,838		$		9,914	$	21,252

Earnings per share:
Basic		$	0.17	$		0.35		$		0.29	$	0.62

Diluted		$	0.17	$		0.34		$		0.29	$	0.61

Weighted average common shares
and equivalents:
Basic			33,942			34,117				33,957		34,037
Diluted			34,790			34,933				34,711		34,928

See accompanying notes to the consolidated financial statements.

HEALTHWAYS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY

For the Six Months Ended June 30, 2011

(In thousands)

(Unaudited)

												Accumulated
				Additional								Other
	Preferred		Common	Paid-in			Retained		Treasury			Comprehensive
	Stock		Stock	Capital			Earnings		Stock			Income (Loss)			Total
Balance, December 31, 2010		$—	$34		$232,524			$206,210		$(4,494	)		$(3,433	)	$430,841

Comprehensive income:

Net income		—	—		—			9,914		—			—		9,914

Net change in fair value of interest rate
swaps, net of income taxes of $416		—	—		—			—		—			643		643

Foreign currency translation adjustment		—	—		—			—		—			111		111

Total comprehensive income															10,668

Repurchases of common stock		—	—		—			—		(9,456	)		—		(9,456	)

Exercise of stock options		—	—		3,736			—		—			—		3,736

Tax effect of stock options and restricted stock units		—	—		(992	)		—		—			—		(992	)

Share-based employee compensation expense		—	—		4,528			—		—			—		4,528

Balance, June 30, 2011		$—	$34		$239,796			$216,124		$(13,950	)		$(2,679	)	$439,325

See accompanying notes to the consolidated financial statements.

HEALTHWAYS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended
	June 30,
	2011			2010
Cash flows from operating activities:
Net income	$	9,914		$	21,252
Adjustments to reconcile net income to net cash provided by
operating activities, net of business acquisitions:
Depreciation and amortization		24,876			26,895
Amortization of deferred loan costs		954			869
Gain on sale of investment		—			(1,163	)
Share-based employee compensation expense		4,528			5,591
Deferred income taxes		(2,757	)		1,908
Excess tax benefits from share-based payment arrangements		(339	)		(806	)
Decrease (increase) in accounts receivable, net		6,391			(11,782	)
Decrease in other current assets		7,238			6,152
Increase (decrease) in accounts payable		2,084			(6,437	)
Decrease in accrued salaries and benefits		(12,421	)		(27,779	)
Increase in other current liabilities		8,962			13,797
Other		(458	)		(1,409	)
Net cash flows provided by operating activities		48,972			27,088

Cash flows from investing activities:
Acquisition of property and equipment		(21,664	)		(23,384	)
Sale of investment		—			1,163
Change in restricted cash		469			—
Other		(3,586	)		(2,814	)
Net cash flows used in investing activities		(24,781	)		(25,035	)

Cash flows from financing activities:
Proceeds from issuance of long-term debt		203,147			417,450
Payments of long-term debt		(223,198	)		(415,766	)
Deferred loan costs		—			(3,166	)
Excess tax benefits from share-based payment arrangements		339			806
Exercise of stock options		3,736			532
Repurchases of common stock		(9,456	)		—
Change in outstanding checks and other		611			(2,881	)
Net cash flows used in financing activities		(24,821	)		(3,025	)

Effect of exchange rate changes on cash		521			(302	)

Net decrease in cash and cash equivalents		(109	)		(1,274	)

Cash and cash equivalents, beginning of period		1,064			2,356

Cash and cash equivalents, end of period	$	955		$	1,082

See accompanying notes to the consolidated financial statements.

HEALTHWAYS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(1)

Basis of Presentation

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In our opinion, the accompanying consolidated financial statements of Healthways, Inc. (the “Company”) and its wholly-owned subsidiaries reflect all adjustments consisting of normal, recurring accruals necessary for a fair presentation. We have reclassified certain items in prior periods to conform to current classifications.

We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

(2)

Recently Issued Accounting Standards

In May 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”, an amendment to Accounting Standards Codification Topic 820, “Fair Value Measurements and Disclosures”. These amendments provide a consistent definition of fair value and ensure that fair value measurements and disclosure requirements are consistent between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011. We do not expect the adoption of this amendment to have a material impact on our consolidated results of operations, financial position, cash flows, or notes to the consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, “Presentation of Comprehensive Income”. This standard eliminates the current option to report other comprehensive income and its components in the statement of changes in stockholders’ equity and requires an entity to present net income and other comprehensive income in one continuous statement or in two separate but consecutive statements. ASU No. 2011-05 is effective for interim and annual reporting periods beginning after December 15, 2011. We have not yet determined which presentation of comprehensive income we will elect but do not expect the adoption of this standard to have a material impact on our consolidated results of operations, statement of financial position, or cash flows.

(3)

Share-Based Compensation

We have several shareholder-approved stock incentive plans for employees and directors. We currently have three types of share-based awards outstanding under these plans: stock options, restricted stock units, and restricted stock. We believe that such awards align the interests of our employees and directors with those of our stockholders.

For the three and six months ended June 30, 2011, we recognized share-based compensation costs of $2.3 million and $4.5 million, respectively. For the three and six months ended June 30, 2010, we recognized share-based compensation costs of $2.6 million and $5.6 million, respectively.

A summary of our stock options as of June 30, 2011 and changes during the six months then ended is presented below:

					Weighted-
					Average
			Weighted-		Remaining	Aggregate
	Shares		Average		Contractual	Intrinsic
Options	(000s)		Exercise Price		Term (years)	Value ($000s)
Outstanding at January 1, 2011	6,208		$	17.12
Granted	368			14.70
Exercised	(332	)		11.06
Forfeited or expired	(172	)		14.93
Outstanding at June 30, 2011	6,072			17.37	5.30	$ 14,598
Exercisable at June 30, 2011	3,576			19.64	3.14	$ 7,407

The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2011 was $9.03 and $8.32, respectively.

The following table shows a summary of our restricted stock and restricted stock units (“nonvested shares”) as of June 30, 2011 as well as activity during the six months then ended:

			Weighted-
			Average
	Shares		Grant Date
Nonvested Shares	(000s)		Fair Value
Nonvested at January 1, 2011	1,153		$	15.29
Granted	183			14.71
Vested	(180	)		16.44
Forfeited	(62	)		12.83
Nonvested at June 30, 2011	1,094		$	15.18

(4)

Income Taxes

Our effective tax rate increased to 43.7% and 43.8% for the three and six months ended June 30, 2011, compared to 37.8% and 39.2% for the three and six months ended June 30, 2010, respectively, primarily due to the favorable impact on the 2010 effective tax rate of an earn-out adjustment recorded during the three and six months ended June 30, 2010, as well an increase during the three and six months ended June 30, 2011 in the level of certain expenses related to international operations for which we currently are not able to recognize a tax benefit.

We file income tax returns in the U.S. federal jurisdiction and in various state and foreign jurisdictions. Tax years remaining subject to examination in these jurisdictions include 2008 to present.

(5)

Derivative Investments and Hedging Activities

We use derivative instruments to manage risks related to interest rates and foreign currencies. We record all derivatives at estimated fair value as either assets or liabilities on the balance sheet and recognize the unrealized gains and losses in either the balance sheet or statement of operations, depending on whether the derivative is designated as a hedging instrument. As permitted under our master netting arrangements, the fair value amounts of our derivative instruments are presented on a net basis by counterparty in the consolidated balance sheets.

Interest Rate

In order to reduce our exposure to interest rate fluctuations on our floating rate debt commitments, we maintain interest rate swap agreements with notional amounts of $335.0 million ($145.0 million of which will become effective in January 2012 and $30.0 million of which will become effective in January 2013) and termination dates ranging from December 30, 2011 to December 31, 2013. These interest rate swap agreements effectively modify our exposure to interest rate risk by converting a portion of our floating rate debt to fixed obligations with interest rates ranging from 0.580% to 3.855%, thus reducing the impact of interest rate changes on future interest expense. Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest. We have designated these interest rate swap agreements as qualifying cash flow hedges. We currently meet the hedge accounting criteria under U.S. GAAP in accounting for these interest rate swap agreements.

Foreign Currency

We enter into foreign currency options and/or forward contracts in order to minimize our earnings exposure to fluctuations in foreign currency exchange rates. Our foreign currency exchange contracts do not qualify for hedge accounting treatment under U.S. GAAP. We routinely monitor our foreign currency exposures to maximize the overall effectiveness of our foreign currency hedge positions. We do not execute transactions or hold derivative financial instruments for trading or other purposes.

Fair Values of Derivative Instruments

The estimated gross fair values of derivative instruments at June 30, 2011 and December 31, 2010, excluding the impact of netting derivative assets and liabilities when a legally enforceable master netting agreement exists, were as follows:

	June 30, 2011		December 31, 2010
(In $000s)	Foreign currency exchange contracts	Interest rate swap agreements	Foreign currency exchange contracts	Interest rate swap agreements
Assets:

Derivatives not designated as hedging instruments:
Other current assets	$98	$—	$136	$—
Total assets	$98	$—	$136	$—

Liabilities:
Derivatives not designated as hedging instruments:
Accrued liabilities	$263	$—	$245	$—

Derivatives designated as hedging instruments:
Accrued liabilities	—	2,253	—	4,465
Other long-term liabilities	—	3,746	—	2,593
Total liabilities	$263	$5,999	$245	$7,058

See also Note 6.

Cash Flow Hedges

Derivative instruments that are designated and qualify as cash flow hedges are recorded at estimated fair value in the balance sheet, with the effective portion of the gains and losses being reported in accumulated other comprehensive income or loss (“accumulated OCI”). Cash flow hedges for all periods presented consist solely of interest rate swap agreements. Gains and losses on these interest rate swap agreements are reclassified to interest expense in the same period during which the hedged transaction affects earnings or the period in which all or a portion of the hedge becomes ineffective. As of June 30, 2011, we expect to reclassify $3.9 million of net losses on interest rate swap agreements from accumulated OCI to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt.

Gains and losses representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings. The following table shows the effect of our cash flow hedges on the consolidated balance sheet during the three and six months ended June 30, 2011 and June 30, 2010:

(In $000s)

Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)

For the Three Months Ended

Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)

For the Six Months Ended

Derivatives in Cash Flow Hedging Relationships

June 30, 2011

June 30, 2010

June 30, 2011

June 30, 2010

Interest rate swap agreements, gross of tax effect

$(235)

$(677)

$1,059

$(1,319)

During the three and six months ended June 30, 2011 and 2010, there were no gains or losses on cash flow hedges recognized in income resulting from hedge ineffectiveness.

Derivative Instruments Not Designated as Hedging Instruments

Our foreign currency exchange contracts require current period mark-to-market accounting, with any change in fair value being recorded each period in the consolidated statement of operations in selling, general and administrative expenses. At June 30, 2011, we had forward contracts with notional amounts of $9.7 million to exchange foreign currencies, primarily the Australian dollar and Euro, that were entered into to hedge forecasted foreign net income (loss) and intercompany debt.

These forward contracts did not have a material effect on our consolidated statements of operations during the three or six months ended June 30, 2011 and 2010.

(6)

Fair Value Measurements

We account for certain assets and liabilities at fair value. Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

Fair Value Hierarchy

The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of

these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

	Level 1: Quoted prices in active markets for identical assets or liabilities;
	Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	Level 3: Unobservable inputs that are supported by little or no market activity and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2011 and December 31, 2010:

(In $000s) June 30, 2011		Level 2		Gross Fair Value		Netting (1)			Net Fair Value
Assets:
Foreign currency exchange contracts	$	98	$	98	$	(45	)	$	53
Liabilities:
Foreign currency exchange contracts	$	263	$	263	$	(45	)	$	218
Interest rate swap agreements		5,999		5,999		—			5,999

(In $000s) December 31, 2010		Level 2		Gross Fair Value		Netting (1)			Net Fair Value
Assets:
Foreign currency exchange contracts	$	136	$	136	$	(116	)	$	20
Liabilities:
Foreign currency exchange contracts	$	245	$	245	$	(116	)	$	129
Interest rate swap agreements		7,058		7,058		—			7,058

(1) This column reflects the impact of netting derivative assets and liabilities by counterparty when a legally enforceable master netting agreement exists.

The fair values of forward foreign currency exchange contracts are valued using broker quotations of similar assets or liabilities in active markets. The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using internal models and third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads.

Fair Value of Other Financial Instruments

In addition to foreign currency exchange contracts and interest rate swap agreements, the estimated fair values of which are disclosed above, the estimated fair value of each class of financial instruments at June 30, 2011 was as follows:

Cash and cash equivalents – The carrying amount of $1.0 million approximates fair value because of the short maturity of those instruments (less than three months).

Long-term debt –The estimated fair value of outstanding borrowings under our credit agreement is based on the average of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Fourth Amended Credit Agreement (see Note 7) at June 30, 2011 are $214.8 million and $222.6 million, respectively.

(7)

Long-Term Debt

On March 30, 2010, we entered into the Fourth Amended and Restated Credit Agreement (the “Fourth Amended Credit Agreement”). The Fourth Amended Credit Agreement provides us with a $55.0 million revolving credit facility from March 30, 2010 to December 1, 2011 (the “2011 Revolving Credit Facility”) and a $345.0 million revolving credit facility from March 30, 2010 to December 1, 2013 (the “2013 Revolving Credit Facility”), including a swingline sub facility of $20.0 million and a $75.0 million sub facility for letters of credit. The Fourth Amended Credit Agreement also provides a continuation of the term loan facility provided pursuant to the Third Amended and Restated Credit Agreement, of which $191.0 million remained outstanding on June 30, 2011, and an uncommitted incremental accordion facility of $200.0 million. As of June 30, 2011, availability under the 2011 Revolving Credit Facility and the 2013 Revolving Credit Facility totaled $245.1 million as calculated under the most restrictive covenant.

Revolving advances under the Fourth Amended Credit Agreement are drawn first under the 2013 Revolving Credit Facility, with any advances in excess of $345.0 million being drawn under the 2011 Revolving Credit Facility. Revolving advances under the 2013 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 1.875% to 2.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.375% to 1.250%. Revolving advances under the 2011 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 0.875% to 1.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.000% to 0.250%. Term loan borrowings bear interest, at our option, at 1) LIBOR plus 1.50% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate. See Note 5 for a description of our interest rate swap agreements. The Fourth Amended Credit Agreement also provides for a fee ranging between 0.150% and 0.300% of the unused commitments under the 2011 Revolving Credit Facility and 0.275% and 0.425% of the unused commitments under the 2013 Revolving Credit Facility. The Fourth Amended Credit Agreement is secured by guarantees from most of the Company’s domestic subsidiaries and by security interests in substantially all of the Company’s and such subsidiaries’ assets.

We are required to repay outstanding revolving loans on the applicable commitment termination date, which is December 1, 2011 for the 2011 Revolving Credit Facility and December 1, 2013 for the 2013 Revolving Credit Facility. We are required to repay term loans in quarterly principal installments aggregating $0.5 million each, which commenced on March 31, 2007. The entire unpaid principal balance of the term loans is due and payable at maturity on December 1, 2013.

The Fourth Amended Credit Agreement contains various financial covenants, which require us to maintain, as defined, ratios or levels of 1) total funded debt to EBITDA, 2) fixed charge coverage, and 3) net worth. The Fourth Amended Credit Agreement also restricts the payment of dividends and limits the amount of repurchases of the Company’s common stock. As of June 30, 2011, we were in compliance with all of the covenant requirements of the Fourth Amended Credit Agreement.

As described in Note 5 above, as of June 30, 2011, we are a party to interest rate swap agreements for which we receive a variable rate of interest based on LIBOR and for which we pay a fixed rate of interest.

(8)

Restructuring and Related Charges

In November 2010, we began a restructuring of the Company primarily focused on aligning resources with current and emerging markets and consolidating operating capacity, which was largely completed by the end of fiscal 2010. We do not expect to incur significant additional costs or adjustments related to this restructuring. The change in accrued restructuring and related charges during the six months ended June 30, 2011 was as follows:

(In 000s)

Accrued restructuring and related charges at January 1, 2011	$	7,607
Additions		—
Payments		(4,448	)
Adjustments (1)		(734	)
Accrued restructuring and related charges at June 30, 2011	$	2,425

(1) Adjustments for the six months ended June 30, 2011 resulted primarily from a favorable adjustment to lease termination costs due to a sublease of certain unused office space.

(9)

Commitments and Contingencies

Shareholder Derivative Lawsuits

On June 27, 2008 and July 24, 2008, respectively, two shareholders filed putative derivative actions purportedly on behalf of the Company in the Chancery Court for the State of Tennessee, Twentieth Judicial District, Davidson County, against certain directors and officers of the Company, seeking damages and equitable and/or injunctive relief. These actions are based on allegations of individual violations of the Securities Exchange Act of 1934 and allegations that misleading statements were made and material information omitted from public communications regarding (i) the purported loss or restructuring of certain contracts with customers, (ii) the Company’s participation in the Medicare Health Support (“MHS”) pilot program for the Centers for Medicare & Medicaid Services, and (iii) the Company’s guidance for fiscal year 2008. These lawsuits were consolidated and the plaintiffs filed a consolidated complaint on May 9, 2009. On June 19, 2009, the defendants filed a motion to dismiss the consolidated complaint. The Court granted the defendants’ motion to dismiss on October 14, 2009. The plaintiffs filed a notice of appeal on November 12, 2009. The Tennessee Court of Appeals heard argument on the appeal on October 13, 2010 and affirmed the trial court’s dismissal on March 14, 2011.

ERISA Lawsuits

On July 31, 2008, a purported class action alleging violations of the Employee Retirement Income Security Act (“ERISA”) was filed in the U.S. District Court for the Middle District of Tennessee, Nashville Division against the Company and certain of its directors and officers alleging breaches of fiduciary duties to participants in the Company’s 401(k) plan. An amended complaint was filed on September 29, 2008, naming as defendants the Company, the Board of Directors, certain officers, and members of the Investment Committee charged with administering the 401(k) plan, alleging that the defendants violated ERISA by failing to remove the Company stock fund from the 401(k) plan when it allegedly became an imprudent investment by (i) failing to disclose adequately the risks and results of the MHS pilot program to 401(k) plan participants, (ii) failing to seek independent advice as to whether to continue to permit the 401(k) plan to hold Company stock, and (iii) failing to closely monitor the Investment Committee and other 401(k) plan fiduciaries. On August 6, 2009, the parties filed a stipulation of dismissal. On February 1, 2010, a new named plaintiff filed another putative class action complaint in the United States District Court for the Middle District of Tennessee, Nashville Division, alleging ERISA violations in the administration of the Company’s 401(k) plan. The new complaint was identical to the original complaint, including the allegations and the requests for relief. Defendants’ answer to this complaint was filed on March 22, 2010. On June 23, 2010, the parties reached an agreement in principle to settle this matter for $1.3 million. The District Court gave preliminary approval of the settlement on December 1, 2010, and granted final approval following a fairness hearing held April 25, 2011. Due to the Company’s fiduciary liabilities insurance coverage, this settlement did not result in any charge to the Company.

Contract Dispute

We currently are involved in a contractual dispute with Blue Cross Blue Shield of Minnesota regarding fees paid to us as part of a former contractual relationship. In 2010, we received a notice of arbitration under the terms of our agreement alleging a violation of certain contract provisions. We believe we performed our services in compliance with the terms of our agreement and that the assertions made in the arbitration notice are without merit. On August 3, 2011, we asserted numerous counterclaims against Blue Cross Blue Shield of Minnesota. We are not able to reasonably estimate a range of potential losses, if any.

Outlook

We are also subject to other contractual disputes, claims and legal proceedings that arise from time to time in the ordinary course of our business. While we are unable to estimate a range of potential losses, we do not believe that any of the legal proceedings pending against us as of the date of this report will have a material adverse effect on our liquidity or financial condition. As these matters are subject to inherent uncertainties, our view of these matters may change in the future.

Contractual Commitment

In May 2011, we entered into a ten-year applications and technology services outsourcing agreement with HP Enterprise Services, LLC (“HP”) that contains minimum fee requirements. Total payments over the ten-year term must equal or exceed a minimum level of approximately $185 million; however, based on initial required service and equipment level assumptions, we estimate that the total payments will be approximately $380 million, $18.0 million of which will occur during the remainder of 2011, $100.9 million of which will occur during 2012 and 2013, $80.8 million of which will occur during 2014 and 2015, and the remaining $180.3 million of which will occur thereafter. The agreement allows us to terminate all or a portion of the services after two years provided we pay certain termination fees which could be material to the Company.

(10)

Share Repurchases

The following table contains information for shares of our common stock that we repurchased during the second quarter of 2011:

Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs

April 1 through 30	178,614		$14.76	907,161		$49,000,274
May 1 through 31	18,443		$15.72	925,604		$48,710,350
June 1 through 30	176,161		$15.11	1,101,765		$46,048,557

Total	373,218

All share repurchases were made pursuant to a share repurchase program authorized by the Company’s Board of Directors and publicly announced on October 21, 2010, which allows for the repurchase of up to $60 million of our common stock from time to time in the open market or in privately negotiated transactions through October 19, 2012.

(11)

Sale of Investment

In January 2009, a private company in which we held preferred stock was acquired by a third party. As part of this sale, we received two payments totaling $11.6 million in January and February 2009 and recorded a gain of $2.6 million during the first quarter of 2009. During the second quarter of 2010, we recognized a gain of $1.2 million related to the receipt of a final escrow payment.

(12)

Comprehensive Income

Comprehensive income, net of income taxes, was $5.9 million and $11.3 million for the three months ended June 30, 2011 and 2010, respectively, and $10.7 million and $20.3 million for the six months ended June 30, 2011 and 2010, respectively.

(13)

Earnings Per Share

The following is a reconciliation of the numerator and denominator of basic and diluted earnings per share for the three and six months ended June 30, 2011 and 2010:

(In 000s, except per share data)	Three Months Ended June 30,				Six Months Ended June 30,
	2011		2010			2011		2010
Numerator:
Net income - numerator for basic earnings per share	$	5,778	$	11,838		$	9,914	$	21,252

Denominator:
Shares used for basic earnings per share		33,942		34,117			33,957		34,037
Effect of dilutive securities outstanding:
Non-qualified stock options		510		456			417		493
Restricted stock units		338		360			337		398
Shares used for diluted earnings per share		34,790		34,933			34,711		34,928

Earnings per share:
Basic	$	0.17	$	0.35		$	0.29	$	0.62
Diluted	$	0.17	$	0.34		$	0.29	$	0.61

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:
Non-qualified stock options		3,746		3,935			4,191		3,601
Restricted stock units		18		83			68		3

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Founded in 1981, Healthways, Inc. provides specialized, comprehensive solutions to help people improve physical, emotional and social well-being, thereby reducing both direct healthcare costs and associated costs from the loss of employee productivity.

We provide highly specific and personalized interventions for each individual in a population, irrespective of health status, age or payor. Our evidence-based health, prevention and well-being services are made available to consumers via phone, mobile devices, direct mail, the Internet, face-to-face consultations and venue-based interactions.

In North America, our customers include health plans, governments, employers, pharmacy benefit managers, and hospitals in all 50 states, the District of Columbia and Puerto Rico. We also provide health improvement programs and services in Brazil, Australia and France. We operate domestic and international care enhancement and coaching centers staffed with licensed health professionals. Our fitness center network encompasses approximately 14,000 U.S. locations. We also maintain an extensive network of over 88,000 complementary and alternative medicine and chiropractic practitioners, which offers convenient access to the significant number of individuals who seek health services outside of the traditional healthcare system.

Our guiding philosophy and approach to market is predicated on the fundamental belief that healthier people cost less and are more productive. As described more fully below, our programs are designed to improve well-being by helping people to adopt or maintain healthy behaviors, reduce health-related risk factors, and optimize care for identified health conditions.

First, our programs are designed to help people adopt or maintain healthy behaviors by:

fostering wellness and disease prevention through total population screening, well-being assessments and supportive interventions; and

providing access to health improvement programs, such as fitness solutions, weight management, and complementary and alternative medicine.

Our prevention programs focus on education, physical fitness, health coaching, and behavior change techniques and support. We believe this approach improves the well-being status of member populations and reduces the short- and long-term direct healthcare costs for participants, including associated costs from the loss of employee productivity.

Second, our programs are designed to help people reduce health-related risk factors by:

promoting the change and improvement of the lifestyle behaviors that lead to poor health or chronic conditions; and

providing educational materials and personal interactions with highly trained nurses and other healthcare professionals to create and sustain healthier behaviors for those individuals at-risk or in the early stages of chronic conditions.

We enable our customers to engage everyone in their covered populations through specific interventions that are sensitive to each individual’s health risks and needs. Our programs are designed to motivate people to make positive lifestyle changes and accomplish individual goals, such as increasing physical activity for seniors through the Healthways SilverSneakers® fitness solution or overcoming nicotine addiction through the QuitNet® on-line smoking cessation community.

Finally, our programs are designed to help people optimize care for identified health conditions by:

incorporating the latest, evidence-based clinical guidelines into interventions to optimize patient health outcomes;

developing care support plans and motivating members to set attainable goals for themselves;

providing local market resources to address acute episodic interventions;

coordinating members’ care with their healthcare providers;

providing software licensing and management consulting in support of well-being improvement services; and

providing high-risk care management for members at risk for hospitalization due to complex conditions.

Our approach is to use proprietary, analytic models to identify individuals who are likely to incur future high costs, including those who have specific gaps in care, and through evidence-based interventions drive adherence to proven standards of care, medication regimens and physicians’ plans of care to reduce disease progression and related medical spending.

We recognize that each individual plays a variety of roles in his or her pursuit of health, often simultaneously. By providing the full spectrum of services to meet each individual’s needs, we believe our interventions can be delivered at scale and in a manner that reflects those unique needs over time. We believe creating real and sustainable behavior change generates measurable, long-term cost savings and improved individual and business performance.

Forward-Looking Statements

Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements, which are based upon current expectations and involve a number of risks and uncertainties. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” or “continue.” In order for us to use the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we caution you that the following important factors, among others, may affect these forward-looking statements. Consequently, actual operations and results may differ materially from those expressed in the forward-looking statements. The important factors include but are not limited to:

our ability to sign and implement new contracts for our solutions;

our ability to accurately forecast the costs required to fully implement new contracts;

our ability to retain existing customers and to renew or maintain contracts with our customers under existing terms or restructure these contracts on terms that would not have a material negative impact on our results of operations;

our ability to accurately forecast variables that affect performance and the timing of revenue recognition under the terms of our customer contracts ahead of data collection and reconciliation;

the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, “PPACA”), on our operations and/or the demand for our services;

the impact of any new or proposed legislation, regulations and interpretations relating to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, including the potential expansion to Phase II for Medicare Health Support programs and any legislative or regulatory changes with respect to Medicare Advantage;

our ability to anticipate the rate of market acceptance of our solutions in potential international markets;

our ability to accurately forecast the costs necessary to implement our strategy of establishing a presence in international markets;

the risks associated with foreign currency exchange rate fluctuations and our ability to hedge against such fluctuations;

the risks associated with deriving a significant concentration of our revenues from a limited number of customers;

our ability to achieve, and reach mutual agreement with customers with respect to, contractually required performance metrics, cost savings and clinical outcomes improvements, or to achieve such metrics, savings and improvements within the time frames contemplated by us;

our ability to achieve estimated annualized revenue in backlog in the manner and within the timeframe we expect, which is based on certain estimates regarding the implementation of our services;

our ability and/or the ability of our customers to enroll participants and to estimate their level of enrollment and participation in our programs in a manner and within the timeframe anticipated by us;

the ability of our customers to provide timely and accurate data that is essential to the operation and measurement of our performance under the terms of our contracts;

our ability to favorably resolve contract billing and interpretation issues with our customers;

our ability to service our debt and make principal and interest payments as those payments become due;

the risks associated with changes in macroeconomic conditions, which may reduce the demand and/or the timing of purchases for our services from customers or potential customers, reduce the number of covered lives of our existing customers, or restrict our ability to obtain additional financing;

counterparty risk associated with our interest rate swap agreements and foreign currency exchange contracts;

our ability to integrate acquired businesses, services (including outsourced services), or technologies into our business and to accurately forecast the related costs;

our ability to anticipate and respond to strategic changes and opportunities in our industry and/or business and to accurately forecast the related impact on our earnings;

the impact of any impairment of our goodwill or other intangible assets;

our ability to develop new products and deliver outcomes on those products;

our ability to implement our integrated data and technology solutions platform within the required timeframe and expected cost estimates and to develop and enhance this platform and/or other technologies to meet evolving customer and market needs;

our ability to obtain adequate financing to provide the capital that may be necessary to support our operations and to support or guarantee our performance under new contracts;

unusual and unforeseen patterns of healthcare utilization by individuals with diseases or conditions for which we provide services;

the ability of our customers to maintain the number of covered lives enrolled in the plans during the terms of our agreements;

the impact of legal proceedings involving us and/or our subsidiaries;

the impact of future state, federal, and international legislation and regulations applicable to our business, including PPACA, on our ability to deliver our services and on the financial health of our customers and their willingness to purchase our services;

current geopolitical turmoil, the continuing threat of domestic or international terrorism, and the potential emergence of a health pandemic; and

other risks detailed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and other filings with the Securities and Exchange Commission.

We undertake no obligation to update or revise any such forward-looking statements.

Customer Contracts

Contract Terms

We generally determine our contract fees by multiplying a contractually negotiated rate per member per month (“PMPM”) by the number of members covered by our services during the month. We typically set the PMPM rates during contract negotiations with customers based on the value we expect our programs to create and a sharing of that value between the customer and the Company. In addition, some of our services, such as the Healthways SilverSneakers fitness solution, include fees that are based upon member participation.

Our contracts with health plans generally range from three to five years with provisions for subsequent renewal; contracts with self-insured employers, either directly or through their health plans or pharmacy benefit manager, typically have one to three-year terms. Some of our contracts allow the customer to terminate early.

Some of our contracts provide that a portion of our fees may be refundable to the customer (“performance-based”) if our programs do not achieve, when compared to a baseline year, a targeted percentage reduction in the customer’s healthcare costs and selected clinical and/or other criteria that focus on improving the health of the members. Approximately 3% of revenues recorded during the six months ended June 30, 2011 were performance-based and were subject to final reconciliation as of June 30, 2011. We anticipate that this percentage will fluctuate due to the level of performance-based fees in new contracts and the timing and amount of revenue recognition associated with performance-based fees. Some contracts also provide for additional fees for incentive bonuses in excess of the contractual PMPM rate if we meet or exceed contractual performance targets.

Contract Revenues

Our contract revenues depend on the contractual terms we establish and maintain with customers to provide our services to their members. Restructurings of contracts and possible terminations at, or prior to, renewal could have a material negative impact on our results of operations and financial condition.

Approximately 17% and 18% of our revenues for the three and six months ended June 30, 2011, respectively, were derived from one customer. No other customer accounted for 10% or more of our revenues during the three or six months ended June 30, 2011.

Technology

Our solutions require sophisticated analytical, data management, Internet and computer-telephony solutions based on state-of-the-art technology. These solutions help us deliver our services to large populations within our customer base. Our predictive modeling capabilities allow us to identify and stratify those participants who are most at risk for an adverse health event. We incorporate behavior-change science with consumer-friendly interactions such as face-to-face, telephonic, print materials and web portals to facilitate consumer preferences for engagement and convenience. We use sophisticated data analytical and reporting solutions to validate the impact of our programs on clinical and financial outcomes. We continue to invest heavily in technology, as evidenced by our long-term applications and technology services outsourcing agreement with HP, and are continually expanding and

improving our proprietary clinical, data management, and reporting systems to continue to meet the information management requirements of our services. The behavior change techniques and predictive modeling incorporated in our technology identify an individual’s readiness to change and provide personalized support through appropriate messaging using any method desired, including venue-based face-to-face; print; phone; mobile and remote devices; on-line; emerging modalities; and any combination thereof to motivate and sustain healthy behaviors.

Business Strategy

The World Health Organization defines health as “…not only the absence of infirmity and disease, but also a state of physical, mental, and social well-being.”

Our business strategy reflects our passion to enhance health and well-being, and as a result, reduce overall healthcare costs and improve workforce engagement, yielding better business performance for our customers. Our programs are designed to improve well-being by helping people to:

adopt or maintain healthy behaviors;

reduce health-related risk factors; and

optimize care for identified health conditions.

Through our solutions, we work to optimize the health and well-being of entire populations, one person at a time, domestically and internationally, thereby creating value by reducing overall healthcare costs and improving productivity and performance for individuals, families, health plans, governments, employers and communities.

We believe it is critical to impact an entire population’s underlying health status and well-being in a long-term, cost effective way. Believing that what gets measured gets acted upon, in 2008, we entered into an exclusive, 25-year relationship with Gallup to provide a national, daily pulse of individual and collective well-being. The Gallup-Healthways Well-Being IndexTM is the result of a unique partnership in well-being measurement and research that is based upon surveys of 1,000 Americans every day, with more than 1.2 million surveys completed to date. Under the agreement, Gallup evaluates and reports on the well-being of individuals of countries, states and communities; Healthways provides similar services for companies, families and individuals. This relationship was recently expanded with the launch of the Gallup-Healthways Well-Being Index in the United Kingdom and Germany, which we believe indicates the growing global interest in gaining clear insights for government and business leaders charged with shaping the policy responses necessary to improve health, increase individual and organizational performance, lower healthcare costs and achieve sustained economic growth.

To enhance health and well-being within their respective populations, our current and prospective customers require solutions that focus on the underlying drivers of healthcare demand, address worsening health status, reverse or slow unsustainable cost trends, foster healthy behaviors, mitigate health risk factors, and manage chronic conditions. Our strategy is to deliver programs that engage individuals and help them enhance their health status and well-being regardless of their starting point. We believe we can achieve health and well-being improvements in a population and generate significant cost savings and increases in productivity by providing effective programs that support the individual throughout his or her health journey.

We are adding and enhancing solutions to extend our reach and effectiveness and to meet increasing demand for integrated solutions. The flexibility of our programs allows customers to provide a range of services they deem appropriate for their organizations. Customers may select from certain single program options up to a total-population approach, in which all members of a customer’s population are eligible to receive our services. Recently signed contracts have expanded both the level of integration and breadth of services provided

to major health plans as they develop and implement a number of patient-centered medical home models. Our services extend beyond chronic care and wellness programs to include care management and pharmacy benefit management, as well as health promotion, prevention and quality improvement solutions.

Our strategy includes as a priority the ongoing expansion of our value proposition through the introduction of our total population management solution. This solution, in addition to improving individuals’ health and reducing direct healthcare costs, targets a much larger improvement in employer profitability by reducing the impact of lost productivity for health-related reasons. With the success of our total population management solution, we expect to gain an even greater competitive advantage in responding to employers’ needs for a healthier, higher-performing and less costly workforce.

Our strategy also includes the further enhancement and deployment of our proprietary next generation technology platform known as Embrace. This platform, which is essential to our total population management solution, enables us to integrate data from the healthcare organizations and other entities interacting with an individual. Embrace provides for the delivery of our integrated solutions and ongoing communications between the individual and his or her medical and health experts, using any method desired, including venue-based face-to-face; print; phone; mobile and remote devices; on-line; emerging modalities; and any combination thereof.

We plan to increase our competitive advantage in delivering our services by leveraging our scalable, state-of-the-art call centers, medical information content, behavior change processes and techniques, strategic relationships, health provider networks, fitness center relationships, and proprietary technologies and techniques. We may add new capabilities and technologies through internal development, strategic alliances with other entities, and/or selective acquisitions or investments.

We anticipate continuing to enhance, expand and integrate additional capabilities with health plans and to pursue opportunities with domestic government entities and communities as well as the public and private sectors of healthcare in international markets. In addition, the significant changes in government regulation of healthcare may afford us expanded opportunities to provide services to health plans and employers as well as collaborate with and/or directly provide solutions to integrated medical systems and provider groups in the post healthcare reform marketplace.

Critical Accounting Policies

We describe our accounting policies in Note 1 of the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010. We prepare the consolidated financial statements in conformity with U.S. GAAP, which requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and related disclosures at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.

We believe the following accounting policies are the most critical in understanding the estimates and judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Revenue Recognition

We generally determine our contract fees by multiplying a contractually negotiated PMPM rate by the number of members covered by our services during the month. We typically set the PMPM rates during contract negotiations with customers based on the value we expect our programs to create and a sharing of that value between the customer and the Company. In addition, some of our services, such as the Healthways SilverSneakers fitness solution, include fees that are based upon member participation.

We generally bill our customers each month for the entire amount of the fees contractually due for the prior month’s enrollment, which typically includes the amount, if any, that is performance-based and may be subject to refund should we not meet performance targets. Deferred revenues arise from contracts which permit upfront billing and collection of fees covering the entire contractual service period, generally 12 months. We typically bill for any incentive bonus after the contract is settled. Fees for service are typically billed in the month after the services are provided.

We recognize revenue as follows: 1) we recognize the fixed portion of PMPM fees and fees for service as revenue during the period we perform our services; 2) we recognize the performance-based portion of the monthly fees based on the most recent assessment of our performance, which represents the amount that the customer would legally be obligated to pay if the contract were terminated as of the latest balance sheet date; and 3) we recognize additional incentive bonuses based on the most recent assessment of our performance, to the extent we consider such amounts collectible.

We assess our level of performance for our contracts based on medical claims and other data that the customer is contractually required to supply. A minimum of four to six months’ data is typically required for us to measure performance. In assessing our performance, we may include estimates such as medical claims incurred but not reported and a medical cost trend compared to a baseline year. In addition, we may also provide contractual allowances for billing adjustments (such as data reconciliation differences) as appropriate.

If data is insufficient or incomplete to measure performance, or interim performance measures indicate that we are not meeting performance targets, we do not recognize performance-based fees subject to refund as revenues but instead record them in a current liability account entitled “contract billings in excess of earned revenue.” Only in the event we do not meet performance levels by the end of the measurement period, typically one year, are we contractually obligated to refund some or all of the performance-based fees. We would only reverse revenues that we had already recognized if performance to date in the measurement period, previously above targeted levels, subsequently dropped below targeted levels. Historically, any such adjustments have been immaterial to our financial condition and results of operations.

During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, we settle any performance-based fees and reconcile healthcare claims and clinical data. As of June 30, 2011, performance-based fees that have not yet been settled with our customers but that have been recognized as revenue in the current and prior years totaled approximately $33.6 million, all of which was based on actual data received from our customers. Data reconciliation differences, for which we provide contractual allowances until we reach agreement with respect to identified issues, can arise between the customer and us due to customer data deficiencies, omissions, and/or data discrepancies.

Performance-related adjustments (including any amounts recorded as revenue that were ultimately refunded), changes in estimates, data reconciliation differences, or adjustments to incentive bonuses may cause us to recognize or reverse revenue in a current fiscal year that pertains to services provided during a prior fiscal year. During the six months ended June 30, 2011, we recognized a net increase in revenue of $1.4 million that related to services provided prior to 2011.

Impairment of Intangible Assets and Goodwill

We review goodwill for impairment on an annual basis (during the fourth quarter of our fiscal year) or more frequently whenever events or circumstances indicate that the carrying value may not be recoverable.

We estimate the fair value of each reporting unit using a discounted cash flow model and reconcile the aggregate fair value of our reporting units to our consolidated market capitalization. The discounted cash flow model requires significant judgments, including management’s estimate of future cash flows, which is dependent on internal forecasts, estimation of the long-term growth rate for our business, the useful life over which cash flows will occur, and determination of our weighted average cost of capital. Changes in these estimates and assumptions could materially affect the estimate of fair value and goodwill impairment for each reporting unit.

If we determined that the carrying value of goodwill was impaired based upon an impairment review, we would calculate any impairment using a fair-value-based goodwill impairment test as required by U.S. GAAP. The fair value of a reporting unit is the price that would be received to sell the unit as a whole in an orderly transaction between market participants at the measurement date.

Except for a certain trade name which has an indefinite life and is not subject to amortization, we amortize identifiable intangible assets, such as acquired technologies and customer contracts, using the straight-line method over their estimated useful lives. We assess the potential impairment of intangible assets subject to amortization whenever events or changes in circumstances indicate that the carrying values may not be recoverable. If we determine that the carrying value of other identifiable intangible assets may not be recoverable, we calculate any impairment using an estimate of the asset’s fair value based on the estimated price that would be received to sell the asset in an orderly transaction between market participants.

We review intangible assets not subject to amortization on an annual basis or more frequently whenever events or circumstances indicate that the assets might be impaired. We estimate the fair value of any trade names using a present value technique, which requires management’s estimate of future revenues attributable to these trade names, estimation of the long-term growth rate for these revenues, and determination of our weighted average cost of capital. Changes in these estimates and assumptions could materially affect the estimate of fair value for the trade names.

Future events could cause us to conclude that impairment indicators exist and that goodwill and/or other intangible assets associated with our acquired businesses are impaired. Any resulting impairment loss could have a material adverse impact on our financial condition and results of operations.

Income Taxes

The objectives of accounting for income taxes are to recognize the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in an entity’s financial statements or tax returns. Accounting for income taxes

requires significant judgment in determining income tax provisions, including determination of deferred tax assets, deferred tax liabilities, and any valuation allowances that might be required against deferred tax assets, and in evaluating tax positions.

We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. U.S. GAAP also provides guidance on derecognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, and income tax disclosures. Judgment is required in assessing the future tax consequences of events that have been recognized in our financial statements or tax returns. Variations in the actual outcome of these future tax consequences could materially impact our financial position, results of operations, or cash flows.

Share-Based Compensation

We measure and recognize compensation expense for all share-based payment awards based on estimated fair values at the date of grant. Determining the fair value of stock options at the grant date requires judgment in developing assumptions, which involve a number of variables. These variables include, but are not limited to, the expected stock price volatility over the term of the awards and expected stock option exercise behavior. In addition, we also use judgment in estimating the number of share-based awards that are expected to be forfeited.

Results of Operations

The following table shows the components of the statements of operations for the three and six months ended June 30, 2011 and 2010 expressed as a percentage of revenues.

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2011		2010		2011		2010

Revenues	100.0	%	100.0	%	100.0	%	100.0	%
Cost of services (exclusive of depreciation
and amortization included below)	74.3	%	69.5	%	74.5	%	70.8	%
Selling, general and administrative expenses	10.4	%	10.7	%	10.7	%	10.1	%
Depreciation and amortization	7.3	%	7.6	%	7.5	%	7.6	%
Operating income (1)	7.9	%	12.2	%	7.3	%	11.5	%

Gain on sale of investment	—		(0.7	)%	—		(0.3	)%
Interest expense	1.9	%	2.1	%	2.0	%	2.0	%

Income before income taxes (1)	6.1	%	10.9	%	5.3	%	9.9	%
Income tax expense	2.6	%	4.1	%	2.3	%	3.9	%

Net income (1)	3.4	%	6.7	%	3.0	%	6.0	%

(1) Figures may not add due to rounding.

Revenues

Revenues decreased $5.9 million and $22.0 million, or 3.4% and 6.2%, respectively, for the three and six months ended June 30, 2011 compared to the same periods in 2010, primarily due to contract and program terminations with certain customers, somewhat offset by increases in revenues due to the following:

·	new and expanded contracts; and

·	an increase in participation in our fitness center programs as well as in the number of members eligible to participate in such programs.

Cost of Services

Cost of services (excluding depreciation and amortization) as a percentage of revenues increased to 74.3% for the three months ended June 30, 2011 compared to 69.5% for the three months ended June 30, 2010, primarily due to the following:

·	costs associated with implementing certain significant new and innovative contracts;

·	an increase in implementation expenses primarily related to our Embrace platform;

·	an increased portion of our revenue generated by fitness solutions, which typically have a higher cost of services as a percentage of revenue than our other programs;

·	costs associated with an initiative to promote member participation in certain of our programs; and

·	certain costs that cannot be reduced in the same proportion and/or timeframe as the decrease in revenues discussed above.

These increases were somewhat offset by the following decreases in cost of services (excluding depreciation and amortization) as a percentage of revenues:

·	a decrease in the level of short-term incentive compensation based on the Company’s year-to-date financial performance against established internal targets for these periods;

·	a decrease in salaries and benefits expense, primarily due to a restructuring of the Company, which was completed during the fourth quarter of 2010;

·	cost savings related to certain operational efficiencies; and

·	a decrease in health insurance costs related to a decrease in claims for the three months ended June 30, 2011 compared to the three months ended June 30, 2010.

Cost of services (excluding depreciation and amortization) as a percentage of revenues increased to 74.5% for the six months ended June 30, 2011 compared to 70.8% for the six months ended June 30, 2010, primarily due to the following:

·	costs associated with securing and implementing certain significant new and innovative contracts;

·	an increase in implementation expenses primarily related to our Embrace platform;

·	an increased portion of our revenue generated by fitness solutions, which typically have a higher cost of services as a percentage of revenue than our other programs;

·	changes in the contract structure of certain incentive-based wellness programs from a utilization model to a PMPM model as well as an increase in the number of members eligible for these programs and their utilization of such programs;

·	costs associated with an initiative to promote member participation in certain of our programs; and

·	certain costs that cannot be reduced in the same proportion and/or timeframe as the decrease in revenues discussed above.

These increases were somewhat offset by the following decreases in cost of services (excluding depreciation and amortization) as a percentage of revenues:

·	a decrease in the level of short-term incentive compensation based on the Company’s year-to-date financial performance against established internal targets for these periods;

·	a decrease in salaries and benefits expense, primarily due to a restructuring of the Company, which was completed during the fourth quarter of 2010; and

·	cost savings related to certain operational efficiencies.

Selling, General and Administrative Expenses

Selling, general and administrative expenses decreased $1.0 million and $0.4 million, or 5.3% and 1.1%, respectively, for the three and six months ended June 30, 2011 compared to the same periods in 2010, primarily due to the following:

·	a decrease in the level of short-term incentive compensation during the three and six months ended June 30, 2011 compared to the three and six months ended June 30, 2010 based on the Company’s year-to-date financial performance against established internal targets for these periods; and

·	cost savings realized during the three and six months ended June 30, 2011 from a restructuring of the Company that was largely completed during the fourth quarter of 2010.

These decreases were somewhat offset by increased costs involved in pursuing business in evolving markets such as domestic government, community, and certain international markets.

Depreciation and Amortization

Depreciation and amortization expense decreased $0.9 million and $2.0 million, or 6.7% and 7.5%, respectively, for the three and six months ended June 30, 2011 compared to the same periods in 2010, primarily related to certain computer software that has become fully depreciated since June 30, 2010.

Interest Expense

Interest expense decreased 12.2% and 6.3%, respectively, for the three and six months ended June 30, 2011 compared to the same periods in 2010, primarily as a result of a decrease in the average interest rate paid on outstanding borrowings due to a decline in LIBOR rates and a lower average level of outstanding borrowings under our credit agreement during the three and six months ended June 30, 2011 compared to the same periods in 2010.

Income Tax Expense

Our effective tax rate increased to 43.7% and 43.8% for the three and six months ended June 30, 2011, respectively, compared to 37.8% and 39.2% for the three and six months ended June 30, 2010, respectively, primarily due to the favorable impact on the 2010 effective tax rate of an earn-out adjustment recorded during the three and six months ended June 30, 2010, as well as an increase during the three and six months ended June

30, 2011 in the level of certain expenses related to international operations for which we currently are not able to recognize a tax benefit.

Outlook

We anticipate that quarterly revenues and earnings will increase for the remainder of 2011 compared to the six months ended June 30, 2011, primarily due to the following:

·	the recognition of performance-based revenues and other revenues based on achieving certain targets and deliverables with respect to certain of our contracts;

·	a decrease in costs associated with securing and implementing certain significant new and innovative contracts;

·	ramping member enrollment on certain contracts throughout the year; and

·	a decrease in incentive costs related to member utilization of certain incentive-based wellness programs, which tends to be higher earlier in the year.

As discussed in “Liquidity and Capital Resources” below, a significant portion of our long-term debt is subject to fixed interest rate swap agreements; however, we cannot predict the potential for changes in interest rates, which would impact our variable rate debt. We anticipate that our effective tax rate for the remainder of 2011 will decrease slightly as compared to the six months ended June 30, 2011; however, we will continue to monitor and adjust the rate based upon changes in the geographic mix of our earnings, changes in our ability to recognize a tax benefit on certain expenses related to international operations, adjustments to uncertain tax positions, and consideration of other tax issues affecting the Company.

Liquidity and Capital Resources

Operating activities for the six months ended June 30, 2011 provided cash of $49.0 million compared to $27.1 million for the six months ended June 30, 2010. The increase in operating cash flow is primarily due to a lower short-term incentive compensation payment during the six months ended June 30, 2011 compared to the six months ended June 30, 2010. These amounts are generally paid following the year in which they are earned.

Investing activities during the six months ended June 30, 2011 used $24.8 million in cash, which primarily consisted of capital expenditures associated with our Embrace platform.

Financing activities during the six months ended June 30, 2011 used $24.8 million in cash, primarily due to net repayments on borrowings under our credit agreement and repurchases of our common stock.

Credit Facility. Revolving advances under the 2013 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 1.875% to 2.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.375% to 1.250%. Revolving advances under the 2011 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 0.875% to 1.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.000% to 0.250%. Term loan borrowings bear interest, at our option, at 1) LIBOR plus 1.50% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate. See below for a description of our interest rate swap agreements. The Fourth Amended Credit Agreement also provides for a fee ranging between 0.150% and 0.300% of the unused commitments under the 2011 Revolving Credit Facility and 0.275% and 0.425% of the unused commitments under the 2013 Revolving Credit Facility. The Fourth Amended Credit Agreement is secured by guarantees from most of the Company’s domestic subsidiaries and by security interests in substantially all of the Company’s and such subsidiaries’ assets.

We currently meet the hedge accounting criteria under U.S. GAAP in accounting for these interest rate swap agreements.

In October 2010, our Board of Directors authorized a share repurchase program which allows for the repurchase over a two-year period of up to $60 million of our common stock from time to time in the open market or in privately negotiated transactions. As of June 30, 2011, $46.0 million of our common stock is still subject to repurchase under this program.

We believe that cash flows from operating activities, our available cash, and our expected available credit under the Fourth Amended Credit Agreement will continue to enable us to meet our contractual obligations, to effect the share repurchase program, and to fund our current operations for the foreseeable future. However, if our operations require significant additional financing resources, such as capital expenditures for technology improvements or additional call centers, or if we are required to refund performance-based fees pursuant to contract terms, we may need to raise additional capital by expanding our existing credit facility and/or issuing debt or equity. If we face a limited ability to arrange such financing, it may restrict our ability to effectively operate our business. We cannot assure you that we would always be able to secure additional financing if needed and, if such funds were available, whether the terms or conditions would be acceptable to us.

If contract development accelerates or acquisition opportunities arise, we may need to issue additional debt or equity to provide the funding for these increased growth opportunities. We may also issue equity in connection with future strategic alliances. We cannot assure you that we would be able to issue additional debt or equity on terms that would be acceptable to us.

Contractual Obligations

There were no material changes outside the ordinary course of our business in our contractual obligations from those reported at December 31, 2010 in our Annual Report on Form 10-K, except for a new ten-year applications and technology services outsourcing agreement with HP that contains minimum fee requirements. Total payments over the ten-year term must equal or exceed a minimum level of approximately $185 million; however, based on initial required service and equipment level assumptions, we estimate that the total payments will be approximately $380 million, $18.0 million of which will occur during the remainder of 2011, $100.9 million of which will occur during 2012 and 2013, $80.8 million of which will occur during 2014 and 2015, and the remaining $180.3 million of which will occur thereafter. The agreement allows us to terminate all or a portion of the services after two years provided we pay certain termination fees which could be material to the Company.

Recently Issued Accounting Standards

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

We are subject to market risk related to interest rate changes, primarily as a result of the Fourth Amended Credit Agreement, which bears interest based on floating rates. Revolving advances under the 2013 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 1.875% to 2.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.375% to 1.250%. Revolving advances under the 2011 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 0.875% to 1.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.000% to 0.250%. Term loan borrowings bear interest, at our option, at 1) LIBOR plus 1.50% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate.

In order to manage our interest rate exposure under the Fourth Amended Credit Agreement, we have entered into interest rate swap agreements effectively converting our floating rate debt to fixed obligations with interest rates ranging from 0.580% to 3.855%.

A one-point interest rate change would have resulted in a change in interest expense of approximately $0.4 million for the six months ended June 30, 2011.

As a result of our investment in international initiatives, we are also exposed to foreign currency exchange rate risks. Because a significant portion of these risks is economically hedged with currency options and forwards contracts and because our international initiatives are not yet material to our consolidated results of operations, a 10% change in foreign currency exchange rates would not have had a material impact on our consolidated results of operations, financial position, or cash flows for the six months ended June 30, 2011. We do not execute transactions or hold derivative financial instruments for trading purposes.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our chief executive officer and chief financial officer have reviewed and evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of June 30, 2011. Based on that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective. They are designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms and to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting during the three months ended June 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II

Item 1.

Legal Proceedings

Shareholder Derivative Lawsuits

ERISA Lawsuits

Contract Dispute

Outlook

Item 1A.

Risk Factors

In addition to the other information set forth in this report, you should carefully consider the risks and uncertainties previously reported under the caption “Part I — Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010, the occurrence of which could materially and adversely affect our business, prospects, financial condition and operating results. The risks previously reported and described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and in this report are not the only risks facing our business. Additional risks and uncertainties not currently known to us or those we currently deem to be immaterial may also materially and adversely affect our business operations.

There have been no material changes to our risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

The following table contains information for shares of our common stock that we repurchased during the second quarter of 2011:

Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs

April 1 through 30	178,614		$14.76	907,161		$49,000,274
May 1 through 31	18,443		$15.72	925,604		$48,710,350
June 1 through 30	176,161		$15.11	1,101,765		$46,048,557

Total	373,218

Item 3.

Defaults Upon Senior Securities

Not Applicable.

Item 4.

Removed and Reserved

Item 5.

Other Information

Not Applicable.

Item 6.

Exhibits

(a)

Exhibits


10.1		Master Services Agreement between the Company and HP Enterprise Services, LLC*

10.2		Capital Accumulation Plan, as amended and restated

10.3		2007 Stock Incentive Plan Performance Cash Award Agreement, as amended

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act, as amended

32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema

101.CAL		XBRL Taxonomy Extension Calculation Linkbase

101.DEF		XBRL Taxonomy Extension Definition Linkbase

101.LAB		XBRL Taxonomy Extension Label Linkbase

101.PRE		XBRL Taxonomy Extension Presentation Linkbase

		*Portions of this Exhibit have been omitted and filed separately with the U.S. Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities Exchange Act of 1934.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Healthways, Inc.
			(Registrant)




Date	August 8, 2011	By	/s/ Alfred Lumsdaine
			Alfred Lumsdaine
			Chief Financial Officer
			(Principal Financial Officer)

EX-10.1 2 ex10-1_063011.htm MASTER SERVICES AGREEMENT BETWEEN THE COMPANY AND HP ENTERPRISE SERVICES, LLC ex10-1_063011.htm

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

MASTER SERVICES AGREEMENT

between

Healthways, Inc. (“HWAY”),

and

HP Enterprise Services, LLC (“Supplier”)

Dated: May 25, 2011

Healthways Proprietary & Confidential

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

TABLE OF CONTENTS

Page

OBJECTIVES AND DEFINITIONS

1.1

Objectives

1.2

Definitions

TERM

2.1

Term

2.2

Extension of Term

SERVICES

3.1

Scope of Services

3.2

Services Performed by HWAY or Third Parties

3.3

Transition

3.4

Transformation

PERFORMANCE STANDARDS AND SERVICE CREDITS

4.1

Performance of the Services

4.2

Service Levels for Services Performed during the Transition

4.3

Service Levels for Services Performed during the Transformation

4.4

Service Levels for Services Performed Upon Steady State

4.5

Quality Assurance and Improvement Programs

4.6

Periodic Reviews

4.7

Failure to Perform

4.8 [______]*

4.9

Measurement and Monitoring Tools

CHARGES

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

5.1

Service Charges and Project Fees

5.2

Pass-Through Expenses

5.3 [______]*

5.4

Taxes

5.5

Incidental Expenses

5.6 [______]*

INVOICING AND PAYMENT

6.1

Invoicing

6.2

Payment Due

6.3

Proration

6.4

Prepaid Amounts

6.5

Refunds and Credits

6.6

Accountability

6.7

Disputed Charges

HWAY FACILITIES

7.1

Provision of HWAY Facilities

7.2

Use of HWAY Facilities

7.3

Relocation of HWAY Facilities

7.4

Return of HWAY Facilities

EQUIPMENT AND THIRD PARTY CONTRACTS

8.1

Existing Equipment

8.2

Retained Contracts

8.3

Assigned Contracts

8.4

Equipment Acquisitions During the Term

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

8.5

Equipment Maintenance

8.6

Required Consents

[______]*

9.1

[______]*

9.2

[______]*

9.3

[______]*

9.4

[______]*

9.5

[______]*

9.6

[______]*

9.7

[______]*

10. MAINTENANCE OF KNOWLEDGE DATABASE/REPOSITORY

11.

PERSONNEL

11.1

Key Supplier Positions

11.2

Key Supplier Position Approvals Procedure

11.3

Retaining Key Supplier Positions

11.4

Use and Compliance of Supplier Personnel

11.5

Turnover of Supplier Personnel

11.6

Replacement of Supplier Personnel at HWAY’s Request

11.7

Restrictions on Supplier Personnel

11.8

Transfer of HWAY Personnel

12. [______]*

12.1

[______]*

12.2

[______]*

12.3

[______]*

Healthways Proprietary & Confidential

Master Services Agreement

iii

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

12.4

[______]*

12.5

[______]*

12.6

[______]*

12.7

[______]*

12.8

[______]*

13.

HWAY RESPONSIBILITIES

13.1

Cooperation

13.2

Savings Section

14.

RELATIONSHIP MANAGEMENT

14.1

Supplier Account Manager

14.2

Key Supplier Personnel Performance Appraisal

14.3

Steering Committee

14.4

Reports

14.5

Meetings

14.6

Technology Plan

14.7

Systems Change Management

15.

CHANGES TO SERVICES

15.1

Scope Changes

15.2

System Changes

15.3

New Services

15.4

Technology Refresh

15.5

Support for Acquisitions

15.6

Due Diligence

16.

AUDITS AND RECORD KEEPING

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

16.1

Audit Rights

16.2

Supplier Audits

16.3

Audit Follow-Up

16.4

Records Retention

16.5

[______]*

17.

SAFEGUARDING OF INFORMATION AND SECURITY

17.1

Rights in HWAY Information

17.2

HIPAA

17.3

Security

17.4

Viruses

18.

CONFIDENTIALITY

18.1

Protection of Confidential Information

18.2

Use of Confidential Information

18.3

Handling HWAY Information

18.4

Handling Supplier’s Confidential Information

18.5

Exceptions to Obligations of Confidentiality

18.6

Period of Confidentiality

18.7

Treatment of Source Code Materials

18.8

Returning Material, Data and Information

18.9

Equitable Remedies

19.

REPRESENTATIONS AND WARRANTIES

19.1

Representations and Warranties by Supplier

19.2

Representations and Warranties By HWAY

19.3

Compliance with Laws

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

19.4

No Additional Representations and Warranties

20.

INDEMNITIES

20.1

Indemnity by Supplier

20.2

Indemnity by HWAY

20.3

Anticipation of Infringement

20.4

Indemnification Procedures

21.

LIMITATION OF LIABILITY

21.1

[______]*

21.2

[______]*

21.3

[______]*

22.

INSURANCE AND RISK

22.1

Insurance Coverage

22.2

Terms of Insurance

22.3

Risk of Loss and Damage

22.4

Coverage Remaining In Effect

23.

FORCE MAJEURE

23.1

Force Majeure Events

23.2

Allocation of Resources

23.3

[______]*

23.4

[______]*

23.5

No Compensation

24.

INFORMAL DISPUTE RESOLUTION

24.1

Dispute Resolution

24.2

Referral to Steering Committee

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

24.3

Special Procedure Following a Notice of Termination

24.4

Equitable Relief

25. [______]*

26.

TERMINATION

26.1

Termination for Cause or Bankruptcy

26.2

Termination for Convenience by HWAY

26.3

Termination for Change of Control

26.4

Termination by Supplier for Non-Payment and for Cause

26.5

Effective Date of Termination

26.6

Termination Charges

26.7

Equitable Remedies

26.8

Termination Assistance

26.9

Accrued Rights

26.10

Survival of Terms

27.

GENERAL

27.1

Non-Solicitation

27.2

Use of Name; Public Statement

27.3

Notices

27.4

Relationship of Parties

27.5

No Security Interest

27.6

Waivers, Consents and Approval

27.7

Entire Agreement

27.8

Variation

27.9

Priority of Documents

Healthways Proprietary & Confidential

Master Services Agreement

vii

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.10

Counterparts

27.11

Cumulative Rights

27.12

Severability

27.13

Costs

27.14

Further Assurance

27.15

Governing Law

27.16

Assignment

27.17

Background Checks

27.18

Federal Healthcare Programs

27.19

Equal Opportunity Employer and Minority-Owned Businesses

27.20

Drug-Free Workplace

27.21

Foreign Anti-Corruption Compliance

27.22

Attorneys’ Fees

27.23

Changes in Laws

27.24

Duty to Mitigate

27.25

[______]*

27.26

Interpretation

Healthways Proprietary & Confidential

Master Services Agreement

viii

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Schedules, Annexes, and Exhibits

Schedule A

Definitions

Schedule B

[______]*

Schedule C

[______]*

Annex C-1 [______]*

Exhibit 1 to Annex C-1 [______]*

Exhibit 2 to Annex C-1 [______]*

Annex C-2 [______]*

Exhibit 1 to Annex C-2 [______]*

Exhibit 2 to Annex C-2 [______]*

Annex C-3 [______]*

Exhibit 1 to Annex C-3

[______]*

Exhibit 2 to Annex C-3

[______]*

Exhibit 3 to Annex C-3

[______]*

Annex C-4 [______]*

Exhibit 1 to Annex C-4 [______]*

Exhibit 2 to Annex C-4 [______]*

Annex C-5 [______]*

Annex C-6 [______]*

Annex C-7 [______]*

Schedule D

[______]*

Annex D-1 [______]*

Annex D-2 [______]*

Annex D-3 [______]*

Annex D-4 [______]*

Schedule E

[______]*

Schedule F

[______]*

Schedule G

Meetings

Schedule H

Equipment and Contracts

Schedule I

[______]*

Schedule J

[______]*

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Schedule K

[______]*

Schedule L

Business Associate Addendum

Schedule M

[______]*

Schedule N

[______]*

Schedule O

[______]*

Schedule P

[______]*

Schedule Q

[______]*

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

MASTER SERVICES AGREEMENT

THIS MASTER SERVICES AGREEMENT is entered into and made effective on May 25, 2011 (the “Effective Date”) by and between Healthways, Inc. (“HWAY”), and HP Enterprise Services, LLC (“Supplier”).

RECITALS

A. HWAY is the leading provider of comprehensive integrated medical management solutions, including without limitation, specialized health, wellness, prevention and care management programs, chronic condition management services, care enhancement services, and decision support services. HWAY desires to engage a vendor to assist HWAY in focusing on its core business by receiving information technology (“IT”) services and solutions, along with key outcomes, from Supplier.

B. Supplier has represented that it has the necessary skill, resources and experience to provide all the Services (as defined herein) set forth in this Agreement and the attachments and schedules hereto.

C. Supplier recognizes the complexity of interrelationships between HWAY, its clients and other related entities, including with respect to IT services, and acknowledges HWAY’s commitment to such entities with respect to, among other things, such IT services in maintaining their standards of excellence and achieving their strategic goals.

D. Based on the foregoing, each Party has agreed to enter into this Agreement, and Supplier has agreed to provide the Services, on the terms set out below.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants set forth in this Agreement, the Parties hereto agree as follows:

1. OBJECTIVES AND DEFINITIONS

1.1	Objectives

The following objectives reflected in this Section 1.1 (the “Objectives”) are not intended to expand or contract the scope of the Parties’ obligations or to alter the plain meaning of this Agreement’s terms and conditions. However, to the extent that the terms and conditions of this Agreement do not address a particular circumstance or are unclear or ambiguous, such terms and conditions should be interpreted to give effect to the following Objectives.

1.1.1

Supplier and HWAY agree that the primary objectives for this Agreement include, but are not limited to:

(a)	[______]*;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)	give HWAY the opportunity to focus its energies on its core business, including achieving leadership in all service lines while also increasing membership volume with increased market share and executing new revenue-generating initiatives, by receiving the Services;

(c)	[______]*;

(d)	provide HWAY with quality, state-of-the-art technology on an on-going basis in a cost-effective manner;

(e)	provide HWAY with services and solutions that are specifically designed or capable of supporting the provision of top-tier integrated well-being support services, including services and solutions that increase satisfaction and improve member experience and meet or exceed regulatory requirements;

(f)	improve access to information and coordination of service delivery across service locations;

(g)	provide HWAY with a framework for predictable variable pricing;

(h)

provide a flexible arrangement that will accommodate changes in the demand for the Services, adapt as a result of changes in the legal and regulatory regime applicable to the services and to HWAY’s operation as a provider of integrated well-being support services, and adapt to developments in technology and processes especially those most applicable to an integrated well-being support services provider;

(i)	[______]*; and

(j)	offer HWAY’s Colleagues the opportunity to operate consistently through standardization of IT.

1.2	Definitions

Capitalized terms shall have the meaning set forth in Schedule A (Definitions).

2. TERM

2.1

Term»

The term of this Agreement shall begin on the Effective Date and shall expire on the tenth (10th) anniversary of the Effective Date unless earlier terminated in accordance with Section 26 or extended in accordance with Section 2.2 (the “Term”).

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

2.2	Extension of Term»

Upon at least six (6) months’ written notice from HWAY to Supplier prior to the then-current expiration date of this Agreement, HWAY shall have the right to extend the Term for two (2) additional periods of eighteen (18) months each on the terms of this Agreement (including pricing as adjusted in accordance with Annex D-2 to Schedule D [______]* then in effect.

3. SERVICES

3.1	Scope of Services»

3.1.1

References to this “Agreement” herein shall be construed as references to the body of this Agreement, together with the Schedules, Annexes, and Exhibits hereto and any Scope Changes or amendments to this Agreement entered into by the Parties.

3.1.2

Upon the Effective Date, Supplier shall provide the services and functions and fulfill the responsibilities set forth in this Agreement (the “Services”); provided, that Supplier shall commence providing the services set forth in the Services Agreements (as defined in Section 3.1.3(c)) upon the dates set forth in Exhibit 1 to Annex C-4 [______]* and the Transition Plan. Supplier acknowledges and agrees that this Agreement does not give Supplier any exclusive rights with respect to the provision of any services, including the Services, or products to HWAY or End Users.

3.1.3

The Services include, without limitation, the following:

(a)

the transition services set forth or described in Exhibit 1 to Annex C-4 [______]* and the Transition Plan, which are undertaken by Supplier in preparation of performance of the obligations and the Services hereunder, and unless otherwise provided for in this Agreement, are an investment by Supplier made in order to perform the Services;

(b)	the transformation services and projects set forth or described in Schedule B [______]*;

(c)	the services set forth in detail in the Annexes to Schedule C (Services Agreements), which are as follows:

(i)	Annex C-1 to Schedule C [______]*;

(ii)	Annex C-2 to Schedule C [______]*;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(iii)

Annex C-3 to Schedule C [______]*;

(iv)	Annex C-4 to Schedule C [______]*;

(v)	Annex C-5 to Schedule C [______]*;

(vi)	Annex C-6 to Schedule C [______]*;

(vii)

Annex C-7 to Schedule C [______]*;

(collectively, the “Services Agreements”);

(d)	Supplier’s cooperation with HWAY’s suppliers, vendors, licensors and consultants to allow HWAY to improve the integration of all IT-related services it receives;

(e)	Supplier’s cooperation with HWAY and other related entities and such entities’ suppliers, vendors, licensors and consultants to allow HWAY to improve the integration of all IT-related services they receive;

(f)

to the extent Schedule N [______]* is entered into by the Parties, Supplier’s testing and recovery of each of the Services in compliance with the Disaster Recovery Plan attached hereto as Schedule N [______]*, including but not limited to (i) providing operational and technical support for disaster recovery planning, development, documentation, testing and execution in accordance with Schedule N [______]*, (ii) ensuring that Schedule N [______]* is updated with improvements, subject to the prior written agreement of HWAY, on an on-going basis, and (iii) proposing, from time to time, changes to such [______]* to meet or exceed industry standards for similar healthcare service providers;

(g)

in addition to Supplier’s compliance with its obligations under the [______]*, Supplier’s reasonable cooperation with HWAY’s global, internal disaster recovery plan, a copy of which is attached to this Agreement as part of Schedule F [______]*, upon HWAY’s declaration of an emergency. For purposes of clarification, “reasonable cooperation” in the event of a declaration of an emergency shall be to support HWAY in HWAY’s performance of the following disaster recovery activities: (i) continue data replication to secondary site in practice as of the Effective Date, (ii) support current “tabletop” testing approach and scope, (iii) remediation of issues or concerns as a result of the “tabletop” test, (iv) update test plan as required, (v) In the event a disaster is declared, assemble identified personnel (DR team, leadership, decision makers), (vi) provide notification to stakeholders, (vii) execute parameters as defined in the disaster recovery plan, (viii) coordination of delivery of equipment, (ix) re-routing of network connectivity, and (x) restoration of systems, databases and applications based on defined priority; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(h)

any services, functions and responsibilities (including any incidental services, functions or responsibilities) not specified in this Agreement as within the scope of Supplier’s responsibilities but reasonably and necessarily required for, or related to, the proper performance and provision of the services, functions and responsibilities set out above.

To the extent that this Section 3.1.3(i) may require performance of material services, functions and responsibilities not described in Sections 3.1.3(a) - (h) above, the Parties shall mutually agree on such additional services, functions or responsibilities pursuant to the Change Control procedures in accordance with this Agreement. Nothing contained in Sections 3.1.3(a) – (i) shall be construed to assign to Supplier any responsibility for services, functions or responsibilities expressly designated as HWAY responsibilities in a Schedule, Annex or Exhibit hereto.

3.1.4

Supplier acknowledges that the Services may be supplemented, enhanced, modified or replaced in accordance with this Agreement.

3.1.5

The [______]* attached as Annex D-3 to Schedule D [______]* shall specify which Party is responsible for providing the facilities, personnel, equipment, Software, Materials, technical knowledge, training, expertise and other resources necessary for the proper performance of the Services.

3.1.6

Supplier covenants that Supplier shall not intentionally or willfully withhold any Services to be provided by Supplier under this Agreement except as expressly permitted in Section 26.4 of this Agreement or as may be required by Laws applicable to Supplier.

3.2	Services Performed by HWAY or Third Parties»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

3.2.1

[______]*

3.2.2

[______]*

3.2.3

Third parties retained by HWAY, to the extent that they have been provided access to the facilities, assets and information specified in Section 3.2.2, shall materially comply with Supplier’s reasonable security and confidentiality requirements and work standards, methodologies and procedures that have been provided to HWAY in writing in advance. Supplier shall promptly notify HWAY if an act or omission of such a third party may cause a problem or delay in providing the Services and shall cooperate with HWAY to prevent or circumvent such problem or delay.

3.2.4

[______]*

3.3	Transition»

3.3.1

Supplier shall conduct the Transition as follows:

(a)	the Transition shall be implemented in conformity with Exhibit 1 to Annex C-4 [______]* and the Transition Plan; and

(b)	Supplier shall perform the Transition without causing any material disruption to the business of HWAY, unless such disruption is caused by planned, mutually agreed outages of the Services; provided, that Supplier will use Diligent Efforts to minimize such planned disruption.

3.3.2

Supplier shall designate an individual to manage the Transition (the “Supplier Transition Manager”) on a dedicated full-time basis. The Supplier Transition Manager shall (a) report to the Supplier Account Executive, (b) serve as the single point of accountability for Supplier for the Transition, and (c) have day-to-day authority for ensuring that the Transition is completed in accordance with Exhibit 1 to Annex C-4 [______]* and the Transition Plan.

3.3.3

Supplier shall be responsible for the overall management of the Transition, and shall identify and resolve or, if the task is expressly designated as a task for HWAY in Exhibit 1 to Annex C-4 [______]* or the Transition Plan, assist HWAY in the resolution of, any problems encountered in the timely completion of each task identified therein.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

3.3.4

Supplier shall provide HWAY with weekly (or more frequent as requested by HWAY) written progress reports that describe, in reasonable detail, the current status of the Transition, indicate the progress of the work being performed, identify any actual or anticipated problems or delays, assess the impact of such problems or delays on Supplier’s provision of the Services, and describe all actions being taken or to be taken to remedy such problems or delays. Such reports shall be as set forth in Exhibit 1 to Annex C-1 [______]*.

3.3.5

In the event that Supplier fails to fulfill any of its obligations with respect to Transition in accordance with Exhibit 1 to Annex C-4 [______]*, the Transition Plan or this Section 3 by the dates specified therein, Supplier shall, at HWAY’s request and without prejudice to HWAY’s other rights and remedies under this Agreement, promptly arrange (at Supplier’s own cost, except as provided below) all such additional resources as are necessary to fulfill the obligation(s) as early as practicable thereafter.

3.4	Transformation

3.4.1

Supplier shall conduct transformation services as follows:

(a)	transformation services shall be performed in accordance with the transformation projects attached as Schedule B [______]*; and

(b)	Supplier shall perform the transformation services without causing any material disruption to the business of HWAY, unless such disruption is caused by planned, mutually agreed outages of the Services; provided, that Supplier will use Diligent Efforts to minimize such planned disruption.

3.4.2

Supplier shall designate an individual to manage the transformation (the “CTO”) on a dedicated full-time basis. The CTO shall (a) serve as the single point of accountability for Supplier for the transformation projects, and (b) have day-to-day authority for ensuring that the transformation services are completed in accordance with the transformation projects attached as Schedule B [______]*. The CTO shall be one of the Key Supplier Positions.

3.4.3

Supplier shall be responsible for the overall management of the transformation, and shall identify and resolve, or if the task is expressly designated as a task for HWAY in Schedule B [______]* assist HWAY in the resolution of, any problems encountered in the timely completion of each task identified in the transformation projects.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

3.4.4

Supplier shall provide HWAY with weekly (or more frequent as requested by HWAY) written progress reports that describe, in reasonable detail, the current status of the transformation, indicate the progress of the work being performed, identify any actual or anticipated problems or delays, assess the impact of such problems or delays on Supplier’s provision of the Services, and describe all actions being taken or to be taken to remedy such problems or delays. Such reports shall be as set forth in Exhibit 1 to Annex C-1 [______]*.

3.4.5

In the event that Supplier fails to fulfill any of its obligations with respect to the transformation projects in accordance with Schedule B [______]* by the dates specified therein, Supplier shall, at HWAY’s request and without prejudice to HWAY’s other rights and remedies under this Agreement, promptly arrange (at Supplier’s own cost, except as provided below) all such escalations and reasonable, additional or alternate resources as are necessary to fulfill the obligation(s) as early as practicable thereafter.

4. PERFORMANCE STANDARDS AND SERVICE CREDITS

4.1	Performance of the Services»

4.1.1

Without limiting the obligations set forth in Schedule C [______]* or elsewhere in this Agreement, Supplier shall, from the Effective Date, at all times achieve or exceed the applicable Performance Standards with respect to the Services and shall perform the Services:

(a)	efficiently and reasonably using the resources or services used to provide the Services;

(b)	in a reasonable and cost-effective manner consistent with the required level of quality and performance;

(c)	in accordance with the Change Control procedures set forth in Schedule E [______]*; and

(d)	using adequate numbers of Supplier Personnel that:

(i) are appropriately experienced, qualified and trained;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(ii) are familiar with IT systems and requirements of HWAY and the requirements set forth in this Agreement; and

(iii) shall perform the Services with all reasonable skill, care and diligence.

4.2	Service Levels for Services Performed during the Transition

4.2.1

During the Transition, the Services provided by Supplier shall meet or exceed the service levels that were provided by or for HWAY prior to the Effective Date, as set forth in the Transition Plan.

4.3	Service Levels for Services Performed during the Transformation

4.3.1

During the period of transformation, the Services provided by Supplier shall meet or exceed the Service Levels attached as Annex C-7 [______]*.

4.4	Service Levels for Services Performed Upon Steady State

4.4.1

From the date of completion of the transformation projects attached as Schedule B [______]*, Supplier shall at all times perform the Services in accordance with, and at a level that meets or exceeds (including without limitation levels with respect to accuracy, quality, completeness, timeliness, responsiveness, and efficiency) the Service Levels attached as Annex C-7 [______]*.

4.5	Quality Assurance and Improvement Programs»

4.5.1

Subject to Section 4.5.2, Supplier shall adopt and comply with the IT quality procedures set forth in Schedule F [______]*.

4.5.2

Supplier shall enhance the delivery of the Services through the introduction of Tools, procedures and other improvements into HWAY’s IT environment such that the Services are performed at least in accordance with the Performance Standards, as such Performance Standards are correspondingly improved over the Term. Such enhancements shall include:

(a)	as part of its total quality management process, Supplier’s provision of continuous quality assurance and quality improvement through:

(i)

the identification and, subject to the Change Control procedures (other than with respect to Supplier’s right to reject such proposed change), application of Supplier’s proven techniques and Tools from other installations, particularly those installations within the health care industry, that could benefit HWAY operationally and/or financially;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(ii)	the implementation of programs, practices and measures (including checkpoint reviews, testing, acceptance, and other procedures for HWAY to assure the quality of Supplier’s performance) which are specified in the Policies and Procedures Manual set forth in Schedule F [______]*; and

(b)	those enhancements set forth in Exhibit 1 to Annex C-4 [______], the Transition Plan and Schedule B [______], each as amended, subject to the Change Control procedures, from time to time;

provided, that each such enhancement will be provided to HWAY without additional cost if such enhancement is not provided as a separately marketed and priced product to all of Supplier’s other customers.

4.6	Periodic Reviews»

Within thirty (30) days following the Cut-Over Date and thereafter on a periodic basis as set forth in Schedule G (Meetings), HWAY and Supplier shall review the Performance Standards and shall make adjustments to them as appropriate and mutually agreed to reflect improved performance capabilities associated with advances made by the industry, particularly with respect to the integrated well-being and health care industry, and by HWAY with respect to the technology and methods used to perform the Services.

4.7	Failure to Perform»

If Supplier fails to meet any Performance Standard including a failure to meet a Service Level (a “Service Problem”), Supplier shall promptly:

4.7.1

investigate, identify, and analyze the chain of events leading to, and the causes of, the failure to meet the Performance Standard, including a thorough root cause analysis for Severity 1 Service Problems, Severity 2 Service Problems if requested, and recurring problems;

4.7.2

take all reasonable steps to preserve any data indicating the cause of the Service Problem;

4.7.3

prepare and deliver to HWAY a summary of an action plan and report in accordance with the timetable set forth in Schedule C (Services Agreements) and as such report is specified in Exhibit 1 to Annex C-1 [______]*;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

4.7.4

take all reasonable steps to minimize the impact of the Service Problem and prevent it from recurring;

4.7.5

correct the Service Problem pursuant to the timeframe and reporting requirements of the Services Agreements and resume meeting the Performance Standard; and

4.7.6

advise HWAY in writing of the status of remedial efforts being undertaken on a weekly (daily or as reasonably requested by HWAY, in the event of a Severity 1 Service Problem or recurring problem, or at HWAY’s request, a Severity 2 Service Problem) basis until a permanent fix is tested and implemented in full production, with such status reports provided in accordance with Exhibit 1 to Annex C-1 [______]*.

4.8	[______]* »

4.9	Measurement and Monitoring Tools»

Supplier shall use reasonable measurement and monitoring tools and procedures as set forth in the Schedules hereto, or as mutually agreed upon by the Parties, that are necessary to measure and report Supplier’s performance of the Services against the applicable Performance Standards. Such measurement and monitoring tools and procedures must utilize industry standard automation and functionality. Such measurement and monitoring shall permit reporting at a level of detail sufficient to reasonably verify compliance with the Performance Standards and in a form as set forth in Exhibit 1 to Annex C-1 [______]*, and shall be subject to Audit by HWAY in accordance with Section 16.

5. CHARGES

5.1	Service Charges and Project Fees»

All charges for the Services, including the charges for the transformation projects described in Schedule B [______]*, are set forth in this Section 5, Sections 7.3, 8.4.3, 16.4.2, 16.4.4, 23.5, and 26.7, and Schedule D [______]* (collectively, the “Charges”). HWAY shall only be required to pay Supplier those amounts set forth in this Section 5, Sections 7.3, 8.4.3, 16.4.2, 16.4.4, 23.5, and 26.7, and Schedule D [______]*, and Supplier acknowledges that no implied amounts will be payable by HWAY for the Services.

5.2	Pass-Through Expenses»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

As of the Effective Date, the Parties do not anticipate that there will be any Pass-Through Expenses. In the event that this changes, Pass-Through Expenses will be set forth in an amendment to Schedule D [______]*. HWAY’s payment of the Pass-Through Expenses shall be in accordance with, and subject to, the following:

5.2.1

In the event that a particular Pass-Through Expense is to be paid directly by HWAY, Supplier shall ensure that the original invoice for any such Pass-Through Expense shall be addressed to HWAY but sent to Supplier and shall, as soon as practicable and in any event not more than ten (10) business days following Supplier’s receipt of the original third party invoice:

(a)	provide HWAY with such original third party invoice;

(b)	review the invoice charges to determine the apparent validity and accuracy of the Pass-Through Expenses; and

(c)	provide HWAY with a statement that the charges appear proper.

5.2.2

With respect to Pass-Through Expenses for which the Parties agree that Supplier shall pay on behalf of HWAY, Supplier shall:

(a)	review the invoice charges to determine the apparent validity and accuracy of the Pass-Through Expense;

(b)	provide HWAY with a reasonable opportunity to review the original invoice; and

(c)	pay the amounts due and invoice HWAY, on a Supplier invoice, for the Pass-Through Expense, without mark-up, fees, increase or overhead charges of any kind by Supplier.

5.2.3

With respect to services or materials paid for on a Pass-Through Expenses basis, HWAY reserves the right to:

(a)

obtain such services or materials directly from a third party, provided that if Supplier demonstrates to HWAY’s reasonable satisfaction that such action will have a material adverse impact on Supplier’s ability to meet the Performance Standards, then in the event that HWAY elects to obtain such Services or materials directly from a third party, then Supplier shall not be liable for such corresponding inability to meet such Performance Standards;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)	designate the third party who will provide such services or materials;

(c)

designate the particular services or materials (e.g., equipment make and model) that Supplier shall obtain; provided, that such services or materials are reasonably consistent with the Services; provided further, that if Supplier demonstrates to HWAY that such designation will have a material adverse impact on Supplier’s ability to meet the Service Levels or Objectives, such designation shall be subject to Supplier’s reasonable approval;

(d)	designate the terms for obtaining such services or materials (e.g., purchase or lease and lump sum payment or payment over time);

(e)	require Supplier to identify and consider multiple sources for such services or materials for the Service Charges set forth in Schedule D [______]* or, at HWAY’s request and expense, to conduct a competitive procurement; and

(f)	review and approve the Pass-Through Expense for such services or materials before entering into a contract for such services or materials.

5.3	[______]*»

5.4

Taxes»

5.4.1

Except as otherwise provided in Sections 5.4.6, 5.4.7 and 5.4.9, each of HWAY and Supplier shall be responsible for:

(a)	any taxes on property or assets for which it has Equipment capital or Software capital ownership or leasehold;

(b)	any taxes based on its net income or gross receipts.

5.4.2

[______]*

5.4.3

Supplier shall be liable for any sales, use, excise, value-added, services, consumption and other taxes and duties payable by Supplier on any goods and services used or consumed by Supplier in providing the Services where the tax is imposed on Supplier’s acquisition or use of such goods or services in its provision of the Services.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

5.4.4

Supplier shall be liable for all sales, use, excise, value added, services, consumption, transfer and other use taxes that are assessed against or incurred on the transfer of assets from HWAY to Supplier, including the transfer of Existing Equipment or Software, the Assigned Contracts or any other good or service transferred or provided from HWAY to Supplier, other than taxes imposed on HWAY that are based on HWAY’s net income or gross receipts. HWAY will use commercially reasonable efforts to minimize sales, use, excise, VAT, or services tax associated with such transfers. HWAY shall be responsible for charging any U.S. sales tax, excise, VAT, or services tax associated with the transfer of such above assets, for consideration where applicable, unless Supplier provides a valid resale/exemption certificate at the time of the transaction.

5.4.5

[______]*

5.4.6

[______]*

5.4.7

[______]*

5.4.8

Each Party shall notify and coordinate with the other Party within a reasonable amount of time in response to taxing authorities for taxes which such other Party is responsible under this Agreement. Supplier reserves the right to settle any and all claims, without notification to, or approval by HWAY, provided however that in such event, HWAY shall not be responsible for such settled taxes.

5.4.9

If withholding tax based on any payment due Supplier under this Agreement is required by Law to be withheld and remitted to a taxing authority, then HWAY will withhold and remit what it believes to be the legally proper amount to the taxing authority on Supplier’s behalf and pay the remainder to Supplier. HWAY shall timely provide Supplier with a written receipt from the taxing authority or other evidence of such remittance payment, and reasonably cooperate with Supplier, at Supplier’s expense and reasonable request, in obtaining any lawfully available exemption from or reduction in such withholding tax requirement. If after sixty (60) days of receipt of such documentation by HWAY from the taxing authority, HWAY has not supplied Supplier with the required certificates of withholding, documentation or receipts, then Supplier shall invoice HWAY or the applicable eligible recipient for such withholding taxes and HWAY or such eligible recipient shall either pay to Supplier an amount equal to such withholding or provide the required certificates of withholding, documentation or receipts within sixty (60) days after HWAY’s or such eligible recipient’s receipt of an invoice for such amounts from Supplier. In the event that Supplier does not agree with any particular withholding, Supplier shall request, and HWAY or such eligible recipient shall provide, a reasonable explanation for such withholding. If, after receipt of such reasonable explanation, Supplier still disputes the withholding, Supplier may use the dispute resolution procedures in Section 24 to resolve such dispute.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

5.5	Incidental Expenses»

Unless otherwise expressly stated in this Agreement, all routine expenses that Supplier incurs in performing the Services (including routine travel and lodging) are included in Supplier’s charges and rates as set forth in this Agreement. Accordingly, such Supplier expenses are not separately reimbursable by HWAY unless, on a case-by-case basis for unusual expenses, HWAY has agreed in writing in advance to reimburse Supplier for the expense.

5.6	[______]*»

6. INVOICING AND PAYMENT

6.1	Invoicing»

6.1.1

Supplier shall render a single consolidated invoice for each month’s Service Charges in the form, and pursuant to the requirements, set forth in Schedule D [______]* and Annex D-4 to Schedule D [______]* that includes at least the following:

(a)	the calculations utilized to establish the charges;

(b)	for each charge listed, the specific Section(s) of this Agreement on which such charge is based;

(c)	itemization of all Pass-Through Expenses for the previous month pursuant to Section 5.2;

(d)	deductions for applicable credits requested, in accordance with Schedule D [______]*, to be levied by HWAY due to Supplier's failure to meet the Service Levels;

(e)	the amount of any taxes Supplier is collecting from HWAY, set forth on an itemized basis; and

(f)	such details or requirements as may be reasonably specified by HWAY including such details that are necessary to satisfy HWAY’s internal accounting and chargeback requirements.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

6.2	Payment Due»

6.2.1

Subject to the other provisions of this Section 6 and Supplier performing the Services in accordance with this Agreement, undisputed invoices provided in accordance with Section 6.1.1 will be paid by HWAY within thirty (30) days after the date of the invoice thereof. Supplier shall provide each invoice to HWAY electronically on the date of the invoice. All payments will be made via ACH in accordance with Schedule P [______]*. Supplier shall give HWAY prior written notice of any change in this account information. Payment by HWAY does not constitute a waiver of any rights and remedies of HWAY or restrict HWAY’s right to make any claims with respect to the Services or deficiencies therein. If HWAY fails to pay such fees within thirty (30) days of receipt of the invoice, Supplier may charge interest from the due date on overdue undisputed amounts at the lesser of (a) one percent (1%) per month or (b) the maximum rate allowable under applicable law.

6.3	Proration»

Periodic charges under this Agreement are to be calculated on a calendar month basis, and shall be prorated for any partial month.

6.4	Prepaid Amounts»

Where HWAY has prepaid for a service or function for which Supplier is assuming financial responsibility under this Agreement, upon either Party identifying the prepayment, Supplier shall credit to HWAY on the first invoice practicable that portion of such prepaid expense which is attributable to periods on and after the Effective Date. A list of pre-paid services and functions, and the corresponding pre-payment amounts, as of the Effective Date, if any, is attached as Annex D-3 to Schedule D [______]*.

6.5	Refunds and Credits»

If Supplier receives a refund, credit or other rebate from a third party for goods or services previously paid for by HWAY as a Pass-Through Expense, Supplier shall promptly notify HWAY of such refund, credit or rebate and shall promptly credit the full amount of such refund, credit or rebate, as the case may be, to HWAY on Supplier’s next invoice.

6.6	Accountability»

Supplier shall provide HWAY with supporting documentation and other information with respect to each invoice as may be reasonably requested by HWAY to verify the accuracy of the invoice and compliance with the provisions of this Agreement.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

6.7	Disputed Charges»

6.7.1

HWAY shall pay undisputed charges when those payments are due. HWAY may withhold payment of any particular charges that HWAY disputes in good faith, subject to the remainder of this Section 6.7, without Supplier’s assertion of a payment default by HWAY or assessment of any late payment penalty. In the event that a particular invoice covers both disputed and undisputed items, HWAY shall pay all undisputed items in accordance with this Section 6 and Schedule D [______]*.

6.7.2

[______]*

6.7.3

For as long as HWAY pays undisputed amounts to Supplier, then Supplier shall continue to provide the Services to HWAY.

7. HWAY FACILITIES

7.1	Provision of HWAY Facilities»

7.1.1

HWAY shall provide to Supplier, at HWAY’s own cost (other than as set forth in Section 7.2), and Supplier shall utilize in providing the Services during the Term, the space, furnishings (including basic furniture, a telephone, an HWAY-standard personal computer and standard office software, utilities and common office supplies) and fixtures of HWAY (the foregoing facilities, collectively referred to as the “HWAY Facilities”). In addition, HWAY shall provide to the Supplier Personnel who provide Services at HWAY Facilities, at HWAY’s own cost, reasonable access to photocopy, printer, facsimile, and similar office equipment. Supplier shall be responsible for providing, at its own cost, any other facilities and support it needs to provide the Services and to perform its obligations under the Agreement.

7.1.2

Subject to Supplier’s obligations in this Section 7 with respect to HWAY Facilities, HWAY shall manage and maintain the HWAY Facilities, including the management and provision, at HWAY’s own cost (other than as set forth in Section 7.2), the facility and property electrical systems, water, sewer, lights, heating, ventilation and air conditioning systems, physical security services, maintenance and repair services, and general custodial services.

7.1.3

Supplier shall permit HWAY and its agents and representatives to enter into those portions of HWAY Facilities occupied by Supplier’s staff at any time and for any reason, including to perform Facilities-related services, subject to Supplier’s physical security policies and procedures as set forth in the Policies and Procedure Manual.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

7.1.4

HWAY shall be entitled to schedule and undertake emergency and, following coordination with Supplier, pre-planned maintenance, repairs, shutdowns and alterations with respect to HWAY Facilities, provided that Supplier shall not be liable for any breach, or delay in performance, of its obligations under this Agreement, including any failure to meet the Performance Standards, to the extent that such breach, delay or failure is caused by any such maintenance, repairs, shutdowns or alterations that are not preplanned. In the event of mutually unplanned maintenance, repairs, shutdowns or alterations, Supplier will, to the extent appropriate under the circumstances, perform its obligations under HWAY’s disaster recovery plan or take other reasonable actions to mitigate the adverse impact, if any, of such unplanned maintenance, repairs, shutdowns or alterations.

7.2	Use of HWAY Facilities»

7.2.1

Supplier shall use HWAY Facilities in a reasonable manner, minimizing interference with HWAY’s and HWAY’s contractors’ operations. With respect to Supplier’s use of HWAY Facilities or other use or access, directly or indirectly of the Facilities or information systems of HWAY, Supplier shall comply with all reasonable policies and procedures as provided by HWAY to Supplier from time-to-time, including procedures for physical security and health and safety requirements.

7.2.2

With respect to Supplier’s use of HWAY Facilities, conference rooms and office space shall be provided on the same basis as such Facilities, conference rooms and offices space are provided to HWAY’s employees or as otherwise mutually agreed upon in writing by the Parties.

7.2.3

Supplier shall not commit or permit waste or damage to such HWAY Facilities, nor use such HWAY Facilities for any unlawful purpose or act, and shall use such facilities in accordance with the reasonable policies and procedures of HWAY as provided to Supplier.

7.2.4

Unless otherwise agreed by HWAY in writing, Supplier shall only use HWAY Facilities for the purpose of providing the Services; provided, Supplier may use the HWAY Facilities for incidental corporate and administrative purposes. Supplier shall not permit any other person to use HWAY Facilities [______]* with respect to access and use of HWAY’s Facilities, without HWAY’s prior written approval.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

7.2.5

Supplier shall be responsible for any damage to HWAY Facilities resulting from any abuse or misuse by Supplier, Supplier Personnel [______]*, or other failure to comply with its obligations with respect to HWAY Facilities. In the event of such damage, Supplier shall repair such damage and/or (if HWAY repairs such damages) compensate HWAY for the reasonable cost of such repairs.

7.2.6

Supplier shall not make any improvements or alterations involving structural, mechanical, electrical or other material aspects of HWAY Facilities without HWAY’s prior written approval. Any and all improvements to HWAY Facilities shall, except as otherwise agreed by the Parties in writing, become the sole property of HWAY.

7.2.7

Supplier shall coordinate the installation of Equipment at HWAY Facilities with HWAY. The installation of Equipment that materially increases the power, cooling or weight requirements for a HWAY Facility, or otherwise has a material impact on the environment of such HWAY Facility, shall be subject to HWAY’s prior written approval.

7.3	Relocation of HWAY Facilities»

HWAY shall be entitled to change or relocate HWAY Facilities upon reasonable advance written notice to Supplier. In the event that such relocation or change is not stated in Exhibit 1 to Annex C-4 [______]*, the Transition Plan or elsewhere in this Agreement and is not due to Supplier’s failure to comply with the terms of this Agreement, HWAY shall reimburse Supplier for Supplier’s Out-of-Pocket Expenses incurred in such relocation or change and, if the cost or difficulty of providing the Services is materially increased as a result of such relocation or change, the Charges under this Agreement shall be equitably increased.

7.4	Return of HWAY Facilities»

In the event any of the HWAY Facilities are no longer required for performance of the Services or upon Termination of this Agreement, Supplier shall promptly return such HWAY Facilities to HWAY (but in no event more than twenty (20) days from such date) in substantially the same condition as when Supplier began to use such HWAY Facilities, subject to reasonable and ordinary wear and tear.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

8. EQUIPMENT AND THIRD PARTY CONTRACTS

8.1	Existing Equipment»

8.1.1

Subject to Supplier’s prior written approval, HWAY shall sell, and Supplier shall purchase and pay HWAY for, the Transferred Equipment, if any, identified in Schedule H (Equipment and Contracts) for the amount set forth in such Schedule pursuant to a mutually satisfactory Sale Agreement.

8.1.2

With respect to Existing Equipment, other than any Transferred Equipment identified in Schedule H (Equipment and Contracts), that is owned or leased by HWAY including Equipment procured for HWAY pursuant to Sections 8.4.2 or 8.4.3 (“Retained Equipment”), HWAY grants to Supplier during the Term the rights to access and use the Retained Equipment solely to the extent necessary for performing the Services.

8.1.3

Supplier acknowledges that no legal or equitable claim to the Retained Equipment owned by HWAY or leased by HWAY from a third party shall transfer to Supplier by way of this Agreement.

8.1.4

Throughout the Term and thereafter for the purposes of Termination Assistance, Supplier shall keep any Retained Equipment that it uses to provide the Services separate, to the extent reasonably practicable, from the property of Supplier and of third parties, and identified as HWAY’s property.

8.1.5

Supplier shall not purport to pledge, or in any way charge by way of security, permit any lien to be placed on, or otherwise encumber or permit the encumbrance in any way, any of the Retained Equipment which shall at all times remain HWAY’s or the applicable third party lessor’s property and shall irrevocably waive any rights which may arise under Law to take a lien over the Retained Equipment for any sums due to Supplier pursuant to this Agreement.

8.1.6

Supplier shall install, operate and maintain at its expense any equipment, software and licenses needed to provide the Services unless expressly identified as HWAY’s responsibility in the [______]* attached as Annex D-3 to Schedule D. During the Term hereof, Supplier shall comply with all applicable requirements of the vendor agreements between a third-party vendor and Supplier, including, without limitation, license requirements, site requirements (including environmental and other requirements), technical requirements, and any other contractual requirements.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

8.2	Retained Contracts

8.2.1

Subject to Section 8.5 hereof, HWAY hereby authorizes Supplier to, and Supplier shall, administer the Retained Contracts. HWAY will promptly notify all corresponding third parties of such authorization through a letter of agency. Supplier has no right to sue, claim or take any legal actions (or any precursors to such actions) in HWAY’s name or with respect to the Retained Contracts, and Supplier shall inform HWAY of any issues arising in relation to the Retained Contracts. Supplier shall inform HWAY when any contracts are due for renewal, and ensure that Supplier’s use of Equipment, Software and any services received under the Retained Contracts is, and Supplier is otherwise, in compliance with the provisions of such contracts. Supplier shall administer such Retained Contracts for the sole benefit of HWAY and shall not use any Equipment and Software provided under such Retained Contracts except in connection with this Agreement.

8.2.2

Supplier shall support and use Diligent Efforts to cause the corresponding third parties to comply with their obligations under the Retained Contracts to maintain in good working order through the industry standard useful life of all Equipment and Software provided under the Retained Contracts.

8.2.3

HWAY will, from the Effective Date, not terminate, extend, amend, or substitute any Retained Contract without prior written notice to Supplier.

8.2.4

Supplier shall comply with the duties imposed on HWAY under the Retained Contracts, including use restrictions and confidentiality obligations, and Supplier shall not seek to modify or otherwise revoke such terms without HWAY’s prior written consent.

8.2.5

HWAY shall pay the charges under the Retained Contracts.

8.2.6

HWAY intends to terminate, or allow to expire, those Retained Contracts as set forth in Schedule H (Equipment and Contracts).

8.2.7

Except as otherwise requested or approved by HWAY (or the relevant licensor), Supplier shall cease all use of the Retained Contracts upon Termination of this Agreement, except to the extent necessary to comply with Supplier’s obligations under Section 26.8.

8.3	Assigned Contracts»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

8.3.1

Subject to Supplier’s prior written approval and Supplier having obtained any Required Consents, HWAY shall on the later of the Effective Date or the date on which Supplier obtains the applicable Required Consent, assign to Supplier, and Supplier shall accept such assignment for, those Existing Equipment Leases, third party service contracts, Third Party Software Contracts, and other contracts, if any, as are listed in Schedule H (Equipment and Contracts) (the “Assigned Contracts”).

8.3.2

Supplier shall comply with the duties imposed on HWAY under the Assigned Contracts, if any, and shall pay directly (or reimburse HWAY if HWAY has paid) the charges under the Assigned Contracts that are attributable to periods on and after the effective date of the applicable assignment.

8.4	Equipment Acquisitions During the Term»

8.4.1

Subject to Sections 8.4.2 and 8.4.3, Supplier shall procure for and on behalf of HWAY, and HWAY shall acquire, Equipment, including modifications, upgrades, enhancements, additions and replacements of Transferred Equipment (if any) and all Retained Equipment as necessary or appropriate to provide the Services and refresh such equipment in accordance with Supplier’s technology refreshment policies set forth in Schedule F [______]* or as otherwise agreed in writing by the Parties.

8.4.2

Modifications, upgrades, enhancements, additions and replacements of the Retained Equipment shall be acquired in the name of HWAY (and title shall vest with HWAY) to the extent that HWAY or its Affiliates remains the owner of such Retained Equipment, and shall be treated in accordance with the governing lease to the extent that HWAY remains the lessee of such Retained Equipment. Supplier will use commercially reasonable efforts to structure such leases as capital rather than operating leases and Supplier shall submit such leases to HWAY’s Corporate Financial Officer for approval prior to execution.

8.4.3

With respect to Equipment acquisitions for which there is a charge set forth in Schedule D [______]*, the acquisition costs, if any, for such Equipment shall be treated as a Pass-Through Expense unless otherwise mutually agreed on a case-by-case basis, and such Equipment shall be purchased or leased in the name of HWAY unless HWAY requires otherwise in writing.

8.5	Equipment Maintenance»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Supplier shall manage the maintenance of the Supplier Equipment and maintain the Systems Software (excluding operating systems) so that they operate in accordance with their specifications, including:

(a)	maintaining the equipment in good operating condition, subject to normal wear and tear; and

(b)	undertaking repairs and preventative maintenance on Equipment and performing Software maintenance in accordance with the applicable manufacturer’s or licensor’s recommendations.

8.6	Required Consents»

HWAY, with the reasonable assistance of Supplier, shall use commercially reasonable efforts to obtain, as of the Cut-Over Date, the Required Consents. HWAY shall pay such fees (such as transfer or upgrade fees) as may be required to obtain a Required Consent with respect to resources or rights of access provided by HWAY, and Supplier shall pay such fees (such as transfer or upgrade fees) as may be required to obtain a Required Consent with respect to resources or rights of access provided by Supplier. If a Required Consent is not obtained, then unless and until such Required Consent is obtained, subject to the Change Control procedures, Supplier and HWAY shall determine and adopt such alternative approaches as are necessary and sufficient to provide the Services without such Required Consents and HWAY shall solely be responsible for all payments due in connection with the alternative approach.

9. SOFTWARE AND PROPRIETARY RIGHTS

9.1 Intellectual Property Rights Existing as of the Effective Date

This Agreement shall not be deemed to assign or transfer ownership by any Party of any Intellectual Property Rights existing as of the Effective Date.

9.2 HWAY Software and HWAY Material

9.2.1

HWAY shall retain all right, title and interest in and to HWAY Software and HWAY Material, including all Intellectual Property Rights therein.

9.2.2

[______]*

9.2.3

[______]*

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

9.2.4

Supplier agrees that all such Modifications, enhancements and derivative works of the HWAY Software and HWAY Material are the sole and exclusive property of HWAY and are “works made for hire” within the meaning of the United States Copyright Act of 1976, 17 U.S.C. §101 et seq. To the extent that any such Modifications, enhancements or derivative works do not qualify as a “work made for hire,” Supplier hereby irrevocably assigns (free from any encumbrance) all right, title and interest (including all Intellectual Property Rights created hereunder) in and to such Modifications, enhancements and derivative works without further consideration for such assignment. To the extent any such rights cannot be assigned by Supplier, including moral rights, if applicable, Supplier agrees to, and hereby does, irrevocably waive any and all such rights and will not seek to assert or enforce such rights for its own benefit. [______]* Supplier agrees to execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further documents and instruments as may reasonably be required to effect the assignment contemplated herein. For the avoidance of doubt, this assignment shall not be affected in any way by the rejection of any Modifications, enhancements or derivative works by HWAY under this Agreement or the termination, in whole or in part, of this Agreement by HWAY.

9.2.5

[______]*

9.3 Developed IP Developed Under this Agreement

9.3.1

[______]* To the extent that any such Developed IP does not qualify as a “work made for hire,” Supplier hereby irrevocably assigns (free from any encumbrance) all right, title and interest (including all Intellectual Property Rights created hereunder) in and to such Developed IP without further consideration for such assignment. To the extent any such rights cannot be assigned by Supplier, including moral rights, if applicable, Supplier agrees to, and hereby does, irrevocably waive any and all such rights and will not seek to assert or enforce such rights for its own benefit. [______]* Supplier agrees to execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further documents and instruments as may reasonably be required to effect the Developed IP assignment contemplated herein. For the avoidance of doubt, this assignment shall not be affected in any way by the rejection of any Developed IP by HWAY under this Agreement or the termination, in whole or in part, of this Agreement by HWAY.

9.4 Pre-Existing Supplier Software, Supplier Material and Supplier Developed Software

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

9.4.1

[______]*

9.4.2

[______]*

9.4.3

[______]*

9.4.4

[______]*

9.5 [______]*

9.6 [______]*

9.7 Third Party Software Acquired During the Term

[______]*

10. MAINTENANCE OF KNOWLEDGE DATABASE/REPOSITORY

Within ninety (90) days of the Effective Date, Supplier agrees to begin capturing, through use of its proprietary tool “Knowledge Center”, information, know-how, processes, policies and procedures, techniques and methodologies, developed or used by Supplier in the performance of Services and inputting this information into a separate repository available to HWAY (“Knowledge Repository”). Throughout the Term of this Agreement, Supplier shall maintain and update the Knowledge Repository on an “as needed” basis. Supplier shall make available to HWAY at all times electronic access to the Knowledge Repository. In addition, Supplier agrees to begin capturing information and know-how developed or used by Supplier in the performance of Helpdesk services only and input this information into a knowledge database made available to HWAY. [______]*

11. PERSONNEL

11.1	Key Supplier Positions»

11.1.1

The Key Supplier Positions approved as of the Effective Date are set forth in Schedule I [______]*. In addition, Supplier acknowledges and agrees that the Supplier Transition Manager shall devote substantially his or her full time and effort to supplying the Transition Services until the conclusion of the Transition related Services.

11.1.2

HWAY may, from time to time, upon thirty (30) days’ prior written notice to Supplier, designate new or alternative Key Supplier Positions but HWAY shall not, without Supplier’s consent (such consent not to be unreasonably withheld), materially increase the proportion of Key Supplier Positions relative to the Personnel required to supply the Services.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

11.2	Key Supplier Position Approvals Procedure»

11.2.1

Prior to assigning an individual to a Key Supplier Position, whether as an initial assignment or a subsequent assignment, Supplier shall:

(a)	notify HWAY of the proposed assignment;

(b)	introduce the individual to appropriate HWAY representatives (and, upon request, provide such representatives with the opportunity to meet with the individual); and

(c)	provide HWAY with such information as HWAY may reasonably request about the individual’s training, experience and skills relevant to the requirements of the Key Supplier Position.

11.2.2

In the event that HWAY objects to the proposed assignment, HWAY and Supplier shall each use commercially reasonable, good faith efforts to resolve HWAY’s concerns.

11.2.3

In the event that HWAY and Supplier are unable to resolve HWAY’s concerns within five (5) days of HWAY’s objection, Supplier shall not assign the individual to the Key Supplier Position and shall propose to HWAY the assignment of another individual of training, experience and skills suitable to the requirements of that position and the provisions of this Section 11.2 shall apply to such other individual.

11.3	Retaining Key Supplier Positions»

11.3.1

Supplier shall (if necessary by temporary personnel provided that Supplier Personnel serving in Key Supplier Positions have vacated their positions as described below) ensure that the Key Supplier Positions are filled at all times and that:

(a)

each of Supplier Personnel identified in Schedule I [______]* to serve in the Key Supplier Positions devotes substantially his or her full time and effort to supplying the Services (except as otherwise provided in Schedule I) for at least two (2) years from the Effective Date except for those Supplier Personnel designated with only a one (1) year retention requirement; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)	Supplier Personnel filling Key Supplier Positions at any time during the Term are not reassigned or replaced for at least two (2) years following assignment to those positions,

unless such Supplier Personnel resigns from his or her employment, or terminates his or her contract with Supplier, or is unable to work owing to mental or physical incapacity for a period exceeding fifteen (15) business days, or is dismissed, or terminated for misconduct, or in connection with a reduction in the volume of Services provided under this Agreement, or has a change in family circumstances, not due to Supplier, resulting in his or her relocation.

11.3.2

Supplier shall not replace a person filling a Key Supplier Position without first complying in full with Section 11.2 and:

(a)	demonstrating to HWAY that the new person is qualified to meet the requirements of the Key Supplier Position; and

(b)	obtaining HWAY’s prior written consent.

11.4	Use and Compliance of Supplier Personnel»

Supplier shall:

11.4.1

use an adequate number of Supplier Personnel to supply the Services;

11.4.2

ensure that all Supplier Personnel who perform the Services are properly trained and capable of meeting the requirements of the Services tasks assigned to them in a workmanlike and timely manner and in accordance with the Performance Standards;

11.4.3

ensure that Supplier Personnel perform their duties in a manner that does not intentionally interrupt and is not intentionally inconsistent with HWAY’s provision of health care services; and

11.4.4

ensure that all Supplier Personnel are informed of and comply with:

(a)

any applicable policies or procedures provided by HWAY to Supplier from time to time which shall include, without limitation, any health or safety requirements, building access and security procedures and policies relating to conduct of personnel admitted to HWAY’s (or a third party’s) premises; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)	Supplier’s obligations under this Agreement with respect to Confidential Information, Protected Health Information and data security.

11.5	Turnover of Supplier Personnel»

HWAY and Supplier agree that it is in their best interests to minimize the turnover rate of Supplier Personnel performing the Services (“Turnover Rate”). Accordingly, Supplier shall use commercially reasonable efforts to keep the Turnover Rate to a level reasonably comparable to the level experienced by other information technology suppliers in the health care sector for the geographic region where the applicable services are being performed. If HWAY notifies Supplier that the Turnover Rate with respect to Supplier Personnel is not acceptable, Supplier shall as soon as reasonably practicable:

11.5.1

provide to HWAY sufficient data to establish the actual extent of the Turnover Rate including, in particular, the Turnover Rate among Key Supplier Positions;

11.5.2

meet with HWAY to discuss the impact of the level of the Turnover Rate; and

11.5.3

submit to HWAY a proposal for reducing the Turnover Rate (including any associated price impact), which, once agreed to in writing between HWAY and Supplier, shall form part of this Agreement.

11.6	Replacement of Supplier Personnel at HWAY’s Request»

11.6.1

HWAY may notify Supplier at any time during the Term that it requires Supplier to replace any (a) HWAY-facing Supplier Personnel or (b) Key Supplier Positions involved in the provision of the Services for the good and lawful reasons stated in the notice. After receipt of such notice, Supplier shall have [______]* business days in which to investigate the matters stated in the notice and discuss its findings with HWAY. In the event that, following that period, HWAY still requires replacement of the individual, Supplier shall replace that individual with another individual with training, experience and skills suitable to meet the requirements of the assigned Services tasks.

11.6.2

In the event that, in its discretion, HWAY believes that an individual is a threat to the health, safety or security of any of HWAY’s or a third party’s personnel, data or property, or is disruptive to HWAY’s services, or threatens to be, or is materially in breach of the terms and conditions of this Agreement or any HWAY written policy or procedure which was previously provided to Supplier, then Supplier shall remove that individual from the provision of the Services forthwith and, not limiting the foregoing, HWAY shall have the right to restrict such individual’s access to HWAY’s premises and systems at its sole discretion.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

11.6.3

Supplier shall bear all costs associated with any removal and replacement of Supplier Personnel pursuant to this Section 11.6, including costs associated with the training and education of replacement personnel. HWAY shall have no liability for claims brought by any replaced Supplier Personnel against HWAY or Supplier as a result of HWAY’s exercise of its rights under this Section 11.6, and Supplier shall indemnify HWAY against any such claims.

11.6.4

Nothing in this Agreement shall grant HWAY the right to require Supplier to terminate any individual’s employment or contract with Supplier, and the rights granted herein are solely in connection with Supplier’s provision of Services to HWAY.

11.7	Restrictions on Supplier Personnel

[______]*

11.8	Transfer of HWAY Personnel

[______]*

12. [______]*

13. HWAY RESPONSIBILITIES

13.1	Cooperation»

13.1.1

HWAY shall from time-to-time designate an individual to whom all Supplier communications concerning this Agreement may be addressed (the “HWAY CIO”).

13.1.2

HWAY shall cooperate with Supplier by making information and approvals of HWAY available as required in this Agreement within the time periods specified herein for such information or approvals or, where no time period is specified, within a reasonable time period.

13.2	Savings Section»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

The failure by HWAY to perform any of its responsibilities set forth in this Agreement shall not be deemed to be grounds for termination by Supplier (other than as provided for in Section 26.4); provided, however, Supplier’s non-performance of its obligations under this Agreement shall be excused if and to the extent that:

13.2.1

Supplier’s non-performance directly results from the acts or omissions of HWAY or any of HWAY’s subcontractors, agents and Affiliates to perform their respective obligations under this Agreement; and

13.2.2

Supplier promptly provides HWAY with written notice of such non-performance as soon as it has knowledge of the non-performance and uses commercially reasonable efforts to perform the Services on a schedule that is extended by (i) no more than one day for each day of HWAY’s or any of its subcontractors’ non-performance of their responsibilities or interference, or (ii) such other time period as is reasonable under the circumstances. However, Supplier shall not be required to incur additional costs in such commercially reasonable efforts.

14. RELATIONSHIP MANAGEMENT

14.1	Supplier Account Manager»

Supplier shall designate an individual to whom all HWAY communications concerning this Agreement may be addressed (the “Supplier Account Manager”).

14.2	Key Supplier Personnel Performance Appraisal»

As part of Supplier’s annual performance review process, Supplier will solicit from the HWAY CIO a reasonable number of performance objectives that will be included among the performance objectives to be achieved by the Supplier Account Manager and other Key Supplier Personnel during the next evaluation year which performance objectives shall be subject to Supplier’s approval not to be unreasonably withheld. In addition, Supplier shall solicit the HWAY CIO’s appraisal of Supplier’s Project Executive and other Key Supplier Personnel in connection with Supplier’s annual employee performance appraisal process, which appraisal shall include whether or not the Supplier Account Manager and other Key Supplier Personnel achieved the performance objectives provided by the HWAY CIO.

14.3	Steering Committee»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

14.3.1

The Parties shall form a steering committee to facilitate communications between them and assist in certain, specified evaluation and decision making tasks (the “Steering Committee”). HWAY’s members of the Steering Committee shall be composed of HWAY’s [______]* and other Key Personnel from Supplier, and such other persons as may be mutually agreed in writing by the Parties. Members of the Steering Committee may be represented at any meeting by a designee appointed by such member for such meeting. Each Party shall be free to designate different senior officers or executives, in accordance with the requirements of this Section 14.3.1, upon prior written notice to the other Party. Each Party may, in its discretion, invite personnel that are not members of the Steering Committee upon the other Party’s written consent to such invitee(s).

14.3.2

The Steering Committee shall have the right to create, and assign responsibilities to, subcommittees. Such subcommittees shall report to the Steering Committee. The Steering Committee shall have authority over such subcommittees.

14.3.3

The purpose of the Steering Committee shall be for overall relationship management and performance reporting.

14.3.4

The Steering Committee shall meet as set forth in Schedule G (Meetings).

14.3.5

HWAY and Supplier shall use Diligent Efforts to reach consensus on the matters properly before the Steering Committee which materially affect Supplier’s obligations under this Agreement. In the event that the Steering Committee cannot reach consensus with respect to such matter, either Party may invoke the provisions of Section 24 of this Agreement.

14.4

Reports»

Commencing on the Effective Date, Supplier shall provide the reports as described and set forth in Exhibit 1 to Annex C-1 [______]*.

14.5

Meetings»

Commencing on the Effective Date, the Parties shall have meetings between representatives of HWAY and Supplier, in accordance with Schedule G (Meetings).

14.6	Technology Plan»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

14.6.1

Supplier shall prepare an annual technology plan in accordance with the provisions of this Section 14.6 which is attached hereto as Schedule K [______]* and shall, subject to the Change Control procedures set forth in Schedule E [______]*, perform the Services in accordance with the Technology Plan. The Technology Plan shall address HWAY’s technology requirements in support of its Objectives for the subsequent three (3) full fiscal years. Supplier shall submit to HWAY a draft of the Technology Plan that shall be reasonably acceptable to HWAY and subject to HWAY’s written approval, which draft shall have been developed with input from key business Colleagues from HWAY. Supplier shall submit a revised Technology Plan for HWAY’s written approval within fifteen (15) days of receiving HWAY’s comments. The draft of the Technology Plan for the first year is attached hereto as Exhibit 1 to Annex C-4 [______]*, and the draft Technology Plan for subsequent years shall be provided by March 1 of the relevant year. After the first year, the Technology Plan shall address the information technology requirements of HWAY’s activities and shall:

(a)	incorporate, conform to, and support HWAY’s desired overall outcomes as provided by HWAY to Supplier for the relevant time period;

(b)	assess the appropriate direction for such systems and services, in light of HWAY’s business priorities and strategies (to the extent such business information is provided by HWAY to Supplier) and competitive market forces;

(c)	specifically identify proposed software and hardware strategies and direction;

(d)	include a detailed summary of the projects and tasks which Supplier proposes to achieve HWAY’s desired overall outcomes as provided by HWAY to Supplier, including:

(i)	in the event that such projects or tasks will result in a scope change, a Scope Change request in accordance with Schedule E [______]*;

(ii)	in the event that such projects or tasks result in New Services the pricing applicable in the event that HWAY elects to have Supplier perform such projects or tasks;

(iii)

a cost/benefit analysis of any proposed changes;

(iv)	a description of the types of personnel skills and abilities needed to respond to any recommended changes or upgrades in technology;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(v)	a general plan and a projected time schedule for developing and achieving the recommended elements;

(vi)	references to appropriate information services operations platforms that support Performance Standard requirements and/or represent potential gains in service quality, cost savings, or efficiency for health and care support providers; and

(vii)

a discussion of the potential regulatory and accreditation impact of any proposed information services operations platforms, provided that HWAY acknowledges that (A) such discussion shall not constitute legal advice or a legal opinion by Supplier and (B) HWAY shall be solely responsible for determining whether Supplier’s proposed technology solution satisfies HWAY’s obligations under applicable law; and

(e)	as necessary to support the overall objectives and directions of the three-year plan described above:

(i)	provide specific guidance as to the information services requirements, projects, and plans for the upcoming year, including details on operations, maintenance backlog and development activities; and

(ii)	include a summary review of Supplier’s performance of the Services in the year then concluding and review and assess the Technology Plan with respect to that year.

14.6.2

The Technology Plan shall be revised annually in accordance with Section 14.6.1 and in a manner that supports HWAY’s annual business planning cycle. The Technology Plan shall also be updated during the year as necessary to reflect changes in the business of HWAY which materially impact the validity of the then-existing Technology Plan. Supplier shall recommend modifications to the Technology Plan as it deems appropriate, and shall revise the Technology Plan as requested or approved by HWAY.

14.7	Systems Change Management»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

14.7.1

Supplier shall be responsible for all changes to HWAY’s IT environment relating to the Services, including changes to programs, manual procedures, job control language statements, distribution parameters and schedules.

14.7.2

Supplier will control changes to HWAY’s IT environment pertaining to the Services according to Schedule E [______]*.

15. CHANGES TO SERVICES

15.1	Scope Changes»

Scope Changes shall be agreed and implemented pursuant to the Change Control procedures as set forth in Schedule E [______]*.

15.2	System Changes»

System Changes shall be implemented by Supplier in accordance with Section 14.7 and Schedule E [______]*. Supplier shall not relocate any HWAY Equipment or HWAY Software without HWAY’s prior written consent. [______]*

15.3	New Services»

15.3.1

HWAY may request Supplier to supply New Services from time to time. New Services are subject to mutual agreement of the Parties as set forth in Schedule E [______]* and Service Charges for New Services shall be determined in accordance with Schedule D [______]* and Schedule E [______]*. New Services shall become part of the Services.

15.3.2

Supplier agrees that where regulatory or legal changes that affect multiple Supplier clients result in New Services, Supplier shall not allocate the charges for those New Services disproportionately to HWAY in relation to Supplier’s other clients.

15.3.3

Supplier shall not begin performing any New Services until the charges are approved by HWAY in writing.

15.4	Technology Refresh

[______]*

15.5	Support for Acquisitions

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

15.5.1

With respect to a potential acquisition by HWAY, upon HWAY request, Supplier shall provide, subject to the Change Control procedures and for an additional charge, acquisition support (including assessments of any application portfolios and related technology environments to be acquired, potential integration approaches, and the impact of the acquisition on the Services, Service Levels, charges and other aspects of this Agreement) as reasonably necessary to assist with HWAY assessment of the portion of the acquisition to which the Services will relate. Such support shall be provided within the timeframe reasonably requested by HWAY or as required by the timing of the transaction.

15.5.2

Supplier shall, subject to the Change Control procedures, transition the application portfolios and other aspects of the IT environment of the acquired entity as they relate to the Services to the HWAY environment.

15.6	Due Diligence»

15.6.1

Equipment, Software and Retained Contracts and Assigned Contracts that are the subject of Section 8 are listed in Schedule H (Equipment and Contracts), Exhibit 3 to Annex C-3 [______]*, Exhibit 1 to Annex C-3 [______]* and Annex D-3 to Schedule D [______]*. While the Parties intend that such Schedule will be comprehensive, neither Party warrants the completeness or accuracy of such Schedule.

15.6.2

During the period commencing on the Agreement Date and ending six (6) months after the Effective Date, if the Parties discover that any Equipment or Software item or Contract is not identified in Schedule H (Equipment and Contracts), Exhibit 3 to Annex C-3 [______]*, Exhibit 1 to Annex C-3 [______]* or Annex D-3 to Schedule D [______]*, respectively (“Unidentified Resources”), the following shall apply:

(a)

Upon discovery of an Unidentified Resource, the Parties’ respective operational, administrative, financial, and legal obligations for a (formerly) Unidentified Resource shall be on the same basis for which the Parties are responsible for the most comparable analogous resource already listed in Schedule H, Exhibit 3 to Annex C-3 [______]*, Exhibit 1 to Annex C-3 [______]* or Annex D-3 to Schedule D [______]*, and such Unidentified Resource shall be added to Schedule H, Exhibit 3 to Annex C-3 [______]*, Exhibit 1 to Annex C-3 [______]* or Annex D-3 to Schedule D [______]* by amendment of this Agreement in accordance with Section 27.8.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)

To the extent that the Parties discover Unidentified Resources after such six (6) month period, then unless otherwise agreed by the Parties: (i) HWAY shall be financially responsible for such Unidentified Resources; and (ii) the Parties’ respective operational, administrative, and legal obligations for a (formerly) Unidentified Resource shall be on the same basis for which the Parties are responsible for the most comparable analogous resource already listed in Schedule H, Exhibit 3 to Annex C-3 [______]*, Exhibit 1 to Annex C-3 [______]* or Annex D-3 to Schedule D [______]*

16. AUDITS AND RECORD KEEPING

16.1	Audit Rights»

16.1.1

Supplier shall provide to HWAY Audit Representatives access to Supplier [______]* service locations where the Services are being provided, during normal business hours at all reasonable times, [______]* provided however, that such access for regulatory audits, HWAY customer-requested audits and internal HWAY audit assistance reasonably requested for purposes of Sarbanes-Oxley compliance shall be provided at any times required or requested, and shall grant HWAY Audit Representatives reasonable access, subject to Sections 16.1.4 and 16.1.8 hereof, to Supplier Personnel to discuss, and to data, records and information relating to, the Services for the purpose of performing audits and inspections (“Audits”) to:

(a)	verify the accuracy of charges and invoices;

(b)	verify the integrity of HWAY Information and examine the systems that process, store, maintain, support and transmit HWAY Information;

(c)

[______]*

16.1.2

Supplier shall reasonably cooperate with HWAY Audit Representatives and provide such assistance as HWAY Audit Representatives reasonably require in carrying out the Audits.

16.1.3

HWAY shall provide at least twenty (20) business days’ notice of any Audit it intends to conduct pursuant to this Section 16 unless any of the following circumstances apply:

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(a)	such Audit is required by HWAY for reasons of suspected fraud or compliance with the security requirements set forth in this Agreement including Section 17.3;

(b)	HWAY has reasonable grounds to suspect that Supplier may be in material breach of its obligations;

(c)	where the Audit is of a regulatory nature and under such circumstances where providing Supplier twenty (20) business days’ notice is impracticable, in which case HWAY shall provide such advance notice as is reasonable and practicable under the circumstances; or

(d)	where any HWAY customer, client or End User agreement or contract requires less than twenty (20) business days’ notice.

16.1.4

HWAY shall ensure that HWAY Audit Representatives (other than regulatory HWAY Audit Representatives) shall comply with Supplier’s reasonable security requirements provided to HWAY and shall obtain executed confidentiality agreements from such HWAY Audit Representatives in a form reasonably acceptable to Supplier.

16.1.5

Supplier shall cooperate with HWAY in dealing with regulatory Audits or requests by certification and regulatory agencies auditing HWAY or HWAY’s clients, customers or End Users, including:

(a)	providing HWAY and the applicable regulatory agencies with all reasonable assistance;

(b)	notifying HWAY as soon as practicable of any regulatory Audit;

(c)	permitting HWAY or its representatives to be present and to participate in such regulatory Audits;

(d)	providing HWAY with copies of any reports or written communications with respect to such regulatory Audits to the extent the report or communication is provided to Supplier;

(e)	liaising with HWAY and HWAY Audit Representatives with respect to responses to such regulatory Audit communications; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(f)

implementing, and complying with, the recommendations or requirements of a regulatory Audit subject to the Change Control procedures (other than with respect to Supplier’s right to reject such proposed change).

16.1.6

Without limiting the foregoing in this Section 16.1, Supplier agrees:

(a)

to make available, upon the written request of the Secretary of Health and Human Services or the Comptroller General, or their representatives, or any other regulator exercising proper jurisdiction, this Agreement and such books, documents and records as may be necessary to verify the nature and price of the Services rendered hereunder to the full extent required by the Health Care Financing Administration implementing Section 952 of the Omnibus Reconciliation Act of 1980, codified at 42 U.S.C. Section 1395x(v)(1)(l), or by any other applicable federal or state authority;

(b)	such access will be granted for four (4) years after the Services are furnished; and

(c)	such access shall be limited to books, documents and records necessary to verify the nature and extent of the price of the Services provided by Supplier.

16.1.7

[______]*

16.1.8

The Audit Representatives shall have no access to any data, records or other information concerning: (i) Supplier’s other customers; or (ii) Supplier’s internal costs of performing the Services or any internal charges (excluding only costs reimbursed by HWAY and Pass-Through Expenses). Neither HWAY nor the Audit Representatives shall have access to personal information about Supplier Personnel if prohibited by law or Supplier policies concerning personal information or personnel matters.

16.2	Supplier Audits»

16.2.1

Supplier shall conduct reviews and audits of, or pertaining to, the Services in a manner consistent with the audit practices of well managed operations performing services similar to the Services. Supplier shall within seven (7) days of the Effective Date provide HWAY with the written results of the last security audit carried out by an independent third party on Supplier’s Service Management Center (“SMC”) from which the Services will be provided [______]*

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

16.2.2

[______]* Supplier shall bear all costs and expenses associated with obtaining and delivering each SSAE 16 Type 2 Report (or successor thereto). [______]* As requested by HWAY, Supplier shall either (1) certify (via a factual self-assessment) to HWAY in writing that during the applicable gap period no changes have been made to the Services or the systems, the manner in which the Services or systems are provided or operated, applicable controls, or the Objectives that could reasonably be expected to have any impact on the contents of, or opinions set forth in, the applicable SSAE 16 Type 2 Report (or successor thereto); or (2) provide HWAY with a written description of any such changes. [______]*

16.2.3

[______]*

16.2.4

Supplier shall promptly make available to HWAY the results of any review or audit conducted by inspectors or regulators (but not including Supplier’s routine internal audits) relating to the Services and advise HWAY of any actual or suspected error with respect to amounts charged to HWAY under this Agreement.

16.3	Audit Follow-Up»

16.3.1

Following an Audit, HWAY shall conduct (in the case of an internal Audit), or request its external HWAY Audit Representatives to conduct, a review meeting with Supplier to obtain factual concurrence with issues identified in the Audit.

16.3.2

Supplier and HWAY shall meet to review each Audit report promptly after the issuance thereof and shall mutually agree upon the appropriate manner, if any, in which to respond to the changes suggested by the Audit report. If the Audit report reveals that Supplier has failed to perform any of its obligations under this Agreement, Supplier promptly shall provide to HWAY for its approval a remediation plan and timetable for achievement of the actions and/or improvements set forth in such plan. Following approval of the plan and timetable by HWAY, Supplier shall implement such plan in accordance with the agreed timetable and will confirm its completion by sending written notice to HWAY.

16.3.3

HWAY and Supplier shall develop and follow procedures for the sharing of reports for Audits carried out pursuant to this Section 16.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

16.3.4

If any Audit reveals any overcharge or undercharge in any Supplier invoice, an appropriate correcting payment or credit shall be promptly made by the appropriate Party. In the event that an Audit reveals an overcharge by Supplier, Supplier’s correcting payment shall be made together with interest at the lesser of one percent (1%) above the U.S. prime lending rate as published by Citibank, N.A. or the maximum rate allowed by applicable law from the date the incorrect payment was made by HWAY to the date of the repayment by Supplier.

16.3.5

Audits shall be conducted at HWAY’s expense unless fees in any Supplier invoice are found to have been overcharged by [______]* or more, in which case Supplier shall pay the reasonable costs of the audit and all adjustments in fees due.

16.4	Records Retention»

16.4.1

Supplier shall maintain all records generated or retained by or on behalf of HWAY in accordance with HWAY’s internal records retention policy, a copy of which is attached to this Agreement as part of Schedule F [______]*, and as such may be amended from time to time subject to the Change Control procedures.

16.4.2

Upon request, Supplier shall maintain and provide access for HWAY Audit Representative to the records, documents and other information required to meet HWAY’s audit rights under this Agreement until the later of:

(a)	five (5) years after the date the applicable Service was completed;

(b)	the date that all pending matters relating to the applicable Service (including disputes) are closed;

(c)	the date when such records, documents and other information are no longer required to meet Supplier’s records retention policy, as such policy may be amended from time to time; or

(d)	the date when such records, documents and other information is no longer required to be retained pursuant to Laws applicable to Supplier.

HWAY shall pay, as a Pass-Through Expense, all reasonable out-of-pocket costs of maintaining and providing access to (i) HWAY’s inactive records, documents and other information, and (ii) to the extent Supplier is required by this Section 16.4 to retain any of its inactive records for a period longer than that provided by Supplier’s records retention policy, Supplier’s inactive records, documents and other information.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

16.4.3

Without limitation to Section 16.4.1, Supplier shall maintain complete and accurate records of, and supporting documentation for, invoices submitted to HWAY and the payments made by HWAY under this Agreement in accordance with generally accepted accounting principles applied on a consistent basis.

16.4.4

Supplier shall promptly provide, at HWAY’s reasonable expense, copies of all records retained under this Section 16.4 as requested in writing by HWAY.

16.5	[______]*»

17. SAFEGUARDING OF INFORMATION AND SECURITY

17.1	Rights in HWAY Information»

17.1.1

HWAY Information shall be and remain, as between the Parties, the property of HWAY and nothing in this Agreement shall grant to Supplier any right, title or interest in such information. No HWAY Information, or any part thereof, may be assigned or leased to third parties by Supplier or commercially exploited by or on behalf of Supplier.

17.1.2

HWAY Information shall only be used by Supplier for the purpose of performing the Services under this Agreement and pursuant to the terms of this Agreement.

17.2

HIPAA»

Notwithstanding anything to the contrary in this Agreement, Protected Health Information shall be subject to the terms of Schedule L (Business Associate Addendum) and Supplier shall use and disclose Protected Health Information only in accordance with Schedule L (Business Associate Addendum). In the event of a conflict between a term or terms of this Agreement and Schedule L (Business Associate Addendum), the term or terms of Schedule L (Business Associate Addendum) shall control and govern. For clarification, and notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall limit Suppliers’ obligations and liability as set forth in Schedule L (Business Associate Addendum).

17.3

Security»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

17.3.1

Supplier shall establish and maintain safeguards against the destruction, loss, alteration or disclosure of HWAY Information or Protected Health Information in the possession of Supplier in accordance with the data, systems and physical security requirements attached as Annex C-5 to Schedule C [______]*.

17.3.2

Without limiting the generality of Section 17.3.1:

(a)

Supplier’s obligations in the prevention of any unauthorized access, alteration, destruction, copying, use, or disclosure of HWAY Information, Confidential Information or Protected Health Information (“Information Breaches”) are as specified in the security requirements contained in Annex C-5 to Schedule C [______]*. In the event Supplier suspects, becomes aware of, or initiates an investigation into any such Information Breach, Supplier shall promptly report such incident, suspected incident, or investigation in writing to HWAY;

(b)	Supplier shall undertake the obligations as specified in the security requirements contained in Annex C-5 to Schedule C [______]* to prevent Information Breaches through physical, network and logical measures, which shall include:

(i)	security procedures and tools to prevent unauthorized access to Infrastructure Systems;

(ii)	requiring all users to enter a user identification and password prior to gaining access to the Infrastructure Systems;

(iii)

controlling and tracking user access in the manner specified in Annex C-5 to Schedule C; and

(iv)	controlling user access to areas and features of the Infrastructure Systems in the manner specified in Annex C-5 to Schedule C;

(c)

During the Term and the Termination Assistance Period, Supplier shall [______]*comply with the security requirements set forth in this Agreement, including this Section 17.3, and such other standard security policies of HWAY which may be incorporated into this Agreement pursuant to Change Control; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(d)

[______]*

(e)

In the event of an Information Breach, Supplier shall be solely responsible and liable for the following: (i) the cost of providing notice to affected individuals; (ii) the cost of providing notice to governmental and regulatory bodies, credit bureaus, and/or other required entities; (iii) the cost of providing affected individuals with credit monitoring services for a specific period not to exceed twenty-four (24) months or the time period provided by applicable Law, if longer; (iv) call center support for such affected individuals for a specific period not to exceed thirty (30) days or the time period provided by applicable law; and (v) any other notices or actions, including the costs associated therewith, as required by applicable Law.

17.4

Viruses»

17.4.1

Supplier shall not negligently introduce, or permit the negligent introduction by any of Supplier’s employees or agents, of any Virus into the Infrastructure Systems or Developed IP. Supplier shall also comply with the provisions of Annex C-5 to Schedule C as to Information Breaches caused by a Virus. Nothing in this Section 17.4.1 shall obligate Supplier to perform services in excess of the Supplier obligations set forth in Annex C-5 to Schedule C [______]*.

17.4.2

Without limiting Section 17.4.1 above, Supplier shall regularly check for and delete Viruses in the Infrastructure Systems and Developed IP.

17.4.3

Without limiting Supplier’s obligations set forth in this Section 17.4, if a Virus is found in the Infrastructure Systems or Developed IP, Supplier shall use all commercially reasonable efforts to mitigate the effects of such Virus upon the Services. If such Virus was introduced by Supplier in breach of Section 17.4.1, Supplier shall perform such mitigation efforts at no additional charge to HWAY for Supplier Personnel to assist HWAY in reducing the effects of the Virus and, to the extent that the Virus causes a loss of operational efficiency or a loss of data, to assist HWAY to restore such loss. If such Virus was not introduced by Supplier in breach of Section 17.4.1, HWAY shall be obligated to pay Supplier’s actual and reasonable expenses for such mitigation efforts performed by Supplier Personnel; provided, that if a Virus affects multiple customers of Supplier, Supplier shall equitably allocate any such expense between HWAY and other affected Supplier customers.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

17.4.4

Supplier shall not, without the prior written agreement of HWAY, insert or knowingly allow the insertion into the Software or Developed IP of any code which would have the effect of wrongfully disabling or otherwise wrongfully shutting down all or any portion of the Services or Developed IP. With respect to any disabling code that may be part of the Software, Supplier shall not invoke such disabling code at any time, including upon Termination of this Agreement, without HWAY’s prior written consent.

18. CONFIDENTIALITY

18.1	Protection of Confidential Information»

HWAY and Supplier each shall:

18.1.1

treat and protect as confidential all Confidential Information given by one Party (the “Disclosing Party”) to the other Party (the “Recipient”), or otherwise obtained by the Recipient, and shall not (except as expressly permitted by this Agreement or by the Disclosing Party in writing) disclose or use such Confidential Information, and shall prevent the unauthorized use, dissemination or publication of the Confidential Information;

18.1.2

implement the security controls against any unauthorized copying, use, disclosure, access, damage or destruction of the Disclosing Party’s Confidential Information required by Annex C-5 to Schedule C [______]*;

18.1.3

segregate all Confidential Information on Infrastructure Systems (including, without limitation, tape media, magnetic media, and all other mobile and print media) from the materials of all others not party to this Agreement, including without limitation any Confidential Information in electronic form, in order to prevent commingling;

18.1.4

enforce against any employees, agents, subcontractors or other representatives (and to assist the other Party to so enforce) any obligation of confidence imposed or required to be imposed by this Agreement; and

18.1.5

do all things, execute all documents and give all assistance reasonably required by the Disclosing Party to enforce any obligation of confidence imposed or required to be imposed by this Agreement.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

18.2	Use of Confidential Information»

Subject to Sections 18.3 and 18.4, the Recipient may only use and copy the Disclosing Party’s Confidential Information to the extent necessary:

18.2.1

to comply with its obligations under this Agreement; or

18.2.2

to enable the Recipient to exercise its rights under this Agreement.

18.3	Handling HWAY Information»

[______]*

18.4	Handling Supplier’s Confidential Information»

HWAY may:

18.4.1

use and disclose Supplier’s Confidential Information to receive and use the Services; and

18.4.2

use and disclose Supplier’s Confidential Information during the Termination Assistance Period following the Termination of this Agreement to the extent necessary to enable HWAY to transition the Services being received as of the Termination Date to HWAY or its new services provider; provided, that any use or disclosure to a third party shall be subject to a written confidentiality agreement that is substantially similar to the terms of this Agreement.

18.5	Exceptions to Obligations of Confidentiality»

18.5.1

Nothing in this Agreement shall prohibit the use, copying or disclosure by the Recipient of Confidential Information (other than the Source Code Materials and other Confidential Information subject to protection by Law) to the extent that:

(a)	such Confidential Information is publicly available other than through the fault of the Recipient or a person that was provided with the information by the Recipient;

(b)	such Confidential Information has been independently developed by the Recipient or its Affiliates without reference to any Confidential Information of the other Party;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(c)	the Disclosing Party has approved in writing the particular use or disclosure of the Confidential Information;

(d)	such Confidential Information is already known by the Recipient without an obligation of confidentiality; or

(e)	such Confidential Information is independently, lawfully and or properly received from a third party without an obligation of confidentiality.

18.5.2

Nothing in this Agreement shall prevent the Recipient from disclosing any Confidential Information where the disclosure is legally required to be disclosed by Recipient pursuant to judicial, regulatory, or governmental order, provided that the Recipient:

(a)	uses commercially reasonable efforts to minimize any such disclosure and, to the extent permitted by applicable law, assists the Disclosing Party in preventing or restricting the disclosure;

(b)	where practicable and permitted by applicable law, gives the Disclosing Party prompt written notice of such requirement to disclose to enable the Disclosing Party to seek an appropriate protective order; and

(c)	uses commercially reasonable efforts to require the recipient of such Confidential Information to preserve the confidential nature of the Confidential Information once disclosed.

18.6	Period of Confidentiality»

Subject to Section 18.8 hereof, the obligations with respect to Confidential Information disclosed under this Agreement shall survive Termination of this Agreement and continue in perpetuity.

18.7	Treatment of Source Code Materials

[______]*

18.8	Returning Material, Data and Information»

Upon a Party’s request, and, in any event, on Termination of this Agreement, the other Party shall promptly return all or any specified part of the Party’s Information and all physical and written records containing the Party’s Information, and all documentation relating to or concerning such Party’s Information (except, in either case, backup or archival copies that are not routinely accessible to personnel of such Party[______]* or, if requested by the Party, destroy or delete in the manner specified by the Party and promptly report such destruction in a writing certified by an officer of the other Party. Notwithstanding the foregoing, subject to Section 9 hereof, HWAY shall not be required to return that portion of Supplier’s Confidential Information to Supplier under this Section 18.8 if HWAY’s retention of such Confidential Information of Supplier is necessary for HWAY to perform services for its clients and End Users during or after the Term hereof.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

18.9	Equitable Remedies»

The Parties acknowledge that, due to the unique nature of Confidential Information, there can be no adequate remedy at Law for breach of this Section 18, and that such breach would result in immediate and irreparable harm to the Disclosing Party; therefore, in addition to whatever other remedies and/or recourse the Disclosing Party might have at Law or under this Agreement, the Disclosing Party shall be entitled to seek immediate injunctive relief to compel Recipient to cease and desist all unauthorized use and disclosure of the Disclosing Party’s Confidential Information.

19. REPRESENTATIONS AND WARRANTIES

19.1	Representations and Warranties by Supplier»

Supplier represents and warrants to HWAY that, with respect to the following (except for Section 19.1.7, which both Parties hereby expressly acknowledge that Supplier is only covenanting thereto):

19.1.1

Supplier’s signing, delivery and performance of this Agreement shall not:

(a)	constitute a violation of any Law, or of any judgment, order or decree of any court or governmental agency to which Supplier is a party or by which Supplier is bound;

(b)	constitute a violation, breach or default under any agreement by which Supplier or any of its assets (whether tangible or intangible) are bound (whether by charge, pledge, lien or otherwise); or

(c)	result in the termination, cancellation or acceleration (whether after the giving of notice, lapse of time, or both) of any contract by which Supplier or any of its assets (whether tangible or intangible) are bound (whether by charge, pledge, lien or otherwise);

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

19.1.2

Supplier has the requisite power, capacity and authority and all necessary licenses, permits and consents to enter into this Agreement and to carry out the obligations contemplated herein;

19.1.3

to the knowledge of Supplier, there is no pending or threatened litigation or other matters which may have a material adverse effect on this Agreement or on the ability of Supplier to carry out its obligations under this Agreement;

19.1.4

as of the Effective Date, Supplier is not aware of anything within its reasonable control which will or is likely to adversely affect its ability to fulfill its obligations under this Agreement;

19.1.5

Supplier has not violated any Laws applicable to Supplier or HWAY’s policies provided to Supplier’s Compliance Officer regarding the offering of unlawful inducements in connection with this Agreement;

19.1.6

the Services will be performed in a diligent, workmanlike and timely manner in accordance with high professional standards of Supplier’s industry, and each of the Supplier Personnel assigned to perform Services under this Agreement has the proper skill, training, education and background so as to be able to perform under this Agreement in a competent and professional manner (but this Section shall in no event be construed to alter any Service Level or other express performance standard, and HWAY acknowledges that all employees transferred by HWAY are so qualified);

19.1.7

the Services and the technology and processes proprietary to and utilized by Supplier in performance of the Services (including Supplier Materials, Pre-Existing Supplier Software and Supplier Developed Software), any deliverables provided by Supplier under this Agreement (including Developed IP but excluding any HWAY Material or third party material incorporated therein), or the use thereof by HWAY or any HWAY Affiliate, will not, to Supplier’s knowledge, violate, infringe or constitute misappropriation or unauthorized use of any Intellectual Property Rights of any third party; provided, that, with respect to any Third Party Software or products utilized in connection with the Services, Supplier provides no non-infringement warranty with respect thereto, but shall pass through any warranties provided by such third party software providers and shall notify HWAY in writing promptly upon knowledge of any infringement claim with respect to such Third Party Software and products;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

19.1.8

[______]*

19.1.9

the Service Charges were independently established by Supplier and proposed to HWAY without collusion with any third party; and

19.1.10

those Supplier Materials and documentation and materials created by Supplier that are reasonably necessary to understand, use, operate, access, support, perform, maintain and modify the Services, shall conform to and accurately describe the Services and be sufficient in scope and description to enable a reasonably skilled professional, trained in the Services to which such Supplier Materials relate, to understand, use, operate, access, support, perform, maintain and modify the Services.

Supplier acknowledges and agrees that its compliance with any or all of the warranties and representations contained in this Section 19.1 shall not of itself constitute performance of any of its other obligations under this Agreement.

19.2	Representations and Warranties By HWAY»

HWAY represents and warrants to Supplier that with respect to the following (except for Section 19.2.5, which both Parties hereby expressly acknowledge that HWAY is only covenanting thereto):

19.2.1

HWAY’s signing, delivery and performance (including receipt of Services) of this Agreement shall not:

(a)	constitute a violation of any Laws, or of any judgment, order or decree of any court or governmental agency to which HWAY is a party or by which HWAY is bound;

(b)	constitute a violation of any Law, or of any judgment, order or decree of any court or governmental agency to which HWAY is a party or by which HWAY is bound;

(c)	constitute a material violation, breach or default under any agreement by which HWAY or any of its assets (whether tangible or intangible) are bound (whether by charge, pledge, lien or otherwise); or

(d)	to the knowledge of HWAY, result in the termination, cancellation or acceleration (whether after the giving of notice, lapse of time, or both) of any material contract by which HWAY or any of its assets (whether tangible or intangible) are bound (whether by charge, pledge, lien or otherwise);

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

19.2.2

to the knowledge of HWAY, there is no pending or threatened litigation or other matters which may have a material adverse effect on this Agreement or on the ability of HWAY to carry out its obligations under this Agreement;

19.2.3

as of the Effective Date, HWAY is not aware of anything within its reasonable control which will or is likely to adversely affect its ability to fulfill its obligations under this Agreement;

19.2.4

HWAY has the requisite power, capacity and authority to enter into this Agreement and to carry out the obligations contemplated therein; or

19.2.5

to the knowledge of HWAY, the technology and processes proprietary to and utilized by HWAY in performance of its obligations hereunder (including HWAY Materials and HWAY Software), or the use thereof by HWAY or any HWAY Affiliate, will not, to HWAY’s knowledge, violate, infringe or constitute misappropriation or unauthorized use of any Intellectual Property Rights of any third party; provided, that, with respect to any Third Party Software or products utilized in connection with HWAY’S obligations hereunder, HWAY provides no non-infringement warranty with respect thereto, but shall pass through any warranties provided by such third party software providers and shall notify Supplier in writing promptly upon knowledge of any infringement claim with respect to such Third Party Software and products.

HWAY acknowledges and agrees that compliance by it with the warranties and representations contained in this Section 19.2 (or any of them) shall not of itself constitute performance of any of its other obligations under this Agreement.

19.3	Compliance with Laws»

19.3.1

[______]*

19.3.2

Subject to the terms hereof and Section 19.3.3, Supplier represents and warrants that it shall be solely responsible for and shall obtain all filings, notifications and registrations, and shall be solely responsible for identifying and procuring permits, certificates, approvals and inspections as are required by Laws to perform its other obligations under this Agreement.

19.3.3

Subject to the terms hereof and Section 19.3.2, HWAY represents and warrants that it shall be solely responsible for and shall obtain all filings, notifications and registrations, and shall be solely responsible for identifying and procuring permits, certificates, approvals and inspections as are required by Laws to perform its obligations under this Agreement.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

19.4	No Additional Representations and Warranties »

The Materials, Equipment, Software, HWAY Facilities, Assigned Contracts, HWAY Information and other assets or resources to be transferred, licensed, provided or otherwise made available by HWAY to Supplier under this Agreement (collectively, the “HWAY Assets”) shall be transferred, licensed, or otherwise provided on an “AS IS” and “WHERE IS” basis, and Supplier acknowledges and accepts that, to the extent permitted by Law, no representation or warranty (whether express or implied) is, has been or will be made or given, by or on behalf of HWAY with respect to:

(a)	the condition, state of repair, design, quality, non-infringement or fitness for purpose of any of HWAY Assets; or

(b)	the accuracy, completeness, currency, design, suitability or efficacy of any of the Materials or HWAY Information provided by HWAY.

NO WARRANTY OR CONDITION, WRITTEN OR ORAL, IS EXPRESSED OR IMPLIED BY SUPPLIER OR MAY BE INFERRED FROM A COURSE OF DEALING OR USAGE OF TRADE.

20. INDEMNITIES

20.1	Indemnity by Supplier»

[______]*

20.1.1

[______]*

20.1.2

[______]*

20.1.3

[______]*

20.1.4

[______]*

20.1.5

any Claim relating to Supplier’s failure to perform the Services in a diligent, workmanlike and timely manner in accordance with high professional standards of Supplier’s industry, or a failure of the Supplier Personnel assigned to perform Services under this Agreement to have the proper skill, training, education and background so as to be able to perform under this Agreement in a competent and professional manner;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

20.1.6

any Claim relating to Supplier’s violation or alleged violation of any Laws applicable to Supplier, or HWAY Anti-Corruption Policies, regarding the offering of unlawful inducements in connection with this Agreement;

20.1.7

any Claim for death or personal injury caused by a wrongful, willful or negligent act or omission of Supplier[______]*

20.1.8

any Claim relating to Supplier’s breach of or failure to observe or perform any duties or obligations to be observed or performed by Supplier under the Assigned Contracts after the date of assignment (to the extent that such Assigned Contract has been delivered fully in writing to Supplier by the date of assignment);

20.1.9

any Claim relating to Supplier’s failure to manage the Retained Contracts in the manner required in this Agreement, after the date Supplier commences management thereof, or the failure to obtain any consent for which Supplier is responsible;

20.1.10

except to the extent HWAY has the obligation to indemnify Supplier under this Agreement, any Claim by a transitioned HWAY employee relating to the Services or this Agreement arising on or after the date such transitioned employee became an employee of Supplier; and/or

20.1.11

[______]*

20.2	Indemnity by HWAY»

Subject to Sections 20.1 and 20.4, and as further provided therein, HWAY shall indemnify, defend and hold Supplier, Supplier’s Affiliates and their respective officers, directors, employees, agents, successors, and assignees harmless from and against any Losses from third party claims arising from any of the following:

20.2.1

any Claim for loss of or damage to real or tangible personal property caused by the negligence or willful misconduct of HWAY[______]*

20.2.2

any Claim for death or personal injury caused by a wrongful, willful or negligent act or omission of HWAY[______]*

20.2.3

any Claim that HWAY has breached its confidentiality or security obligations under this Agreement;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

20.2.4

any Claim that HWAY[______]* failed to observe or perform any duties or obligations to be observed or performed by such parties relating to:

(a)	the Assigned Contracts before the date of assignment to Supplier in accordance with this Agreement; or

(b)	the Retained Contracts before the date of grant of rights to Supplier as set forth in this Agreement; or

20.2.5

[______]*

20.2.6

any fine or other penalty imposed by Laws or by any governmental agency arising as a result of any breach of any such Law by HWAY[______]*;

20.2.7

any contravention of Laws by HWAY[______]* or by any other third party acting on behalf of HWAY;

20.2.8

[______]*

20.2.9

[______]*

20.3	Anticipation of Infringement»

If any item [______]* used by a Party to perform its obligations hereunder becomes, or in such Party’s reasonable opinion is likely to become, the subject of a Claim, such Party shall, at its own expense (except for any expense attributable to one or more of the exceptions to the Party’s indemnification obligations, which shall be at the other Party’s expense) and in addition to its obligation to indemnify (or right to be indemnified) and the other rights either Party may have under this Agreement, promptly either:

20.3.1

obtain the right for the item to continue to be used on terms which are acceptable to the other Party;

20.3.2

if the right described in Section 20.3.1 cannot be obtained with Diligent Efforts, replace or Modify the item to make it non-infringing, provided that any such replacement or Modification shall not materially degrade the performance, functionality or quality of the affected component;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

20.3.3

if neither the right described in Section 20.3.1 can be obtained nor the replacement or modification described in Section 20.3.2 can be accomplished with Diligent Efforts, remove the infringing item and substitute an alternative for the obligation affected by such removal, provided that such substitution shall be effected only pursuant to the terms of Section 15 and provided further that the Service Charges shall be equitably adjusted to reflect any changes in performance or functionality; or

20.3.4

subject to prior written notice to the other Party, remove the item if none of the remedies in Sections 20.3.1 through 20.3.3 can be accomplished with Diligent Efforts, and the Service Charges shall be equitably reduced to reflect such removal and the effect thereof; provided, that in the event such removal materially and adversely affects the rights of HWAY or the Services hereunder, HWAY shall have the right to terminate this Agreement in accordance with Section 26.1.1 hereof.

20.3.5

Notwithstanding the foregoing, if HWAY determines that any such removal would present a material risk with respect to security or member care or would cause any violation of any Law, Supplier shall not remove the item unless HWAY agrees in writing to such removal; provided, however, that in the event HWAY exercises this right, Supplier shall have no further liability to HWAY to the extent that such liability could have been avoided by such removal and HWAY shall indemnify Supplier for any and all third party claims to the extent liability arises or continues as a result of compliance by Supplier with this Section 20.3.5.

20.4	Indemnification Procedures»

20.4.1

The indemnified Party (the “Indemnified Party”) shall give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for indemnification under this Section 20, but in no event shall the Indemnifying Party be liable for any Damages that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a reasonable description of the claim and the nature and amount of such Losses (to the extent that the nature and amount of such Losses are known at such time). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received with respect to any Losses. All indemnification claims with respect to a Party or its Affiliates, or their respective trustees, officers, directors, employees, agents, successors, and assignees (collectively, the “Indemnitees” and each an “Indemnitee”), shall be made solely by such Party to this Agreement.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

20.4.2

The obligations of an Indemnifying Party with respect to Losses arising from claims of any third party that are subject to indemnification as provided for in this Section 20 (a “Third Party Claim”) shall be governed by the following additional terms and conditions:

(a)

at its option, the Indemnifying Party may assume and control the defense of any Third Party Claim by giving written notice to the Indemnified Party within thirty (30) days after the Indemnifying Party’s receipt of an Indemnification Claim Notice. In the event that HWAY reasonably determines that the Claim, or defense of the Claim, includes or introduces a material liability with respect to or allegation or possibility of HWAY’s compliance with Laws, HWAY may assume the control of the defense of such Claim at its own expense; provided, however, that in assuming such control, (i) HWAY shall confer with Supplier on a regular basis, (ii) HWAY shall reasonably consider input from Supplier, and (iii) Supplier shall have no obligation to pay any Losses under any settlement agreement or other consensual disposition of such Claim agreed by HWAY without Supplier’s consent. The assumption of the defense of a Third Party Claim by the Indemnifying Party shall not be construed as an acknowledgment that the Indemnifying Party is liable to indemnify any Indemnitee with respect to the Third Party Claim, nor shall it constitute a waiver by the Indemnifying Party of any defenses it may assert against any Indemnitee’s claim for indemnification. Upon assuming the defense of a Third Party Claim, the Indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the Indemnifying Party. In the event the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall promptly deliver to the Indemnifying Party all original notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. Should the Indemnifying Party assume and maintain the defense of a Third Party Claim, except as provided in Section 20.4.2(b) below, the Indemnifying Party shall not be liable to the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)

without limiting Section 20.4.2(a) above, any Indemnitee shall be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnitee’s own expense unless (x) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (y) the Indemnifying Party has failed to assume and maintain the defense and employ counsel in accordance with Section 20.4.2(a) above (in which case the Indemnified Party shall control the defense). If (i) the Indemnified Party and the Indemnifying Party are both named parties to the proceeding, and (ii) the Indemnified Party has reasonably concluded that the Indemnifying Party has a material conflict of interest in connection with the control of such defense or that there are one or more legal defenses that are different from or in addition to those available to the Indemnifying Party which counsel to the Indemnifying Party reasonably determines cannot be advanced on behalf of the Indemnified Party by counsel for the Indemnifying Party under applicable standards of professional conduct, the Indemnified Party shall have the right to participate in the defense of such action with counsel of its own choice at its own expense; provided, however, that in assuming such control, (i) the Indemnified Party shall confer with Indemnifying Party on a regular basis, (ii) the Indemnified Party shall reasonably consider input from the Indemnifying Party, and (iv) the Indemnifying Party shall have no obligation to pay any Losses under any settlement agreement or other consensual disposition of such Claim agreed by the Indemnified Party without the Indemnifying Party’s consent;

(c)

with respect to any Losses relating solely to the payment of money damages in connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in a material manner, and as to which the Indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses, on such terms as the Indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 20.4.2(a) above, the Indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Losses. The Indemnifying Party shall not be liable for any settlement or other disposition of Losses by an Indemnitee that is reached without the written consent of the Indemnifying Party (which consent shall not be unreasonably withheld or delayed). Regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, no Indemnitee shall admit any liability or wrong doing with respect to, or settle, compromise or discharge, any Third Party Claim without the prior written consent of the Indemnifying Party; and

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(d)

regardless of whether the Indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall, and shall cause each other Indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and the Indemnifying Party shall reimburse the Indemnified Party for all its reasonable Out-of-Pocket Expenses in connection therewith.

21. LIMITATION OF LIABILITY

[______]*

22. INSURANCE AND RISK

22.1	Insurance Coverage»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

22.1.1

During the Term of this Agreement, Supplier shall maintain, at Supplier’s expense, insurance coverage (and such other insurance coverage required by Law) which shall include:

(a)	Commercial General Liability insurance with limits not less than [______]* per occurrence and [______]* General Aggregate;

(b)	Workers Compensation insurance as may be from time to time required under the applicable laws of the state(s) or country in which the Services are performed;

(c)	Technical Errors and Omissions insurance with limits of [______]*;

(d)	Automobile Liability insurance with limits of not less than [______]* per occurrence covering owned and non-owned vehicles;

(e)	Property Insurance to cover Supplier’s risk of loss under Section 22.3;

(f)	Employer’s Liability insurance with limits of [______]* each accident, [______]* disease—policy limit, and [______]* disease—each employee;

(g)	Excess Liability insurance (excess of the primary Commercial General Liability, Automobile Liability, and Employer’s Liability policies), with limits not less than [______]* each occurrence and aggregate; and

(h)	any other insurance required for Supplier to comply with Laws applicable to Supplier.

22.1.2

This Section 22.1 shall not be construed as to constitute acceptance by HWAY of any responsibility for liability in excess of the insurance coverage contemplated herein.

22.1.3

If Supplier fails to maintain insurance coverage as contemplated in this Section 22.1, in addition to any other remedies available to HWAY under this Agreement or at law, HWAY shall give notice to Supplier of such default, and if not remedied by Supplier within seven (7) days of receipt of such notice, HWAY shall be entitled to procure such insurance at Supplier’s expense. All reasonable sums paid by HWAY for such insurance shall immediately become due and payable to HWAY and HWAY shall be entitled to deduct such sums from any monies due or becoming due to Supplier.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

22.2	Terms of Insurance»

Supplier shall:

22.2.1

provide HWAY with certificates or evidence of insurance for each of the insurance policies set forth in Section 22.1;

22.2.2

require its insurer to endeavor to provide HWAY at least thirty (30) days’ prior written notice of its intention to cancel the policy for any reason;

22.2.3

take out insurance policies that are primary and without any right of contribution by HWAY or any insurance affected by HWAY;

22.2.4

be solely responsible, in the case of loss or damage or other event that requires notice or other action under the terms of any insurance coverage specified in Section 22.1, to take such action;

22.2.5

comply with the insurance policies taken out to provide the coverage contemplated in Section 22.1; and

22.2.6

ensure that HWAY is named as loss payee on the Property Insurance, as HWAY’s interests may appear, and as an additional insured under the Commercial General Liability Insurance taken out to provide the coverage contemplated in Section 22.1.

22.3	Risk of Loss and Damage»

Supplier shall be responsible for the risk of loss of, and damage to, property of HWAY (or its supplier or vendor) in the care, custody, or control of Supplier, unless such loss or damage was proximately caused by the negligent or intentional acts or omissions of HWAY or any of its agents. HWAY is responsible for the risk of loss of, or damage to, property of Supplier at HWAY Facilities, unless such loss or damage was proximately caused by the negligent or intentional acts or omissions of Supplier [______]*. The risk of loss of, or damage to, property in transit will remain with the Party arranging shipment.

22.4	Coverage Remaining In Effect»

Supplier shall maintain in effect, during the Term and for a period of one (1) year thereafter, the Professional Liability Insurance required hereunder and if, for any reason, such policy insurer cancels or fails to renew the policy, Supplier shall immediately purchase a replacement policy containing substantially the same terms as such policy and including a Prior Acts Coverage Endorsement effective from the Effective Date or a run-off “tail” policy effective for a period of one (1) year following the Termination of this Agreement.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

23. FORCE MAJEURE

23.1	Force Majeure Events»

23.1.1

Neither Party (“Non-Performing Party”) shall be liable for any breach, or delay in performance, of its obligations under this Agreement if, and to the extent that:

(a)	the breach or delay is directly caused by:

(i)	fire, flood, earthquake or act of God;

(ii)	war, riot, civil disorder or revolution;

(iii)

industry-wide strikes, lock-outs or labor disputes; or

(iv)	other events beyond the Non-Performing Party’s reasonable control; and

(b)	such breach or delay:

(i)	is not the fault of the Non-Performing Party; and

(ii)	could not have been prevented by the Non-Performing Party taking reasonable precautions,

(a “Force Majeure Event”).

23.1.2

Notwithstanding the foregoing, the Parties shall, upon the occurrence of a Force Majeure Event:

(a)	promptly implement and adhere to their respective obligations under Schedule N [______]* or another disaster recovery plan agreed by the Parties in writing;

(b)	diligently pursue all actions necessary and practicable to restore performance being affected by the Force Majeure Event as expeditiously as possible; and

(c)	use commercially reasonable efforts to otherwise attempt to mitigate the damages in time, cost, and other losses caused by the Force Majeure Event.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

For purposes of clarification, except as set forth in Section 23.1.5(b), a Force Majeure Event shall not relieve Supplier of its obligations under this Agreement with respect to implementation and performance of the Disaster Recovery Plan.

23.1.3

Upon the occurrence of a Force Majeure Event:

(a)	the Non-Performing Party shall promptly notify the other Party of the occurrence of the Force Majeure Event, describing the circumstances causing such delay of performance to a reasonable level of detail, and giving an estimate of when performance will recommence; and

(b)

the Non-Performing Party shall perform (or recommence performing) its obligations as soon as, and to the extent, possible, including through the use of alternative sources (subject to Section 23.4 hereof), workarounds, plans and, in the case of Supplier, subject to the terms herein, complying with its obligations, if any, to perform disaster recovery services as described in Schedule N [______]*.

23.1.4

For the duration of the Force Majeure Event, Supplier’s performance under the Services Agreements shall be extended for so long as such performance is prevented by the circumstance of the particular Force Majeure Event.

23.1.5

[______]*

23.2	Allocation of Resources»

23.2.1

If a Force Majeure Event affecting HWAY causes Supplier to allocate limited resources between Supplier’s customers, Supplier shall allocate the same resources to HWAY as Supplier allocates to any other similarly affected customer receiving the same or substantially similar services (except to the extent that Supplier is contractually or legally obligated to perform more extensive disaster recovery services for other customers).

23.2.2

Supplier shall not redeploy or reassign any person ordinarily assigned to HWAY’s account on a full-time basis to another customer in the event of a Force Majeure Event, but may temporarily redeploy persons or reassign such persons, other than Key Supplier Positions, to assist another customer in the event of a Force Majeure Event that is not affecting HWAY.

23.3	[______]* »

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

23.4	[______]* »

23.5	No Compensation

In the event that Supplier fails to perform any of the Services due to a Force Majeure Event affecting the Services, HWAY shall only be obligated to pay for such Services that Supplier actually provides in accordance with the terms hereof. Supplier shall not have the right to any additional payments from HWAY as a result of any Force Majeure Event affecting a facility owned or leased by HWAY, its Affiliates or the performance of its obligations under this Section 23 with respect to Services provided from such facility, except as set forth in Schedule D [______]*. Notwithstanding the foregoing, and solely to the extent not addressed in the Disaster Recovery Plan, HWAY shall reimburse Supplier for travel, lodging, meals and other out-of-pocket expenses incurred as a result of a Force Majeure Event affecting a facility owned or leased by HWAY or its Affiliates. »

24. INFORMAL DISPUTE RESOLUTION

The parties desire to avoid litigation with respect to disputes, controversies or claims concerning, arising out of or relating to this Agreement (“Disputes”) wherever practicable and therefore agree that any such Dispute between the Parties will be resolved as provided in this Section 24.

24.1	Dispute Resolution»

24.1.1

Subject to Section 24.1.2 and Section 24.3 below, the Parties will attempt to resolve Disputes using the informal Dispute resolution procedure as set forth in this Section 24.1.

24.1.2

Nothing in this Section 24.1 will, at any time while the informal Dispute resolution procedures as set forth in this Section 24.1 are in progress or before or after they are invoked, restrict either Party’s right to remedy or to protect confidentiality or any Intellectual Property or trade secret right, or prevent any violations of Law.

24.1.3

Disputes shall be referred to the [______]* who shall use good faith efforts to resolve the Dispute.

24.1.4

Disputes that cannot be resolved by the [______]* shall follow the procedures as set out below:

(a)	Upon the written request of a Party, each Party will appoint a designated representative who does not devote substantially all of his or her time to performance under this Agreement, whose task it will be to meet for the purpose of endeavoring to resolve such Dispute.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)

The designated representatives will hold an initial meeting within five (5) business days of the request to attempt to resolve the Dispute and thereafter meet as often as the Parties reasonably deem necessary in order to gather and furnish to the other all information with respect to the matter in issue that the Parties believe to be appropriate and germane in connection with its resolution. The representatives will discuss the problem and attempt to resolve the Dispute without unreasonable delay and without the necessity of any formal proceeding. The Parties will seek to reach a resolution of the Dispute as expeditiously as practicable.

(c)	During the course of discussion, all reasonable requests made by either Party for non-privileged information reasonably related to this Agreement will be honored in order that each of the Parties may be fully advised of the other’s position.

(d)	The specific format for reaching a negotiated resolution will be left to the reasonable discretion of the Parties, but may include the preparation and submission of statements of fact or of position.

24.1.5

Each Party agrees to continue performing its obligations under this Agreement while a Dispute is being resolved, except to the extent the issue in dispute precludes performance and without limiting either Party’s right to terminate this Agreement as provided in Section 26.

24.2	Referral to Steering Committee and Executive Officers»

If the Dispute has not been resolved as a result of the procedure in Section 24.1 within thirty (30) days of the meeting described in Section 24.1.4(b) or, in disputes involving payment of Charges within ten (10) days of the meeting described in Section 24.1.4(b), either Party may submit the Dispute to resolution by the Steering Committee in accordance with Section 14.3 hereof.

If the Steering Committee has not resolved the matter within thirty (30) days of referral or, in disputes involving payment of Charges, within ten (10) days of referral, then any Steering Committee member may present the Dispute, in the case of HWAY to the [______]* and, in the case of Supplier, to the [______]* for resolution.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

If the Parties’ respective executive officers provided for above are unable to agree upon a resolution within ten (10) days of the date of presentation to them, then either Party may pursue its rights in a court of competent jurisdiction.

24.3	Special Procedure Following a Notice of Termination»

If a Party has delivered a notice of termination of this Agreement as a whole as provided herein, [______]* (or the relevant individuals holding similar positions) shall meet within fourteen (14) days after the date of such delivery for the purpose of defining the scope of the Dispute, if any, that may be referred to formal dispute resolution. Such executives may include as attendees at such meeting a reasonable number of business managers and/or legal or other advisors as he or she requires to assist in the purpose of such meeting, provided that notice of such attendees is provided three (3) business days in advance of the meeting.

24.4	Equitable Relief»

Each Party shall be entitled to seek equitable relief against the other Party (in addition to any other rights available under this Agreement or at Law) for any breaches of its obligations under this Agreement.

25. [______]*

25.1.1

26. TERMINATION

26.1	Termination for Cause or Bankruptcy»

26.1.1

Without prejudice to any other rights or remedies it may have, HWAY, by giving written notice to Supplier, may terminate this Agreement in whole or on a Service Sub-Tower basis, as of the date specified in the notice of termination (as the same may be amended in accordance with Section 26.5) if any of the following circumstances occur or exist:

(a)

Supplier commits a material breach of this Agreement, which breach is not cured within thirty (30) days after written notice of the breach from HWAY to Supplier; provided that if such breach is not capable of being cured within thirty (30) days HWAY shall not have the right to terminate this Agreement, in whole or in part, provided that all of the following are met: (A) Supplier proposes, for HWAY’s approval, which shall not be unreasonably withheld, a plan to cure such breach, (B) Supplier diligently pursues such plan, and (C) Supplier cures such material breach within ninety (90) days of the original notice of breach from HWAY; or

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(b)	Supplier commits a material breach of this Agreement which is not capable of being cured;

(c)

Supplier commits repeated breaches of its obligations under this Agreement (whether of the same or different obligations and regardless of whether these breaches are cured) within a rolling twelve (12)-month period, the cumulative effect of which is a material breach of this Agreement and fails to cure such breaches within thirty (30) days after receipt of notice from HWAY of the occurrence of an aggregated material breach; or

(d)	Supplier fails to meet (i) the Minimum Service Level for the [______]* (ii) the Minimum Service Level for the [______]* or (iii) the Minimum Service Level for the [______]*.

26.1.2

Either Party may immediately terminate this Agreement by giving written notice to the other Party in the event that:

(a)	a voluntary or involuntary petition is filed for protection of the other Party under the United States Bankruptcy Code which, in the case of an involuntary petition, is not dismissed within ninety (90) days; or

(b)	the other Party ceases, or threatens to cease, to carry on business or trade.

26.1.3

If this Agreement is terminated in part pursuant to Section 26.1.1, the Service Charges shall be equitably adjusted with effect from the Termination Date taking into account (a) the portion of the Services that (i) prior to such termination, were provided as part of a terminated Service Agreement and (ii) after such termination are necessary to the performance of the remaining Service Agreements, and (b) any increase in the effort to provide the Services under the remaining Service Agreements resulting from such termination, subject to Schedule D [______]*

26.2	Termination for Convenience by HWAY»

26.2.1

HWAY, by giving one hundred eighty (180) days prior written notice to Supplier, may terminate this Agreement or a portion of the Services after the second anniversary of the Effective Date for convenience, as of the date specified in the notice of Termination (as the same may be amended in accordance with Section 26.5).

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

26.2.2

If HWAY terminates this Agreement or part of the Services pursuant to Section 26.2.1:

(a)

[______]*

(b)

[______]*

(c)

[______]*

(d)	Supplier shall provide Termination Assistance in relation to any removed Services (or part thereof) in accordance with Schedule M [______]* or as otherwise reasonably requested by HWAY.

26.3	Termination for Change of Control»

26.3.1

HWAY, by giving written notice to Supplier, may terminate this Agreement as of the date specified in the notice of Termination (as the same may be amended in accordance with Section 26.5) if Supplier undergoes a Change of Control, provided that such right of Termination shall only be exercisable if HWAY gives written notice of such Termination within six (6) months of completion of the relevant transaction. Notwithstanding any other provision of this Agreement, Supplier shall provide prompt notice to HWAY in the event of a Change of Control of Supplier, and in such event, the six (6)-month period in which HWAY has a right to exercise Termination in accordance with this Section 26.3.1 shall not commence until receipt of such notice from Supplier.

26.3.2

If HWAY terminates this Agreement pursuant to Section 26.3.1:

(a)

[______]*

(b)

[______]*

(c)

[______]*

(d)

[______]*

26.4	Termination by Supplier for Non-Payment and for Cause»

26.4.1

[______]*

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

26.4.2

Subject to Section 26.4.3 below, Supplier, by giving written notice to HWAY, may terminate this Agreement as of the date specified in the notice of Termination, which date shall not fall before the expiration of the twenty (20)-day period described in Section 26.4.3 below, if HWAY knowingly or willfully breaches: (i) Section 18 of this Agreement in any material respect with respect to Supplier’s Confidential Information; or (ii) Supplier’s intellectual property rights.

26.4.3

Supplier shall not terminate the Agreement in accordance with Sections 26.4.1 or 26.4.2 above unless Supplier has given HWAY:

(a)	twenty (20) days of notice of HWAY’s failure to make such payment or material breach of Section 18 hereof and HWAY fails to cure such breach within such twenty (20)-day period; and

(b)	a further written notice to HWAY’s Chief Executive Officer, Chief Financial Officer, Chief Information Officer and Chief Counsel delivered not less than ten (10) days prior to the expiration of the twenty (20) day period referred to in Section 26.4.2 above.

26.4.4

[______]*

26.4.5

If Supplier properly terminates this Agreement pursuant to this Section 26.4:

(a)	HWAY shall pay to Supplier the amount specified in Schedule D [______]*, which shall have been calculated as of the Termination Date;

(b)

[______]*

(c)	HWAY’s total liability to Supplier for Charges arising from such Termination shall be limited to the applicable amounts specified [______]*; and

(d)	Supplier shall provide Termination Assistance in relation to any removed Services (or part thereof) in accordance with Schedule M [______]*.

Supplier acknowledges and agrees that Sections 26.1.2, 26.4.1, 26.4.2, and 26.4.4 set forth the sole and exclusive grounds upon which Supplier may terminate this Agreement.

26.5	Effective Date of Termination»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

HWAY may extend the termination date in any notice of termination given by HWAY in accordance with this Section 26 one or more times, provided that the total of such extensions shall not exceed twelve (12) months from the date the notice of termination was given.

26.6	Termination Charges»

Any termination by HWAY shall not result in the payment of any termination fee or other additional termination charges except as may be (i) specified in Schedule D [______]* or (ii) in connection with Termination Assistance.

26.7	Equitable Remedies»

Due to the critical nature of Termination Assistance to HWAY as provided for in Section 26, there can be no adequate remedy at Law for breach of Supplier’s obligation to provide such assistance, and that such breach may result in immediate and irreparable harm to HWAY; therefore, in addition to whatever other rights and remedies HWAY might have at Law or under this Agreement, HWAY shall be entitled to immediate injunctive relief to compel such assistance. Supplier waives any defense to the effect that monetary damages are an adequate remedy for any such breach or threatened breach, but otherwise reserves all rights. HWAY acknowledges that any order compelling performance of Termination Assistance may be conditioned upon payment of undisputed Charges for all Services including Termination Assistance, or, in the case of termination by Supplier, prepayment.

26.8	Termination Assistance»

Commencing on the earlier of:

26.8.1

[______]* prior to expiration of this Agreement; or

26.8.2

upon any notice of termination of this Agreement (or any part of this Agreement), (including a termination notice given by Supplier pursuant to Section 26.2 of this Agreement);

and for a period of [______]* following the termination date, and as the Parties may mutually agree to extend such period, Supplier shall provide to HWAY, or at HWAY’s request, to the Successor Supplier, the reasonable termination assistance requested by HWAY to allow the Services to continue without interruption or adverse effect and to facilitate the orderly transfer of the Services to HWAY or the Successor Supplier, including the termination services set forth in Schedule M [______]*. If this Agreement is terminated by Supplier for non-payment by HWAY under Section 26.4.1 hereof, Supplier shall only be required to provide Termination Assistance if HWAY pays all amounts due and owing and prepays at least six (6) months’ fees for Services and Termination Assistance as reasonably estimated by Supplier. Supplier shall perform Termination Assistance using its then existing resources dedicated to providing Services under this Agreement. To the extent that resources additional to those then dedicated to providing the Service are needed, Supplier shall provide such resources on a time and materials basis at Supplier’s then current rates.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

26.9	Accrued Rights»

Termination or expiration of this Agreement shall not affect any accrued rights of either Party.

26.10

Survival of Terms»

The following terms shall survive the Termination of this Agreement and the Termination Assistance Period: [______]*; and such Schedules (or portions thereof, including Annexes and Exhibits) as necessary to describe or interpret such surviving provisions of this Agreement and/or the Parties’ respective rights and obligations thereunder.

27. GENERAL

27.1	Non-Solicitation»

During the Term and for a period of twelve (12) months after the later of the Termination Date or the completion of the Termination Assistance Period, neither Party shall directly or indirectly solicit or attempt to solicit, without the prior written consent of the other Party, (i) in the case of HWAY, Supplier Personnel employed or engaged in the provision of the Services at the date of such solicitation or attempted solicitation or who have been so employed or engaged during the preceding twelve (12) months, and (ii) in the case of Supplier, HWAY Personnel employed or engaged in the provision of its information systems at the date of such solicitation or attempted solicitation or who have been so employed or engaged during the preceding twelve (12) months. For the purposes of this Section 27.1, “solicit” means an approach by a Party or a third party on its behalf to an individual with a view to employ or engage or procure the employment or engagement of such person as an employee, director, officer or independent contractor or consultant, other than by way of general advertising. For the purposes of this Section 27.1, “solicit” does not include indirect or non-targeted communications such as advertisements in newspapers, trade press, or on the Internet.

27.2	Use of Name; Public Statement»

27.2.1

Neither Party may use the name, logo or corporate identity of the other Party for advertising or publicity without the prior written consent of the entity whose name, logo or corporate identity is proposed to be used. For HWAY, this includes the name, logo and corporate identity of HWAY. For Supplier this includes the name, logo and corporate identity of Supplier, including without limitation, the name.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.2.2

Notwithstanding the provisions of this Section 27.2, nothing contained herein shall preclude either Party from using the other Party’s name:

(i)	in order to comply with applicable Law,

(ii)	in a public announcement, news release, advertising, or promotional literature, provided that the same shall have been first approved in writing by the other Party, approval not to be unreasonably withheld,

(iii)

for purposes of describing this Agreement to licensing and accrediting bodies, or

(iv)	for communications necessary in rendering member care, whether such communications are with physicians, members or other health care providers.

27.2.3

Without limiting the applicability of Section 27.2.2 (ii-iv), in no event shall Supplier identify HWAY as a Supplier client for publicity or advertising purposes in and publications and advertisements without HWAY’s prior written consent, and Supplier shall submit to HWAY any advertising, written sales promotions, press releases, public announcements and other marketing or publicity material relating to this Agreement in which the HWAY name or other corporate logo or trademark of HWAY or its Affiliates is mentioned or which contains language from which the connection of said name, logo or trademark may be inferred or implied (“Publicity Material”).

27.3

Notices»

All notices, requests, and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficiently given, served, and received for all purposes upon the first to occur of (a) actual receipt; (b) delivery by a generally recognized overnight courier service; (c) facsimile transmission (with the original subsequently delivered by other means permitted by this Agreement, although the effective date of such notice shall be the date of such facsimile transmission provided the original is subsequently delivered as provided herein); or (d) three (3) days after deposit in the United States Mail, certified or registered, return receipt requested, with postage prepaid, addressed as follows:

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

If to HWAY:

Healthways, Inc.

[______]*

701 Cool Springs Blvd.

Franklin, TN 37067

[______]*

With a copy to (which shall not constitute notice):

Healthways, Inc.

[______]*

701 Cool Springs Blvd.

Franklin, TN 37067

[______]*

Healthways, Inc.

[______]*

701 Cool Springs Blvd.

Franklin, TN 37067

[______]*

Bass, Berry & Sims PLC

[______]*

150 Third Avenue South, Suite 2800

Nashville, TN 37201

[______]*

If to Supplier:

HP Enterprise Services, LLC

[______]*

248 Chapman Road

Newark, DE 19702

[______]*

With a copy to:

HP Enterprise Services, LLC

[______]*

5400 Legacy Drive

Plano, TX 75024

[______]*

Or at such other address(s) set forth in any written notice delivered to the other Party.

27.4	Relationship of Parties»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.4.1

Supplier, in furnishing the Services, will be acting as an independent contractor. Nothing in this Agreement shall create any relationship of agent and principal, partnership, or employer and employee between the Parties or between one of the Parties and the other Party’s personnel, agents, employees or subcontractors.

27.4.2

Nothing in this Agreement shall give either Party any authority to act or make representations or commitments on behalf of the other Party or to create any contractual liability to a third party on behalf of the other Party.

27.5	No Security Interest»

Supplier shall not give or purport to give any security interest in any of its rights to receive payment from HWAY under this Agreement without HWAY’s prior written consent which HWAY may withhold in its discretion.

27.6	Waivers, Consents and Approval»

27.6.1

The failure of any Party to insist upon strict performance of any provision of this Agreement, or the delay or failure of any Party to exercise any right to which it is entitled hereunder, shall not constitute:

(a)	a waiver or diminution of that right or any other right hereunder; or

(b)	a waiver with respect to any subsequent breach by the other Party.

27.6.2

A waiver by any Party of any of the terms of this Agreement shall not be effective unless it is expressly stated in writing and executed by the duly Authorized Representative of such Party.

27.6.3

The waiver by any Party of a breach or default of any of the provisions of this Agreement by the other Party shall not be construed as a waiver with respect to any subsequent breach of the same or other provisions, unless expressly stated by the waiving Party in writing.

27.6.4

Any consent given by a Party under this Agreement shall not relieve the other Party from responsibility for complying with the requirements of this Agreement, nor shall it be construed as a waiver of any rights under this Agreement, except as, and to the extent, expressly so provided in such consent.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.6.5

Except where expressly provided as being in the discretion of a Party (in which event such discretion shall be sole and absolute), where agreement, approval, acceptance, consent, or similar action by either Party is required under this Agreement, such action shall not be unreasonably delayed, conditioned or withheld.

27.7	Entire Agreement»

27.7.1

This Agreement:

(a)	constitutes the entire agreement between the Parties as to its subject matter; and

(b)	with respect to that subject matter and, in the absence of fraud, supersedes any prior warranties, indemnities, undertakings, conditions, understanding, commitments or agreements between the Parties, whether oral or written.

27.8	Variation»

Except as expressly permitted in this Agreement, and subject to Section 27.9.3, no amendment or variation to this Agreement shall be effective unless it is in writing and signed by a duly Authorized Representative of each Party.

27.9	Priority of Documents»

27.9.1

Subject to Section 27.9.2 hereof, the Schedules, Annexes, Attachments, and any other documents expressly identified in the same or this Master Services Agreement form part of, and are hereby incorporated into, this Agreement and shall have the same force and effect as if expressly set forth in this Master Services Agreement, and any reference to this Agreement shall include the Schedules, Annexes, Attachments and any such other documents.

27.9.2

Any conflict, ambiguity or inconsistency between the terms and conditions in this Master Services Agreement, the Schedules, the Annexes, Attachments and any document referred to in or incorporated into this Agreement shall be resolved in accordance with the following decreasing order of priority:

(a)	The Business Associate Addendum attached hereto as Schedule L;

(b)	this Master Services Agreement;

(c)	Annex C-2 to Schedule C [______]*;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(d)	Schedule N [______]*;

(e)	Exhibits to Annexes to Schedule C [______]*;

(f)	Schedule C [______]*and its Annexes and Exhibits;

(g)	Schedule B [______]*;

(h)	Schedule D [______]* and its Annexes;

(i)	The other Schedules, Annexes, and Exhibits; and

(j)	such other referenced or incorporated documents.

27.9.3

Notwithstanding the foregoing, to the extent that the Parties desire to supersede a term or condition of this Agreement, the Parties may do so only in writing and by expressly referencing the section of the Agreement that will be superseded, and including an acknowledgment that it is the intent of the Parties to supersede such section; provided, however, in no event shall any term of this Agreement be superseded in a subsequent writing unless such writing is executed by the HWAY CIO.

27.10

Counterparts»

Any amendment or modification of the terms and conditions set forth herein or any waiver of such terms and conditions must be agreed to in a writing signed by the parties hereto. This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will constitute one and the same agreement. Signatures to this Agreement transmitted by facsimile transmission, by electronic mail in “portable document format” (“.pdf”) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.

27.11

Cumulative Rights»

Except as otherwise expressly provided herein, a right, power, remedy, entitlement or privilege given or granted to a Party under this Agreement is cumulative with, without prejudice to, and not exclusive of any other right, power, remedy, entitlement or privilege granted or given under this Agreement or by Law and may be exercised concurrently or separately.

27.12

Severability»

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

If any article, section, provision, or clause in this Agreement shall be found or be held to be invalid, unconscionable, or unenforceable in any jurisdiction in which this Agreement is being performed or enforced, such clause shall be enforced, in accordance with the Parties’ intrinsic intent, to the maximum extent allowable by applicable law whereby such intent of the Parties is preserved to the greatest extent possible. The provisions of this Agreement will be deemed severable and the invalidity or unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof; provided, that if any provision of this Agreement, as applied to any Party or to any circumstance, is adjudged by a governmental body, arbitrator, or mediator not to be enforceable in accordance with its terms, the Parties agree that the governmental body, arbitrator, or mediator making such determination will have the power to modify the provision in a manner consistent with its objectives such that it is enforceable, and/or to delete specific words or phrases, and in its reduced form, such provision will then be enforceable and will be enforced.

27.13

Costs»

Each Party shall bear its own legal and other costs and expenses of, and incidental to, the preparation, negotiation, execution, completion and, if applicable, notification and/or registration of this Agreement and of any related documents or instruments.

27.14

Further Assurance»

The Parties shall, and shall procure that their agents, employees and subcontractors shall, do all things reasonably necessary, including executing any additional documents and instrument, to give full effect to the terms and conditions of this Agreement.

27.15

Governing Law»

The construction, performance and validity of this Agreement shall be governed by the laws of the State of Tennessee without regard to choice of Law provisions. Subject to Section 24, any legal action or proceeding relating to this Agreement shall be instituted in a state or federal court located in Davidson County, Tennessee. The Parties agree to such jurisdiction and waive any objection to the conduct of such action or proceeding in such court. Notwithstanding the foregoing, the Parties agree that in the event that any of the provisions of the Uniform Computer Information Transactions Act (“UCITA”) is enacted by the State of Tennessee and such provisions add to or conflict with any portion of this Agreement, this Agreement shall govern, and to the extent permissible by law, such UCITA provisions shall not apply to the terms and conditions of this Agreement.

27.16

Assignment»

27.16.1

This Agreement shall be binding upon and shall inure to the benefit of the Parties and their respective permitted successors and permitted assigns.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.16.2

HWAY agrees that, by giving HWAY prior written notice, Supplier may assign this Agreement to any entity which acquires all or substantially all of the stock or assets of Supplier to which the Services (or applicable portions thereof) relate or all or substantially all of the assets of Supplier or to any successor entity in a merger or acquisition of Supplier, provided that Supplier’s assignee or successor in title is bound by Law to fulfill, and agrees in writing to HWAY to be bound by the, obligations of Supplier under this Agreement.

27.16.3

Supplier agrees that, by giving Supplier prior written notice, HWAY may assign, transfer, or sub-contract this Agreement to any Affiliate of HWAY or any entity which acquires all or substantially all of the business of HWAY to which the Services (or applicable portions thereof) relate or all or substantially all of the assets of HWAY or to any successor entity in a merger, acquisition, Change of Control, corporate reorganization, or consolidation of HWAY, provided that HWAY’s assignee or successor in title agrees in writing to Supplier to be bound by the obligations of HWAY under this Agreement and has a credit rating at least as favorable as HWAY’s credit rating at the time of execution of this Agreement. In the event of an assignment or transfer of this Agreement to an Affiliate of HWAY, HWAY agrees to execute a guaranty in favor of Supplier substantially similar to the Guaranty provided by Guarantor in the form attached as Schedule O.

27.16.4

Notwithstanding anything to the contrary contained in this Agreement, either Party may provide a copy of this Agreement to a permitted prospective assignee or successor in title, provided that such assignee or successor in title is subject to a non-disclosure agreement containing obligations of confidentiality at least equivalent to, and no less restrictive than, those contained in Section 18.

27.16.5

The Parties acknowledge and agree that the Pre-Existing Supplier Software and Supplier Developed Software are “intellectual property” as defined in Section 101(35A) of the Bankruptcy Code, which has been licensed hereunder in a contemporaneous exchange for value. The Parties further acknowledge and agree that if Supplier or its Affiliate that owns any Pre-Existing Supplier Software or Supplier Developed Software: (a) commences, or has commenced against it, any bankruptcy, reorganization, debt arrangement, or other case or proceeding under any bankruptcy or insolvency law, or any dissolution or liquidation proceedings; or (b) elects to reject, or a trustee on behalf of it elects to reject, this Agreement or any agreement supplementary hereto, pursuant to Section 365 of the Bankruptcy Code, or if this Agreement or any agreement supplementary hereto is deemed to be rejected pursuant to Section 365 of the Bankruptcy Code for any reason, then this Agreement, and any agreement supplementary hereto, shall be governed by Section 365(n) of the Bankruptcy Code and HWAY will retain and may elect to fully exercise its rights under this Agreement in accordance with Section 365(n) of the Bankruptcy Code. Supplier hereby consents to assignment of this Agreement, an assumption of this Agreement by HWAY pursuant to Section 365 of the United States Bankruptcy Code and/or an assumption and assignment of this Agreement by HWAY pursuant to Section 365 and/or any other applicable sections of the United States Bankruptcy Code.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.17

Background Checks

[______]* Supplier represents and warrants that in no event will any person who has been convicted of any criminal offense involving dishonesty, a breach of trust, money laundering or has participated in a pre-trial diversion with respect to such an offense, or who has been convicted of a felony within the last ten (10) years, participate directly or indirectly in the provision of Services hereunder. [______]*

27.18

Federal Healthcare Programs

Supplier has not been, and during the Term of this Agreement will not be, sanctioned by the U.S. Department of Health and Human Services Office of the Inspector General List of Excluded Individuals/Entities and the General Services Administration List of Excluded Providers [available at <http://oig.hhs.gov/fraud/exclusions.html> and <http://epls.arnet.gov/>].

27.19

Equal Opportunity Employer and Minority-Owned Businesses

Supplier is an equal opportunity employer and does not discriminate in employment on the basis of age, national origin, race, religion, disability, sex or any other basis prohibited by law. Supplier acknowledges that HWAY is required, pursuant to certain contracts with HWAY’s clients and customers, to ensure the inclusion and utilization of minorities and women, and minority- and women-owned businesses in all business activities. [______]*

27.20

Drug-Free Workplace

[______]* Supplier certifies that it has implemented appropriate policy in accordance with the Drug-Free Workplace Act and will comply with the notification requirements set forth therein in the event that an employee is convicted of violating a criminal drug statute.

27.21

Foreign Anti-Corruption Compliance

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.21.1

Both Parties understand the provisions of the U.S. Foreign Corrupt Practices Act (the “FCPA”), and agree to comply with those provisions with respect to the Services and to take no action that might be a violation of the FCPA.

27.21.2

HWAY has provided to Supplier a complete copy of HWAY’s written foreign anti-corruption compliance policies (“HWAY Anti-Corruption Policies”), which are attached to this Agreement as part of Schedule F [______]*. In the event that the HWAY Anti-Corruption Policies are revised, HWAY shall promptly provide to Supplier copies of such revised HWAY Anti-Corruption Policies.

27.21.3

Each Party will not, in connection with the transactions contemplated by this Agreement or in connection with any other business transactions involving the other Party, make, offer or promise to make any payment or transfer anything of value, directly or indirectly, (a) to any governmental official or employee (including employees of government-owned and government-controlled entities and public international organizations); (b) to any political party, official of a political party, or candidate for political office; (c) to an intermediary for payment to any of the foregoing; or (d) to any other person or entity if such payment or transfer would violate the Laws of the country in which the transfer would be made or the Laws of the United States. It is the intent of the Parties that no payments or transfers of value shall be made which have the purpose or effect of public or commercial bribery, influence trading, acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining or retaining business or gaining any improper or unlawful business advantage. Each Party agrees that should it learn of or have reason to know of any payment, offer, or agreement to make a payment to a government official, political party, or political party official or candidate in connection with any transaction contemplated under this Agreement, such Party will immediately advise the other Party of such knowledge or suspicion.

27.21.5

All payments pursuant to this Agreement shall be made by check, ACH or wire transfer only, and no requests for cash payments shall be accepted.

27.22

Attorneys’ Fees»

Should either Party be required to bring legal action to enforce its rights under this Agreement, the prevailing Party in such action shall be entitled to recover from the losing Party its reasonable attorneys’ fees and costs in addition to any other relief to which it is entitled.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.23

Changes in Laws

27.23.1

Supplier shall affirmatively monitor Laws applicable to Supplier’s business (“Supplier Regulatory Requirements”). Supplier shall promptly identify and notify HWAY of any changes in Supplier Regulatory Requirements that affect Supplier’s provision of the Services or Supplier’s other obligations under this Agreement. HWAY shall affirmatively monitor Laws applicable to HWAY’s business (“HWAY Regulatory Requirements”). HWAY shall promptly identify and notify Supplier of any changes in HWAY Regulatory Requirements that affect Supplier’s provision of the Services. The Parties shall mutually monitor all other Laws and promptly notify the other Party to the extent that such Party believes that a change in such other Laws may affect the Services. Supplier and HWAY shall work together to identify the impact of such changes on how HWAY uses, and Supplier provides, the Services, including any modifications to the Services reasonably necessary as a result of such changes. Subject to Sections 27.23.2, 27.23.3 and 27.23.4 below, Supplier shall perform the Services regardless of changes in Laws.

27.23.2

If any changes in Supplier Regulatory Requirements prevent, hinder or otherwise affect Supplier’s performance of its obligations under this Agreement, Supplier shall (a) continue to perform the Services, or in the event such continued performance would violate any Law, attempt to provide a mutually acceptable workaround that allows HWAY to receive the benefit of the Services and (b) conform the Services at its cost and expense to comply with applicable Supplier Regulatory Requirements, to the extent that the Services can comply with such Supplier Regulatory Requirements.

27.23.3

If any changes in HWAY Regulatory Requirements prevent, hinder or otherwise affect Supplier’s performance of its obligations under this Agreement, Supplier shall (a) attempt to continue to perform the Services, or in the event such continued performance would violate any Law, attempt to provide a mutually acceptable workaround that allows HWAY to receive the benefit of the Services and (b) promptly develop in conjunction with HWAY and, upon HWAY’s final approval, implement in accordance with the Change Control procedures a suitable plan to conform the Services to comply with applicable HWAY Regulatory Requirements.

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

27.23.4

If any changes in Laws other than the Supplier Regulatory Requirements or the HWAY Regulatory Requirements prevent, hinder or otherwise affect Supplier’s performance of its obligations under this Agreement, subject to the Change Control procedures, the Parties shall implement a suitable plan to conform the Services to comply with the applicable changes in Laws.

27.23.5

In the event such changes in Laws, other than the Supplier Regulatory Requirements, result in a material increase in Supplier’s costs to deliver the Services, such changes shall be at HWAY’s expense; provided, that Supplier shall equitably allocate any such expense between HWAY and other affected Supplier customers. [______]*

27.24

Duty to Mitigate

Each Party has a duty to mitigate the damages that would otherwise be recoverable from the other pursuant to this Agreement by taking reasonable actions to reduce or limit the amount of such damages.

27.25

[______]*

27.26

Interpretation»

27.26.1

In this Agreement, unless the contrary intention appears:

(a)	words suggesting the singular include the plural, and vice versa;

(b)	words suggesting any gender include all other genders;

(c)	references to a person or entity include a company, corporation, firm, unincorporated or incorporated association, or statutory authority;

(d)	headings are for ease of reference only and shall not affect the interpretation of this Agreement;

(e)	references to any schedule, annex, agreement or instrument are to that schedule, agreement or instrument as amended or replaced from time to time;

(f)	use of the word “including” (and its derivatives such as “includes” or “include”) means including, without limitation;

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

(g)	a reference to any body is:

(i)	if that body is replaced by another organization, deemed to refer to that organization; and

(ii)	if that body ceases to exist, deemed to refer to the organization which most nearly or substantially serves the same purposes as that body;

(h)

references to any statute, enactment, order, regulation or other similar instrument shall be construed as a reference to the statute, enactment, order, regulation or instrument as amended by any subsequent statute, enactment, order, regulation or instrument, or as contained in any subsequent enactment thereof; and

(i)	references to Sections and Schedules are to sections of and schedules to this Agreement, and references to Annexes, Attachments and Exhibits are to annexes, attachments and exhibits to the Schedules.

27.26.2

No rule of construction will apply in the interpretation of any provision of this Agreement to the disadvantage of one Party on the basis that such Party put forward or drafted such provision.

[Signature Page(s) and Schedules, Annexes and Exhibits Follow this Page.]

IN WITNESS WHEREOF, HWAY and Supplier have executed this Agreement to be effective on the above stated Effective Date.

Executed by HWAY:	Executed by Supplier:

Authorized Signature: /s/ Ben R. Leedle, Jr.	Authorized Signature: /s/ Susan D. Arthur
Name: Ben R. Leedle, Jr.	Name: Susan D. Arthur
Title: President & CEO	Title: Vice President
Date: May 25, 2011	Date: May 25, 2011

Healthways Proprietary & Confidential

Master Services Agreement

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE A

DEFINITIONS

“ADM Service Commencement Date”	has the meaning set forth on Exhibit 1 to Annex C-4;
“Affiliate”	means, with respect to any entity, any other entity Controlling, Controlled by or under common Control with such entity;
“Agreement”	has the meaning set forth in Section 3.1.1;
“Assigned Contracts”	has the meaning set forth in Section 8.3.1;
“Audit”	has the meaning set forth in Section 16.1.1;
“Audit Representative”	means HWAY and its appointed contractors (including internal audit staff), HWAY’s external auditors and their appointed contractors and regulator(s) and/or any other auditors, regulators, inspectors or contractors whom HWAY designates in writing from time to time; provided that none of the above shall be a competitor of Supplier;
“Authorized Representative”	means any person authorized from time to time by Supplier or HWAY to exercise any powers and/or undertake any activities of Supplier or HWAY under and in accordance with this Agreement;
[______]*	[______]*
“Business Associate Addendum”	has the meaning set forth in Section 12.6.1;
[______]*	[______]*
“Change Control”	means the change control procedure set forth in Schedule E [______]* for agreeing and implementing a Scope Change or other Change as permitted pursuant to the terms of this Agreement;
“Change of Control”	means the purchase or sale by a person or other entity or group of persons or entities acting in concert in a single transaction or a series of related transactions of fifty percent (50%) or more of the Party’s voting shares or securities, or that the Party transfers to a third party a controlling interest or all or substantially all of its assets or business;
“Claim”	has the meaning set forth in Section 20.1.1;
“Colleagues”	means employees, officers and personnel of HWAY;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

[______]*	[______]*
“Confidential Information”	means all information (excluding Protected Health Information) whether commercial, financial, technical or otherwise, whether or not disclosed by one Party to the other Party, which information may be contained in or discernible from any form whatsoever (including oral, documentary, magnetic, electronic, graphic or digitized form or by demonstration or observation), whether or not that information is marked or designated as confidential or proprietary, and all matters arising prior to or during the Term including information belonging to or with respect to Supplier, any of its Affiliates and/or any of their customers or suppliers, which relates to research, development, trade secrets, know-how, ideas, concepts, formulae, processes, designs, specifications, past, present and prospective business, current and future products and services, internal management, information technology and infrastructure and requirements, finances, marketing plans and techniques, price lists and lists of, and information about, customers and employees, and all materials and information belonging to third parties with respect to which HWAY or Supplier or any of their Affiliates or any of their customers or suppliers owe obligations of confidence;
[______]*	[______]*
“Control”	means, with respect to an entity, (i) the right to exercise, directly or indirectly, more than fifty percent (50%) of the voting rights attributable to a class of the capital stock (or other ownership interest, if such entity is not a corporation) ordinarily having voting rights to elect or appoint the Board of Directors (or similar governing body if such entity is not a corporation) of such entity, or (ii) the power, directly or indirectly, to elect or appoint more than fifty percent (50%) of the Board of Directors (or similar governing body if such entity is not a corporation) of such entity, whether through ownership of voting securities, by contract, or otherwise;
“CTO”	has the meaning set forth in Section 3.4.2;
“Cut-Over Date”	means the actual date Supplier is required to begin performing a particular Service in the Transition Plan;
“Desktop Device”	means a desktop PC, laptop, printer or other related device;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

[______]*	[______]*
“Diligent Efforts”	means, for purposes of clarification, the good faith performance of obligations in a sustained manner consistent with the efforts a commercially reasonable entity that wants to obtain a favorable result would use in similar circumstances to obtain that result as expeditiously as practicable. Notwithstanding the foregoing, an obligation to use Diligent Efforts under this Agreement does not require a Party to take actions that would result in a material adverse change in the overall benefit of this Agreement or that would reasonably foreseeably result in a material adverse change in such Party’s business taken as a whole. Without limiting the generality of the foregoing, and with respect to operational objectives, “Diligent Efforts” requires that a Party in good faith: (a) promptly assign responsibility for such obligations to specific employee(s) who are held accountable for progress and monitor such progress on an on-going basis, (b) set and consistently seek to achieve specific, meaningful and measurable objectives for carrying out such obligations, and (c) consistently make and implement decisions and allocate commercially reasonable resources designed to advance progress with respect to such objectives;
“Disputes”	has the meaning set forth in Section 24;
“Disclosing Party”	has the meaning set forth in Section 18.1.1;
“Drug-Free Workplace Act”	has the meaning set forth in Section 27.20;
“Effective Date”	has the meaning set out in the first paragraph of this Agreement;
“End Users”	means those persons or entities who are authorized by HWAY from time to time to access and use the Services for the benefit of HWAY, including without limitation, its Colleagues, employees, contractors, licensors, service providers, staff, and vendors;
“Equipment”	means the equipment, and the associated peripherals and connecting equipment and used in connection with the Services;
“Emergency Change”	means a Change of a critical business nature that must be processed immediately to avoid severe impacts and/or unintended disruptions to HWAY’s (or its Affiliate’s) business or use of the Services by HWAY, its clients and/or End Users. If HWAY believes that any Change requested by it is an Emergency Change, it will so inform Supplier. If HWAY notifies Supplier of an Emergency Change, Supplier will begin implementing the Change in accordance with HWAY‘s written instructions, and the Parties will prepare the appropriate form of Change Order documenting the Change in parallel with Supplier carrying out the Change. In doing so, the Parties may amend or vary any otherwise applicable aspect of the Change Control process by mutual agreement. If the Parties are unable to agree on Supplier’s charges (if any) for carrying out an Emergency Change, the matter will be referred to the dispute resolution process described in this Agreement;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

[______]*	[______]*
“Existing Equipment Leases”	means those lease agreements pursuant to which a third party is immediately prior to the Effective Date, furnishing or providing to HWAY the Existing Equipment. Existing Equipment Leases are those lease agreements identified as such in Schedule H (Equipment and Contracts);
“Existing Equipment”	means Equipment existing on the Effective Date and utilized by HWAY immediately prior to the Effective Date in performing functions that form part of the Services. Existing Equipment is the equipment identified in Schedule H (Equipment and Contracts) on the Effective Date;
“FCPA”	has the meaning set forth in Section 27.21.1;
“Force Majeure Event”	has the meaning set forth in Section 23.1.1;
[______]*	[______]*
“HWAY Anti-Corruption Policies”	has the meaning set forth in Section 27.21.2;
“HWAY Assets”	has the meaning set forth in Section 19.4;
“HWAY Audit Representatives”	means HWAY (including HWAY’s internal audit staff), professional contractors appointed by HWAY to conduct audits under this Agreement, HWAY’s external auditors and governmental regulators whom HWAY designates in writing from time to time, none of which shall be a competitor of Supplier;
“HWAY CIO”	has the meaning given in Section 13.1.1;
[______]*	[______]*
“HWAY Facilities”	has the meaning set forth in Section 7.1.1;
“HWAY Indemnitees”	has the meaning set forth in Section 20.1;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“HWAY Information”	means all Confidential Information of HWAY Personnel or any Authorized User;
“HWAY Material(s)”	means any Materials owned by HWAY or its Affiliates (including Material in which all of the Intellectual Property Rights are owned by HWAY), including without limitation any HWAY Materials created, developed or Modified hereunder;
“HWAY Personnel”	means all Colleagues, employees, officers, consultants, contractors and agents employed or engaged by HWAY from time to time;
“HWAY Regulatory Requirements”	has the meaning set forth in Section 27.23.1;
“HWAY Software”	means the Embrace platform and any Software which is owned by HWAY or its Affiliates (including any Intellectual Property Rights in such Software), including Software identified as such in Schedule Q [______]*
[______]*	[______]*
“Incident”	means any event that is not part of the standard operation of a service and that causes, or may cause, an interruption to, or a reduction in, the quality of that service;
[______]*	[______]*
“Incidental Users”	means: (i) those persons or entities who are authorized by HWAY from time to time to access and use certain Services on an incidental basis for the convenience of such persons or entities; and (ii) governmental regulators and auditors;
“Indemnification Claim Notice”	has the meaning set forth in Section 20.4.1;
“Indemnified Party”	has the meaning set forth in Section 20.4.1;
“Indemnifying Party”	has the meaning set forth in Section 20.4.1;
“Indemnitee”	has the meaning set forth in Section 20.4.1;
“Information Breaches”	has the meaning set forth in Section 17.3.2;
“Infrastructure System(s)”	means all or any part of the Equipment and Software;
“IMAC”	means installs, moves, adds and changes;
[______]*	[______]*
“Intellectual Property Rights”	means patents (including submitted and pending patent applications and provisional patent applications), designs, trademarks and service marks (whether registered or otherwise), domain names, copyright, database rights, design rights and other intellectual property rights, including in other jurisdictions, that grant similar rights as the foregoing, including those subsisting in inventions, drawings, performances, software, semiconductor topographies, and in applications for the protection thereof, throughout the world;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“IT”	has the meaning set forth in Recital A;
“ITO Service Commencement Date”	has the meaning set forth on Exhibit 1 to Annex C-4;
[______]*	[______]*
“Knowledge Repository”	has the meaning set forth in Section 10;
“Law”	means, with respect to a Party, (a) any statute, regulation, or ordinance in force from time to time to which such Party is subject; (b) the common law and the law of equity as applicable to the Parties from time to time; (c) any binding court order, judgment or decree; or (d) any applicable direction, policy, rule or order that is binding on such Party and that is made or given by any government regulatory body having jurisdiction over such Party or any of such Party’s assets, resources or business, in any jurisdiction that is applicable to this Agreement, including to the extent applicable (i) the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), (ii) the rules and regulations of the U.S. Food and Drug Administration (“FDA”), and the Center for Medicare and Medicaid Services (“CMS”), and (iii) the rules and regulations of governmental regulatory bodies applicable to such Party or its obligations under this Agreement;
“Losses”	means all losses, liabilities, damages, reasonable and actual costs, claims and expenses (including reasonable legal fees and disbursements and costs of investigation, litigation, settlement, judgment, interest and penalties) paid to a third party, but excluding costs of inside counsel, management, related overhead and other internal charges of a Party;
[______]*	[______]*
“Material”	means any materials in whatever form (including written, magnetic, electronic, graphic or digitized), including any methodologies, processes, know-how, reports, specifications, business rules or requirements, manuals, user guides, training materials and instructions and material relating to Software and/or its design, development, Modification, operation, support or maintenance, but excluding Software produced by a Party to provide or receive the benefit of the Services;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Modify”	means to add to, enhance, reduce, change, replace, vary, derive or improve, and “Modification” and “Modified” have corresponding meanings;
[______]*	[______]*
“New Services”	means services which are materially different from and in addition to the Services;
“Non-Performing Party”	has the meaning set forth in Section 23.1.1;
“Objectives”	has the meaning set forth in Section 1.1;
[______]*	[______]*
[______]*	[______]*
“Out-of-Pocket Expenses”	means reasonable, demonstrable and actual out-of-pocket expenses incurred by Supplier for equipment, materials, supplies, or services in connection with providing the Services, excluding Supplier’s overhead costs (or allocations thereof), administrative expenses or other mark-ups associated with such expenses, and further excluding Pass-Through Expenses;
“Party” or “Parties”	means either or both of HWAY and Supplier as the context requires;
“Pass-Through Expense”	means the categories of expenses specified in Schedule D [______]*;
“Performance Standards”	means, individually and collectively, the performance standards and commitments for the Services contained in this Agreement, including the Service Levels;
“Policies and Procedures Manual”	means the standards and procedures set forth in Schedule F [______]*;
“Pre-Existing Supplier Software”	means any Software existing as of the Effective Date, the Intellectual Property Rights in which are owned by Supplier, its Affiliates or any Supplier Personnel;
“Project”	means a mutually agreed upon, discrete unit of non-recurring work to be performed by Supplier, that (i) is not an inherent, necessary or customary part of the day-to-day (i.e., regular, not daily) Services or (ii) is not otherwise part of the Services to be provided within the Charges.

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Protected Health Information”	has the meaning set forth in Schedule L (Business Associate Agreement);
“Publicity Material”	has the meaning set forth in Section 27.2.3;
“Recipient”	has the meaning set forth in Section 18.1.1;
“Required Consents”	means such consents as may be required for the assignment to Supplier, or the grant to Supplier of rights of access and use, of resources otherwise provided for in this Agreement or with respect to a Termination as may be required for the assignment to HWAY; or the grant to HWAY of rights of access and use of resources used by Supplier in the terminated Services and required for HWAY to continue those Services in accordance with the Termination Assistance provided for under this Agreement;
“Retained Contracts”	means the contracts set forth in Schedule H (Equipment and Contracts);
“Retained Equipment”	means the Equipment as defined in Section 8.1.2;
“Scope Change(s)” or “Change(s)”	means a change, reduction or addition to the Services or any other change to the Agreement which may include bringing a New Service within the scope of the Agreement;
[______]*	[______]*
“Service Charge(s)”	means the charges payable by HWAY to Supplier pursuant to this Agreement, but excluding the Pass-Through Expenses and Out-of-Pocket Expenses;
“Service Level(s)”	means those levels of performance of the Services set forth in Annex C-7 to Schedule C [______]*
“Service Level Credit”	has the meaning set forth in Schedule C [______]*
“Service Problem” or “Problem”	has the meaning set forth in Section 4.7;
“Service Tower”	means each collection of independent Services (e.g., ADM Services, Infrastructure Services, Transition Services and Security Services) to be provided under this Agreement;
“Service Sub-Tower”	means each subset of a Service Tower set forth in the Schedules attached hereto (e.g., Maintenance, Development, User Services, Help Desk, Network Administration, and Data Center Services) to be provided under this Agreement;
“Services”	means the services, functions and responsibilities identified in Section 3.1;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Services Agreements”	has the meaning set forth in Section 3.1.3;
[______]*	[______]*
[______]*	[______]*
[______]*	[______]*
[______]*	[______]*
“SMC”	has the meaning set forth in Section 16.2.1;
“Software”	means any computer program (including source code and object code), program interfaces and any Tools or object libraries embedded in that Software, which is used to provide, or which forms part of, the Services;
[______]*	[______]*
[______]*	[______]*
“Steering Committee”	has the meaning set forth in Section 14.3;
“Successful Change”	means (i) the performed actions described in the Change Request are completed within the agreed upon change window, (ii) if the Change was successfully executed, but exceeded the agreed upon change window (for reasons other than those covered in (iii) below) without an impact to Client, and did not require any material additional action by Client, (iii) if the Change was successfully executed, but exceeded the agreed upon change window because limitations in the capabilities of the test environment for the Change precluded identification of the problem that caused Supplier to miss the change window; provided, that, notwithstanding the foregoing, is understood by the Parties that HWAY may request an upgrade to the test environment at any time during the Term, in HWAY's sole discretion, which shall be implemented via the Change Control Procedures;
“Successor Supplier”	means a third party to whom, on the termination of this Agreement for any reason, HWAY proposes or intends to contract the Services or any part of the Services or any other services as HWAY may require in substitution for or in addition to the Services;
“Supplier Account Manager”	has the meaning given in Section 14.1;
“Supplier Developed Software”	means Software developed by Supplier independently of this Agreement and not in connection with the Services;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Supplier Information”	means the Confidential Information of Supplier, its Affiliates and any Supplier Personnel;
“Supplier Material(s)”	means Materials owned by the Supplier or its Affiliates (including Material in which the Intellectual Property Rights are owned by the Supplier) developed prior to the Effective Date or independently of this Agreement which is used to provide, or which forms part of, the Services;
“Supplier Personnel”	means all employees, officers, consultants, contractors and agents of Supplier assigned to perform the Services, or any part of the Services, pursuant to this Agreement;
“Supplier Regulatory Requirements”	has the meaning set forth in Section 27.23.1;
[______]*	[______]*
“Supplier Transformation Manager”	has the meaning set forth in Section 3.4.2;
“Supplier Transition Manager”	has the meaning set forth in Section 3.3.2;
“System Changes”	means changes in the manner in which the Services are performed or provided, including changes in the Software or systems used in the Service;
“Systems Software”	means those programs and programming (including the supporting documentation, media, on-line help facilities, and tutorials) that perform tasks (i) basic to the functioning of the Equipment and which are required to operate the Software; or (ii) otherwise supporting the provision of the Services by Supplier. Systems Software includes mainframe and mid-range operating systems, server operating systems, network operating systems, systems utilities (including measuring and monitoring tools), data security software, middleware, database management systems, database management software, development tools (other than development tools specific to a particular item of applications Software which is provided by the licensor of such applications Software);
“Technology Plan”	has the meaning set out in Section 14.6;
“Term”	has the meaning set forth in Section 2.1;
“Termination Date”	means the date of the termination or expiration of the Agreement;
“Termination”	means the expiration of this Agreement at the end of the Term without renewal, or the expiration of the Term after extending the Agreement in accordance with Section 2.2) or the termination of this Agreement with respect to all of the Services, however caused;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Termination Assistance”	has the meaning set forth in Section 26.8;
“Termination Assistance Period”	means the period during which Supplier provides Termination Assistance;
“Third Party Claim”	has the meaning set forth in Section 20.4.2;
“Third Party Material”	means Material used in connection with the Services which is not HWAY Material or Supplier Material;
“Third Party Software Contracts”	means those agreements pursuant to which a third party is, immediately prior to the Effective Date, furnishing or providing Third Party Software to HWAY. Third Party Software Contracts consists of those contracts identified as such in Schedule H (Equipment and Contracts);
“Third Party Software”	means Software which is not HWAY Software, Pre-existing Supplier Software or Supplier Developed Software, including third party applications and systems software;
“Tools”	shall mean any software that is used for Software development or testing, data capture, system maintenance, data search, analysis, project management, measurement and monitoring, including related methodologies, processes and know-how;
“Transferred Equipment”	is the Equipment set forth in Schedule H (Equipment and Contracts);
“Transition Plan”	means the plan for transition which will be mutually agreed upon by the Parties in accordance with Section 3.3 and Exhibit 1 to Annex C-4 [______]*;
“Transition”	means the transition of the Services, Transferred Equipment, and Assigned Contracts to Supplier as described in and in accordance with the terms of Exhibit 1 to Annex C-4 [______]*, the Transition Plan and the terms otherwise set forth in this Agreement;
“Turnover Rate”	has the meaning given in Section 11.5;
“UCITA”	has the meaning set forth in Section 27.15;
“Unidentified Resources”	has the meaning set forth in Section 15.6.2;
“Unsuccessful Change”	means (i) the Change exceeded the agreed upon change window (for reasons other than those covered in Successful Change-Item (iii)) and impacted HWAY or required material additional action by HWAY, (ii) the service is impacted based upon a (Severity 1 or 2) Incident that occurs subsequent to the scheduled change window for a period of up to two weeks following the Change completion date and (iii) the Change Request was backed out and not implemented as planned;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

“Virus”

means: (a) any program code, or programming routines or instructions intentionally constructed to damage, improperly interfere with, surreptitiously intercept or expropriate from, or otherwise adversely affect computer systems, information systems, programs, data, data files, systems, Equipment or operations; (b) any code typically designated to be a virus, worm, time or logic bomb, trojan horse, backdoor, trapdoor or similar device which is intended to damage, improperly interfere with, surreptitiously intercept or expropriate from, or otherwise adversely affect computer systems, information systems, programs, data, data files, systems, Equipment or operations; and/or (c) or any other code or routine commonly considered to be malicious or wrongfully disabling;

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE B

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE C

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-1

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 1 TO ANNEX C-1

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 2 TO ANNEX C-1

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-2

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 1 TO ANNEX C-2

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 2 TO ANNEX C-2

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-3

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 1 TO ANNEX C-3

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 2 TO ANNEX C-3

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 3 TO ANNEX C-3

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-4

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 1 TO ANNEX C-4

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

EXHIBIT 2 to ANNEX C-4

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-5

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-6

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX C-7

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE D

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX D-1

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Annex D-2

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX D-3

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

ANNEX D-4

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE E

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE F

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE G

MEETINGS

Supplier and HWAY will participate in at least the episodic and/or periodic meetings regarding the Services and Supplier’s performance of the Agreement that are indicated in the table below. Additional meeting requirements may be established from time-to-time by the Supplier’s Account Executive and HWAY. Such meetings shall include, but not be limited to, the HWAY Steering Committee and regularly scheduled meetings between the members of the HWAY CIO and Supplier Account Executive.

At the initial meeting, the participants will establish procedures and administrative details, including exchanging contact information, calendaring meeting dates (if applicable), and responsibility for preparing and circulating meeting agendas and meeting minutes.

At the end of each contract year; the Parties shall hold a meeting to:

a.	review the overall operation of this Agreement to ensure that the Services continue to meet HWAY’s Objectives, and Supplier shall work with HWAY and provide advice and guidance to HWAY with regard to technology trends and technology planning specific to HWAY’s business requirements;

b.	review the Performance Standards and make adjustments to them as appropriate to reflect improved performance capabilities, if any;

c.	review satisfaction surveys as defined in Exhibit 2 to Annex C-1 [(Customer Satisfaction)]; and

d. review any other matters reasonably required by HWAY.

Supplier shall prepare and circulate an agenda sufficiently in advance of each scheduled meeting to give participants an opportunity to prepare for the meeting. Supplier shall incorporate into such agenda items that HWAY desires to discuss. Supplier shall prepare and circulate minutes promptly after a meeting for the review and approval of HWAY.

HWAY and Supplier may modify, revise, add or delete meetings as necessary and required by business operations. Meeting times and dates may also be modified as required by business operations, as mutually agreed.

Proposed preliminary meetings are provided below:

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Committee	Key Functions	Required Supplier Participants	Minimal Meeting Frequency
Executive Steering Committee	· Provide guidance for the strategic direction of the relationship in alignment with HWAY business and outsourcing strategies · Receive, facilitate, review and serve as the final point of escalation for unresolved change requests in accordance with the Change Control Procedures · Receive, facilitate, review and serve as the final point of escalation for unresolved disputes according to the escalation procedure set in the Agreement · Review progress on continuous improvement and innovations to the Services	TBD after contract signing	Quarterly
Relationship Management Committee	· Receive, facilitate, review and serve as the point of escalation for unresolved disputes according to the escalation procedure set forth in the Agreement · Maintain dialogue between key executives at HWAY and Supplier · Review whether relationship between the Parties under the Agreement is aligned with the expectations of each of the Parties’ executive management, and review recommendations from Supplier and HWAY governance team members on how to take corrective action where needed · Review and address findings of satisfaction surveys on Supplier’s performance of the Services · Discuss Supplier’s outlook in the areas of technology and outsourcing relevant to the Services, and HWAY’s business goals · Discuss Supplier technology and investment plans relevant to the Services	TBD after contract signing	Monthly

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Operational Oversight Committee

· Receive, facilitate, review and serve as point of escalation for unresolved change requests in accordance with the Change Control Procedures. Analyze and review reports on Supplier’s performance of the Services.

· Validate that the Service delivery model is being followed

· Make recommendations to Executive Steering Committee based on the outcome of Service delivery reviews e.g., root cause analysis, benchmarking studies

· Drive enhancements to the Services, or processes and practices at HWAY which would enable enhancements to the Services

· Oversee the transition of the Services

TBD after contract signing

Monthly

Nothing herein shall be construed or interpreted in any way to supersede or conflict with the Master Services Agreement between the Parties, in whole or in part. If and to the extent anything in this Schedule conflicts or is otherwise inconsistent with the terms of the Master Services Agreement or any provision thereof, the terms of the Master Services Agreement shall control.

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE H

EQUIPMENT AND CONTRACTS

Intentionally Left Blank.

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE I

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE J

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE K

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE L

BUSINESS ASSOCIATE ADDENDUM

This Business Associate Addendum (the “Business Associate Addendum”) amends and is made part of the Master Services Agreement dated May 25, 2011 (the “Agreement”) by and between Healthways, Inc. (“Healthways”) and HP Enterprise Services LLC (“Contractor”). To the extent that there are any inconsistencies between this Business Associate Addendum and the Agreement, this Business Associate Addendum shall govern. The parties enter into this BAA in order to comply with the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the American Recovery and Reinvestment Act of 2009 (Pub. L. 111-5) (“ARRA”) and their implementing regulations set forth at 45 CFR Parts 160 and 164 (the “Privacy and Security Rule”) (collectively, HIPAA, ARRA, the Privacy Rule and Security Rule and any other state or federal legislation relating to the confidentiality of health information are referred to herein as “Applicable Privacy Law”). Healthways contracts to provide care enhancement services to, and is considered a Business Associate of health plans (“Clients”) that are subject to the Privacy Rule and Security Rule. As a business associate of its Clients, Healthways is required to obligate its subcontractors to the terms of this Business Associate Addendum. Contractor is a subcontractor of Healthways and may create or receive PHI (as defined below) in providing services to Healthways. Therefore, Healthways and Contractor desire to enter into this Business Associate Addendum in order to set forth the permitted uses and disclosures of PHI by Contractor.

DEFINED TERMS

Unless otherwise indicated in this Business Associate Addendum, all capitalized terms shall have the meanings provided in Applicable Privacy Law, as may be amended from time to time. “PHI” refers to Protected Health Information that is created or received by Contractor (directly or indirectly) for or from HEALTHWAYS or its Clients. “EPHI” refers to PHI that is transmitted by, or maintained, in electronic media. “Services” shall mean the services specified in the underlying service relationship between the parties (“Service Relationship”) and any additional services specified below:

SECTION 1. Use and Disclosure of PHI.

Contractor shall not use or disclose PHI except as Required By Law or as permitted or required by this BAA. Contractor will not sell PHI or use or disclose PHI for purposes of marketing or fundraising, as defined and proscribed in the Privacy and Security Rule and ARRA. Contractor may: (i) use and disclose PHI as necessary to provide the Services, provided that such use or disclosure would not violate Applicable Privacy Law if done by Healthways’ Clients; (ii) use PHI for the proper management and administration of Contractor or to carry out the legal responsibilities of Contractor; and (iii) disclose PHI for the purposes described in (ii) above, if Required By Law or if Contractor obtains reasonable assurances in writing from the recipient of such information that the PHI will be kept confidential and only used or further disclosed if Required By Law or for purposes described in (ii) above and that the recipient will notify Contractor of any instances of which it is aware in which the confidentiality of the information has been breached. In the event Contractor becomes aware of a restriction request that would restrict a use or disclosure otherwise permitted by this BAA, Contractor shall comply with the terms of the restriction request. In all cases, Contractor will limit its uses and disclosures of, and requests for, PHI (i) when practical, to the information making up a Limited Data Set; and (ii) in all other cases subject to the requirements of 45 CFR §164.502(b), to the minimum amount of PHI necessary to accomplish the intended purpose of the use, disclosure or request.

SECTION 2.

SAFEGUARDS; SECURITY

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Contractor shall maintain appropriate safeguards to prevent the use or disclosure of PHI other than as provided herein, including but not limited to maintaining policies and procedures to detect, prevent or mitigate identity theft based on PHI or information derived from PHI. Contractor agrees to implement administrative, technical and physical safeguards that reasonably and appropriately protect the confidentiality, integrity and availability of EPHI and that meet the requirements applicable to Business Associates under 45 CFR §§ 164.308, 164.310, 164.312 and 164.316. Without limiting the foregoing, Contractor shall ensure that all EPHI that Contractor transmits to Healthways or (as permitted by this BAA) to any third party is rendered unusable, unreadable or indecipherable to unauthorized individuals through the use of a technology or methodology specified in guidance issued by the Secretary of Health and Human Services (“Secretary”) in accordance with ARRA.

SECTION 3.

ADDITIONAL RESTRICTIONS

Unless Healthways gives its prior, express written consent, Contractor will not disclose any PHI to any agent, subcontractor or other person or entity that is located or organized outside of the United States of America. Further, Contractor shall not allow any PHI to be transmitted to, received by, or stored at any location outside of the United States of America and shall not permit any person outside of the United States of America to access or view PHI. Unless Healthways gives its prior, express written consent, Contractor shall not de-identify any PHI except as necessary to provide the Services or for Contractor’s management, administration and legal responsibilities as described in Section 2. Contractor shall train or adequately inform its employees, agents and subcontractors regarding its obligations to handle PHI confidentially.

SECTION 4.

REPORT BREACHES

To the extent known to or discovered by Contractor, Contractor shall report to Healthways any (i) use or disclosure of PHI in violation of this BAA; (ii) any Security Incident; (iii) any Red Flag (as defined at 16 CFR §681.2(b)) related to any individual who is the subject of PHI; and (iv) any Breach of Unsecured Protected Health Information. Such reports shall be made within 24 hours of Contractor becoming aware of or discovering the Breach, incident or other reportable item. Contractor will be deemed to have discovered a Breach, incident or other reportable item if the item is known, or would have been known by exercising reasonable diligence, to Contractor or any employee or agent of Contractor. Contractor shall take reasonable steps as reasonably requested by Healthways to respond appropriately to, assist in any investigation by a government agency and mitigate to the extent reasonable and practical the harm caused by any item required to be reported pursuant to this provision. Contractor will implement appropriate monitoring of Contractor’s employees and agents and require Contractor’s employees and agents to report actual or suspected Breaches, Red Flags, non-permitted uses and disclosures and Security Incidents. Notwithstanding the foregoing, the parties acknowledge and agree that this section constitutes notice by Contractor to Healthways of the ongoing existence and occurrence of attempted but Unsuccessful Security Incidents (as defined below) for which no additional notice to Healthways shall be required. “Unsuccessful Security Incidents” shall mean pings and other broadcast attacks on Contractor’s firewall, port scans, unsuccessful log-on attempts, denials of service and any combination of the above, so long as no such incident results in unauthorized access, use or disclosure of EPHI or the disruption of services.

SECTION 5.

DOWNSTREAM CONTRACTS

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Prior to disclosing PHI to any agent (including subcontractors) of Contractor (collectively “BA Subcontractors”), Contractor shall ensure that BA Subcontractors agree in writing to the same restrictions and conditions as those contained herein with respect to PHI.

SECTION 6.

MEMBER ACCESS

To the extent Contractor maintains PHI in a Designated Record Set, Contractor at the sole cost and expense of Healthways shall provide access to individuals receiving services from Clients to PHI about such individuals as required for Clients to comply with Applicable Privacy Law and in the time and manner requested by Healthways. Upon request and at the sole cost and expense of Healthways such PHI shall be provided in electronic form.

SECTION 7.

AMENDMENT AND CORRECTION

To the extent Contractor maintains PHI in a Designated Record Set, Contractor shall at the sole cost and expense of Healthways make PHI available for amendment and amend or correct such PHI as required by Applicable Privacy Law and in the time and manner reasonably requested by Healthways and consistent with Applicable Privacy Law.

SECTION 8.

ACCOUNTING

For each disclosure by Contractor of PHI required to be recorded under 45 CFR § 164.528 or ARRA, Contractor will record will record such information as would be required for a Client to respond to a request for an accounting of disclosures in compliance with Applicable Privacy Law. Contractor shall provide such accounting information to Healthways upon its reasonable request. The information shall include the date of the disclosure, the name and address (if known) of the recipient of such PHI, a brief description of the PHI disclosed, and a statement of the purpose of such disclosure of PHI.

SECTION 9.

ACCESS TO BOOKS AND RECORDS

Contractor shall make available to the Secretary, upon request, Contractor’s internal practices, books and records relating to the use or disclosure of PHI for purposes of determining any Client’s compliance with the Privacy and Security Rule. To the extent permitted by law, Contractor shall notify Healthways within 24 hours of receipt of a request from the Secretary or other regulatory agency to access Contractor’s internal practices, books or records relating to PHI.

SECTION 10.

RETURN/DESTRUCTION OF PHI

Upon termination or expiration of this Business Associate Addendum or the Agreement for any reason, Contractor will, at its expense, either securely destroy or return to Healthways all PHI that Contractor has or maintains in any form (including copies of such PHI). To the extent that it is not feasible for Contractor to return or destroy all PHI, Contractor shall extend the protections of this BAA to such PHI and limit its further use and disclosure to those purposes that make return or destruction of such PHI infeasible, for so long as Contractor maintains such PHI.

SECTION 11.

BREACH/TERMINATION

Section 11.1. In the event of a breach by Contractor of a material term of this Business Associate Addendum Healthways may terminate the Agreement pursuant to the terms forth in the Agreement. Whether such termination constitutes a termination arising pursuant to Section 26.1 or 26.2 of the Agreement shall depend on whether such breach constitutes a material breach of the entire Agreement. This Business Associate Addendum shall automatically terminate upon termination of the Agreement.

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Section 11.2. Contractor’s obligations under this Business Associate Addendum shall survive termination of this Business Associate Addendum for any reason and shall remain in effect (a) until Contractor has completed the return or destruction of PHI as required by Section 11 hereof, and (b) to the extent Contractor retains any PHI pursuant to Section 11 hereof.

SECTION 12.

OBLIGATIONS OF HEALTHWAYS

Section 12.1. Healthways shall forward copies of privacy notices that it receives from Clients within ten (10) business days of receipt of Contractor’s request and shall provide Contractor with a copy of any material changes to such notices that it receives from Clients.

Section 12.2. Healthways shall notify Contractor of any changes in, or revocation of, permission by an individual to use or disclose PHI, of which Healthways becomes aware, if such changes affect Contractor’s permitted or required uses and disclosures.

SECTION 13.

CHANGES IN LAW

To the extent there are material changes to HIPAA, the Privacy Rule, the Security Rule, other Applicable Privacy Law (including state law not preempted by HIPAA) or provisions of Healthways’ contracts with Clients related to privacy or security following the date that this Business Associate Addendum is executed, then the terms of this Business Associate Addendum shall be amended, mutually agreed and implemented pursuant to the Change Control procedures as set forth in Schedule E[(Change Control Procedures)] to account for such changes.

SECTION 14.

MISCELLANEOUS

Section 14.1. Regulatory References. A reference in this Business Associate Addendum to a section in the Privacy Rule or Security Rule means the section as in effect or as amended.

Section 14.2. Interpretation. Any ambiguity in this Business Associate Addendum shall be resolved to the extent reasonable in favor of a meaning that permits Clients and Healthways to comply with Applicable Privacy Law. Nothing in this Business Associate Addendum shall be construed to create any rights or remedies in any third parties or any agency relationship between the parties.

Section 14.3. Effective Date. This Business Associate Addendum shall be effective as of the effective date of the Agreement.

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE M

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE N

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE O

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE P

[______]*

* CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION

SCHEDULE Q

[______]*

EX-10.2 3 ex10-2_063011.htm CAPITAL ACCUMULATION PLAN, AS AMENDED AND RESTATED ex10-2_063011.htm

Exhibit 10.2

Amended and Restated Corporate and Subsidiary

Capital Accumulation Plan

Section 1. Establishment and Purpose

1.1 Establishment. Healthways, Inc. established the CORPORATE AND SUBSIDIARY CAPITAL ACCUMULATION PLAN (hereinafter called the “Plan”) effective as of September 1, 1987, as a deferred compensation plan for Participants as described herein. This Amended and Restated Plan is adopted effective June 1, 2010.

1.2 Purpose. The purpose of this Plan is to provide a means whereby compensation payable to eligible Company and Subsidiary employees may be deferred for a specified period and, when combined with Company additions, provide for capital accumulation toward savings goals.

1.3 Plan for a Select Group. The Plan shall cover certain Employees of the Company who are members of a “select group of management or highly compensated employees” within the meaning of ERISA Sections 201(2), 301(a)(3) and 401(a)(1). The Company shall have the authority to take any and all actions necessary or desirable in order for the Plan to satisfy the requirements set forth in ERISA and the regulations thereunder applicable to plans maintained for Employees who are members of a select group of management or highly compensated employees.

1.4 Not a Funded Plan. It is the intention and purpose of the Company that the Plan shall be deemed to be “unfunded” for tax purposes and deemed a plan as would properly be described as “unfunded” for purposes of Title I of ERISA. The Plan shall be administered in such a manner, notwithstanding any contrary provision of the Plan, in order that it will be so deemed and would be so described.

1.5 Section 409A. The Plan is intended to conform with the requirements of Section 409A of the Code and the Regulations issued thereunder and shall be implemented and administered in a manner consistent therewith.

Section 2. Definitions

2.1 Definitions. Whenever used hereinafter, the following terms shall have the meaning set forth below:

(a) “Account” means the total of a Participant’s pay deferrals, Company additions and growth additions thereon.

(b) “Alternate Payee” means any spouse, former spouse, child or other dependent of a Participant who is recognized by a Domestic Relations Order as having a right to receive all, or a portion of, the benefits payable under this Plan to that Participant.

(d) “Compensation Committee” means the Compensation Committee of the Board of Directors of the Company.

(e) A “Change in Control” shall be deemed to have occurred upon the first to occur of any of the following events:

(i) Any one person or group (as described in Regulations promulgated under Section 409A) acquires ownership of stock of the Company that, together with stock held by such person or group, constitutes more than fifty percent (50%) of the total fair market value or total voting power of the stock of the Company; or

(ii) Notwithstanding that the Company has not undergone a Change in Control as described in 2.1(d)(i), a Change in Control of the Company occurs on the date that either:

(A) Any one person or more than one person acting as a group (as described in Regulations promulgated under Section 409A), acquires or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons ownership of stock of the Company possessing thirty percent (30%) or more of the total voting power of the stock of such corporation; or

(B) A majority of members of the Company’s Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Company’s Board prior to the date of the appointment or election; or

(iii) Any one person or group (as described in Regulations promulgated under Section 409A) acquires or has acquired during the 12-month period ending on the date of the most recent acquisition by such person or persons assets from the Company that have a total gross fair market value equal to or more than forty percent (40%) of the total gross fair market value of all the assets of the Company immediately prior to such acquisition or acquisitions. For this purpose, gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.

In determining whether a Change in Control has occurred, the following rules shall be applicable:

(I) For purposes of a change in ownership described in Section 2.1(e)(i) above, if any one person or more than one person acting as a group is considered to own more than fifty percent (50%) of the total fair market value or total voting power of the stock of a corporation, the acquisition of additional stock by the same person or persons is not considered to cause a change in the ownership of the corporation (or to cause a change in the effective control of the corporation as described in Section 2.1(e)(ii)). An increase in the percentage of stock owned by any one person, or persons acting as a group, as a result of a transaction in which the corporation acquires its stock in exchange for property will be treated as an acquisition of stock. Section 2.1(e)(i) applies only when there is a transfer of stock of a corporation (or issuance of stock of a corporation) and stock in such corporation remains outstanding after the transaction. For purposes of Section 2.1(e)(i), persons will not be considered to be acting as a group solely because they purchase or own stock of the same corporation at the same time or as a result of a public offering. Persons will, however, be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the corporation. If a person, including an entity, owns stock in both corporations that enter into a merger, consolidation, purchase or acquisition of stock, or similar transaction, such shareholder is considered to be acting as a group with other shareholders

only with respect to the ownership in that corporation prior to the transaction giving rise to the change and not with respect to the ownership interest in the other corporation.

(II) For purposes of a change in effective control of a corporation described in Section 2.1(e)(ii) above, if one person, or more than one person acting as a group, is considered to effectively control a corporation within the meaning of Section 2.1(e)(ii), the acquisition of additional control of the corporation by the same person or persons is not considered to cause a change in the effective control of the corporation within the meaning of Section 2.1(e)(ii) or to cause a change in the ownership of the corporation within the meaning of Section 2.1(e)(i). Persons will or will not be considered to be acting as a group in accordance with rules similar to those set forth in the preceding clause (I) and as specifically provided in section 1.409A-3(i)(5)(vi)(D) of the Regulations under Section 409A.

(III) For purposes of a change in the ownership of a substantial portion of a corporation’s assets described in 2.1(e)(iii) above, there is not a Change in Control event when there is a transfer to an entity that is controlled by the shareholders of the transferring corporation immediately after the transfer. A transfer of assets by a corporation is not treated as a change in ownership of such assets if the assets are transferred to (i) a shareholder of the corporation (immediately before the asset transfer) in exchange for or with respect to its stock, (ii) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the corporation, (iii) a person, or more than one person acting as a group, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the corporation, or (iv) an entity, at least fifty (50%) of the total value or voting power of which is owned, directly or indirectly, by a person described in immediately preceding clause (iii). For purposes of the foregoing, and except as otherwise provided, a person’s status is determined immediately after the transfer of assets. Persons will or will not be considered to be acting as a group in accordance with rules similar to those set forth in the preceding clause (I), and as specifically provided in section 1.409A-3(i)(5)(vii)(C) of the Regulations under Section 409A.

(IV) Section 318(a) of the Code applies for purposes of determining stock ownership. Stock underlying a vested option is considered owned by the individual who owns the vested option (and the stock underlying an unvested option is not considered owned by the individual who holds the unvested option). If, however, a vested option is exercisable for stock that is not substantially vested (as defined by Regulation 1.83-3(b) and (j)) the stock underlying the option is not treated as owned by the individual who holds the option.

(V) Whether a Change in Control has occurred will be determined by the Company in accordance with the rules and definitions set forth in this Section 2.1. This determination shall be made in a manner consistent with Section 409A and the Regulations thereunder.

(f) “Code” means the Internal Revenue Code of 1986, as amended. References to any section of the Internal Revenue Code shall include any successor provision thereto.

(g) “Company” means Healthways, Inc., a Delaware corporation.

(h) “Company 401(k) Plan” means the Healthways, Inc. Retirement Savings Plan.

(i) “Disability” means a “disability” as determined under the Company’s long-term disability insurance policy if the Participant receives a distribution from the Plan due to the Participant’s Separation

from Service in connection with the Participant’s Disability. Notwithstanding the foregoing, if the Participant will receive a distribution from the Plan upon his Disability and such distribution is not made due to the Participant’s Separation from Service, then Disability means a period of time during which a Participant is (i) unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, (ii) by reason of any medically determinable physical or mental impairment which can be expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months, receiving income replacement benefits for a period of not less than three (3) months under an accident and health plan covering employees of the Company or (iii) is determined to be totally disabled by the Social Security Administration.

(j) “Domestic Relations Order” means a judgment, decree or order (including approval of a property settlement agreement) which is made pursuant to a state domestic relations law, which relates to the provision of child support, alimony payments or marital property rights to an Alternate Payee, and which creates or recognizes the existence of an Alternate Payee’s right to, or assigns to an Alternate Payee the right to, receive all or a portion of the benefits payable to a Participant.

(k) “Early Retirement” means a Participant’s Separation from Service where (i) the sum of the Participant’s age plus years of employment at the Company as of the proposed early retirement date is equal to or greater than 70, (ii) the Participant has given written notice to the Company at least one year prior to the proposed early retirement date of his or her intent to retire and (iii) the Chief Executive Officer has approved in writing such early retirement request prior to the proposed early retirement date, provided that in the event the Chief Executive Officer does not approve the request for early retirement or the Chief Executive Officer is the Participant giving notice of his or her intent to retire, then in both cases, the Compensation Committee shall make the determination of whether to approve or disapprove such request.

(l) “Employee” means a full-time regular salaried employee of the Company or any of its Subsidiaries.

(m) The acronym “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. Whenever a reference is made herein to a specific ERISA section, such reference shall be deemed to include any successor ERISA section having the same or a substantially similar purpose.

(n) “Identification Date” means the date determined by the Company in accordance with Section 1.409A-1(i)(3) of the Regulations which is the last day of the 12-month period for determination of Specified Employees. Unless otherwise designated, the Identification Date shall be December 31.

(o) “Normal Retirement” means a Participant’s Separation from Service on or after the date the Participant reaches age 65.

(p) “Participant” means an Employee of the Company or an Employee of any Subsidiary of the Company who is designated by the Compensation Committee to participate in this Plan.

(q) “Plan Year” means the 12-month period beginning January 1 and ending December 31.

(r) “Regulations” means the regulations promulgated by the Treasury Department under the Code.

(s) “Section 409A” shall mean Section 409A of the Code, related Regulations and guidance thereunder, including such Regulations and guidance promulgated after the Effective Date of the Plan.

(t) “Separation from Service” means for any Participant the occurrence of any one of the following events:

(i) The Participant is discharged by the Company;

(ii) The Participant voluntarily terminates employment (including an Early or Normal Retirement) with the Company;

(iii) The Participant terminates employment due to the Participant’s Disability; or

(iv) The Participant dies while employed with the Company.

For purposes of determining whether a Separation from Service has occurred, the term “Company” shall include a Subsidiary, and no Separation from Service shall be deemed to have occurred if the Participant remains employed by a Subsidiary.

A Separation from Service does not occur if the Participant is on military leave, sick leave or other bona fide leave of absence if the period of leave does not exceed six months or such longer period during which the Participant’s right to reemployment is provided by statute or contract. If the period of leave exceeds six months and the Participant’s right to reemployment is not provided either by statute or contract, a Separation from Service will be deemed to have occurred on the first day following the six-month period. If the period of leave is due to any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than six months, where the impairment causes the Participant to be unable to perform the duties of his or her position of employment or any substantially similar position of employment, a 29-month period of absence may be substituted for the six-month period.

Whether a Separation from Service has occurred is based on whether the facts and circumstances indicate that the Company and the Participant reasonably anticipated that no further services would be performed after a certain date or that the level of bona fide services the Participant would perform after such date (whether as an employee or as an independent contractor) would permanently decrease to no more than twenty percent (20%) of the average level of bona fide services performed (whether as an employee or an independent contractor) over the immediately preceding 36 month period (or the full period of services to the Company if the Participant has been providing services to the Company for less than 36 months).

If a Participant provides services both as an employee and as a member of the Board, the services provided as a director are not taken into account in determining whether the Participant has incurred a Separation from Service as an employee for purposes of Plan, unless this Plan is aggregated under Section 409A with any plan in which the Participant participates as a director.

All determinations of whether a Separation from Service has occurred will be made in a manner consistent with Section 409A and the Regulations thereunder.

(u) “Specified Employee” means a “key employee” of the Company as described in Section 416(i)(1)(A)(i), (ii) or (iii) of the Code (without regard to Section 416(i)(5) of the Code) (generally, an officer having annual compensation of more than $150,000 (in 2008, as adjusted); a 5% owner; or a 1% owner having annual compensation of more than $150,000), determined at any time during the 12-month period ending on the Identification Date. A Participant who is a Specified Employee on an Identification Date shall be treated as a Specified Employee for the twelve month period beginning on January 1 (or such other date designated in accordance with Section 7.3) immediately following such Identification

Date. For purposes hereof, the term “officer” shall be determined on the basis of all facts, including the source of his authority, the term for which elected or appointed, and the nature and extent of his duties. Generally, the term “officer” means an administrative executive who is in regular and continued service. An Employee who merely has the title of an officer, but not the authority of an officer, is not to be considered an officer hereunder. Similarly, an Employee who does not have the title of an officer but has the authority of an officer is an officer for this purpose. Furthermore, for purposes hereof, during any 12-month period following an Identification Date, no more than 50 employees of all members of the controlled group consisting of the Company and any corporation required to be aggregated with the Company under Section 414(b) or 414(c) of the Code, or if less, the greater of three individuals or ten percent (10%) of such employees of all members of such controlled group, shall be treated as officers hereunder.

(v) “Subsidiary” means any corporation, 80% or more of the total combined voting power of all classes of stock of which is directly or indirectly owned by the Company.

(w) “Unforeseeable Emergency” means a severe financial hardship of the Participant resulting from an illness or accident of the Participant, the Participant’s spouse, the Participant’s beneficiary, or the Participant’s dependent (as defined in Section 152 of the Code without regard to Sections 152(b)(1), (b)(2) and (d)(1)(B) of the Code), loss of the Participant’s property due to casualty (including the need to rebuild a home following damage to a home not otherwise covered by insurance), or other similar extraordinary and unforeseeable circumstances arising as a result of events beyond the control of the Participant. Examples of an Unforeseeable Emergency include:

(i) the imminent foreclosure of or eviction from the Participant’s primary residence;

(ii) the need to pay for medical expenses, including nonrefundable deductibles, as well as the costs of prescription drugs; and

(iii) the need to pay for the funeral expenses of the Participant’s spouse, the Participant’s beneficiary, or the Participant’s dependent (as defined in Section 152 of the Code without regard to Sections 152(b)(1), (b)(2) and (d)(1)(B) of the Code).

Notwithstanding the foregoing, the purchase of a home or the payment of college tuition are not normally deemed to be an Unforeseeable Emergency. Whether an event constitutes an Unforeseeable Emergency shall be determined in accordance with Regulation 1.409A-3(i)(3).

(x) The acronym “USERRA” means the Uniformed Services Employment and Reemployment Rights Act of 1994, as amended.

2.2 Gender and Number. Except when otherwise indicated by the context, any masculine terminology when used in the Plan shall also include the feminine gender, and the definition of any term herein in the singular shall also include the plural.

Section 3. Eligibility for Participation

3.1 Eligibility. Participation in the Plan shall be limited to Employees who are designated as Participants by the Compensation Committee. In the event an Employee no longer meets the requirements for participation in this Plan, he or she shall become an inactive Participant effective as of the end of the Plan Year in which such determination is made and he or she shall retain all the rights described under this Plan, except the right to make any further deferrals or receive any additional Company additions, with

the exception of the Discretionary Company Additions for inactive participants described in Section 5.2, until the time that he or she again becomes an active Participant.

Section 4. Election to Defer

4.1 Deferral Amount. No later than the December 31 preceding each Plan Year, any Participant may, by written notice to the Company, elect to defer an amount not less than 1% nor more than 10% of the Participant’s base salary for such Plan Year. Notwithstanding the foregoing, with respect to the first Plan Year a Participant is eligible to participate, the Participant must, by written notice, make his deferral election (subject to the percentage limitations discussed in the previous sentence) during the designated election period. There will be a thirty (30) day waiting period following the initial eligibility date. Following the waiting period, an election period will begin and will last for thirty (30) days. Such election shall only apply to base salary which is payable for services rendered by the Participant during the remainder of the Plan Year following his election. If the Participant fails to make an election during the election period, then the Participant will not be permitted to make a deferral election until the next Plan Year.

4.2 Deferral Period. Simultaneous with a Participant’s deferral election specified in Section 4.1, the Participant shall also designate the time for payout of his or her Account. Payments must begin no earlier than four years from the beginning of each Plan Year, and no later than the earliest to occur of: (a) the date specified in the election (or in the event that no date is specified, the date will be four years from the beginning of such Plan Year), (b) Disability, or (c) Separation from Service.

4.3 Manner of Payment Election. Concurrent with the election in Section 4.1, the Participant, by written notice to the Company, also shall elect the manner in which the Account will be paid. The Participant may choose to have payment made either in a lump sum or in periodic annual installments over a fixed number of years. Notwithstanding the foregoing, if payment results from a Participant’s Separation from Service, such payment shall be made in a lump sum at a date one year following the date of the Participant’s Separation from Service. If payout results from the death or Disability of the Participant, payout will be made in a lump sum within ninety (90) days of the Participant’s death, or after the determination of Disability, with the determination of the date upon which such payments shall be made to be determined by the Company in its sole discretion.

4.4 Separate Payout Elections. The Participant may elect separate payout elections for time and manner of payment during the term of his or her participation. Each separate election regarding time and manner of payment must be made at the time the Participant’s deferral election is made for the particular Plan Year (no later than December 31 preceding the Plan Year as provided in Section 4.1) and will apply only to the amounts deferred during such Plan Year, including base salary, Company additions and growth additions.

4.5 Irrevocable Elections. The elections in this Section 4 are irrevocable and may not be modified or terminated by the Participant or his or her beneficiary except as provided in Section 7.2 following a distribution due to an Unforeseeable Emergency or following a determination that the Participant suffers from a Disability as defined in Section 2.1(i)).

4.6 Fully Vested. Amounts deferred under this Section 4 are fully vested to the Participant.

4.7 USERRA. Notwithstanding any provision of this Plan to the contrary, the Company may permit a deferral election to be made at a different time than specified under this Section 4 as required to satisfy the requirements of USERRA.

Section 5. Company Additions

5.1 Mandatory Company Matching Additions. Effective as of the last day of each Plan Year, the Company shall add to each Participant’s Account a matching addition equal to not less than 25% of the Participant’s deferrals during that Plan Year; provided, however, that the amount of deferrals upon which the Company’s aggregate matching additions to the Participant’s Account under the Plan and the Participant’s account under the Company 401(k) Plan are based shall not exceed 6% of the Participant’s base salary for that Plan Year. Actual crediting of each Participant’s Account is estimated to occur within ninety (90) days of the end of the Plan Year. No Mandatory Company Matching Addition shall be made for persons who (i) are no longer employed by the Company or (ii) no longer meet the definition of Employee on the last day of the Plan Year.

5.2 Discretionary Company Additions. The Compensation Committee, in its sole discretion, may provide for discretionary additions to the Plan based solely on the Company’s financial performance for the Plan Year. The maximum discretionary Company addition which may be made in any Plan Year is 20% of a Participant’s base salary paid during the Plan Year. Discretionary Company additions are made to all Participants regardless of a Participant’s deferrals into the Plan and such additions are credited to the Account of Participants following the completion of the audit of the Company’s financial statements for the Plan Year, estimated to occur within ninety (90) days of the end of the Plan Year. In the event that a Participant becomes inactive during a Plan Year (as referenced in Section 3.1), he or she will receive the Discretionary Company Addition for such Plan Year, if any, but will not receive any additional Discretionary Company Additions until the time he or she again becomes an active Participant No Discretionary Company Addition shall be made for persons who (i) are no longer employed by the Company or (ii) no longer meet the definition of Employee on the date such Discretionary Company Additions are credited to the Participants’ Accounts.

5.3 Vesting. Company additions shall vest 25% per year over four years as long as the Participant continues to be employed by the Company or any of its Subsidiaries. The first vesting date is the date the addition is credited to the Participant’s Account. Subsequent vesting dates occur on the last day of each Plan Year, with the exception of the Discretionary Company Additions for Plan Years 2010 and beyond, which subsequently vest 25% per year for each of the following three years on the anniversary of the date the addition was originally credited to the Participant’s Account. Notwithstanding the foregoing, a Participant shall fully vest in any Company additions pursuant to Section 5.1 and Section 5.2 (i) if the Participant Separates from Service with the Company and any Subsidiary by reason of his or her death, Disability, Normal Retirement or Early Retirement or (ii) as separately provided for in the Participant’s separate employment agreement with the Company. Except as otherwise provided in this Plan, a Participant shall forfeit any Company additions that have not vested as of the Participant’s Separation from Service.

Section 6. Deferred Accounts

6.1 Participant Accounts. The Company shall establish and maintain a bookkeeping Account for each Participant, to be credited as of the date the deferred compensation would have been paid. Accounts also shall be credited as of the date Company additions are made as described in Section 5, and their status as vested or nonvested noted according to Section 5.3.

6.2 Growth Additions. Each Participant’s Account shall be credited with a growth addition. The growth addition shall be equal to said Account balance multiplied by a growth increment, the amount of which shall be determined from time to time by the Compensation Committee. Growth additions shall be calculated on a daily basis based on the Participant’s Account balance but shall be credited to the

Participant’s Account and compounded monthly as of the last day of the month. However, for Participants whose payout results from a Separation from Service, the growth factor on employee deferrals and on associated compounded growth factors will be calculated through the distribution date defined by the Plan or the payment election date(s), as applicable, both as described in Section 4.3.

Growth additions shall vest to the extent the Company additions to which they apply are vested under Section 5.3. Growth additions on Participant deferrals are fully vested when credited to the Participant’s Account. Growth additions will be paid at such time and in such manner as the Participant’s other Account balances.

6.3 Charges Against Accounts. There shall be charged against each Participant’s Account any payments made to the Participant or to his or her beneficiary in accordance with Section 7 hereof.

6.4 Contractual Obligation. It is intended that the Company is under a contractual obligation to make payments from a Participant’s Account when due. Account balances shall not be financed through a trust fund or insurance contracts or otherwise unless such trust fund or insurance contracts are owned by the Company. Payment of Account balances shall be made out of the general funds of the Company.

6.5 Unsecured Interest. No Participant or beneficiary shall have any interest whatsoever in any specific asset of the Company. To the extent that any person acquires a right to receive payments under this Plan, such right shall be no greater than the right of any unsecured general creditor of the Company.

Section 7. Payment of Deferred Amounts

7.1 Payment of Deferred Amounts. Payment of a Participant’s Account shall be paid in a lump sum or in periodic annual installments over a fixed number of years, in the manner provided for by the Company and elected by the Participant under Section 4.3 of this Plan. Subject to Section 4.3 and Section 7.3, payments shall begin within ninety (90) days following the dates described by Section 4 of this Plan with the determination of the date upon which such payments shall be made to be determined by the Company in its sole discretion.

7.2 Unforeseeable Emergency. The Compensation Committee, in its sole discretion, may permit a distribution from a Participant’s Account in the event that the Participant establishes, to the satisfaction of the Compensation Committee, an Unforeseeable Emergency. In making its determination, the Compensation Committee shall examine the relevant facts and circumstances of each case. A distribution may not be made to the extent that the Unforeseeable Emergency is or may be relieved through reimbursement or compensation from insurance or otherwise, by liquidation of the Participant’s assets (to the extent the liquidation of such assets would not cause severe financial hardship) or by cessation of deferrals under the Plan. If the Compensation Committee determines that an Unforeseeable Emergency exists, then a distribution from the vested portion of the Participant’s Account may be made to the Participant, provided that such distribution shall not be in excess of the amount reasonably necessary to satisfy the Unforeseeable Emergency (which may include amounts necessary to pay any Federal, state, foreign or local income taxes or penalties reasonably anticipated to result from the distribution). A distribution, if any, under this Section 7.2 shall be made as soon as practical following the Compensation Committee’s determination of the occurrence of an Unforeseeable Emergency, but not later than ninety (90) days following the date of the Compensation Committee’s determination, with the determination of the date upon which such distribution shall be made to be determined by the Company in its sole discretion. A Participant’s deferral elections under Section 4.1 for the remainder of the Plan Year will be cancelled upon such a withdrawal due to Unforeseeable Emergency.

7.3 Six-Month Delay of Certain Payments. Except as otherwise provided in this Section 7.3, a distribution made because of a Separation from Service to a Participant who is a Specified Employee as of the date of his Separation from Service shall not occur before the date which is six months after the Separation from Service.

For this purpose, a Participant who is a Specified Employee on an Identification Date shall be treated as Specified Employee for the twelve-month period beginning on the January 1 immediately following such Identification Date. The Company may designate another date for commencement of this twelve month period, provided that such date must follow the Identification Date and occur no later than the first day of the fourth month thereafter, provided that such designation is made in accordance with Regulations under Section 409A and is the same for all nonqualified deferred compensation plans of the Company or any Subsidiary.

The Company may elect to apply an alternative method to identify Participants who will be treated as Specified Employees for purposes of the six-month delay in distributions if the method satisfies each of the following requirements: (i) the alternative method is reasonably designed to include all Specified Employees, (ii) the alternative method is an objectively determinable standard providing no direct or indirect election to any Participant regarding its application, and (iii) the alternative method results in either all Specified Employees or no more than 200 Specified Employees being identified in the class as of any date. Use of an alternative method that satisfies these requirements will not be treated as a change in the time and form of payment for purposes of Section 1.409A-2(b) of the Regulations.

The six-month delay provided for in this Section 7.3 does not apply to payments made to an Alternate Payee pursuant to a Domestic Relations Order described in Section 7.5 or to payments that occur after the death of the Participant.

7.4 Permissible Delays in Payment. Distributions from a Participant’s Account may be delayed beyond the date payment would otherwise occur in accordance with the provisions of this Section 7 in any of the following circumstances as long as the Company treats all payments to similarly situated Participants on a reasonably consistent basis.

(a) The Company may delay payment if it reasonably anticipates that its deduction with respect to such payment would not be permitted by the application of Section 162(m) of the Code. Payment must be made during the Participant’s first taxable year in which the Company reasonably anticipates, or should reasonably anticipate, that if the payment is made during such year the deduction of such payment will not be barred by the application of Section 162(m) of the Code or during the period beginning with the Participant’s Separation from Service and ending on the later of the last day of the Company’s taxable year in which the Participant Separates from Service or the 15th day of the third month following the Participant’s Separation from Service.

(b) The Company may also delay payment if it reasonably anticipates that the making of the payment will violate Federal securities laws or other applicable laws provided payment is made at the earliest date on which the Company reasonably anticipates that the making of the payment will not cause such violation.

(c) The Company may delay payment during the periods specified in Section 11.2 for review and appeal of claims or during any other period while there is a bona fide dispute as to the amount or timing of such payment in accordance with Section 1.409A-3(g) of the Regulations.

(d) The Company may delay payment upon such other events and conditions as the Secretary of the Treasury may prescribe in generally applicable guidance published in the Internal Revenue Bulletin.

7.5 Permitted Acceleration of Payment. The Company may permit acceleration of the time or schedule of any payment or amount scheduled to be paid pursuant to a payment under the Plan upon the following events:

(i)

payments to an Alternate Payee (but in no event to a Participant) at such times and in such amounts as specified in a Domestic Relations Order which is determined by the Company to be valid and which does not require the Plan to pay benefits in excess of the balance of the Participant’s Account. The Company may require that reasonable expenses incurred and paid by the Company in evaluating the Domestic Relations Order and complying with its terms shall be deducted from the Participant’s Account;

(ii)

to the extent necessary for any Federal officer or employee in the executive branch to comply with an ethics agreement with the Federal government;

(iii)

to the extent reasonably necessary to avoid the violation of an applicable Federal, state, local or foreign ethics law or conflicts of interest law (in accordance with Regulation 1-409A-3(j)(4)(iii));

(iv)

to the extent required to pay employment taxes on base salary deferred under the Plan (in accordance with Regulation 1.409A-3(j)(4)(vi));

(v)

at any time the Plan fails to meet the requirements of Section 409A (any such payment may not exceed the amount required to be included in income as a result of the failure to comply with Section 409A);

(vi)

upon the occurrence of any of the circumstances when the Plan is terminated pursuant to Sections 12.1(b) or 13.1 of the Plan; or

(vii)

upon the occurrence of any other events permitted by the provisions of Regulation 1.409A-3(j)(4) or any successor thereto.

Notwithstanding the foregoing, the Company shall not allow any Participant discretion with respect to whether a payment will be accelerated and shall not permit any election, direct or indirect, by a Participant as to whether the Company’s discretion under this Section 7.5 will be exercised.

Section 8. Federal Income Tax Consequences

8.1 Federal Income Tax Consequences. It is intended that the Plan shall be considered nonqualified for Federal income tax purposes. Thus, the Company shall not be entitled to a tax deduction until the earlier of (i) the year payment is actually made or (ii) the year in which the Participant reports such amounts as income.

Section 9. Beneficiary

9.1 Beneficiary. A Participant must designate a beneficiary or beneficiaries who, upon his or her death, are to receive the distributions that otherwise would have been paid to him or her. All designations shall be in writing and shall be effective only if and when delivered to the Chief Financial Officer or his or her designee or a replacement designated by the Compensation Committee during the lifetime of the Participant. If a designated beneficiary predeceases the Participant and no revised beneficiary designation is made, amounts will be prorated to living beneficiaries. If all beneficiaries predecease the Participant, amounts shall be paid to the Participant’s estate.

A Participant may from time to time during his or her lifetime change his or her beneficiary or beneficiaries by a written instrument delivered to the Chief Financial Officer or his or her designee or a replacement designated by the Compensation Committee. In the event a Participant shall not designate a beneficiary or beneficiaries pursuant to this Section 9.1, or if for any reason such designation shall be ineffective, in whole or in part, the distribution that otherwise would have been paid to such Participant shall be paid to his or her estate and in such event, the term “beneficiary” shall include his or her estate.

Section 10. Rights of Employees, Participants

10.1 Employment. Nothing in this Plan shall interfere with or limit in any way the right of the Company or any of its Subsidiaries to terminate any Employee’s or Participant’s employment at any time, nor confer upon any Employee or Participant any right to continue in the employ of the Company or any of its Subsidiaries.

10.2 Nontransferability. Except for payments to an Alternate Payee pursuant to a Domestic Relations Order, no right or interest of any Participant in this Plan shall be assignable or transferable, or subject to any lien, directly, by operation of law, or otherwise, including executive, levy, garnishment, attachment, pledge, and bankruptcy. In the event of a Participant’s death, payment of any amounts due under this Plan shall be made to the Participant’s designated beneficiary, or in the absence of such designation, to the Participant’s estate within ninety (90) days of the Participant’s death with the determination of the date upon which such distribution shall be made to be determined by the Company in its sole discretion.

10.3 Participation. No Employee shall have a right to be selected as a Participant, or, having been so selected, to be selected again as a Participant.

Section 11. Administration

11.1 Administration. The Compensation Committee shall be responsible for the administration of the Plan. The Compensation Committee is authorized to interpret the Plan, to prescribe, amend, and rescind rules and regulations relating to the Plan, provide for conditions and assurances deemed necessary or advisable to protect the interests of the Company, and to make all other determinations necessary or advisable for the administration of the Plan, but only to the extent not contrary to the express provisions of the Plan. The Compensation Committee shall determine, within the limits of the express provisions of the Plan, the Employees to whom, and the time or times at which, participation shall be extended, and the amount which may be deferred. In making such determinations, the Compensation Committee may take into account the nature of the services rendered by such Employees or classes of Employees, their present and potential contributions to the Company’s or its Subsidiaries’ success and such other factors as the Compensation Committee in its discretion shall deem relevant. The determination of the Compensation Committee, interpretation or other action made or taken pursuant to the provisions of the Plan, shall be final and shall be binding and conclusive for all purposes and upon all persons.

11.2 Claims Procedures. The Company shall make all determinations in its sole discretion as to the right of any Participant to a benefit under the Plan. Any denial by the Company of a claim for benefits under the Plan by a claimant shall be stated in writing by the Company and delivered or mailed to the claimant within a reasonable period of time but not later than 90 days after receipt by the Company of his claim, unless special circumstances require an extension of time for processing the claim. If such an extension is required, written notice thereof shall be provided to the claimant before the end of this 90-day period which shall indicate the special circumstances requiring the extension and the date by which the Company expects to render a decision. In no event shall the extension exceed 90 days from the end of the initial 90-day period.

If a claim for benefits under the Plan is wholly or partially denied, the Company shall notify the claimant of the denial of the claim in writing, delivered in person or mailed by first class mail to the claimant’s last known address. Such notice of denial shall contain:

(a) the specific reason or reasons for denial of the claim;

(b) a reference to the relevant provision(s) of the Plan upon which the denial is based;

(c) a description of any additional material or information necessary for the claimant to perfect the claim, together with an explanation of why such material or information is necessary; and

(d) an explanation of the Plan’s claim review procedure.

If no such notice is provided, and if the claim has not been granted within the time specified above for approval of the claim, the claim shall be deemed denied and subject to review as described below.

Any claimant or authorized representative of the claimant whose claim for benefits under the Plan has been denied or deemed denied, in whole or in part, may upon written notice delivered to the Company request a review of such denial of benefits. Such claimant shall have 60 days from the date the claim is deemed denied, or 60 days from receipt of the notice denying the claim, as the case may be, in which to request such a review. The claimant’s notice must specify the relief requested and the reason the claimant believes the denial should be reversed. In pursuing his appeal, the claimant will be permitted to submit written comments, documents, records, or other relevant information relating to his claim. In addition, the claimant will be provided, upon receipt and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to his claim.

The Company will conduct the review of any appeal. This review will take into account all information submitted by the claimant regarding his claim, regardless of whether or not such information was submitted or considered in the initial decision. A decision regarding such review will be made within a reasonable period of time but not later than 60 days after receipt of the claimant’s appeal, unless special circumstances require an extension of time for processing the claim. If such an extension is required, written notice thereof shall be provided to the claimant before the end of this 60-day period which shall indicate the special circumstances requiring the extension and the date by which the Company expects to render the final decision. In no event shall the extension exceed 60 days from the end of the initial 60-day period.

If the claimant’s appeal is denied in whole or in part, the claimant will receive a written notification of the denial which will include (i) the specific reasons for the denial, (ii) reference to the specific provision(s) of the Plan upon which the denial was based, and (iii) a statement of the claimant’s right to bring an

action under ERISA. The interpretations, determinations, and decisions of the Company shall be final and binding upon all persons with respect to any right, benefit and privilege hereunder, subject to the review procedures set forth in this Section 11.2.

Section 12. Amendment, Modification, and Termination of the Plan

12.1 Amendment, Modification, and Termination of the Plan.

a. Power to Amend. The Compensation Committee from time to time may amend or modify the Plan in accordance with Section 409A and the Regulations promulgated thereunder, provided, however, that no such action of the Compensation Committee, without approval of the Participant, may adversely affect in any way amounts already deferred pursuant to Section 4.1 of this Plan nor the vesting schedule for an Account as it exists at the time of the modification.

b. Power to Terminate Plan. The Plan may be terminated by the Company under one of the following conditions:

(i) The Company may terminate the Plan at its sole discretion, provided that:

(A) All arrangements sponsored by the Company that would be aggregated with the Plan under Section 1.409A-1(c)(2) of the Regulations are terminated with respect to all Participants;

(B) No payments will be made, other than those otherwise payable under the terms of the Plan absent a Plan termination, within 12 months of the termination of the Plan;

(D) The Company does not adopt a new arrangement that would be aggregated with any terminated arrangement under Section 409A at any time within the three-year period following the date of termination of the Plan; and

(E) The termination does not occur proximate to a downturn in the financial health of the Company.

(ii) The Company, at its discretion, may terminate the Plan within 12 months of a corporate dissolution taxed under Section 331 of the Code, or with the approval of a bankruptcy court pursuant to 11 U.S.C. §503(b)(1)(A), provided that amounts deferred under the Plan are included in the gross income of Participants in the latest of the following years (or, if earlier, the taxable year in which the amount is actually or constructively received):

(A) The calendar year in which the Plan termination occurs;

(B) The first calendar year in which the amount is no longer subject to a substantial risk of forfeiture; or

(iii) The Company, at its discretion, may terminate the Plan pursuant to irrevocable action taken by the Company within the 30 days preceding or the 12 months following a Change in Control, provided:

(A) All agreements, methods, programs and other arrangements sponsored by the Company (or its successor) immediately after the Change in Control which are treated as a single plan under Section 1.409A-1(c)(2) of the Regulation are also terminated;

(B) All payments to Participants due under the Plan are made within 12 months of the date of the Plan’s termination; and

(C) All participants under the other terminated similar arrangements described in clause (i) are required to receive all amounts of deferred compensation within 12 months of the action taken by the Company (or its successor) to terminate such arrangements.

(iv) In accordance with such other events and conditions as may be prescribed by the Secretary of the Treasury in generally applicable guidance published in the Internal Revenue Bulletin.

If the Plan is terminated pursuant to this Section 12.1(b) at a date other than the date that the Company additions would normally be credited to Participant’s accounts, the Company may make, in the Compensation Committee’s sole discretion, a pro-rated discretionary Company addition to each Participant’s Account based on operating earnings of the Company generated through the date the Plan is terminated.

12.2 No Liability for Plan Amendment or Termination. Neither the Company, nor any officer, nor any Compensation Committee member thereof shall have any liability as a result of the amendment or termination of the Plan (including a termination pursuant to Section 13.1 below). Without limiting the generality of the foregoing, the Company shall have no liability for terminating the Plan notwithstanding the fact that a Participant may have expected to have future allocations made on Participant’s behalf hereunder had the Plan remained in effect.

Section 13. Change in Control

13.1 Change in Control. Notwithstanding any other provision of the Plan to the contrary, if the Company is involved in a Change in Control, the Plan will be terminated in accordance with Section 12.1(b) and Section 409A and all amounts deferred, including any growth additions and Company additions, will immediately vest and be paid out to the Participants in accordance with Section 12.1(b) and Section 409A.

Section 14. Requirements of Law

14.1 Requirements of Law. The payment of cash pursuant to this Plan shall be subject to all applicable laws, rules and regulations as may be required.

14.2 Governing Law. The Plan, and all agreements hereunder, shall be construed in accordance with and governed by the laws of the State of Tennessee.

Section 15. Withholding Taxes

15.1 Withholding Taxes. The Company shall have the right to deduct from all payments under this Plan an amount necessary to satisfy any Federal, state, or local withholding tax requirements.

Section 16. Effective Date of the Plan

16.1 Effective Date. This Amended and Restated Plan shall become effective as of May 25, 2011 (the “Effective Date”).

EX-10.3 4 ex10-3_063011.htm 2007 STOCK INCENTIVE PLAN PERFORMANCE CASH AWARD AGREEMENT, AS AMENDED ex10-3_063011.htm

Exhibit 10.3

HEALTHWAYS, INC.

2007 STOCK INCENTIVE PLAN, AS AMENDED

PERFORMANCE CASH AWARD AGREEMENT

This PERFORMANCE CASH AWARD AGREEMENT (the “Agreement”) dated as of the GRANT DATE (the “Grant Date”) is by and between Healthways, Inc., a Delaware Company (the “Company”), and PARTICIPANT NAME (the “Grantee”). Capitalized terms used but not defined in this Agreement shall have the meaning ascribed to such terms in the Company’s 2007 Stock Incentive Plan, as amended (the “Plan”).

Section 1. Performance Cash Award. The Grantee is hereby granted the right to receive a cash payment in the amount of $SHARES GRANTED (the “Cash Payment”), subject to the terms and conditions of this Agreement and the Plan.

Section 2. Performance Cycle. Subject to the vesting provisions of Section 3 hereof, the Grantee shall be eligible to earn the total Cash Payment granted hereunder as follows: one-third of the total Cash Payment during the fiscal year in which the award was granted (year one), one-third of the total Cash Payment during the following fiscal year (year two) and one-third of the total Cash Payment during the next following fiscal year (year three). Each such fiscal year shall hereinafter be referred to as a “Performance Cycle”. No later than ninety (90) days following the beginning of each Performance Cycle, the Committee shall establish and direct the Company to communicate to the Grantee (i) one or more performance metrics (each, a “Performance Metric”) which will be used during the applicable Performance Cycle and (ii) the methodology for determining, based upon such Performance Metric(s), whether or not the Grantee earned the applicable portion of the Cash Payment during the applicable Performance Cycle. Following the conclusion of each Performance Cycle, the Committee shall determine whether or at what level the Performance Metric(s) established for such Performance Cycle has been met and the amount of the Cash Payment, if any, which was earned by the Grantee in respect of such Performance Cycle. If one or more of the Performance Metric(s) for each Performance Cycle has not been met, as determined in the sole discretion of the Committee, then the portion of the Cash Award eligible to be earned during such Performance Cycle will be immediately forfeited and the Grantee shall have no further rights with respect to that portion of the Cash Payment. The determinations of the Committee under this Section 2 shall be final and conclusive as to the Grantee.

Section 3. Vesting.

(a) Vesting Date. The amount of the Cash Payment earned by the Grantee during each Performance Cycle, if any, (as determined in Section 2 above) shall vest on the third anniversary of the Grant Date (the “Vesting Date”); provided the Grantee remains continuously employed with the Company through the Vesting Date. If prior to the Vesting Date the Grantee’s employment with the Company is terminated for any reason other than as set forth in Section 3(b) of this Agreement or the Grantee’s employment agreement, then the entire Cash Payment set forth in this Agreement

(including amounts earned in a previous Performance Cycle) shall be immediately forfeited and the Grantee shall have no further rights with respect to such Cash Payment.

(b) Accelerated Vesting Event. Notwithstanding the foregoing, if the Grantee dies while employed by the Company or if the Grantee’s employment is terminated by Disability or Retirement (each an “Accelerated Vesting Event”), the Grantee shall be entitled to receive the amount of the Cash Payment previously earned by the Grantee during any Performance Cycle(s) which ended on or prior to the Accelerated Vesting Event. For illustrative purposes only, in the event a Grantee’s employment is terminated by reason of death, Disability or Retirement during year two (prior to the completion of the Performance Cycle for year two) and the Performance Metrics for the Performance Cycle ending year one were achieved, then the Grantee shall be entitled to receive 1/3 of the Cash Payment based on meeting the Performance Metrics for the Performance Cycle ending year one but shall not be entitled to any Cash Payment for the Performance Cycle ending year two or year three. The terms of any applicable employment agreement between Grantee and Company shall supersede the terms and conditions set forth in this Section 3(b).

Section 4. Distribution of the Cash Payment.

(a) The portion of the Cash Payment which (i) is earned by the Grantee during each Performance Cycle pursuant to Section 2 above and (ii) becomes vested as of the Vesting Date (as determined in Section 3(a) above) shall be distributed to the Grantee within ninety (90) days (as determined by the Company in its sole discretion) of the Vesting Date.

(b) Notwithstanding the forgoing, in the event of the occurrence of an Accelerated Vesting Event, the portion of the Cash Payment which (i) is earned during each Performance Cycle pursuant to Section 2 above and (ii) becomes vested due to an Accelerated Vesting Event, shall be distributed to the Grantee between January 1 and March 31 of the year following the year in which the Accelerated Vesting Event occurs.

Section 5. Tax Withholding. The Company may withhold from any distribution of the Cash Payment an amount equal to such federal, state or local taxes or as otherwise shall be required to be withheld pursuant to any applicable law or regulation.

Section 6. Change of Control. Unless the Committee otherwise determines, if before the Vesting Date described in Section 3(a) above or an Accelerated Vesting Event as described in Section 3(b) above, there occurs a Change in Control, the entire amount of the Cash Payment (to the extent not previously vested or forfeited) shall be deemed fully vested and shall be paid to the Grantee at the time of the Change in Control.

Section 7. No Right to Continued Employment. This Agreement shall not be construed as giving the Grantee the right to be retained in the employ of the Company, and, except as expressly set forth herein, the Company may at any time dismiss the Grantee from employment, free from any liability or any claim under the Plan.

Section 8. Adjustments. The Committee may make adjustments in the terms and conditions of, and the criteria included in this Agreement, as supplemented by the Performance Metric(s) and methodology communicated to the Grantee annually, in recognition of unusual or nonrecurring events affecting the Company, or the financial statements of the Company, or of changes in applicable laws, regulations, or accounting principles, whenever the Committee determines that such adjustments are appropriate in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan and this Agreement; provided, that the circumstances under which such adjustments shall be made to a Covered Employee that would increase the amount of the Cash Payment otherwise earned shall be set forth at the time the relevant Performance Metric is established.

Section 9. Plan Governs. The Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof. The terms of this Agreement are governed by the terms of the Plan, and in the case of any inconsistency between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall govern.

Section 10. Confidentiality, Non-solicitation and Non-Compete. It is the interest of all Grantees to protect and preserve the assets of the Company. In this regard, in consideration for granting the Grantee the rights hereunder and as conditions of Grantee's receipt of any Cash Payment, Grantee acknowledges and agrees that:

10.1 Confidentiality. In the course of Grantee's employment, Grantee will have access to trade secrets and other confidential information of the Company and its clients. Accordingly, Grantee agrees that, without the prior written consent of the Company, Grantee will not, other than in the normal conduct of the Company's business affairs, divulge, furnish, publish or use for personal benefit or for the direct or indirect benefit of any other person or business entity, whether or not for monetary gain, any trade secrets or confidential or proprietary information of the Company or its clients, including without limitation, any information relating to any business methods, marketing and business plans, financial data, systems, customers, suppliers, policies, procedures, techniques or research developed for the benefit of the Company or its clients. Proprietary information includes, but is not limited to, information developed by the Grantee for the Company while employed by the Company. The obligations of the Grantee under this paragraph will continue after the Grantee has left the employment of the Company. Grantee agrees that upon leaving the employment of the Company, Grantee will return to the Company all property and confidential information in the Grantee's possession and agrees not to copy or otherwise record in any way such information.

10.2 Non-Solicitation. While employed by the Company and for a period of one year thereafter, Grantee shall not, upon Grantee's own behalf or on behalf of any other person or entity, directly or indirectly, (a) hire or solicit to leave the employ of the Company any person employed by or under contract as an independent contractor to the Company; or (b) contact, solicit, entice away, or divert any business provided by the Company from any person or entity who is a client or with whom the Company was engaged in discussions as a potential client within one year prior to the date of termination of Grantee.

10.3 Non-Compete. While employed by Company and continuing during the period while any amounts are being paid to Grantee and for a period of twelve (12) months thereafter, the Grantee will not own or be employed by or assist anyone else in the conduct of any business (i) which is in competition with any business conducted by the Company or (ii) which Grantee knows the Company was actively evaluating for possible entry, in either case in the United States or in any other jurisdiction in which the Company is engaged in business or has been engaged in business during Grantee’s employment by the Company, or in such jurisdictions where Grantee knows the Company is actively pursuing business opportunities at the time of Grantee’s termination of employment with the Company; provided that ownership of five percent (5%) or less of the voting stock of any public company shall not constitute a violation hereof.

In the event Grantee breaches any provisions of this Section 10, this Agreement shall immediately expire, the Grantee shall have no further rights with respect to the Cash Payment, and the Company shall be entitled to seek other appropriate remedies it may have available to limit its damages from such breach.

Section 11. Repayment of Certain Amounts. If any of the Company's financial statements are required to be restated, resulting from errors, omissions, or fraud, and if, as a result, it is determined that any Cash Payment paid to Grantee as described above was greater than the amount that should otherwise have been accrued and payable hereunder (the excess an “Excess Payment”), then the Company shall be entitled to recover the Excess Payment, if any.

Section 12. Miscellaneous.

12.1 Entire Agreement. This Agreement and the Plan, as supplemented by the Performance Metric(s) and methodology communicated to the Grantee annually, contain the entire understanding and agreement between the Company and the Grantee concerning the Cash Payment granted hereby, and supersede any prior or contemporaneous negotiations and understandings. The Company and the Grantee have made no promises, agreements, conditions, or understandings relating to the Cash Payment, either orally or in writing, that are not included in this Agreement or the Plan.

12.2. Severability. If any provision of this Agreement is, or becomes, or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any person or the award of the Cash Payment, or would disqualify the Plan or the Cash Payment under any laws deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Cash Payment, such provision shall be stricken as to such jurisdiction, person or Cash Payment, and the remainder of the Plan and Agreement shall remain in full force and effect.

12.3 Captions. The captions and section numbers appearing in this Agreement are inserted only as a matter of convenience. They do not define, limit, construe, or describe the scope or intent of the provisions of this Agreement.

12.4 Counterparts. This Agreement may be executed in counterparts, each of which when signed by the Company and the Grantee will be deemed an original and all of which together will be deemed the same Agreement.

12.5 Notice. All notices required to be given with respect to the Cash Payment shall be deemed to be received if delivered or mailed as provided for herein, to the parties at the following addresses, or to such other address as either party may provide in writing from time to time.

To the Company:		Healthways, Inc. 701 Cool Springs Boulevard Franklin, Tennessee 37067

To the Grantee (Grantee name and address)		PARTICIPANT NAME Address on File At Healthways

12.6 Amendment. Subject to the restrictions contained in the Plan, the Committee may amend the terms of this Agreement, prospectively or retroactively, but, subject to Section 8 above, no such amendment shall impair the rights of the Grantee hereunder without the Grantee's consent.

12.7 Successors in Interest. This Agreement shall inure to the benefit of and be binding upon any successor to the Company. This Agreement shall inure to the benefit of the Grantee’s legal representative and permitted assignees. All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee's heirs, executors, administrators, successors and assignees.

12.8 Governing Law. The validity, construction and effect of this Agreement shall be determined in accordance with the laws of the State of Delaware without giving effect to conflicts of laws principles.

12.9. Resolution of Disputes. Any dispute or disagreement which may arise under, or as a result of, or in any way related to, the interpretation, construction or application of this Agreement shall be determined by the Committee. Any determination made hereunder shall be final, binding and conclusive on the Grantee and the Company for all purposes.

12.10. No Guarantee of Favorable Tax Treatment. Although the Company intends to administer this Agreement so that any Cash Payments will be exempt from, or will comply with, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), the Company does not warrant that any Cash Payments made under this Agreement will qualify for favorable tax treatment under Section 409A of the Code or any other provision of federal, state, local or foreign law. The Company shall not be liable to the Grantee

for any tax, interest, or penalties that Grantee might owe as a result of any Cash Payments made under this Agreement.

12.11. Delay of Payments Pursuant to Section 409A. It is intended that the Cash Payment eligible to be made under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A of the Code, including those provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(9)(iii), and 1.409A-1(b)(9)(v). Notwithstanding anything to the contrary in this Agreement, if the Company determines (i) that on the date the Grantee’s employment with the Company terminates or at such other time that the Company determines to be relevant, the Grantee is a “specified employee” (as such term is defined under Treasury Regulation 1.409A-1(i)(1)) of the Company and (ii) that any payments to be provided to the Grantee pursuant to this Agreement are or may become subject to the additional tax under Section 409A(a)(1)(B) of the Code or any other taxes or penalties imposed under Section 409A of the Code if provided at the time otherwise required under this Agreement, then such payment shall be delayed until the date that is six (6) months after the date of the Grantee’s “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)) with the Company, or, if earlier, the date of the Grantee’s death. Any payments delayed pursuant to this Section 12.12 shall be made in a lump sum on the first day of the seventh month following the Grantee’s “separation from service” (as such term is defined under Treasury Regulation 1.409A-1(h)), or, if earlier, the date of the Executive’s death.

IN WITNESS WHEREOF, the Company and the Grantee have executed this Agreement to be effective as of the day and year first above written.

HEALTHWAYS, INC.

By: /s/ Ben R. Leedle, Jr.

Name: Ben R. Leedle, Jr.

Title: Chief Executive Officer

GRANTEE: PARTICIPANT NAME

Online Grant Acceptance Satisfies

Signature Requirement

EX-31.1 5 ex31-1_063011.htm EX-31.1, SECTION 302 CEO CERTIFICATION ex31-1_063011.htm

Exhibit 31.1

CERTIFICATION

I, Ben R. Leedle, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Healthways, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2011

	/s/ Ben R. Leedle, Jr.
	Ben R. Leedle, Jr.
	Chief Executive Officer

EX-31.2 6 ex31-2_063011.htm EX-31.2, SECTION 302 CFO CERTIFICATION ex31-2_063011.htm

Exhibit 31.2

CERTIFICATION

I, Alfred Lumsdaine, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Healthways, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2011

	/s/ Alfred Lumsdaine
	Alfred Lumsdaine
	Chief Financial Officer

EX-32 7 ex-32_063011.htm EX-32, SECTION 906 CEO AND CFO CERTIFICATION ex-32_063011.htm

Exhibit 32

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Healthways, Inc. (the "Company") on Form 10-Q for the period ended June 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, Ben R. Leedle, Jr., President and Chief Executive Officer of the Company, and Alfred Lumsdaine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ben R. Leedle, Jr.

Ben R. Leedle, Jr.

President and Chief Executive Officer

August 8, 2011

/s/ Alfred Lumsdaine

Alfred Lumsdaine

Chief Financial Officer

August 8, 2011

GRAPHIC 8 hwaylogo.jpg begin 644 hwaylogo.jpg M_]C_X``02D9)1@`!`0$!+`$L``#_X0!F17AI9@``24DJ``@````$`!H!!0`! M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@`````` M```L`0```0```"P!```!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$! M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H* M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H* M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`&@` MWP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_ MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-CH.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($ M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B M7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X MN;K"P\3%QL?(RKR\_3U]O?X^?K_V@`,`P$` M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`&,]))N*EL MY].:^;/VV/\`@H]\-?V4;_3/AGX=\/:AXX^)OB4[/"WP^\._/>7A.0)93@BW M@RIS(P/"N55MC[6E'[OQ;X`^&]OXRLK?5KG3I?$&JZUJ6H" MZN8'\NCJ&RI`?*K7-YX;#TI)?`O[(_[0?Q`^&'C7P7=PIK>G>&/& M-\8K:2:$2V[S:=J#2036[J$];M=1T^_MDN+&^L[A9 M8KB)U#)(CJ2&5@000<$&MY2I8XJ6NYPSA.G)QDK-#J***0@HHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBD;H?I0!\^?\`!1W]M30/V%?V9M<^ M,VIQQ76I!19^'-,D?'V[4)01%&>0=HPTCXY$<;D9(`KQ+_@D)^Q7X@\,^$;K M]MS]IVZFUKXN_$]1J6H:CJ4>9=+LI0&AM(P?]5E-A95"A<)$`!$,^&_\%C=2 ME_:7_P""EW[/?[%-S&9M%2[BUO6[(L?+NHI;E@ZL.A*P65P`>WGMZU^J6CP0 MV>G0PK&%V1@8`QC`HUOZ'TF(2RW**:AI.I=M];+9>A\&_P#!>']KCQ_\)?A3 MX(_8O^`VNMIOC[X^^)8O#=GJ%NQ$MAISRPP7$B$'*/(]Q#"IX.V24J0R`C[1 M^"OPD\&_`;X2>&O@O\.M,6TT/PMHMOIFEVZ@9$,*!`6(^\QQN9NK,23R:_'W M_@M=\0%\*?\`!?#]F?4/%-V(]%T-/"=Z?-/R1*WB.Z\V;GN!&N?^N8K]'?VO M/^"I?[(?[$?BW2_`OQT\?((P=B;E8#/S-M; M:#M./0Q-%4\-3LMTVWW=_P!#Y[!X7%8ZM*%*+E+LE=V/GW_@MKX\\2_L(?%C MX,_\%/OAE#*)]"\1CP=\0].MC@:[H%VLEP()>Q\IX9FC)^[+.K,,IP>JLK`CZBOSS_X.//CS\,_B M1_P2I.6.G MS2NW^A[R>`T@>(J.LGEN%7SVK]2(IEG4/&ORD9%?FK_PQ]%FU*&(P-+&15G*ZEZJVOS/0J***D^>"BBB@ M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*1QE"*6@C(Q0!^3G[;TL7P M]_X.!_@?XNUM=FG:GX9BLK:YD.%:>5M3M@@]P\\7_?8K]6;+8MK&JC.$&:_/ M'_@OQ^S5XW\3?![PK^V#\(+*1O$_P>UM=6#PH6=;(O')))M`RWE20P2G/"HL MIKZM_9<_:^^&'[1'[+>D?M-:9K$5IHDVA&]U5I'+G3FB4_:(I-HSNB=74X'. MS(X(JVKK0^GS1_6LJHUH.ZBN67D^ES\W/^#K3]D_Q-KGA?X?_MI^#].EFC\- M%_#WBFX@4EK:"67S;*8D?=19C/&6/\=Q$!R:X_0/V3M._P""^?PW$?M;_#W MXZ:;X?\`'VA:!9^&OBQH&I6+3[+RWW[;Z,(P*K.K&15QL(RNX-')G[I_:@_X M*W?\$?=5^%6O_#?XU?M+>%?%.A:WILUEJOA_2X+C4GNXW4AHMMLC%&]&)7:P M!W*0"/QY^%OQ-UI]1\4_L[?\$-_V=OB;)=>-`]AXD^)&N3^?K4FG-)E;2/R` MMKI5N.]P[&5N"9(\8KW\+%8S`QHU%RN+NI/16>]SY[`9IB%I&)2:R MANHHV\V[P-LMP%$2@F)'_P!87_7SX'_MZ_L=?M+:Z?#/P"_:&\->+-26V:XD ML=&O?.ECB7&6=0,H.1][%8YM4A:%"DGR16_1M[LY/;5<7B)5JCO.3;?S/F3_ M`(.+?%6EZ%_P3WU71M0G59M:\1:7:62D\M(L_P!H('_`('/X5]&?\$X_#.J> M$OV'_A1H6LP-%>6GP[T:.ZB?K'(+*'_-[XJ\&:4AFO_``G,!?#7 M@#QO!/@R:C:;XM^)5R&@N#X;LH MUT;PFA^5KF\E0"%64YQ%G[RX;G:C^A:I_P`$U]5^*P^S?M.?MB_%+QYITB%+ MOP]%JT&B:9=(>JRPZ9#`\BGT:0BOEPD'[ M+I5DD0=L`;W(&9'(`R[$L>Y-)S=K7-,.\%A)>T?O26RM9>K[GC'_``39_P"" M>'A_]B3P/?:YXHUY_$_Q%\7W7V_QSXONB6DO;IBSE$+_`#>4K.Y!/S.S,[8R M%7ZA#$=?YT@`SDD9^E)D9(W@$5!QXK$U,55=2;NW_5D2T444&(4444`%%%%` M!1110`4444`1@'=TXQ41NX/.^SBX3=G!3>,YQG'Y([&$@#_OY^M.GAG/#SJ7MRVT[W93G[RCW/U?> M\MDE^SM<('*Y\LN-V/7%1&]M1*L`N4+RD[$WC)P,\#OP":_(+_@O-$O"WQC M_P""K?[*?PM\;P32Z'XMN+?2-;@@NW@::T?58UD0/&0R$I*P!!!&>"*^SOV< M/^"*?["7[*?QX\/_`+1?P/\`"7B#2O$?AU;H67G^*;F[@D%Q:RVT@=+AGS\D MS$%2I!`[9!)X>%*C&I*3O)72MYVW)C4U5C>V1NUL&O(A.R META,@WE>Y`ZX]ZL2?NX]['A1S7X3?M!?\%!OB%X7_P""VGAC]OVZAGC^#>E^ M.+OX5Z?K!G_T:>RM$CCU*0XX9%GOGND;H_D@`GRVP83!RQ+:3M9-^K[#J5%3 MLV?NR"0.O;FH3=0++Y4EPH;(!7(R">@IT4B7,:SH>&&0<]C7Y$?MD:;<-_P= M`_!"W65Q%=^&+*Z>,.=K&.'5<$C../*J<-AGB)2C>W*F_NZ#G444GW9^O$\L M4$;32R*JA269S@`>I/I2+=6TB!XKJ/:>C*X(-8?Q-\":+\5OAQK_`,+?$\DZ MZ9XET6ZTO47M)`DH@N(6BM+-<0VS?Z3(B?*6RS`<#J?PR/SK\ M^_V"?^"*7["WAWP9\&?VN=!\.>)+/QE9Z!HGB-+E?$]Q-!+>M:Q3.6AF+KM9 MV8[5QC/RD8&/'/\`@ZVTJ74/AS\#I4E90_C6^M'VL1E988<@XZCY*TCA85<2 MJ-.5[WU:MMKM!OM*KOX#OI^BJ3C_MH?SJ:&%=53=[WN*_*#_@Z&^#.OZ) M\/?A9^W1\/D>'6OA]XMCL+^Y@!SY$K"XM9),?PQ7-OM'O='UX^]_B9^UKX+\ M(?L(ZI^VOID\3Z/#\-6\5:R^T01Y[ERR(!W+`4GA'[.%2+OS-JW9Z M`JFLD^A[!9:A9WRL]I>13*IP3%(&QQ[4Z:ZMK9"UQ.B!5+%G8`8'4_05^,O_ M``:]_&#Q]X$^-7Q<_9*^+ZWEKK.M:3IOC6QL]1)$N9$3SI"#_%+%>6+XZ@+R M.N/HS_@I3X.'[8?_``5?_9D_8[57FT;P=;:A\1/'5NIRC6<4L<=JLB_W'GMF MA(/47-:5<%*C7=.3T2O?RMFWT?PIH5UJFHR`_,8H(FD*KGJQV MX4=R0.]?CW_P0L_:M^./@/\`X*8>.?A?^U%9S:9??M'Z%#XZT>&YDRDEU+&^ MH6_E9.%1K.>X7'4&V1,97`BAA)UX3G%_"KV[]_N14JL8R2?4_:N6\LXYA;37 M4:R%2X1G`;:#UQZ>]3AUD4-GCU!KXH_X+K?L"3?MQ?L6ZC<^!-+>;Q]X$$NM M>$C;J?-NE5/]*L1CD^=$HVKWEBASP#6%_P`$@_\`@I9X!^+_`/P2YC^,'QA\ M7);:E\'-"ETSQ_-.^91'8V^Z&Z()RYFME0Y_BE$BC)%3'#.=#VD'>SLUVOL_ MF#J6GRL^[3>6K2BW\U=[,0$W#)(&2,?3FF7VJZ;IBAM3U&"!7;:IEE"@GT&3 MUKX'_P"".'P&\87GAGQ__P`%4/CYX>G/C_XXWMSK&C:;(2\FC^'2=]I:1Y[R MHD+9_BCCMLX*FO`_^"3/P(_9H_X+,>!OB'^U'^WM++\1OB%<^-+FS30+WQ)= MP0>%=+,4;VT-I;P3)Y4;%I-LN.3&0#N60MHL)I*3=XQLFTKZO]/,EU;65M6? MK\KJV=N"/8T^OGS_`()X_L57/["7PCUKX+0_%76_%.E3>,+[4/#I69BL-0GQ%*/NAPNQ MO578=Z_9YMRMC':OSO\`$O[!G[5>J_\`!?\`T#]N^'P1:M\,-+T!]/DUM]9M MA*I.B7,&1;[_`#-_P"U-,BM-7@O%DA:S@B8EH78*0T1&#[=171'%RJX M&I"I)7;5EHGOKL#IJ,XN*[GS_P#\%ZO`E_\`$S_@J1^R7\.-*\9ZIX:NM9U% M;2W\0:'*([S37?4K=5N(&((61#AE.."!7VW^RU_P3Y^+'[./QJA^*?BG_@H3 M\8?B/IJ:3/9GPIXYUO[39EY"FV<*A5?,3:0"5/#GI7SK_P`%=?V*_P!NCXU_ MM^?`S]I_]E;X+:?XKT_X6PP7]PFH>)K33TFNX]0\_P"SGS7#@%$3+JI`W<S?!?X]_P#!9'Q)\:/#/A_XT_L+^`?"_@BZO]GB77;#Q]%?W-G;[&.^.,2J M6)8*.%;`).#BHK.4\+3C&2LD[IM7W^\FFK5).S.T_P""KO[5]W^QQ^PYXS^) MOAFYE_X2K4;5="\$VT/,TVKWI,,!C7^)H\O/M[K`P%?E]^T-^QI_P4FO?^"5 M&E_L:>(?^":&F:;I/PZB/B)/&EI\4-/N[W[7$9I[RY^R)\TK2I-(]3DU:`->:TB2/:I]E+ M^8ZQO#`H;;C%U-G(%?:$]O#+;M;,JLK*596&1CITI8?%0P<(N*4FW=WOIT2T M'.G[5NY\C?\`!$#]KT_MB_\`!/+P7XIUG4C<^(_"T!\,^)R[[G-U9HB)*Q/5 MI;=H)B?[TK#M7RI^ULB2_P#!T7\!E9>/^%?J0!ZBWUPC^5>D?\$E_P!@3]KS M_@GE^VU\9/#%W\/K8?`GQOJ5S=>%M0M]=MI'LGAN':R+6_F>8H:WFDA#_P!OS]EW]GW2/%^C>"O"4%E:1ZSXMM+" M*ZG,5]'(A#2>:H47><[,$BNBA*C'%5&FDI1=M=+NVA$N=THIK5-?@?J$H8KN M=>?2OSI_X.@W5?\`@F0P+`$_$#20,^NV>O7OV;/C=_P5L\8_'W1_#'[3'[$W M@SP7\/YX+DZQXATCQO#J5S!(L#M"JHLRMAI0BDB-\`]A\PP/^"[/['G[0?[< M?[&6G_!/]F[PO;:MKO\`PG5E?W<-WJD-HD=I%;W09R\K*"=[Q+M&3\V<8!(X M*$50Q47)JR=[IW1M.\XNR/HG]BN-8?V.OA5&G"CXW]@S]J;]NK M3?A'IG[-7@BTUB/PKXAOM0U_[7K%O:>4K+;"+;YSKO)VR\#IMYQD9UP=>%/' M>T;LDWK\B)Q;A9>1I6__``1)^(Z0"*/_`(*Y_M2JC#)0?$A_3Z5\R?\`!+CX M)ZE^SW_P<.?&/X.:S\6O$?CBYT3X6LLGBKQ??&ZU*^,@T*4&:4\L5$GEKZ*B MCM7[)6\/DPK$YSM4#-?GU^SG^PO^U/\`#_\`X+I?%G]MSQ9X%M(/AUXO\)R: M9I&K)K-L\LCB/2PFZ!7,B@FTD'*\8&>HST4,"/$RQRD3)X?\$:OC!^R3_P`%0OB)^T;\1O"EC:_#_3Y= M;'PKEAU2&9B+R[58Y#$C%H2MEOC.X#.\>F*QPF(IO#SC.5G%WCYO;_(=2,G- M-==S`_X**Z?;?\$__P#@N%^S_P#ME:':P:?X7^(EFGA?Q-Y*!(0R!;!Y),8` M1+>ZLG4?].G&<8'T3_P3)A;]I#]M']I3]ON]B\ZPO/%T7P]\"S-RJZ9I"*MQ M+$>\4]P5D_WD;Z5H?\%U/V!OB9^WY^Q[9^"?@?H-O?\`C?PUXLL]5T*">^BM MO-C(>"X3S92JJ/+F\T@D9,*@9.!7L'_!-']F#4/V.?V&_AS^S_XAM$@UO2=" M6?Q,B2K+_P`32Y=KF['F*2)-L\LBA@2"JC'&*NOB*-3!QE?W]GZ=_P!`A3E& MHUTW/F7_`(+V_$+XF?$[PU\/_P#@F[^S]X3?Q1XQ^+FN&_UCP]!J<=FTVA:; MBZFC>>0A;<2R1H!(>"()%P2<'XM_X*QM_P`%$O!7COX5?\%#OB'^P5I/PH?X M/:C964>JZ'X^M-6BN85N5DM+::.`!HH5<31YP5(NBAQD`_HA^SC^RA^TAK7_ M``5A^+O[=?[2_@Z#3=$@\,V_A3X06XU6WNF_LT3%IIML3L8&=H1+A\'_`$UU M[,![[^W)^SKIO[67[(_Q"_9UO;:)W\4^&+FUT]YL;8;T+YEK+S_";S[1HOBO0;75 M-,E/WC#/$LBAAV8!L,.Q!!Z5^*?[2G[$MK\.O^"XJ?L*>`O'%UH_PL_:-DT[ MQ/XV\+6(V13VD%S=WDMB<8V@W%A<>64QL2YVC(!!_0?_`((>?`G]LW]EG]D` M_LT?M?\`@>'2KGPOJ\K>$;NVUNVO4FTZX)F:$F&1BKQ3M-][`VRQA+QAX9^*&K_M5?\`!+_]H#4OASXN MFN)K[_A%#J$MI;-*[%WCM+N`A[=&/2&17CRV-R(`!^HWC.V\1WWA+5;/PA=1 M6VKRZ=.FF3W!81QW!C81LQ4$A0^TG'.!7P/\#/C_`/\`!N M:DUHD$MTDIN$59T0!!<1RVEPCE`%("'&=Q/WX'`7`/-?)O\`P2I_8*\:?L7? M#WQEXY^-WB/3=7^*7Q9\73^)_']YI$3"T@N)7=UM82P!9(VEF;<0,M,X'RA3 M7UDK#/BI4ZF(E*"LGVV\[?,NDI*FN;<=11169H%%%%`!1110`4444`%%% H%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_ ` end EX-101.INS 9 hway-20110630.xml XBRL INSTANCE DOCUMENT 0000704415 2011-06-30 0000704415 2010-12-31 0000704415 2011-04-01 2011-06-30 0000704415 2010-04-01 2010-06-30 0000704415 2011-01-01 2011-06-30 0000704415 2010-01-01 2010-06-30 0000704415 us-gaap:PreferredStockMember 2010-12-31 0000704415 us-gaap:CommonStockMember 2010-12-31 0000704415 us-gaap:AdditionalPaidInCapitalMember 2010-12-31 0000704415 us-gaap:RetainedEarningsMember 2010-12-31 0000704415 us-gaap:TreasuryStockMember 2010-12-31 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2010-12-31 0000704415 us-gaap:PreferredStockMember 2011-01-01 2011-06-30 0000704415 us-gaap:CommonStockMember 2011-01-01 2011-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2011-01-01 2011-06-30 0000704415 us-gaap:RetainedEarningsMember 2011-01-01 2011-06-30 0000704415 us-gaap:TreasuryStockMember 2011-01-01 2011-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-01-01 2011-06-30 0000704415 us-gaap:PreferredStockMember 2011-06-30 0000704415 us-gaap:CommonStockMember 2011-06-30 0000704415 us-gaap:AdditionalPaidInCapitalMember 2011-06-30 0000704415 us-gaap:RetainedEarningsMember 2011-06-30 0000704415 us-gaap:TreasuryStockMember 2011-06-30 0000704415 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2011-06-30 0000704415 2009-12-31 0000704415 2010-06-30 0000704415 2011-08-04 iso4217:USD iso4217:USD xbrli:shares xbrli:shares

82210000

89108000

-2679000

-3433000

172860000

154528000

239796000

232524000

954000

869000

0.17

0.35

0.29

0.62

222005000

207077000

955000

1064000

2356000

1082000

6391000

-11782000

-12421000

-27779000

2084000

-6437000

120000000

33808298

34018706

34000

10668000

15302000

10117000

126009000

121985000

247917000

250852000

8970000

9928000

17994000

20161000

124071000

125233000

-2757000

1908000

13657000

11272000

24621000

23050000

6275000

5931000

<div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td align="left" valign="top" width="5%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(5)</font></div></td><td align="left" valign="top" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Derivative Investments and Hedging Activities</font></div></td><td valign="top" width="34%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">We use derivative instruments to manage risks related to interest rates and foreign currencies.  We record all derivatives at estimated fair value as either assets or liabilities on the balance sheet and recognize the unrealized gains and losses in either the balance sheet or statement of operations, depending on whether the derivative is designated as a hedging instrument.  As permitted under our master netting arrangements, the fair value amounts of our derivative instruments are presented on a net basis by counterparty in the consolidated balance sheets.</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Interest Rate</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">In order to reduce our exposure to interest rate fluctuations on our floating rate debt commitments, we maintain interest rate swap agreements with notional amounts of $335.0 million ($145.0 million of which will become effective in January 2012 and $30.0 million of which will become effective in January 2013) and termination dates ranging from December 30, 2011 to December 31, 2013.  These interest rate swap agreements effectively modify our exposure to interest rate risk by converting a portion of our floating rate debt to fixed obligations with interest rates ranging from 0.580% to 3.855%, thus reducing the impact of interest rate changes on future interest expense.  Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest.  We have designated these interest rate swap agreements as qualifying cash flow hedges.  We currently meet the hedge accounting criteria under U.S. GAAP in accounting for these interest rate swap agreements.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Foreign Currency</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">We enter into foreign currency options and/or forward contracts in order to minimize our earnings exposure to fluctuations in foreign currency exchange rates.  Our foreign currency exchange contracts do not qualify for hedge accounting treatment under U.S. GAAP.  We routinely monitor our foreign currency exposures to maximize the overall effectiveness of our foreign currency hedge positions.  We do not execute transactions or hold derivative financial instruments for trading or other purposes.</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><br /> </div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Fair Values of Derivative Instruments</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The estimated gross fair values of derivative instruments at June 30, 2011 and December 31, 2010, excluding the impact of netting derivative assets and liabilities when a legally enforceable master netting agreement exists, were as follows:</font></div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td bgcolor="#ffffff" valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="39%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="2" valign="middle" width="14%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2011</font></div></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="2" valign="middle" width="14%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31, 2010</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="39%" style="border-bottom: black 2px solid;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(In $000s)</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Interest rate swap agreements</font></div></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Interest rate swap agreements</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Assets:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="39%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: times new roman;">  Derivatives not designated as hedging instruments:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="middle" width="39%" style="padding-bottom: 2px;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"><font style="display: inline; font-style: italic;">     </font>Other current assets</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$98</font></div></td><td align="right" valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></div></td><td valign="top" width="2%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$136</font></div></td><td align="right" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></div></td><td valign="bottom" width="4%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr bgcolor="#eaf9e8"><td bgcolor="white" valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> </font></td><td bgcolor="#eaf9e8" valign="middle" width="39%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> <font style="letter-spacing: 9pt;">   </font><font style="display: inline; font-size: 10pt; font-family: times new roman;">Total assets</font></font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> </font></td><td bgcolor="#eaf9e8" valign="top" width="7%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$98</font></font></td><td bgcolor="#eaf9e8" valign="top" width="7%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> <font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></font></td><td bgcolor="#eaf9e8" valign="top" width="2%" style="text-align: left;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$136</font></font></td><td bgcolor="#eaf9e8" valign="middle" width="7%" style="text-align: right;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></font></td><td bgcolor="white" valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;"> </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="39%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;"><font style="display: inline; font-style: italic;"> </font><font style="display: inline; font-weight: bold;">Liabilities:</font></font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: times new roman;">  Derivatives not designated as hedging instruments:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">     Accrued liabilities</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$263</font></div></td><td align="right" bgcolor="#ffffff" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></div></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$245</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$-</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: times new roman;">  Derivatives designated as hedging instruments:</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">     Accrued liabilities</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">2,253</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">4,465</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">     Other long-term liabilities</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td align="right" bgcolor="#ffffff" valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3,746</font></div></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">2,593</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="39%"><div align="left" style="display: block; margin-left: 36pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Total liabilities</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$263</font></div></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$5,999</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$245</font></div></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$7,058</font></div></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="white" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="39%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"> </div></div><div style="display: block; text-indent: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="letter-spacing: 9pt;">   </font> See also Note 6.</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"> </div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;"><font style="display: inline; text-decoration: underline;">Cash Flow Hedges</font></font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Derivative instruments that are designated and qualify as cash flow hedges are recorded at estimated fair value in the balance sheet, with the effective portion of the gains and losses being reported in accumulated other comprehensive income or loss (“accumulated OCI”).  Cash flow hedges for all periods presented consist solely of interest rate swap agreements.  Gains and losses on these interest rate swap agreements are reclassified to interest expense in the same period during which the hedged transaction affects earnings or the period in which all or a portion of the hedge becomes ineffective.  As of June 30, 2011, we expect to reclassify $3.9 million of net losses on interest rate swap agreements from accumulated OCI to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Gains and losses representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.  The following table shows the effect of our cash flow hedges on the consolidated balance sheet during the three and six months ended June 30, 2011 and June 30, 2010:</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td bgcolor="#ffffff" valign="top" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="24%"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(In $000s)</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="24%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)</font></div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">For the Three Months Ended</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="3" valign="bottom" width="24%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)</font></div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">For the Six Months Ended</font></div></td><td bgcolor="#ffffff" valign="top" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="4%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="middle" width="24%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Derivatives in Cash Flow Hedging Relationships</font></div></td><td valign="top" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2011</font></div></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="13%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2010</font></div></td><td valign="top" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="12%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2011</font></div></td><td valign="top" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2010</font></div></td><td colspan="3" valign="top" width="7%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="4%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="24%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Interest rate swap agreements, gross of tax effect</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="11%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$(235)</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="13%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$(677)</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="12%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$1,059</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="11%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$(1,319)</font></div></td><td colspan="3" valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">During the three and six months ended June 30, 2011 and 2010, there were no gains or losses on cash flow hedges recognized in income resulting from hedge ineffectiveness.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;"><font style="display: inline; text-decoration: underline;">Derivative Instruments Not Designated as Hedging Instruments</font></font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Our foreign currency exchange contracts require current period mark-to-market accounting, with any change in fair value being recorded each period in the consolidated statement of operations in selling, general and administrative expenses.  At June 30, 2011, we had forward contracts with notional amounts of $9.7 million to exchange foreign currencies, primarily the Australian dollar and Euro, that were entered into to hedge forecasted foreign net income (loss) and intercompany debt.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">These forward contracts did not have a material effect on our consolidated statements of operations during the three or six months ended June 30, 2011 and 2010.</font></div><div style="display: block; text-indent: 0pt;"><br /></div></div>

0.17

0.34

0.29

0.61

521000

-302000

4528000

5591000

27437000

27328000

1885000

8695000

-469000

91297000

94255000

496265000

3170000

3612000

6588000

7034000

41147000

40662000

845383000

861689000

3166000

4178000

3935000

223200000

243425000

-24821000

-3025000

-24781000

-25035000

48972000

27088000

5778000

11838000

9914000

21252000

9914000

109000

1274000

13438000

21494000

24225000

40837000

111000

643000

2802000

3064000

3586000

2814000

611000

-2881000

5000000

0.001

10393000

12577000

203147000

417450000

3736000

532000

305891000

285184000

133031000

130656000

21664000

23384000

1163000

223198000

415766000

9456000

216124000

206210000

169596000

175523000

332565000

354522000

17706000

18703000

35547000

35938000

339000

806000

111902000

125780000

34790

34933

34711

34928

33942

34117

33957

34037

845383000

861689000

4080000

3309000

34166000

39140000

<div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td align="left" valign="top" width="5%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(3)</font></div></td><td align="left" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Share-Based Compensation</font></div></td><td valign="top" width="48%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">We have several shareholder-approved stock incentive plans for employees and directors.  We currently have three types of share-based awards outstanding under these plans: stock options, restricted stock units, and restricted stock.  We believe that such awards align the interests of our employees and directors with those of our stockholders.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">For the three and six months ended June 30, 2011, we recognized share-based compensation costs of $2.3 million and $4.5 million, respectively.  For the three and six months ended June 30, 2010, we recognized share-based compensation costs of $2.6 million and $5.6 million, respectively.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">A summary of our stock options as of June 30, 2011 and changes during the six months then ended is presented below:</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="25%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="9%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Weighted-</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="25%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="9%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Average</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="25%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="9%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Weighted-</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Remaining</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Aggregate</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="25%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Shares</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="9%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Average</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Contractual</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Intrinsic</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="25%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Options</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(000s)</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="9%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Exercise Price</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Term (years)</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="8%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Value ($000s)</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Outstanding at January 1, 2011</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">6,208</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="3%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">17.12</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Granted</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">368</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14.70</font></div></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Exercised</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(332</font></div></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td bgcolor="#eaf9e8" valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">11.06</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Forfeited or expired</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(172</font></div></td><td align="left" valign="bottom" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14.93</font></div></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Outstanding at June 30, 2011</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">6,072</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">17.37</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">5.30</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$ 14,598</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Exercisable at June 30, 2011</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3,576</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">19.64</font></div></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3.14</font></div></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$   7,407</font></div></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="3%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2011 was $9.03 and $8.32, respectively.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The following table shows a summary of our restricted stock and restricted stock units (“nonvested shares”)<font style="display: inline; font-size: 10pt;"> </font>as of June 30, 2011 as well as activity during the six months then ended:</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="24%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="11%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Weighted-</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="24%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="11%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Average</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="24%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="7%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Shares</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="11%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Grant Date</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="24%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Nonvested Shares</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(000s)</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="top" width="11%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Fair Value</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="24%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Nonvested at January 1, 2011</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">1,153</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="top" width="4%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15.29</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="24%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Granted</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">183</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="top" width="4%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">14.71</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="24%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Vested</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(180</font></div></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="4%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">16.44</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="24%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Forfeited</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="top" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(62</font></div></td><td align="left" valign="bottom" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="top" width="4%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">12.83</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="17%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="top" width="24%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Nonvested at June 30, 2011</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">1,094</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="top" width="4%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">15.18</font></div></td><td valign="top" width="13%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div></div>

<div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td align="left" valign="top" width="5%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(6)</font></div></td><td align="left" valign="top" width="23%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Fair Value Measurements</font></div></td><td valign="top" width="50%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">We account for certain assets and liabilities at fair value.  Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.</font></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Fair Value Hierarchy</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:</font></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="71%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Level 1:  Quoted prices in active markets for identical assets or liabilities;</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="71%"><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Level 2:  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and</font></div></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="top" width="71%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Level 3:  Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.</font></div></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="display: inline; font-size: 10pt;">The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2011 and December 31, 2010</font>:</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="36%" style="border-bottom: black 2px solid;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(In $000s)</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30, 2011</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="5%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Level 2</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Gross Fair Value</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="6%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Netting <font style="display: inline; font-size: 70%; vertical-align: text-top; font-family: times new roman;">(1)</font></font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Net Fair Value</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Assets:</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="top" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">98</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">98</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(45</font></div></td><td align="left" bgcolor="#ffffff" valign="middle" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="2%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">53</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="36%"><div align="justify" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Liabilities:</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">263</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">263</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(45</font></div></td><td align="left" valign="middle" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td align="right" valign="bottom" width="2%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">218</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Interest rate swap agreements</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">5,999</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">5,999</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">5,999</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><div style="display: block; text-indent: 0pt;"><br /></div></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="36%" style="border-bottom: black 2px solid;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(In $000s)</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">December 31, 2010</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="5%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Level 2</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Gross Fair Value</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="middle" width="6%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Netting <font style="display: inline; font-size: 70%; vertical-align: text-top; font-family: times new roman;">(1)</font></font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%" style="border-bottom: black 2px solid;"><div style="display: block; text-indent: 0pt;"> </div><div style="display: block; text-indent: 0pt;"> </div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Net Fair Value</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Assets:</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="top" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">136</font></div></td><td bgcolor="#ffffff" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">136</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(116</font></div></td><td align="left" bgcolor="#ffffff" valign="middle" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="2%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">20</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="36%"><div align="justify" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Liabilities:</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="middle" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Foreign currency exchange contracts</font></div></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">245</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">245</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="1%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">(116</font></div></td><td align="left" valign="middle" width="1%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">)</font></div></td><td align="right" valign="bottom" width="2%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">129</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td valign="top" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="middle" width="36%"><div align="left" style="display: block; margin-left: 54pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Interest rate swap agreements</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="top" width="5%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">7,058</font></div></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">7,058</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">-</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="middle" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">7,058</font></div></td><td valign="bottom" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><div style="display: block; text-indent: 0pt;"><br /></div><div style="display: block; text-indent: 0pt;"><br /></div></div><div align="left" style="display: block; margin-left: 54pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="display: inline; font-size: 70%; vertical-align: text-top;">(1)</font> This column reflects the impact of netting derivative assets and liabilities by counterparty when a legally enforceable master netting agreement exists. </font></div><div style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><div style="display: block; text-indent: 0pt;"><br /></div></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The fair values of forward foreign currency exchange contracts are valued using broker quotations of similar assets or liabilities in active markets.  The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using internal models and third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads.</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-style: italic; font-family: Times New Roman;">Fair Value of Other Financial Instruments</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">In addition to foreign currency exchange contracts and interest rate swap agreements, the estimated fair values of which are disclosed above, the estimated fair value of each class of financial instruments at June 30, 2011 was as follows:</font></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr valign="top"><td style="width: 36pt;"><div><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">  </font></div></td><td style="width: 18pt;"><div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="display: inline; font-family: Symbol, serif;">·</font></font></div></td><td><div align="left"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Cash and cash equivalents – The carrying amount of $1.0 million approximates fair value because of the short maturity of those instruments (less than three months).</font></div></td></tr></table></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div><div><table align="center" border="0" cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr valign="top"><td style="width: 36pt;"><div><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">  </font></div></td><td style="width: 18pt;"><div style="margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;"><font style="display: inline; font-family: Symbol, serif;">·</font></font></div></td><td><div align="left"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">Long-term debt –The estimated fair value of outstanding borrowings under our credit agreement is based on the average of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Fourth Amended Credit Agreement (see Note 7) at June 30, 2011 are $214.8 million and $222.6 million, respectively.</font></div></td></tr></table></div><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><br /> </div></div>

13950000

4494000

-339000

-806000

12888000

14733000

10268000

19045000

17637000

34966000

0.001

1101765

429654

439325000

430841000

34000

232524000

206210000

-4494000

-3433000

34000

239796000

216124000

-13950000

-2679000

4490000

7207000

7723000

13714000

3736000

9456000

-992000

<div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td align="left" valign="top" width="5%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(13)</font></div></td><td align="left" valign="top" width="25%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Earnings Per Share</font></div></td><td valign="top" width="50%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div><div style="display: block; text-indent: 0pt;"><br /></div><div align="justify" style="display: block; margin-left: 0pt; text-indent: 36pt; margin-right: 2.15pt;"><font style="display: inline; font-size: 10pt; font-family: Times New Roman;">The following is a reconciliation of the numerator and denominator of basic and diluted earnings per share for the three and six months ended June 30, 2011 and 2010:</font></div><div style="display: block; text-indent: 0pt;"><br /></div><div><table cellpadding="0" cellspacing="0" width="100%" style="font-size: 10pt; font-family: times new roman;"><tr><td align="left" bgcolor="#ffffff" valign="top" width="5%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%" style="padding-bottom: 2px;"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">(In 000s, except per share data)</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="5" valign="bottom" width="17%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Three Months Ended</font></div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30,</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="7" valign="bottom" width="17%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">Six Months Ended</font></div><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">June 30,</font></div></td><td bgcolor="#ffffff" valign="bottom" width="2%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="top" width="1%" style="padding-bottom: 2px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr bgcolor="#ffffff"><td valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="45%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="9%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="4" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"> </div></td><td colspan="2" valign="bottom" width="9%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2011</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="center" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-weight: bold; font-size: 10pt; font-family: times new roman;">2010</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Numerator:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%" style="padding-bottom: 4px;"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Net income - numerator for basic earnings per share</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 2px; border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="8%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">5,778</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" colspan="3" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">11,838</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="2%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">9,914</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="6%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">21,252</font></div></td><td colspan="2" valign="bottom" width="2%" style="padding-bottom: 4px;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="45%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Denominator:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Shares used for basic earnings per share</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">33,942</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,117</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">33,957</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,037</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Effect of dilutive securities outstanding:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 36pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Non-qualified stock options</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">510</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">456</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">417</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">493</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 36pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Restricted stock units</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">338</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">360</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="7%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">337</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 2px solid;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="6%" style="border-bottom: black 2px solid;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">398</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Shares used for diluted earnings per share</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="8%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,790</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" colspan="3" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,933</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%" style="border-bottom: black 4px double;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,711</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="6%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">34,928</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="45%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 18pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Earnings per share:</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Basic</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="8%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.17</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" colspan="3" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.35</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="2%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.29</font></div></td><td bgcolor="#ffffff" valign="middle" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#ffffff" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#ffffff" valign="bottom" width="6%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.62</font></div></td><td colspan="2" valign="middle" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 27pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Diluted</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.17</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.34</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="2%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="7%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.29</font></div></td><td bgcolor="#eaf9e8" valign="middle" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="1%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">$</font></div></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="6%" style="border-bottom: black 4px double;"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">0.61</font></div></td><td colspan="2" valign="middle" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="45%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#ffffff" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#ffffff" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:</font></div></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="8%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" colspan="3" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="7%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#ffffff" valign="bottom" width="6%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr><td bgcolor="#eaf9e8" valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" bgcolor="#eaf9e8" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 36pt; text-indent: -18pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">Non-qualified stock options</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3,746</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" colspan="3" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3,935</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">4,191</font></div></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td bgcolor="#eaf9e8" valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" bgcolor="#eaf9e8" valign="bottom" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3,601</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr><tr bgcolor="#ffffff"><td valign="top" width="5%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="left" valign="bottom" width="45%"><div align="left" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">      Restricted stock units</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="8%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">18</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" colspan="3" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">83</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="7%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">68</font></div></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td valign="bottom" width="1%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td><td align="right" valign="bottom" width="6%"><div align="right" style="display: block; margin-left: 0pt; text-indent: 0pt; margin-right: 0pt;"><font style="display: inline; font-size: 10pt; font-family: times new roman;">3</font></div></td><td colspan="2" valign="bottom" width="2%"><font style="display: inline; font-size: 10pt; font-family: times new roman;">  </font></td></tr></table></div></div>

12443000

13341000

24876000

26895000

24296000

22555000

29896000

31532000

31905000

39157000

4528000

-458000

-1409000

7238000

6152000

8962000

13797000

-1163000

false --12-31 2011-06-30 No No Yes Accelerated Filer 396100000 HEALTHWAYS, INC 0000704415 33702609 2011 Q2 10-Q 23441000 18814000 EX-101.SCH 10 hway-20110630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001000 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 001010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 002010 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 003000 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 006010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 006020 - Disclosure - Recently Issued Accounting Standards link:presentationLink link:calculationLink link:definitionLink 006030 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 006040 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 006050 - Disclosure - Derivative Investments and Hedging Activities link:presentationLink link:calculationLink link:definitionLink 006060 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 006070 - Disclosure - Long Term Debt link:presentationLink link:calculationLink link:definitionLink 006080 - Disclosure - Restructuring and Related Charges and Impairment Loss link:presentationLink link:calculationLink link:definitionLink 006090 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 006100 - Disclosure - Share Repurchases link:presentationLink link:calculationLink link:definitionLink 006110 - Disclosure - Sale of Investment link:presentationLink link:calculationLink link:definitionLink 006120 - Disclosure - Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 006130 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 000990 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 hway-20110630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 hway-20110630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 hway-20110630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts receivable, net Accumulated other comprehensive loss Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Amortization of deferred loan costs CONSOLIDATED BALANCE SHEETS (Unaudited) CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) [Abstract] Basic (in dollars per share) Computer equipment and related software Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Decrease (increase) in accounts receivable, net Decrease in accrued salaries and benefits Increase (decrease) in accounts payable Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Common stock, $.001 par value, 120,000,000 shares authorized, 33,808,298 and 34,018,706 shares outstanding Common Stock, Value, Issued Total comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Capital projects in process Cost of services (exclusive of depreciation and amortization of $8,970, $9,928, $17,994, and $20,161, respectively, included below) Depreciation and amortization Total current liabilities Liabilities, Current Current liabilities: Deferred income taxes Deferred tax asset Long-term deferred tax liability Deferred revenue Derivative Investments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Diluted (in dollars per share) Effect of exchange rate changes on cash Share-based employee compensation expense Share-based Compensation Furniture and office equipment CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Income Taxes Income Tax Disclosure [Text Block] Income taxes receivable Change in restricted cash Increase (Decrease) in Restricted Cash Intangible assets, net Goodwill, net Interest expense Leasehold improvements Total liabilities and stockholders' equity Liabilities and Equity Deferred loan costs Payments of Loan Costs Current portion of long-term debt Long-term debt Net cash flows used in financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net cash flows used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net cash flows provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net income Net income Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Recently Issued Accounting Standards New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Operating income Operating Income (Loss) Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Foreign currency translation adjustment Comprehensive income: Net change in fair value of interest rate swaps, net of income axes of $416 Other current assets Other Payments for (Proceeds from) Other Investing Activities Change in outstanding checks and other Preferred stock, shares authorized (in shares) Preferred stock, shares outstanding (in shares) Preferred stock, par value (in dollars per share) Prepaid expenses Proceeds from issuance of long-term debt Exercise of stock options Proceeds from Stock Options Exercised Property and equipment, gross Property, Plant and Equipment, Gross Property and equipment, net Property, Plant and Equipment, Net Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Sale of investment Payments of long-term debt Repayments of Long-term Debt Repurchases of common stock Payments for Repurchase of Common Stock Restructuring and Related Charges and Impairment Loss Restructuring and Related Activities Disclosure [Text Block] Retained earnings Revenues Sales Revenue, Services, Net Selling, general and administrative expenses CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Stockholders' equity: Comprehensive Income Stockholders' Equity Note [Abstract] Excess tax benefits from share-based payment arrangements Excess Tax Benefit from Share-based Compensation, Financing Activities Total current assets Assets, Current Current assets: Treasury Stock [Member] Diluted (in shares) Basic (in shares) Common Stock [Member] Preferred Stock [Member] Total assets Assets Current portion of long-term liabilities Other long-term liabilities Share-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Property and equipment: Statement [Table] Statement [Line Items] Share Repurchases Equity [Abstract] Sale of Investment Investments, All Other Investments [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Treasury stock, at cost, 1,101,765 and 429,654 shares in treasury Treasury Stock, Value Excess tax benefits from share-based payment arrangements Excess Tax Benefit from Share-based Compensation, Operating Activities Other assets Earnings per share: Earnings Per Share Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Long Term Debt Common stock, par value (in dollars per shares) Treasury stock Total stockholders' equity Balance, December 31, 2010 Balance, June 30, 2011 Stockholders' Equity Attributable to Parent Income tax expense Income Tax Expense (Benefit) Preferred stock, $.001 par value, 5,000,000 shares authorized, none outstanding Statement, Equity Components [Axis] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] Equity Component [Domain] Long Term Debt Long-term Debt [Text Block] Exercise of stock options Repurchases of common stock Treasury Stock, Value, Acquired, Cost Method Tax effect of stock options and restricted stock units Earnings Per Share Earnings Per Share [Text Block] Weighted average common shares and equivalents: Depreciation and amortization Depreciation, Depletion and Amortization Adjustments to reconcile net income to net cash provided by operating activities, net of business acquisitions: Accounts payable Accrued liabilities Accrued salaries and benefits Share-based employee compensation expense Recently Issued Accounting Standards Description of New Accounting Pronouncements Not yet Adopted [Text Block] Other Basis of Presentation Organization, Consolidation and Presentation of Financial Statements [Abstract] Sale of Investment Investments and Other Noncurrent Assets [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Abstract] Income Taxes Income Tax Disclosure [Abstract] Fair Value Measurements Fair Value Disclosures [Abstract] Share Repurchases Treasury Stock [Text Block] Derivative Investments and Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Abstract] Share-Based Compensation [Abstract] Restructuring and Related Charges and Impairment Loss Restructuring and Related Activities [Abstract] Decrease in other current assets Increase (Decrease) in Other Current Assets Increase in other current liabilities Increase (Decrease) in Other Current Liabilities Gain on sale of investment Amendment Flag Current Fiscal Year End Date Document Period End Date Entity [Text Block] Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Public Float Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Billings In Excess Of Earned Revenue Liabilities representing performance-based fees billed on contracts that exceed the performance-based revenues earned to date by the entity based on the entity's inability to measure its performance or its performance results to date not achieving contractual targets. Contract billings in excess of earned revenue EX-101.PRE 14 hway-20110630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Jun. 30, 2011	Dec. 31, 2010
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per shares)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares outstanding (in shares)	33,808,298	34,018,706
Treasury stock	1,101,765	429,654

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 16 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $) In Thousands, except Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
Revenues	$ 169,596	$ 175,523	$ 332,565	$ 354,522
Cost of services (exclusive of depreciation and amortization of $8,970, $9,928, $17,994, and $20,161, respectively, included below)	126,009	121,985	247,917	250,852
Selling, general and administrative expenses	17,706	18,703	35,547	35,938
Depreciation and amortization	12,443	13,341	24,876	26,895
Operating income	13,438	21,494	24,225	40,837
Gain on sale of investment	0	(1,163)	0	(1,163)
Interest expense	3,170	3,612	6,588	7,034
Income before income taxes	10,268	19,045	17,637	34,966
Income tax expense	4,490	7,207	7,723	13,714
Net income	$ 5,778	$ 11,838	$ 9,914	$ 21,252
Earnings per share:
Basic (in dollars per share)	$ 0.17	$ 0.35	$ 0.29	$ 0.62
Diluted (in dollars per share)	$ 0.17	$ 0.34	$ 0.29	$ 0.61
Weighted average common shares and equivalents:
Basic (in shares)	33,942	34,117	33,957	34,037
Diluted (in shares)	34,790	34,933	34,711	34,928

ZIP 17 0000704415-11-000025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000704415-11-000025-xbrl.zip M4$L#!!0````(`#>("#^FBB.61&(``">X!0`1`!P`:'=A>2TR,#$Q,#8S,"YX M;6Q55`D``[I.0$ZZ3D!.=7@+``$$)0X```0Y`0``[#UK;]LZEM\7V/^@R?3. MM("=2+(=VWT-TJ1WFKM]H>G=N\!B,:`EVN94ECPD%<0^IA67;LO-.X M0%';(GF>/`_J'/;UWRXFD7/.I1))_&;/VW?W'!X'22CBT9N]5#69"H38^]O; M__R/UQ<#&3DP/%8O\:-XLS?6>OKRX&`VF^WC+_N)'!WXKMLZ$+'2+`[XGAT? MB?C'FN'X>,!4/OQB:?RL1:.]?K]_0$_SH4K4#81EO8/_^?3Q+!CS"6M6\4'P M83&QC,WA@7F8#14J:?M>=QVQ9D0^(3[G2B^NK7BP/TK.#\PSF.9Y3==KMKQL M$G!ZQ-@TGS5D:D`0[(.:*2$7]4#@0:#G4WX`([@403XAB3>8 MD\3-RKSQC,WS6?MCSB*-/ZG]()D07NYAR[6#-U$A4#W'>8TR?ZE(FM_XT"$= M>(DHO-E38C*-4+3TVUCR(2P+$)L9L/T+%>XY!V8A4MV701)K?J$=$;[9"W*D M:$0^AL=:Z+G]+?]5A/C[4'#I$#I\@89,!L>G_[7WUH4_7;?=]CJO#ZJ3,U`' M-;`LI"EP-0F7X!-?]%LCX<-FR\T7MT\65RZMDOUDB5_'#]?S074>&3_# MQM\&/SRW[7HZ>52:`M1+?<(TM[K2!H.0K5(\JTSB<5B:4E:O[,F-J%?.3O=Q MLM/=GIWN[;'3PPW[R+73>TC:Z3UZ[=R6G;>HG>1+_G&F8;T)$/3^7RG0=)Q, MIDD,7]71A5#_^`I>FTO)PS.=!#\^\\%./D)<\Y_M@Q#0N)A&(A#: MX.B$`L:9X-F&:B_74KKW-AM61_+K@UHH!78'=>@]5*>YB>#AZR2)GX[4E^A] M>B(_"D.A@7!H?LZG0+'H2XE]+^]-3A6]<,Q'S\#V3L8A'ZDGH0#W1 M3T_XWR5G*I7SIV/\:RA^>F(_"H)TDD8P)/RBQUSB8\G'R-)S?AH'R80_"678 MF`\_EXI4[M&*G,=MIS"XKN>>LY*?1I%U2<^=)S4^C M.[N<:*&(?)?_/)RW,O>L M"KL$YC[?RMRS\'<9R),4^RZ%>*`IQ)VHB-M_A/6^;O\67V0^FL*_A;=VMVA" M>F[[L?$#]DNOZ;9O@A]I+`PS?G?=ZCZ9D/O@;VT?R,O?STZRE;)'Y=5QJ55+ M^Y6E0W$.+*F2B#,^8],%TTEA<+;%I\R$^A5+X$YXG$Q$O!Z@-7AC)KG:!.+R MHMG3$MV;L*VU0B*7(;2\]I^:3?``20I^P9$\X.*<#2+><&*NFTTSI.0I:-RW M?-AGKH]3*4%7':M"W[`7I>@O<1`0_49JY(0\$!,6J3=[32"AY_L>;HG7!YN` MN%U\3?_')?CVT2IPZ<(#'&#AF`X-L4(:0U'RB!R`$=Q6%X^6YR6AF?YNE=2!J_K]PZ7 M-N.-X/-S,'$3??,Z[8Z_9"%NF(GYT8TS92)LBM@)S.G-$BOJ#WFNI!Y^J]_M M'RY25K_\+2*ZB0C\EM_QV]LA6N*_DPQA07,@#F:+`]BL])Z`OJ="O9K0-T9"=4&H4O\Y&%_>Q+>,24"YSEH29A$$9/* MF6)$C:',BRKNV9'55R[/<("9N\SW]FJ^^V6D(0IU][UN@7$M@%M$M=H>>`FJ MK<[]H;I6FY=1]?OWR=4U6KN,ZJ&_*:H8-:0:L..YNT"G)+GQ;2H9ZAE,JF)M M#8_X-P^S%<[LT+]+B#JN9IE]WW4["_OM,CAW3L=&AALRXV[WBG0P-2;,`_R` MQ)RS"(^ZEC%78_"J^,_[8M21/F92SD'>_\VBE%])#/U.508;0+HK`C:*7=S# M]H.EP![77>;Z.XDE_XU*#CA`9[LZ5ON\BGZ7G=B@BO1J$A2Z9HA1DX0\$5Z>:`QWPH MEG5R&[E3.2 M*]&:37*>A[Q.$(`V%815+QW/G>I7#OTP9!,1S5\Z6DR`W)C/')E,6/QJ+P=3'.(G5_V2D@OCK=XA$)-(P8@!\B+5\Z$R9&( MFSCFI4.((6^:(L:7)/87.T:*T=C^E(-!*I:6%G$D8FY)G'$S;9!$H?UI.S8\ M[[]`2`A98@YEC`R4,Q011&Z0G1M!A(5,6(`2A%@@E=-$0F@$RR8QQ'5C M%@WQF%*/N8.9/8OG&#S0US'>@2?G\'LJ-5`@Z6_!@B)U@4\1$S#P`P:`&^!DZ!D'.11,4#X@`/4FEBVO<7`7!I MQ)VC0.-CK]]J$V+E]?28:6@-+8<2#DS#DA,6$CXPP<-(@.8(@9N M3^P9,EAP/`(:@GT$^0TB.EZ;3"#X"BP`":`D+?UKTCS\:W\2(4A`GH.2*/,&"O!<0G24BA#5EY8:0K@'7)US)FDCE72B^&24 M([+&RT@&>*.2"%9"3B(HXFT$;--B.,PV'%L?M M7^JG;MVU%*)[/([M[F./]]].SXYVH<8U0@V(`%I>%EBPDL<((@9;WWA)X\?0 M8RR[P>RPQ?G&-7APVINF;B/SD'-RBV4W0&);<`0SEAD.ZTU^WS_;SZ.'2NSQ M280A^/K\Z6(4\IFI\;F(:,"Y4(2^#37*X0T=+%OGAZY>JU412$[\0'(6@'_` M\4,("R#"@;@H3"D&`'N9NT6TV%GXE/NBMNL]__$"+65<:YF/`$_@7KC@.PJ^ M`!EG?*J-^?3[F10(3O2R@]GE7@& MEBMC5U8/&U:5`&-HG,.:\*EW[E`YGB]O.,MT?CA<<'L!\P^ M)T4+UJW8;IGQ`5;`+,IQU$U9H=)>,.I>LJ46;K:79,Z'[4P(1E#(A$7[84J: M,?0%<>.""7@7$5,H9,34BS) M8C4S6JO'0JVR:R;X\GTCR;4!LM_*Q%U6(F.74@J`((S?%83&MW_&EL3V#72K8S]U2L\%)UIT48ZACO5N_]@9D#]!1@+@$OB%:(M)"@*7MZXPCK M@079'F+F.M3('=E8$IPX8$1NBH[/,C]:HM5R`"6)2R>I=O`_"ZD_'2F"%>-G M/.*G@0)HT_\SDJ3HR%(\HH(H0@".67JQ@0JLXA*BAW:5#C$I^&4JB>';W`&? M*_!($&0AZ9`1UILF>Z*`8>[.$)F!@Z.YM[;S;W2ZJC)/FQ,[7;FEK4>Q8I MB,[2P3\A,T7=SQI6E@PM)JUVQX$1P`@U0@,4<(XVU9ZP0Z`$V9M)#P$H!27X MKS4-"=I?C'SP&%#QS+X,4B4PTBJ?1_XQA@"5]C\@F<;9UMQL/\*T,*$MG1E` M@QU$2S9&7,8?,S\RNM:>&+]@AX?V?0M%9)+3T?H,PE9GC,$H*]X:0-[(D3(^ M'")#T7`#@9'X5RI"/(RADW"J^#85_:86O_Y(@HX2%+?QLGE94I*4B$%2:)33 MV'H&#"0;!/!<@+`-[J4%)HRB162;%<@PU:GD.\-UO\$B[K*B3&!GQ[:R8Z?F M!4\>+]#K*PH888\P0"YNTDLGR/&B_&T=Q3$\&,=)E(SF130$`8J"_1,80Y!% M/105??CJO,>EIV3BBK=?'S\>+QRO?OBZ<+9*A@?-*5H5!T\8)ND$(U!*Z>V9 M;7W\]CW1U"TT-^\I,2VTL9DE"8,T9X(!$YZ616A<^`4:-+1(%E($UB^R[X%D MKYQQ,H-ALE&\BX799%$MDF'&HOR-KZF/-ZM#B)9.IL19 M(X+,2.>AHEXDA4SG@%=Q:O7<#*<&8KB??T4"9F,1C,W4)(`LP0G3_-03V,@$ MQ=4PT*C",\]U]_N;+`#C?:(+/D#D^:SG[OZ]];!`>K'5=`V$ MNR:@IE?B-@E`^ZM9;.LH-J?@2VG>%630`LO3\_N]-124(-P]"1M(H=5VO5[7 M/;P:"6>&!&J@:#BG8,]YN`;CJS<&M=JK%*72?G*#>&W2[[,%7J5.?ONJ]3DV MR;]H0&1B7D2PBX9SI+44@U1GBQ5:5H%:Q/R MG,^09EU6[+T$`.;LRKL?:>7R<\^_V?KN[L_(I;HM<\VR[DY[5];]:/+/1?D+ MDC\UW)D:5K*@FEW0L113SK-.*2G!E.&95WH'FK_?UF,(^K$L0(^58^I2Z!5L MRS5'XUG>X58+DLV2[GYW$8COU@!1XF)[$/<=[:]U,:7V57-I!J0Z>%ZFS`OI M!+*AY0962%NI+!=8T13A2I M>)YE/N<70932+J`[-XKK74PQ:.52CF>]1K\+NO6LW^C[/?U'S(FU%VS4<,+K M]SH_)R>V[!!M=_M+6^4GX<1VG:5^Q^UUJE:NEA,GZTA=CV-Y:N5FJ&MN[EZ_ M6SVQV!#P7=.UW5;M]_UJTO=`Z=HRF^V"\C\.PK;<1RYLY&L25FJQ;SCVNL4J M/:4QU[FCTO/;;G<1W^65;QJQC6(8O^-7+C=<@]A)=B%8.3ZO8I8-,F'F=W;Q M_F(*@2=_9RYBN.Z]$7ZWL^A)+H%WN\AOI[5>OW+SY]:X`])4V;.D#]D(6.,( MGZMKWJKJM0Y7\+D&PBWAN9$">W[7WQK/CTD\:M)KP+",<598.E^#=6E[?$[B MX!HL]MN'E1M0+@-S=_AO=DDBW1AV%?QS/9'\G,?IT@4?V?-OYO%U%/D0#$8M MDHMKWS1JFS"PTV_5RW\E:GE3]"DEFL7M"!]X2*6/1QC5FLKH#:\:*18MK0DN MTZY8++B[>.31G[D^[]SHP72K_S,R:6&792U%JW;9-4^L6[L3Z\=S8OT'=U*U M<#6%*%EAG0`N,1ME77?9]9=4<8BE54H[DEJS4).&B00]C6W5?K"J$>T/JHM/ M)%W*4((,B^B\7"BDEAO4KY0Z[[B@6E0*O^C^A'*_C.U`'["("M?5F//LNLX@ M&<7`$'J>QI*;.S,=JNLTQ:M4)HHGK!;$\DH`+;\B@LI4I]P4\4$F8[H$Z0J' MN.@-'"]R%%M"%7#&7%L`<)VQW70%LU>5?9K&0IQH>@6PHG/"L,L3WRMH*DZ3 M5/Y*(C/M6&7>3^R,R.\C M6;CK8(%CZD[:]M>:U=ONVK^^3;]^S>EIM@6_L;KFHIVI6RH.!:-CFB`A'DVQ M&R?%*LFI"2BK1LT91G@_2]9D;ZJWAU'":-/1B)`/-%W^8JO.J.(1*_ZHA&YQ M-35CTZ)^S][N$B?V'OC2-GW6:G5*U8[/GWGMSLKJQP&GO-^4F)M=[?S&8FK( MS6L9G[7F'K8XMJP)`,/IH\K&=5 MCAQU1X=B.+]$G)K5,^SUK M&U.EDE!5;CG#?C$F!>4CTC8LY$OGE;T?3]]]^6;>(]CR3V8Y4)VSRI-3ST/) MN^D-Q`D>$$N408Q4WX9W"H,P9N045\<,12_@!)TR#Y#.\0*>X)$R7'1J7^&/"2@;17]2]8R@6O)N)E>#R[0XUL77UW M9BK7S"LPLXU7=K?3OEO:LQJ"DA0FEF_*2.K1,33;+.;"L(4Z MS["G'EQ?[E:HLS]S"]5U#,*P%G5GK31/EE1^P0/L1`8&Q"J[V0[)QEM`2L%W MT?A5#L/),$ES*QW29:_*D`"=WTU0?:GRYYOO*438OV(>146_I!_U9Y4[`W<9 M&[%SI4CL1U2<5*2HRA1!U.>ENJ8.K1I8PC,JJ`B7HZTL12Y?O6F.$"CW+YTA MT(U%S/2"8J\WWO@8<(J?JNEVWH/#+X0R89>D0PIS8XAZ><,:L7:G;:U<#^:X M>C`*DBB1;_;^/*0_]>>QO7L_3%R+ZB#1.IG4GAX_`G2]AXDM?`<%C/$_'\HQ MG]`E3P7F[4(9!Q3]-`UMN`-8\,/QIQ<.'4\M:'YF/@,*N/Z_O6]_GH=5\V^DKFS=_=FQW&E4JD4AX)&C"E2YF,>^>N_;H"D M2(F22$H:`12<.ULCD4!WH]]H-"1.Z!>T8HV$?36A,Q1?2,H7:[:QP6;.BI(X M_79.9;X]O3[+[3S):NP*'F8MR[>'X$F^OWIQ[9'7FJ:%=?:B93?3&U3P\+PU M\*?=>9%C\,B94_UZ6R+W&/06U$52,JED4A2J'THFE5]Z/+]4-B^46M,Q'6W4 M<^VLWN,EW]O3BIO8GQ"BWSI0!3-6NX-N!6T+C94*]52H=XB2HQUD6W[ZD#LC M@T5FQ=,DZV=)5*BH0%6AHH*VE=:W3:%B"F%2?I=M#QB+I[VLSC$,\Q8S7`D- M<6WTSK+%"F,6S/Q&0[[C4WXUOO"[5Y).#+QHM895WVS#Y>`YMK0;+>8>NVK) MP'(PW^OQJ,::*]+E2==M("TKWHZ4HG+0G7^YEEPW!WN+RQF3KXG$K+N*@@M- M13]29"P*3N9ZB%$3V1=)`1TJ3,I[FTQ8V&/?$Y2AEUB7U=%=BK>I=9/C,M^3 M<WC$@YM=%;?(:FRS$9D?R5.MPB-1+&0Y,UYX\H-C?3Y24/!ME[5@V M[@!I,2E%8;.G([LTE/J!BD3[R\&*&W&*/&'EM3SY)MT!\X0"NDDQ2K4;;FE7U.CU MC\#W+23486HG3\_K*IEQULF,C:W&56Y`@:IR`PI:.8V9R@VHW,")\O)'RLG+ MD"QHW3:S1*`*9G=EV&.6"UHI[*X*(L\QB#PJB5XZ*R]#@+LI[U8QAI0UZ58G MYW:F)#(Z1K_.SH5$07W5%6U?LOD8?-\^*O4ZO4&=S0LI'"J5R%")C).X4[P= ME>M[]]V(!G-5[+`Y17`N_6(.8884*=F89F?8J].Z2*(<4/.:@'-9_&/(T?E2 MT^CTQW4B'BGS1R<7#QX8RB5%&MMQN=`I:IMIU*_,QZ/56*L72F? M`Y6KG@&AAAVM7Z>UL!1>DDJ.O8SSJ3H^J7H3B4$5PDC+56PB%[12&"MY0OKO M(NO.I64^`KH_&QR>-?=F==]AU=W8:]C]Z'3+Z/09Z'2SN9'203H]9U]_HQ0< MQ]`GG_V(DL'E5E?L0)M,//M0^^3'B\S>;`&W%>M66M2U>1C($VK[@14YOO<] MB0'\@/W&!GAOA3/RR?4?R5_IY+XL>[)M$6LS]5U`OCL91QQ!J):%T?D*:!+- MK(A8`2T42WL3\GL,2$Z?L7#:1L)/D?`S1GCV>(`+-<&'(T)#4'?LS:GE!*A5 M8YP$QJ;DSG(MSZ8DG%$:=4#)1C/V/9U.JPO`8R"X?AC" M;'<4J[8#BL_!%#"N9=OQ/';9C#Z_J\>?+P(ZHU[(\8._*?$#-@2YX`(V,@SM M;?[5+^^OLU_TMV\NRW3(^U73T)R&!:4,@)`QG^S![&&$RG[K/ MB(X#W\//$0&.!@H\6@MBW0>4,LJ73O>75>1]1L60;A\K71'7"D-GZ@`PD;]\ M@SXM@##9BH06T(:#3R9Q@,2%Z,WFR\*PA-<#RPLMFZV+Q58J)-0*/'@X1+KB MH\D0,"I_':F"Q%E=4#8DK"*N20B/9RM?2H&K$-_[G]BCQ-0ZQ-!T';B&,B3L M"/'*\'PFK\W+,0&>=Y/I/!KE"+>=9%,PS&2%'4K)ABR;D,X#"2:Z0>8@;;,0 MJ$?Q#494&]",71AF83WC!(7U!W!]VV&S,`'PXP#D[2[:;7O.7FVM200H`BYR MR+C48>+/62S'6AX-&9_R'U`[^!Y;=?IDNS&J+;;\N')X44,8IDM6'"%5=/<> MP,Q8/;T4+!6&4AZ^A6&GO@M:`V%D+ASH/_\QS&D^G`S98$VY--E+$#H!E3R?!WZ";`%9SJ]CM419BH\L9 M2,R_5W,_YA87#3RY^`F,^QMR4["U5RO.&5C&_.G.BX]9"/&5>YS;9:%-Y/N4 M^."WS/[_S.W^1[3[#3:6A!-^)3]*?EY&?KZ!U]Q0>JI9J($(\B2UW:^@#$X/ M>9T=9O'OZ=RPP73N.C>O/$&]%O/1&)'?4)>EKL.9LVAR8;A$]Z!*>W'S)A6B MGS=O%[)%#5A7NKON-P%N*C[(X;3AE*IB"D`5PB?5PSACH]C9N=9%K=B:ZW;:QWR'V`51>X^V\] M);N=C?(JVTY[G#[DE^M@2F7VU/52]CRU#:MYQN+",/O-=L8D9KK5E31;L9*# MX?#L5])HPTKJ':U_^&-_DJUD.[2KWC'U<1VIK!`)G'X5A=U=$':O]D@G%=SV ME3%^:%BSAQ%W!U\+*'G$?WE^4B&=5#?SBL&U*L)BU6)2$`T^>^RRNDE6_5A: M-:E*4OV3G&[(E>=?Y\KS/_L1^5!H8YYN-N6>6E^R`=+?NI'?Q?_2"$O(L10#EB0Y MW6!YSR09"T0O=R(B/!W M^($4INJ84\04&!;9^XF^PM%!W;'3)LE$6/:?J+@+EQ7"X'"L^AY+OW%!5+5] M)=&X96=-UIE@XDS8+<R;[C"OVOEZV#)*EK" M%US!]/,/W\5A]]ZR%M\O-71.]5YYDT0A7Z$)96U]/CBA#6P8!_06IGV'$/SX MA_\BY(?_[G8_.&Z,U+EP4M8/40>0<&8%]$VWRQ],I_R8G#+X2H-O^$#Z-BX, M#'U#IQ`[((6TGJ9'/OLT,+578%P<_NLOFF:\`NZW0?S<\,^OC%<_:I?Z<(G5 MABF.#+"6`:Q5`=CLG1I@'2"M06%C?&J`M0S@2A0>Z-4!_I@=8,E4/DL$\\^9 M/[H&.7OMR_1C\M(-O//%PRH:$"+\STV>%P$7OP5R"U\`T]2IB[+EW^%C^J3U7JMLDW@VK,>R9PP*P&\<_.KR:;ICZ3GC-%4[8#>\U]_ENK2>RM+GD M'VAU"3.[_UR%F;\!+Y38Z)V<_&/B9.3\C2Q#<])#:@5/LRQ3U!=PRW'_(U"] M.AG(G3321=R7W9M(2Q&IU6ZRM)1=4_E&:0(YS'$L6RS@1CSS72!*#B@SGA!/ M]\S+X1^9JH=/HS^RU@9U$I0==K#:"OAHYA#'P+?,\:51>S3X-^CW!0?8?O`S#SRQ.]Q@#)\P7FS/'98N^O'$;$F_X[#B.54LC1,_=/4 M\&\K)(^@W''PE*2-CF4G>1^7`LX(K$V#",_SI,D;`).?WTD;$WA6DHC)!=1( M:=Z"X3%+5@'9+)8M!J217+QO`D\)0P"/!+JC'ITZ%;(B)SX(+J7\_0J\ZKA9 M*Q+&D!1<&)Z_PS7_Y?+;)9G2"T($`YGNF&$D&=`X,A8P9QG?_3EIHT">`G;-2`@[P;V%4!!P;)0";:B-\ M)6FZ<-(,S#;O;=4IC-#B(<]3"'A``C9Z@C2\R1YJY&GKHU&_X+B6#GT<^*IX MUJ/!N"9\7)]=?*#\TQODD1L:1@$P!\9=)5%O^E;ZSK6W?($=E-DO3.SV!N-5 M'+;.]]+HU`LDFR$204CO(!=@RQ(LM//H6E"V?.J*/?291A]9RQ/0`'_Q_/=6,\7%F"W5.]!/159&#<,_JK0E`#^O2+4J#W(FMO/#`&1<@.-'L5 MLE29/2OV3'R2DC5COW],VB75RDVO063JR&3%=AMJ9J\26#^AQIM!;(ON?.`_\/VB5>"RIZYS#S7/C/5TO5?4 M9)LG.!ZDE<13&PR,VI`N[Y?@NZJ_QT[TO`;I\JDK;_(M`@\*AZ5!R)]O1-E1 MKV^.S"+`.^8Y-MC5'"1],!HW`_LK[_;&]CA_\B$=H<;]VM<`+_>PH\?X+?TY6:: M8%A4GR4#'Q?**NQICLU^92A_J@S29]^S]Z"=89BHFC;!M1S]L*!5VDKHF>#N MU0$-G#]^G/\K*%4'TS1WS^3BEY`5G[PAGR!6]C"+3Y:;_*OPPQ`X0CK`NV=\ M^]K+7EV^N6\H9/1&*]N;U><6!./ZVYS](R-\[3U@%]LF"&>O'G*)AZ-*2UPR MMR`8UUQB6&"STAKO@?$7GC)M@G'VZL'6N#<:#XTJ")=,+0C"]9;8&&HKP4I# MA'E*M00/GM?ZJ3PNJ!.$]H?#-4B7@^\-3+W04]='YC&AJ<>VX['>.RII:K&4 M;O379&@[-%\#.J4!;EDQIY[\XV9J\G$27:XOEK.I,OZ+"VP#O]%4%M. MC[-?>\GS@[HQ[.V/]=);+/#S*E[98P=SMW2S MM^+AE,QQ###K.6*&WAOW3@%F/0DP>L9*M/QBU*S#LSUMM%*?NA7,X-[RG/^P MBH4.:-_TG$E:+O&55R=8:68NR02`U_!M>0RE8HUH?J["3"!1^7F^3+-9EI.H MNE+I2R8O],/6E>Y[<[F01'IGA0[;5"B\G)1?H>7'TS8K3;\U&QVC!8K/V'4A0MO)>=;L9K1 MMNDBN?^+E<^!<6%1O(6C`R->S<&]L:W";5^LQNXO5U=?=][S=B<+:Q%'&`X:_4/D`'K/!\R#P\O]\*#MS`=$ MN_XCQH5A?!YI33YE?+SGH6+Q=(*5:#^G-4RPFK!F.EU M:)&/4,$L<_8QW<5)WK>MI&11'<3=73_*:._/G2C*D7W)>0ZC,O=XV)EIT,>< M!4!:DNI-)BVES+I-%#.I(7=QE!L[2D_$LTI47H_LS).;^9C@QL'"QR/GY.]^ MC#=>Q>X$?K8F3<3)8:>U_AU[O"@VNSAPH]+A>H:URF#5TDL*H&1?>1Z(`KEA MP&+9^"?D45WK_F]6J3X%WPT>P;K9I%@;8B0611-3[YS^`/*A'=/EN:_59@CL M^C\W<:\SA5,Y>;HI)9',\SZ9YG9YR2!@<+N<\RJ;\C.-ODQOK:=FN8*CYF5? M"LG:JU0I'RS)$NV1:A9V?1JDN"59K0-ESX5=N>I9>TD6K-&&@`PK57$+0I)E MVFMW0]@U.LRNBB1+>*@-&UTOU@4)N[J"+I/HY,5=Q]+F8:77B?-3-/PW)BSL M4!GVYNKI@[W=]5\\@,W%'H)XQQR*X1"$8#1X9T..5HJDD(YYDG6YHC..2"KH6"K>O+E$8>LG*G3K2A^^KR4/OP@^#X'RHS1 M2D.^]7$/#5:E$V3:H%<5K.S$(.Z*7'P-?)O22<@:AK])]$.5DR/I,!`HI6-\ M@B'8`(<_,&/V1^7'#2M.+QKV-LW93XQKW5-1H]%AL%VF`D)T93J\N2P@&D_5C7ULY.[I]BM/@4:):CXU' MGA=K(O(ES\;U5V0'#KG13X5$A>4X!!(+*W6[JC5D+D[TU0J^!,PSG?P-!TE[ M*%=9DD)79HPE+D$G;,)HTT0G1ZQDF0Z.V,)R)EF/O!*X\?>DU\@^[IRNF6-S M5;S7QSXP9%4\.MWH#X>U(,MY,L0)PYB5^^SL89"W-]?)6]C"87F:?M]J=\Y3H%6SNET?]OJKEJ$A6CQG\F7!^_)]?**![81TL@TG]DKR1O;"OC[V MT!QL1*ATPI?&IV8S;]-HC@YHS>BY0[ZZ%L9N2;L:UB6[0U@[GA)LV#OLC2MO MDCW?O(^1J?5'XS7W<,LL+XE`I3X=H[X^ZAT!@<_K;=(V#LR2+DUL@VF"ZJH& M/,SQ4J!7,AZF-NBOR7(%T-/@./(A]N5W(ZV@TRGBLRDNOO63]S?.NZ]9T0># M\IAX]]1BX%LS!6":JY)4']]OEIOD&C%%L`V?E<3"=?;"$=I:;9[KN(#7/(*I M#\PJ.9@R\&_`<\NWZ4H]EP\EGLORV<.Z8:`UQL4SF)MF.B[8==VL_G"ET=A. ML`LI/G@Z#NP9%HX`#ODM^2TJD[>.>,)<&KLE(6R_K4@#$ZZ('-_J"-1-HL M5.]G`-C>MX/DC[FJPYN"GRZ[]LAG[!Z+1YL,=J'%(UY/>F]YQ,)K.'*<`B8$ MST:]3^[17-[*,?7M&*-P+/M$$O"[34,?5#M-;@W--C>!V^B6GYM*M]C M69X"8U-EO0AL"Y4E>MG)O1962%SD4O>9W3GBTHCW.D/0*+NK*CV]Q4]IE9]F MG/CL%!NFY_@]"`YV@B1XNRX[G(B@+JN_;-8'%<]+YHY(('4LM/VNZS^&W[_HX4HQ[%ZI0C). MKI!6KV[?O#G5_]OROY9VI^Y,YFX-(.]9[31!%V`V@$/-ZQCK3>3[,Z/ M(G^^7&X15KOR`I_>6$I'VUUWMIW>Z9!$)3720B*"*R*7*@V@-(#P&F"#4T*M MZ9B.CN>4Z*,UKZ3+OSM.Z%-*I:O*#K@5D?^QO!B[IO#N#WK]+`/#:!N--\M9 MCL3)**=R_.H1^/41J+19=\I*I6%GH`T;^<'5.4AIZK9JZF.'CV)HZB054RIU>;U3?1ZXI!^6! MQ&D3R/4(52=+W!*EFX*8;*%TN>1^3XS%T_'HW%`C;]&_E="05SE?Y;8#ZXP_ MU/[XECS0(')LR^TRW+_GN``?O-W<>KJ>"*QK>SFX*E'BFQ5_"MV='TQHD&%Q MYUKV;X@+83O)I0PFEX$8FKVFYF%/)CAC2R&RD"C?72KS4"O!G"_D4.EE8=++ M6XU-#XS-Q(_O7"J_M3$Z/:-_I#`SA9,AF/@[B/?)%6I[(@9Q""ED[8#(*1"1 MZP)DH)NXDJN*C[<6'T.02_(Q='K]PHXJ5_"G8A?=IUP),AXGQMM,'OR`U9\N M*W6Q0-=E#6'Q3)+C\?ZTO*1W$E/\V<)+5O@S_C2[8"/V>%7S=.K8`-/"LNE) M+WUHRKFL73,=%>I* MYY&U@:%K3:'&0X@AN:$/U(MIAWRCP0-P4%AZI)<]FSR:/EA^$+G6/8J#<7]< M/$.V8:*C`EWS>NMAOV^8)P>Z9B\$T^@/^B<'NMYA/+/?ZQM&/:"I"VK^OI/> MP\4O]YJ`/G5`*[$6?!N;G23O_H6_"9KKJO!>TJAD7Y8?#K45CJ\T[2DQK"D? MHZ%F2H9AW>9]_94.,.)C6%?RQBL7W-;$\.,3WM]&L.WF.WAE"@:.MU+!QDC= M.PL]%CRA!2\E5Z1FS>"V="GDH\*@R9BL\PF.^`X'S(]W^#9^IEF\IWDO6*2B M4SW6&:VHM\/0B;?^[)"D3=0JPOLW0M5U?;S2"K6\W>A>D%3ME#72*D#RP7'C M:'O_P%_9"2APOA]`:N_IYQ@/4'Z9)F]6:<.WQ;:M]K(S>\-Q#NB:<[\D6EL- MVCI:8].4`JVM"JUDM71="K2VZI^2U3)&^Z.%MP7;#9!:&Y$/M)].>L1.E M\IE?"J&:$J7K0\$1JB=+YK@O.D(UI4@S]T;HJK1#./^VD8T>]?KFR"RQC,VF MK&*,1P-],!IOFS(U]>Q*6=\KMG)T'>O.<4M]--8!^:?E[_LX+SUMQ6'8,/B+ M`5VIQ[NIC6L!S;N9-X+SL^_9>]`7%-9*TZ;-$QP9W$J4';/VZO7`S;4GXDV8 M,K]\V7<%D]&=0FR2]7':UM)H.31KGY0-G(S+AEV&!%D?.-7=2-*N">9!NQL9 MK202%Z)W:P'^GI5AO9':5Y1F7_%72F;6`R4A?6!90.;WS8"C:-"U%HO`?TA[ MH6/?'X`1\X(PJ\>W(.E\X?K/E/+.1!,GH';D!^&F7D*)PG>?^:31+*#P[^<% MOX,GS"EUZ]$*)L6N^#'0B&UZA@D$WR>`^;SG<(=7CSEVE(&,)BKL)'5DQ=\V M@7A'78K$"J.VL%15R#3\SFV)\A+ M9*I"L",8?%^LH6`]UU@OLDW]Q>!/+UEL)R0+6!)`#GNM4==_?-G68F?2I\P\ MN8NQ`;"\IR@89*("=GIW4?#B/=M'.0/@C/+H1*CJ1]E8+F?(T+W%JRVE#>C2 M'&F=1@%2K9NP:E\H'28%Q4X/6)UC`Z>'5OD;K915Y6^<&,.5MG+WJ/SU@DGL;;;*=K8_56^KSW-"YY>"QMK:NF[#&IZ4,=75_ M']![*]K7C19VW4X/F/*]SM[W:I/&X#7/#=2%'+ M4Q%2M3`?=`RMSH5*[;PI:P5V4_YU/4:G_Q4JE:LZJ:BD#R]UXQC<+X16:Z+' M)(!6+MH*X`H2T4T(.91A38537F(")K?W=S99U72SLXY' MJ!*H$BSLA6G6R2!5Y/Y*5X_*Q/]U]M6J\;U(RNP<4Z?ZI38XR***Z+S)E3!K M*6V%D'"Y.$%812DF8'([SRUUE3_YP90ZV#<3&PL_+9S@O/*H>Y1B2>5!7.C# MQIZS\I,ET%+GD.8=FPT63$2O3`:O1B*Z"2&',JRI<,I+3,#D]E3/)LV[6CR; M;R!_\`R8$/JO>>;W7/S<04>KY>C*56*KDK42L*`^O#2'QV!!R560[.O:OS3K ME)G(M:QRY8G/EPE?$[W7Z8^;%,\)9R+$!$QNY[^EKGY2T<&N1-K#U9?$L6_H MQO?`C9_X,=!(?C_>[/2'=7:\1?;:1=<<[4\=CR\'O?V922I-(?N:F9=Z6Y9, M'D^ZO>ST>DF2LD_#3D^K$[,+J]+%!$S:JZ&/R*:WC)Z?:>&FU-L9)8]IDWJ+ MMRLE]WB\K3NQ(DJFEA/@&L?\^OY MW@,\E5Y>'&8_Z;R*H19**Z);6.#2RWA#8$K7Q?]:R!5.]+SS4MZ7O8$WTX#" M79JK#T^N?3<%OCU1(1,V:A-V+86EF!`.^*[>D'IY*9OTO=8.==V-+I0'J53N M.2D08==26(HIE2O]%1-*X2J%*X#";9-@-KZ_1XI%4SK_A*S%VD^1#_O?)J?4 M_@'5_AX5K])SY._LGURG/OI ME3IAU??;]-$:'W;Y=R^XG;\T<"_0-5\(#5FUY'EW*"=5W8;>T?MU3OU*M*(M M/'>6!WP@/_,=HZ]_GD3EJE@J$NG]2V.L3+^(5?^M,/2':>TMA+XO+[5LF[T> M->G1(=Q:"6N)=UA:D;F[#=:N=SG<][R1LG8JT*U.HK^Q*+>=`="9AK07^JC. M.?**K'_6S=DD"J5K!\]RR6<;C/S@LM?DZ)DR\BJDK;1EDK9<;4.@5"FHW6.# M3"K-<3%0/58/W6-5"*,MB8ENJT$V+O?/*BF#K*+NAMO+1^TK*:`5KQR)GTTW M&KVCC>N$!!(MO42AL]J%KNI3GEW(WK_4]VV))Y:'\$)M,M+//WP7A]U[RUI\ M_\$);=PVSA+R$;F-A`,_CC MAD[__,I&4ZS!_R*??1J8VJL?$^+DZ)2M^$F[`NQ,:XC8GF__VN1!G\?\2HEEVWX,HT[]`)12$%F.1ZPPI%'( MNL.XCG7GN$[DP,L0CBQ;`%TN%V/YZ=.R0Y`3D@F=`F`3[-R"G5H6@6-C;R`8 MYM&/7?#^*`FH39T'>"9>^!X)+9>U%K(2$/!:J(7E)+]&@>6%4QJP)S+`G@D" M[!$6!;C/_"EL%`-OW-'HD5(/*?H;C+:P@LBQG87E10P9!&J^Y'R"38XZ.',\ MSSH9Y4;S;3L.0IPNP<;#L5P$<@Z&B5B3!QC9NJ=^'*93(E49QAD^&=R[6QLE M'/7O.(RV:/,L6<`S"*& MUV-\!(2(2QX*6FX`<.V(?Q?2X(%Y38FL<6'*:1S06S8(Z[T?`$Z$6C!ZTN(J M-U9.M)G4^AY3+C!@2(M(%,`&1"E(,_N)P\PE&!1:",OH3!W;XFCAT^7SX738 M1`L^.@$%62>W;-9D/L!R9X\X.@6%_*_TN29WLMA#LNTR.3-D_U7CX M.&S;#NDP*D@'RD+HP)@6R(071D&<&8>BU+PEOZ^]N!2BS:.D0L==/K!EGA\E M0[]E[O36Z!7O#W-*DY>8V*XG0P0OH M7-M^$/AW?H"I$W+WG'\E>18\7HM3);[#VZPB!Z9]YH8M!@`B&LP3F[E!=2!6 MV]6'4B7*$AY8ULU26?_%*\@$1'0KZG\"M@X!L#E+%W-^\8++IRJ)-'O""ZXO"BDHE M#3#KQH62B9!<^1<1HM6K9>[EIUSN);;2\"""L0P''V'-#VFR>6[I\"VU98J2[T-<7'OD]>YF,NU!>/^: MGFU!HV"%'2T!M=],0NNIWJW9>#&':DLK(19AD&:7][:$Q04'=<5F-JSL5ZQ? MTN7`#T/2J)=6Y=62B[<$AW;N3"8NS5<9*M/48OG\3*,((\0Z[#C4_OB6/-"` M):R[C!+?<\1`XU=RRO42;_RLE<+I\VIUH&V54FB1)#>SL[MO1ST=2XJ9@Q;V MV*K<^TN;B_I7G!*S_.R#9$>Q>#)^>X:UY8=O)`)5"'78.JH*#NJ*WA%"939I ME*.@/3`G"'%$OBVT%3L6DH$3E`NO7'C!7/@=><6]7?A^3P`7_I,?0-CN$:RS MH)[]3.B3/;.\>\K.=`:67>O$FT0[*9M.8U=/RLEZ(/L09]9W[`7+3J)QG0/K MBNDE6-%C,/WFV$I6*AV([T5TWA7K'Y'U6]#)Y:+7KT^GFBZC_"<-&O2-J"MQ MAOR\I"2N"I5JW1VE\@,J/R!\)FU#2J!6APHA-O9R1VO.;G=/1.=5;?`I'E![ M?`K:FIP@Q,Y.6VBK]OC4'I\@@)U>4J3SX4O;0*@=OW8'O.&!P@=:2X6&8N;L%FF^)BV5;LX%S<@BS^'OMF:I>LJNR<]9Y8>V7' M:'0QA@J?5?@L2(GLL4^Y"1%07^.Q6NQYC9U"2?AH+8AU']#:UT&T8F=$.%`W MU4]4W"B3U73T.^/Q6#&?),S7ON#U!_@7HIZ383UORJKZ* M\$<*6P>J:F7<[BYSJI6QZ*"J5L9'8GW5RE@R:%4KX[.23]7*6`BE($3.0[4R MEER252MCE1]L15I+M3+>H:"%WZ9N':A"J,/6455P4-4Q9P6MN(=;VT);L6,A M&3A!N?#*A1?,A5>MC%4K8W4@KQJ56E8HKIL#Q?6*Z\^OE_&A&%]$]UWQOFJM MNGU/3Z_#_,V\QG,^IZVZ&2N16SG+7:>^4Z4(5(I`^&2:ZF;<@DT3$;U7M<>G M>$!M\REH:W*"$)L[;:&MVN93VWR"`'9Z29'.AR_D6M2F7NVX6RSV4QTT:]"D MA=V,:W70%-G=4%S.!S\`#-\7>RE7' MW-Y1+$F3%G."Y';FA`349#SW2$"G+K6CD$0S2ISYPK(CXD^!*WESLPD-G`\MUGPGUIGY@4]:: M>FZ%\%@V=A;($OKDA%%X6<+Q\G'S$?HCFX,79L!;X(4I-L1ZP(98(3($K.*C M%4SPO[NV^(D54/[FA,0AKO1=X/\&"_][[$?`2[['1@P=@,`*4K[R@P);..!RJ1F7GTH`=;9E3!AHB\"!,0%[X&YX=@Y4`I_'"N'?OL?D8`$# M(%^R41GV<13#F[85SLC4]1_#!#$VF6>Y9.Y/J,N%(YHYP:3+A0&FPL;K)*3! M@V,#@(].-"/^'?[-1,+Q%G$4=N"_MAM/LB%3^.&79X>Z$R3W`^7C6XN%"\+. M>KT'=.+`R@.\U@0HU%!\FJEL,?=&V-/P4`3@V55X?=GX#1?Z"RQ_0#XYGN79 M#JSKM1=&0;P[VR8B=5]<;5R#S$Z`(1T4([^:J@"&WBJQ'2:0\"O(;`02NB+M MCS/'GC&I!@1LUTS7&YB1>1_8H\24V,= MX77R:,&7(:#EH@;8?CCA)01D6V_&S(%E>B*!)&W4R#M/9K=#O-AM$05?.N=B M)^.RN1*V?56"R\'=K&VN]L8@J@@LVQ`H_==C"T@ MQ+B+\AKG=HM7XD,H$('*8B&3'P3^(WR"4`.6+8`?@]3?7P;.$,<7`A?K@0;6 M?::2,/P`X""^PC"=1?AA&+/A+>\W<@_A5>J>14FDHVDX%I[32EO)0^" M\0EH!.'5%9!F`B.^Y]2ZRJAU$8+&_>R#DSE\L^[>H1/YVM![EZ.EY@=`7AN& M<3E(O^H`;N&"LLC4?99/;>>CCHTJ//W\PW=QV+VWK,7W&"2Q&.D#][(A&`YO M8=)W"-&/?_@O0G[X[V[W%M8=?GHFWR+XNL.CJFZ7_YX.E3[$GN%Q%X8#,-@- MG8*9P+70!B:H_]AS^'>_:)K^"B3)!E9QPS^_ZIJO?M3-<5^#?Y8PK@]\<,`T MW3#U'8#U>N->5;@^/J%4D5OKB;RC'IT"MT[!<)%O,V#&+I?L]_Y\0;V0Y4TZ MY,L"!)QESZZ0!UFN9!41/BH,FHSY"89D([[#`?/C9:,M!RM9#/A?Y%=.ONS[Z5JN9'P&:/1J`!] MZ=@'A*J*Y.F]H6G6@.K:L_TY)1<_^6'XAO/3>YC6\9B%3*B,=O".8BJ#?(08 M`AS[GRGX]1-R[3V`\4IR%,E0L'J8LOOX%`46N+F.9X'.N8[H'+Y$`##MX8,= M@>'3PJY5,6CX$J(1BJQ#UC/&@WZL&$/MNYKL3&H1_ M2O7,510%SEW,B4@M\]X;$W^KAK\V,'3M&/@7$V['1KY@ M"RIAWEW+TAU*$&P[GL=Y&/+QA(8!DL!%`Y)-6J9 MO97$BGC&@5GE"",^:*&532+[DKSK?(<1B5# MBH1-E51%16R6%3@?L`+G'UBM0%BYPIH^Q4=OX4E\,"MJV,G_/ZX4B*W5O;UH M==OZ>_]QWN%\,&C8\VTTC?MWN(D$1B0G&;"D6#DZ,%-AI) M?PKR?(YF?/'(SU9@S])R-_CW(R6L))>R$QA^604=UK_=T)#M1I24T^$;:6FC MH;W=47Z7/:F_?;/Q,->N$KY%X#\X$XKGK_A9*HN\[O=SQ=H!??#=!]P23(HE MIZ!Q7?21V8YDD0CHFG^@-O-RB9[4`:ZBQ;Z\R89-0/J4#)O'BA_/(J_-WB$A M,LL@,JM!E#]89I$0"R:1A4@8WRW!P'IW0\L7O',TAGDL"F],\;`>C8!YV/D9 MCE?C-073[B\7UF*6U_%BML695I@R2^[ZEK<$(GEC0A9Q$,86#)0P\2T>P*O& MPYWE&:+7^E@OK-J+,?E1R2?(!P!3K78%[]24O MA,2V7#L)6I>3SGT\L`5T#1Q^3-/V'Z@'JR#?*<075\;+1;`F#Y:')=K5BYC9 M6;?`>@26<@)8@P(?;%G@3J(OO>?EK(Z'Y=B4GX);45MWE)W_9C-5Y;525MZ* M[0ZFO(>(*V#GR.\HQ"'I2<$.5F]C0;R_X-6>\*?^AOQT_>[+#5FX,6H1?B@6 M$=,O1\/^'U$[&)?#OO9'/&ILO&'3`U4M/)*>:)DIG>!T9`H`AOPX(AM-N^S_ ML8.O)47U$*CBCYWUN;1+,YE+OS1@KD84V2;-!Z&(EE%$?P&*0,#(YM(V4^0V M4^_+PO[EKS4QU2\/B5(IO-_2@P1]9@LMB%%#.W`6J:SV0L>233RF" MZMVS@Q$T>J34`VQTI`(J?^!)7($$_=B+L5J:VRM>N%3+E,`J(N_PCSVC7WG@ M+7+>E!K+AQT\Y6+'Z,S>@9#$%M`CHD@A]+&8L4K`Q#0G*,$_A63BS_'XB8V^ M3>A,'"MPDB/V,`0;#7%.EY%I2WP2G('(81((_UH?%=\/8W`H\J/^*2E^/HUQ MK'4)G`#V\5?*K%R`AS9Q14%W!'1A/1=\L:5;C7HCS$Y`Y;HC9)Q(>)L'[E%. MF)[B3A^PS9K_/_4KR\*:IYY[=QN[DXT89GXN8[??@8_A&Y3:<*,$PC0`(4CR MPG(F.3#N+!0/GX8-J6#0Y2+SU,F2-A08RG@0DQYL%7.^CW3^@4(Z`.8=6FO$,+?<`V M)^A4O>$1`S.C``0[YP@C?'QW??OAJH.V=^H\H3V8`7%X>(!'$WG(9+[!+D#D MT0<\]C.%:0C"&Q@!P[&?`$!88#"1:.)YQR)0!6'^L"(\`B(7@S18(>\E4=3C M=JYPM'J(]DCA_P)V\A$&`%7$A(1[WDMKD:Y"2GTNS,F/.]!6,K)31J["Q!^[ M8^%XZJDE?4&L#>N&"MDBO&\/,/+V/D*HZ+D`/:(:MRGKD,4$CFD\]E*^&U%V M3)<[JLB3A3%0^5N)R*R^_()+OG[TLW1W)'D&+[%!N90[.DU.C`-*Q9=_2"I&M4H'1D:M6I4GI!4M4O9SJV9!ZNINDE MA?5`Q4]')NZQJ?1R:JFT!4.'7-D\`NX`UX"7Q`^F5?8=UELKI./A:,G)PE.Z M"U4`;$:B2D[#"]!G#S_A>,1IX"V\`*GV<1!>A&S5'807H-:^/L'QR%31,W@! M&M5W!L:]?E&C'U$(#^(8O(1<'MX7.!Y5CT">X[*,]43H=$IY6_&"=\.2(&G^ M+BT[9;!4SQY<37!S@^5D;OT-"A8+>!D$FUOJG-1).!`.^Y*\DDAW>.4!)G7.K]HU_*Q.X>8=<$895M0$';84U9X:R$%\^Q01R6 MAGI8F./YK/;-9Q6P=U;HV/P'QXW1]M"4M[(V:%D9&[^C@%4T.D_)706$EZ6L M],Z&1_#XRNY+40ZYF`+J[>7UDU/VST9-GD*00-SE=S("%RV>#L)"Q[ES?16I ME9LD>U41:X]FOKCV"#A&88>=I%A$.2F:6)%5Q[95)K,N//NLHP)_@S`"+OW- M:`V7>/%;0C*T[EP+7#M`CH2^ZTQ*&2F]8$1:5KIEVO9GKF4_HI;=J4W;@GIJ M38XL+56Y2B3!::,.&"H=L(&\W\#/4AK@P!K`$%Y6-EPR+3+4N?`M"M;78E?\ M>?+P<_-]Z#V1@3O]U>/19*G(C8TR-SYO/8Y1<8,4C="+W=NXV&=NM#'ST9+% MW@W;RRST6T>;&5(JJCB"H0U#CYPA?\S%+OGUK3,1WMW#,3+IFZ M"O<6-[11OI1=#UODT2[_[CAG,4NI]#G=C-B^-;`ILMM!(R'T4DNA/7U[O_;2 M5E!H,X-@;K.P(D(N%YU;`>WI78,ZT"J^5=!R:`GL7.1A#$9QV&F$;4RP&[N;*B;`LB-1@'"JU$4]`K^NP2T-23S:D0D"!B(3/[YSJ?SD['>&PY$2P&8"V'KN.*2P M50L0SX:TNMX9F62U"I:$2,[5;05%%KYG&\YZ=P* M:$_O'*AZ005M?6B5\WU&6>?F)8%[.=]"5/VQOG(A8;>XGJ#4[_2++Q>TS0OC M2EA5J@T]T^R,>W4V].1:6+F@/4S)F/0LV>OH^E"QI%S0GMYEVJM<2GJA`3W> M5T(C!K3-"XFD9\->1S/KL&%+@C&U$R)P,/8QNSB`]6G&ZQE":L>!$SEX6WD< MA9'E8=V9VB>1#%JU3W)VT*I]$@6MVB<1`%JY.$$N:-4^B=HG.?8^";]WY=3= M$7RO^WL,L$^=[.JNY%XOEJR@6MVA?!,7O]@>)'N:`] MO7]TUILB/;6-*`BTY[LCTAN;-7BP)3&7V@X1..:Z*;TKN9&B;%721:K+S38I MU-T;)G5QE%7QF@V[22F>%I6G#]`QK4W\/6B6GE#\+3Q6N[JA"8550TMT3I): MJR)*2>KIL6K(T[LZ@;6)I\=UO*N6A+5J*U'@*K_5(U>LU@\^JT-7]95Q6YZ.%;;E2UC;-4B?)7)QV:=;+IBG<"FA/;YA5 MHVL%;7UHU1DR5<]X%HVN/ZYM\*@^#I)!*Y@/WBK:"@JM?#ZXG'1N!;2G]Q%4 M'P<%;7UHE0]^1LGGH?]K1MYW3+$W`VWQ-0]NPPM\P%[%*0YER$J!SX]('8A^V7+!//CV!XVXTG=`(?2#2CP)3S11Q9>/$;WM.\ MWK.1W%';BD.*3SL!H?Q*9R^OUF&2@&YH&U>X%;"G5)M")J=8:_9C;DRK*M< MT!ZF+DQ^CAPW/'LFPQJW%-K3^TA[E5/)+C.]CCYNUD.\55PH!+3-JY!DYT*S M,]#VK2X23J\48J_UX#:'CARQ5WNW5)8$J?]I[^N>1=9((L-6U'/MC;/T.CYZ$GGQ)(3M]-Y)50W:`D8?*`TJ"#.U(51I<9CR763= MN;04K^3S#]_%8??>LA;?IVW!O]*`70U["XOR#E?LQS_\%R$__'>W^X$N`FH[ MK.JH0^`OE[("),N;D*NY'T3.?]AOW2Y_)1TY_U[VUI4WR;\#I/60#6[H],^O M;$/3=:VGZ9'//@U,[15SP]FOOVB:_HI,8,2YY89_?M4U7_VH&[V>J6G:$ITJ MDYX&,RW#3*N"F6GV=$DPTP&EZFMF]$;#@228:1EF5=;,&(S&_>:87=FV'WM1 M2!;6,\KO*@;I[U_YS^_C(`#-6;(:5=;`&!?7H'SP0\.FZ8:I[X+-Z/?[-6$+ M8@C;7<>Z-AD"&EFL%6(^* M0G5'/3IUHC5P/\X7KO],Z0UUK>A@M#7UL59<_9WSO!3XE:@^UOO#AN`S\]N] ML_!F=IJ\Q2I^J1=R]42?\#/M?@WHE,++$_*-I:K^\3.=W]'@GVL<-?EW'$9S MF"2\]:\F$P='L=ROEC.Y]MY;"R>R7#8KF_1];JH;^GOLA$Y$O]'@P;$I>`>. M/[FAMG_OL5'^9KDQW64)_O4M`IQQ_H\P7/2,,_@>@G/UY(3_RM!@6'`<=M`W MS\Y'1J[!NL`D<_A3ZD7A.+1E1990$`0#H@V2`"+K^FR`J-):]?K&J&@2Q%NQ M&QI9$"E-2'9?D:0+E2*2XM$":;H-J!7&P;/<&B[%HC4ZSK;C>+[HVH/7*+GXR0_#-[(N6@Y)AF,!18YA"Y92L#41UIQ\H*$=.(OT M'-QG^DB2(!%/SGT-?`\^VXR;0O+9C\@SC*3\M3O?G31*J%X8;VHD?W?2R#3; M2"20/0#%?2;788A!=4Z^ON$152N8-*F.R!.NI\F1-,=%W;".:ZN6(707D.\V M#78`#N''&HZS7W++"(I*]69)T&N/_&P]$]1I'786^9/C69[M0"15QAKDG0__ M(1?X)%^+D6%H;S]=?7N7_:F_?4.,OE]\NR5^NKKZR!Z\_W7P+N]/G*ECYH]$CI&B'!=`:>E03I M2Z:ZH0O,D>>IE\.3`"/D%Q^/N//#[NCQ3OT`5@S&=>9L#LOS8A@RR(9<,/C".#W`RRH0=,LTH ML_!#A^]^V%8X(U/7?X3?`66`B#)^YZT":L4T-91+9;@H&+PH3Y"76=.:PB6V%LM]8)>0,7`@:A'\B ME`5F;)A$SE'^04U$^#6`L.!8@RV.\G-N`0GF`$B8`^UXL1^'>5`"!MZC3T*Z ML`(T!7.B/'S2447%FAEU823.B])/J84'AWSC);CS/'GJ7$REBD ME#Z/\'^.Z\+JHYY!]"MHGHQG#J)X"KQ1IH6`CDM%]():9;V6H5'TE@65+*^P M&A"R+[]P*IH.0!_/ZMP47&[7"'IA:X? M-'#7RZO*):?2T@1]LX!%06DO96+/@+U_^M8=*F"OX[Q:X-($&+1K8PA0P>5P M'M"-0E?#\I[1O>*^"+@9,^I.T"=)"@OX&9A'"S2QS5R]";D#UP\=#'`LP!V+ MGLM=KI#]N/1%@`<[.'X`7A,X-A/FT"VLYS0XCX"VX%J]!C=J0``=%ST99PD[ M&H)/]"[($$G\3QL;=8.0DWO+8:[/:R,WP"0.<%1TCZ9.$$;D=W@?G3=X$`Y&V94L)],*PK MD%8M\Q\BS$#^1RS'"SHOV]:&#=4_(U<&S*ZK%9XW(FOTIHVX*#V0(<]/YY2^HN M$TLL^"-)\WV-[US'=I_)E<>WV";DJVM!S`-ASM?`OP^L^6':Z,C/52W`02KI MKF"2]5UW/[9DF,FP]@6$3F6Y*O[4/ M-E-@V'0ANJ]*N*@BPR8TPXD,FQ*&)MY[TK4[AT*5;LIZ>;]%F;HI7RT"QR4Z MQ'6!']_/B*D=))A3+*BZ(4=O]>&H,]![BJ-4"",HW)9>]=GX\&.C7YGH*ETYGFSN\AT.QM1?-T;=8:ZUC'[K=BO M4MN2*W1C'=G4KJ1XRJ,-T>-PH'+"*GP4F&[G%#[J2A#/VY\^&Y]5[^B:WAD. M^HKASYKA1:;;V0CCZ]Z@HT$0V>\/:XAC"WA3'-WS6=I-:O&W$6AHUB>=V MTN;D:RT=M,6L0&78=\4H/8A1)GY\Y]*W9=PJ51+"')H=0Q\IAI4+6B%"J9;2 M5HAPJZ6TE0M:(7SFZK05PE-M*2O(!:UDC"L7M(*)6;*?(BYQ3W*U1T:J$UP= MD:X$7K&R,1I)9F$S?T_ZBZ="+%$D[W:'/`7>,(VR<.3?<1@YT^=LQM,%(+>, M9I]IX3J3U3%=&D40<26K\ST99Y.7W*2U0J*,`9?7A+DNOP,E=\U)2!XI?#&W M)I3`=V%L>>SN9&OM2;S+&KN+$BN.9G[@_(??3H8-2-_SJ\W^E%Y`[D_)!R>@ M=N0'_%+)1=JNV,K:%?L>^0(/8*]C0^^D-WVQB]$LO,\E)'AE"[_**P,!!HX7 M"-[K@9;=_%5VG\L4&)&Q);L/S.&7WN)@_H)ZN**_T?2NV^1^-@#.H_=^Y/!; MQ`++"RV;W<::5;VF\.IC!J^Q_0JQDPK]^I5CY5>"Y:X!M?$!2BX^4/[I#1*' MWP;ZOG`5Z/KMG_R%],5KC[WU/G^;V9X7M0X-LWA1:Y4Y3X9;O4M.RBV#K(9A[<<\5'(T'=;#,32P`JO465#>'X^&>N/Z%77'HL9L<4<$Y MV86!JUCADS_Y8?C%PYM'OTSS]_FN+UFOQI+E$-@RR9%!UC*0JUV(K,-#FA"0 MUY,/(4"N>_MT$V)?P9\3=O?U)]>Z3Z&=4.?[[!?\8?==E5,`A/[PW=J;V4RI M2OCDA+;EDK]3*R`?P1GY`!8^/V_R''\,GX*'/O`;6W>`T.WJ1M?4.1";ALG@ M^>#;,4.<7PU6"DOZ#'^D,B#XJ:L-NJ;&82D=)@/DHQ_^B1 M;Z"5?`_\GNLPC)?WF>-0_&%\]G_QT?1)_N!NR#[['**MPZQ"]C??C;T([Y[] MY+@T"-?AR9[@#]2%8^7UU?E3SKFA"S_`B]0)WIL>E\"1/)D]R)_;#<[?:9B' MIWR85;`8L.0]+.6]'SRO`\-^3W_>#<.5#9$?WA0/Z\Y>S4-4&&L5$'[["`BP M;T7K8/!?V8\E&F:'7NF_^M$<#^`YIEA*!UV%YH;>.R$Z[!'Y;,WI.D#+!_#W MW83YZ\>KGV[_^NO5W[]UR/7G]R0/1W&L-<:!10Q`UUR#K_Y$_I>6+%+R"'L" M'M@-#5)BJ/5Z>K_`,<5AU@#AP1!S]COI71)?XBB,(!P#!BN!B[W!7N"/YYXN M`7*D]8K+:.:7$<`VS:%F#+1Q`>@M_@1?AF6*R6=YA2.W= MA\#`Y..334-@FBGY:`5H&V[H`_7B;/+9(T2HZ0O7'G_\RY0_G#Q;`M!NO$P M@=F9^%>9XN5@AXC?U'?Y_J.1WJL#^P_?/=T%+GSX_U!+`P04````"``WB`@_ M&8N!2'`.``"!O0``%0`<`&AW87DM,C`Q,3`V,S!?8V%L+GAM;%54"0`#NDY` M3KI.0$YU>`L``00E#@``!#D!``#M75ESX[@1?D]5_H/+^^R1O9-L,E,[V?+X MF*C*LU+9,ZF\;<$D)"%+`0I`VM;^^@`D*%XX24F$JO(RA]AH]/&AT3C8_/F7 MMW5R]@(I0P1_.K]Z=WE^!G%$8H27G\XS=@%8A-#Y+__X\Y]^3A#^_:/XXQDP M>,;;8?;QC:%/YZLTW7R<3%Y?7]^]OG]'Z'+RX^7EU>3?7Q^>HA5<@PN$60IP M!,_/./U'EO_X0"*0YIW6FK\]TZ1D\'ZRZTM+(?YW49)=B)\NKGZ\>'_U[HW% MYU)$\=BADY+\K4,O=;KZ\.'#)'^Z(^6,D('U3FUNO;.SPGZ4)/`1+L[$W]\? MI[O6[U80).GJ%6S9NXBL)^+YY)9$V1KB]!K'=SA%Z7:*%X2N<[MQ(7*&Z78# M/YTSM-XDL/QM1>&"<^;,N$VNKBY_>G\I+/*#F=^DKYAW@&*.%S:']&D%*.PC M6I=';W%NR'I#X0IBAE[@E(-YW4LB)9O>0CV!!,X64_P"62IB+H_^X@@; M/$-1J,5!S_K)4Z'QQ"7K5&N$^/8O"$7< M.-]'F(`4QC?<#$LH.IJN-P!1T>T#8;T$]^ZBMS(/!"^_0;J^A<^]L-ALWUN, M>Z[-OT"2P:\0L(S"W&=]Y-$PZBW8+:3HA0=&,?3+\28<\$\8+X5O(OX(I3WQ MZ<&\MP)%Q/H&WOJ)V&@^+,Q\YL$A%M&4A]+>4Y>.TX#1''&K)]LI8QF,KZ.( M9'F8>.)3=@QHW'/\6IGV%I@KC]AL,:>0\3YZ&U+)9D#@QHPD*!91BBN9%N-N MMK@!;'6?D%?V'8,L1OQIOSCNSGV_*O`^5H#/&6R*GU(2_;XB2T*B1H^) M6/(2VE*RZ#!?.2X`>\Z7CWSAO01@,Q'*3V"2LO*7W!P7EU=RC?N#_/FW!P2> M49+G##R/Z,:0LL\$/,/DT[DK.5\C"J/8R2=C*6Y5U:I<4.KPE"%;9WG2/^.C MD"H6H2+Q_Q7R*8,G9RU=>[:6AO!NW;12;:Q=TZ;!`(W*OO@_&P.MNVLB*28L M6Q<[$Q=\9*W+]@M*UD:GDJ%FJ.GQ\:S;T5E*SKP[()0SD-MKKQ`M5ZG\SVA` M^T;S==(V5S!?.+6PI">0=E(1A(H(JS(.3E?QD'[]L>[7BW$=^PA3@#",RPVU M&E9OX0)%*&TYVKV!M)5+@U"!X*VL`S!<>$J@O`\G`%S'/&/A6H%D#E`\Q3=@ M@](JJRQG%#-5.7/HJ$*%@9M:+C.!CI%T^%_"<;C8%"58&^]UCZ4MNH]#]:U% M$0>G=CE(;_XU'&_..2](*8RU#C502%,H*4)UJUT=!\\JF4CG_F1Q[C%-X;P^ M(PX+G(9=;)R%E50F#!Q M5F7!XV+C5@YSOOAR08@KN32>G?PTT.*IMC=F[/S#2XOKYYI:O)B)RDTS#=%I M8,-)16]$Z+B&ERW7M+E18T!+T-TTO5'[?L3)4JV3A4HS36JT&PG9;9D5LZ): M+1V8);5J$KQIX3>@[*@^TC0`UE,H(ECP3K:KX^!@)9.]IC>=(RWQRV^?49*( MK:,IOGN+(&.SA=A,@O$C?(&XL[)SI)9J6ZE#]:B?F@[>M3(,+QTI4R@IHGHD MFXE:26N;*%3O.RGEX'0=G_!2CNLHHAF,K;.TE:XZS]/1A>IT5]4<_&Y@%=YN MWMUZDY`MA/*^IQ4"SO327@[TH4+"5U4':#BP=-P3/&YT$)<)V1QLP7.BF0G, M1%5<4!*%B@`GI=PB@I*/]/7?3G3_M_>(T*_23R)F7C,&J[OBY0!H_%@"7OXX MFJA?"(E?>?+9$K;]LQ2W^GD\`+;L2+3"-L!5M!(0JJC#6QI/<0KP$O$04,C[ M*TSY>B#)Q#MO&D_Y-)&&<6L2DH=[**GQOANG\(X-\OT=*;+Q-$E'4]\AZ]*$ MY&P7-33>U30-;_$\IV0#:;J=)Z!XYY'/YL+%FZ+<65/AKB6%C*GT M=:#<7?$R4`8XS)HZ$!]5W<9.WK*X$&9@'%Z">Y]1C-*,0J[,/7H3_U)"PTHG MK66@.P58N*KI"0H#V_`R6WDO%?U1O#^;I9`^D47Z"BA4!@U'\C)R6,E/`2>> M2OO&$"OW\!+H!P@8%-M#T_6&DI?BM4<57NR$Y9&R@?`4,.*LJ"KID"M(J3>26?\++J6D444>8#O8A#I,X^L8%F MMS&LI`G0T2[:F%VLX1!>?ES;TS1'GKG,(-0/'= MFR@4I#DJ-])4+TBI:`)TJXLV9L]J.`280LAC_"J@:.=@%]+6I0@U:8`>]]#- M['@SH_#._47Q)U'5C_\ELMT7D(BUTG5Z`RC=(KQ4OMSJTV:WJ>'4)D!H]-'6 MC!%'C@&^2=E=='E.?OD044YXNC'Q\Z2MY0/__XA5B0PUG0XGBJU.UECA@P>W MJD)+*TPHGTEHM)Z-OPR1,_5GB.&B4]3#0M5>BK2IQANO:A<05XT:`[C!J[$< M:?,(\%"SDOR>&Z:H89OQ4%N-I<]P02BL+;&^(DQH7M4YA10RL1_4Y%)<\?L* MTQ6):Y5'E=@Y:L\-/!ZIYS'OG^6B2A!VKYJIGE:WRII/QQNI8\"$V.S3&/]' ME%#>>FM*%F!4D:KCI78.-%"4.QTJBA%W9.W763I;L^Y-=GNT+DW&&XPFKY%> M&C=&DH)]L8/KPC;`8?`$\S5\8!UMB[(2R=+9X@?4$1[-R=4#[E=`'> MH+!L#HRQ9'79<#B27!:'C;@MV?\K`$>0R?';"R.6[6S7EM94_W:@K(IYZBG' M/8-7B';/!PA:XF+[/=I^HP`S$,FE1OX_&7[B_V3%8"B5F4.*Q"")1.EF>`N+ MOU4G^T?LMGY?X"C=CA>O71!)1O-`(W0;1-W=>SB*B.%=?-+I_AUSD?,+S5\` MPF)ZFN'JRU;LFB+&I[K;_%MFA;::P'6X#BQC;4@')SNJ]F;5?8R?(<*$=XOL M(&>+`4++I(L/*EI\+!?)`DE@%1\?"^LJC%/6TZ>I\6*,6_9QS)I*BP6,.-;N MWJ(\OW_D+IQAM?`MX_1I6E9:\FHZXDCOXW\RR#3-R.#1?UZSR:O?\)(H<:>. M2SFGY`7Q,/1Y^YU!KN@]P@!'R@^*5O.&9\-J4G%N..:KVQ&$<;ZQ,0?;/,3R MG#I/%^RVZ=FZ>KG;K_6H&U^^("!#S=/>V7(40+Z5Y-=Q>..U)G;UB6L^^5>? M!FECT;E!"3^'!B>'.%\C#`&90U\!GAW6QT8NY6R3[X;>O4$:(59EJ(H89Z17 M1#4-_XI]VEJ&;,UU3R/F,NO/)[V?8I=2^\REQX&*]3@^D^ M33<`P@/%".^%GS+0SQ8/!&!QKZ"3!^HI6I-M@^+4`&97U"]]Q-0FC5E+!.OQ1@!X]Y`D6CI M&IP:B+R-L*=42]=7@*69^VZ<]=['&;1MYM-KD.#[.0GQK8/`TP`%WVGD+<*Y-#XANYCOAL1Z%KU6+_ MAJWPYM+PU,#6VRA["&HN?;J^(7#"V9[G!+*G;,\T>P2TC:F1?GU;+=;)U=)..\MJVP47`4TN5TZW;B9Q"8"*KM7SKK;+ M\`Y!N\+K/YUE19^]J1:`IJ:GCT%GP^P5AJ9>P]L)Z,K?^IJ7%7X:>BWF.O2G M#S2S"?:*KDY7X:4;YLBL_+J83Q.GV53]9;)3Q);5$`>;0\O>PCNXU`\+4P%9 MYR;6T!5&>=E]1R^W4K3["F"*LK4!U4)T/^NWKZ+VPLO[YH?#6BM\L.[3=`-0 M/%",\+YY6U8(=ZMYYTC=JKH>9@V\'B#T4W\`S*P=.9[:'K/2AW(4M/!C)BKK M?&B(3@TM3LH.`(F.O\3&W\/!1KU8U6RQ.QE7W3-S(2WK21M)3PTM'HH/P(RY M%XF<#^$@Y_^EYX;,5L,JTOE.63Z%ZB[#@=C)OU'<#QW.+QC[P4#]OO%50#ON M^<:&0OKRI>/=B\@M+'BWJU=&<&MW:ACJ:Y(!^/+HLL1>2.6U]GS8[;G6W=-A MMVEIJ]L;/')E`9X6(S9;S"ED7,7&!'Z([L06%DZ3K;AD"V.YL<4-Q-&(8T!C M=LC.S>NE0_18JZ5VR&ZJ*B6U(FPX!HOFW-[[R49%1V"AM M?H@.5=?;#X/9XH/+>>$7;E5Y2GG#T;2$PLS3]8;K+O2M9SB'J0.R7J.=>XL: M?DO(5R:'=6T^<*H76P_;%X^ULT6%XP.;LUT2YI#=W0&*N;_$/));]*`A@429 M,)^XUL91(FHX+@A=UR*>G&C$'\_^<]/-%A\^3M.D]0Q"4LXN MVMVCXW8+6,@CRL87[4QVB`PI;7_\[<7HY?3(R[&PD<]H]FLJHG5/4MRV4S,6G&_*Y3=VSL[/` MW%V((A"M@%XRV\BK[D)X6?"]^1:I-CJYU9JY6?`$!C!JZ?^?!_U%NZ,82*+B M%_(JCT*>!OI^<,7#+`6F>BRZ9HJJUSX;<9$:]Z)N`ZA>)W#1EC2=)#"_%@L8 M(3*"H>NZW>.?3X^UX]Y5XP6N-*^)8)A6\@'$8TP$N%#;Q'"F<\G3B8`8F*3/ MT,><3YT8%<(XDWHD"=R/^NP9I-(A<&&TB>%.1_MX`)-,A#'6B'2BLX&Q3\A2 M:FR2F)N7').3C;&[HF[,*N&<20[0[2(+5280#7$'D!`%T26Z80Q:43^=$"JT MVELNG8COK,+9F%O.QD\@TBL8.N7B:GMG&C=HS5\DR>`.B,P$F)BY\"D!H2W]>;SH`?T`TUK$)\195COFY`[BS`;,>ZXE,W2BN--^OF_F$G4.D M>U/L2IV'KC*D/:HY1*\GKWTI,XAZ8<@STTT\XL@>$1$YUN]64&?":#R5]Z,' M`1)U.#NR$&:/CIM)GM!(]U)HI)K5W?WHDLCX)N$O\C,C643QKEL_;H_NUP34 M$1,<,V2?/2H>?HUY$N%<^OK?#&=-_FVR5><]3O<3$"8'WESY@(7&5`R*AB3Q M&;7MNKZ%>35;Y,F(3R31"XS'&$#5%!HK%34:4P__59LMQP)LOXQY M2JC->.5`.(?VP==`=5)(AR!\DEW%]<`T1E(BS(;063C"(]]"]&76F"244=WS MW>+7%<4P5<"BM_+6=/?O*@ZHO*)'K(W)3H/,H5@$*E43O M5')16"2F0$9$#DV59+(S)F02Z,$H@$3)^14S/'6.N_G6Y+O\\I<%3[0?^OAQ ML9Q(R!"2BW:Y@*)*>Z1((#B<.>LNWC"G3&!ASJ;`JCEO.=,3JX9AIS='R_L_ MQZY\)'A:Z7IN8ZQ64;"O^9D)K#OZ M'T2_H]/TSM(]>]NCD#U!)2YBK\RNU`->Y]&?@!7X1*9K:5"?@MSY=2AH9!K6 M[LGM:5P'A;P,3AM9!C=<`!VSRTS@P!:^/@G")`E-*K#(?$O,$-B+_LEFFW9S MPV9F(@IZ1L(5S/Y;%D==:K>4C'^UWU4AU>QU]_+R3RPONI\.6G0%EI8,(A:2 MN9,K)1N9C?:V;4^@2JP\YN\/&O,G81[&O)H)D7DZTPMQ/B3T)KY4=Z!B'JT% M?Y`@(*F"1Q#/-(19`0\@Y..9`TTM.R2Z#W4[5,!^ZK[;TO#H93\ULQ^AO)C. M#CS]R(U_(L-D/?6+;Z[OSN8WZTRKI:>1=G.!"MXV`_UJ\SQ0Y@5BU3T/.5,P M5=>)D;EH2Q@OOXIX@"#.=EAU#G*&3*Y6GC3FL:R4R5U3(G,PNQX0"X30SSQP M>G6WTJGD9E6)Y%85BQRH%ZP.`[;8Q740IA&;$?VPC!+,_-&?=GF>V&<=VXW7\W8MVMJ M3KB:;I4I.X`W8K>R9"%4G#,VLHM5;Z5L8W-C!Q/M\J$:L!'/CA?+HS4K9&]* M2]_QJ9)=7U`6R]::`R5O::XM-BN-X'9KK,+E9Q&P3H<2P$;,XIT7G5].7):= MM05\]45B'Q'?,'#_F&O(B:!`L``00E M#@``!#D!``#M?6UOY#:VYO<%]C\0N0&F`U2G7=TSF70PHPNW[4Z\X]A>VYG9 MBV`QD*MH6S.R6"NIW'9^_9+4NT0>DB(EJCOW0]+ETGEAB<]S^'[XE_]\?HS1 M$TZSB"1__6K][<%7""<;LHV2^[]^M<]>A]DFBK[ZS^!__H^_Q%'R[Q_8_V[# M#".JEV0_/&?17[]ZR//=#V_>?/KTZ=M/[[XEZ?V;MP<'ZS?_Y^>SZ\T#?@Q? M1TF6A\D&?X6H_`\9__*,;,*<.VVI/]^F<67@W9O:EU2"_?6Z$GO-OGJ]?OOZ MW?K;YVS[55E$]EC#227^/)`O?]/Z_?OW;_C36I0:B@#3]<^F;P^AXOVE),97 M^`ZQ?W^Y.I5JOW_#)-XD.#\+;W%,77+U_&6'__I5%CWN8EQ]]Y#B.[&=.$UK M,^SMO&=O9_T=>SO_T5A^8U.\^S#'VQN2A[&;N"G^=A^D,4!DZL_\!TY=:4-28?75& M/W7\XN<<)UN\K3PSVT#LY*YYL.66:]MDT[$:LU:$I,*?PPW>A=DMMTK;LOLP MW%'KZ_4;'.=9]_7'^%HJV!>E!)H+0662':8OWE3?.SAZ_J,.V"(TPWU0^@ M'Q4_NI1XLR&TQ=[EKSN__RXECYK53,RKHWR[W.,/"-)".4'ZUM]XI,[^<1^S M^'"1/^#TB#SN4OR`DRQZPJ>T>_F(STB6T?)>W-V$ST,VC=%N"&:F;<\Y$W^. M:3C"M8*9QA:#EA(B3`MMVFHHIAK>B3L*4<1)-0_H;6*HQWCS,BPA"!QC6LY- MQ,=[]'.,V8?#9'OX2-(\^HU_?YF2'4[SETL*SIP^._E_^VCW*&QKG9H=A@U+ ML^[BB55!M`,-U&.4QAL71=,,1/:N@C.<92ALA:EMR^9B0I,;.(MCEC,H28.9 ME0=)E'-0Z@6Q<3U!N^^D4',1<=WM*[3MK5!M$87)%K5MKE!EE7YB=E="USQ[,=ANQ`H;Q91AM3Y.C=;G@X9H10I0U)89@'&G]%#[`3FB4@_:$HC&:-3X\2\9GK<`;0Z!%):]\:BZYRVB:QEJ\M%64XRSO?#VRQ/PTU_N&NB M4KXO/15+=NDXF6`(:N`6(IVVF>#HXOSZXNST^/#FY!A].#P[/#\Z0=<_G9S< M7*-7OR3AGD9KO/W&+P&-0$+&5V*7D#K:;6+J>YL)F\X&9"8.7.U=7@C%VT0`['D#?CDTBG[#6[84LL]IV49/V!B:YX^6;4XI;, M4#EP21)-7Q!?M$P$U2.$ZYDA-EF7XF+.+RLU_+)(&PED7&UUN:72;--,SXM' MQF4/A\F6_<-FZ9["F%9P=I@?A6GZ0L/#W\-XWX>[D4[-/2T=:P)J>''+0GV' M,!5U[01,AC-PPS[@1MHW`TU`02SJK,]%#?4N(;7]S85&HV'+3K:%<20R54,8 M`T-R;*[0+;Z/$M;A8!->Q6_XT@$K&;%,A]CAF&4RR+XUA^Q@R_!(P+YU!=BW M(&`Q_?9W`]6W]OAAHE*^0CT52[[J.''9 MWS'P!U%4VTQ02;"Q>_'I&T1'\>$BMQ,;H82,K\4N276TVQS5][8@AIX\[F+R M@O%5,>P\B\+;*([R"/?G!,:H2AD+J3IGKMS9M`Q6^C5CLL)32*$ M<9A2"=X4W^($WT6^QS.C<`1R6J]^5=R66X$YKO*^(*Y7X>@R?#%JBGORRG:X MEI^L$2X]S-,"=YV-:W[;-H)*#+W:8E';NRN$E\93&1RT&EQ!C>FVMJ6J7E/; M\>-O]H\\/D;Y(^^CTUX[27+:1\?)AD:%XRC;Q"3;I_@&/^WI'^2MS>Z'5,`<)1K;C!HZ?"6MJ/E>8@[#DS$117W MQKQ&=CJ#WQ$EF!W7SK9(C'/M%M)K!:91HX=^99J(JWK>*>$#Z[*YR!G![G-' M!2LM2:YS6A2^V)T=[O,'DK)5.4&KII!L-6%220>\EMAVNGRE=*/B*Z0=%`(H M8Q*K8K<%)6DMQ/=C%-]ZWH2A4^G$N':&5),H]7D%VEX.AR[V.4N'PS(+J4@D M$)6QJ"/JFD8MXY/R:.C'B$A]=3&32".U8"J)JA[BDJ2*%&1J:8%L&EA?`IV$ MFRPDCX>T<;1UHF=PHC&0P(4F,]I;(#IL^/K;@X,UVH4I>F(B*[1^>[`Z..#_ M#1N=%7KW;O7]P?>KM^^_YQW&=W]<':R_7_WYX#L!KQ;#)?D2'U!O4LX,U^V$ M5B:`E-/AA\BX*9K6-9RN"SC]O0#1:9;ML>]UWY'U#W3V30#@NSX0A22ZC M(=G$3+FD/=9EMDTC:3[,O3>`OL*7@@2@=L"3\O4ROD10RB*K\6$"I"*TM%!4BZ!7+:?/-"E%9ML.&2J_089ZGT>T^KV;0 MBT,N7Q+@Y$'9`>*6%JI)#BT;:(D#0;LK/@'7V@ZFZ0CKN#2EWL"$D'[+XY2P M]A7$DM60FEQM317#AEYF`-NDT5WDS!9G<)Q'3'Y9L^^3(-`@OMM`T&^D3[(\ MW6_861?>)-G M;`\&_;S!OI,PZE0R,:Z-/GVD2EWF*&Q[Y$Q&NVG7.'V*-H/-BN*'-3.Z#ZW) MT#;G%O\"RS#D!PH!^XZ-!K+R6_0*/V_B/6]/>(J4)NT4G[8+>SE4OOY^]?[/ M!ROT]?O5^[??TW_7?UZ]?__'(K/8UV\/5NOOUBM$W]&.8 M;3F,R2?O$^="+!"=&NQSIBW7I&-S:1"Q.HR\7*-^22,"2 M?$.3SB=@I2X@3DF4JNG6,AU\W$CY)0Y0=43W97>I,)1M8UYF:1(T.!MBR\V; M0X$.HUL/5JA\]/G"0#(B'H,#GZ/>88DDF=W4@M*HYRR+F]RTR[Z&THL9^GL) MVH:A$>ED0!*:*57!2I.B')7J2Q[H\AQF<"RF+.Z"9]/GG4U20EF%!3PC+`BW>J7>$GG.PQW"")A7JT MZ@LY(E/7[!04$GK0(8Y`L6EWTN+A,N@AJ4`!*>2O6TR%KKR(`"*+'F&?1D]A MSA?FV5)C=?+M)[R]CY+[0[:HQ(FJ/CCMPE1-(1M3UD0;[WR"754.B@-SU])\ MT%A`I\D3SEJG5DLCJ+'BF_X.($K<0Z4?2L9;[08 MBVH;$A8M\P#XTM@EF:A?"KV6E(K_.(KW^>#0N$)*DHZ_EG*_=WLUEY)TAQ;0%.,M%6/%BHNKU,(F1[)Y30 M[`3C2M`1>/F37#'@SU[?LH<(EZD9^9G+2HR2D"]%>;[4":Y@8E(=O7N;A/*= MFYH`BY-AQ]T-8J"+<;!9=W'3?OSYPT1VOY<%3GP.'#[N:?\MIT,9&MD_1L_L MD_"DC%*N?!V`G"49I)9=]FY43B!"P+I!_9C/`9"[NVB#F\N*_!)#7;O$L"*Z M[)"JM`FBL.LS\R]YQ/6%?))==0JI)LNO6,H^MZ_(KDMJP"X4>7REFMW[)*]O MZ#\_GYS?7*.+C^CB\N3J\.:4"BSGQE-5-1.C.AGD[!4I]#+URFU.AR&C[H9& M7U7A:B28^K>3ZJ"I?T_IEX`N21?%#EX^.RGUOC?UHJ6.:"<6RT2=D$EL?(+! MGX8[-:D`]:`\*W_C?X^F5@T/B**N"1%9Q%I#QD#6)P:2LY&@CB,;#*W;(%KF M@I=K:(&!V!Y;BPC)&+R-2B[3#$=&5>D:5MUWQD6.]`BR4"O(@??!=^Z+VHA MC!!6H8@*LC@%,7]SY_2]= M!]K\>%_P(\'W_(H>F"8Z+LTN@1&8"(Z*A:`H8:D3RJ<+6`;2A@!XZ8N\FE1W MOG0UX2M?1%YF0)S+_HN6,UNPK=LW#AVW;QQJ9/F-E%\F].1]&J?8\]NWR2E` M(MK@U,='3EB2%Y9I^4="MI^B.![$>GV5.M[KJ%@S4.W$;;](VQ_,0TTS02-9 M'(+*%G&_I@$8R/C*ZC-0K=UEH:XW;T24D$U"*&>DF8(8!N#O`KSZ:P&XAK"K MQJ<(@PO!&:4"9OW&\ECM,+:+GC9AO/O4/F*W[3D.S@+3BC@\T`BJ+Y>Q]4-6 M.T3KE0Y":%NP%RV'-OSE^F#=I@<2;T\?=REYXI/UPF5[M6"5ZP,0M,WU(37M M-->'R@N8ZP-6#NKG*&H)>,[VH:Y:8EH)O6P?4IU.M@^%Y24DQ#E,MOS."%9, MG&9L^V+^TJ>*IO@P.8Y$W%V*'*&#*=.%00XU<^;(392IQ%IY<_B.F*PE_0>^ M,<;WV6MM1(BSZBAK39I;1Z@IR;`#>)D!@%-D*`.=V:*OF[V,`^_D"X::.K>9 M$ZSYG*VY#%]XDW-Q=T;"A.6D['>"`(GRM0@E+.DCL#G!#+O<"\04F59SNC^F MWZ,->^"7&%#=$>V7W46_0+@->*FM:0#A+(0"]D=@@0;*Z@D[:\.>\2RQGS4> M).%P'""\)GLDR?T-3A^/\:TDUQ8@4?5@11*V?8:A3:>#/*EYL%\@T:I3..Y8 MJN(B/WO<^-;(&Q4-%"?]C.W-2XX+"3WOJ3`18;!$5U:0!&."4+% M:6*!P-5<75JYZQ$!0&9,UJ6-*OFE=VDA$*EIKZA>+;H+;&C07.IY5AQ/W:4% MW+H#L;I+6RLNO4L["9K-NK1.X;S`+JV@I&9=6@T#QLW7U%U:P.4,75JU=S?! M`.[2BIJT979I=1`V*AJ,[M("ML8%AV5W:2]V.`W'=&D!13@F"!6GB04"5W-U M:>6N1P0`F;%^EW;7ZA*02F?IW5H(2&KJ*ZI8B_("&QI4EWJ>%OI]9VOCW1ZWH[(N@W$.!V[.RC,#V?@@\5.; M85U;18^@O)",]G,[@I5!]&METG/:XV734CJF72(O?78VZAE%Z>P=(%&^7*&$ M9:@1V'0^GR?W`44#F5;0K(TM81X(JC:B_9Z[]!$(M^D@M34-%IPU(X#]$4!8 MMY%0YN=^Q1YZ'L'9`4(24, M_,^+NW);?!C75YM`=U97T7(B\U6H=6[>EIN."S3!B&RB(H*A80J7P8 MC;8)ST%E*KB3>2#6BV:./75"X22_8H'L==GD?28JC^Z3( M!+-YN4G#)&,;A?@/Y7_%Q<_>_FN?Y>S7G>/\XNXF?-9:MIW;;=7SFLVM;4R? MJ:`NM[O-7&:P!9BS*$%I%6U*LRAO+*&P-N4YQL_-..(7S;TF8:82=)J*67_U MXEH0-D]`RRQ9S3344L3O@=9$X;?G9X[H*78Y)OB)+`4=N7+.T_,V8%-H:`0: MH-[TXD3/@`[-A3X7Q])?$AI#XN@WO/TQC!)6YHODF(:9)QJ"GG!VF$99E-P? M[U.V\,'#3Q6,-`EM[T#!?1L'$X6)\46:(Z)8EVY,\+%T6AS.JZ_ZNPNC%#V% M\1ZS@79474N2TH$6RCZ%N^(NJ.(9G[OG5VO2/[_^X_J[948W!SS1"(1ND*D7 M,\?[T@FOMK_$;R0N+MX2Y^^5"[0C84_`123KF'0>B436E9%DJ!3P[U&5S[.X M^FT!E!976)^2TEZV4SK3*VBLZ+ MJ\[./5*[:N-,M6V#@YD_EUW%<:[!T##"8NM6>;+/,[:'GH6`S0/>_+O8XDL6 MT/J-Q!1Q4M&].&!FJ!,'QI3!8Q@H[TGBUV%=/X242H?[_(&D;"@Z8+V.<$UR M6-B:TY!YMQ36\`0S5FD@J&6*VP-7*.-B**SET"O*WN);SYLV-6%`QE16GX:0 M7I=U:@^+(ME%$X;->;6_>#/)5$IBFK9+Q6`LK4QYPCTO/Y%QY'YRR7% M2GZ8;%D&KAV;K/\Q'::;T!-N(CXH;,\ZP+SS?!1:[A244QD(*AF^%(4K@16Z M9R+>::93]61,!0WX!>CUR*7T,#G*7`9V#5=V$%LW&%LA+L:A=M)`[<=BEG4^'S1NW$VBEB5NC1R)]C_P%A=W3I4ZE6+ M)H_8_GX=%M76)T;5]-&ZY<@&4NI(??ZE0_FD=14=[3M6N)MPUK>U<9[NIIK&`2V51E1ED)VP$EK&MU`!`@AVE M9E4KWDNJMB':1JKK>58,.]\RK>_6'7S;&Z7IBR]54*_5676;G=\/F!4[HZ=$ M\Q):JM[V[6+G-G\B::'4"O#)GH["-*<@6BZ<+L?I>AMQTJ%O)+@.X_)P;/5@ M&934J'[U205)!6F=36CI:AQ'&'CR1K@KO"N+"*YZJ\3*=R07LZ24S/`$73J% M*XA%H&K3W"UL\5I9M\2L'KI\D6FT60);G1`ZSGI2*B=C4;-FUS#L6L`YJX%S M_,4`1]+7L47.0OHQM(@4G0]AAB_NCLCC(TGX2IR\'Z-0&/9CI`KN^C$2%].> M0X:=:G9G("-!\Y"3:\.?%_L;%M.O4<%!W*_1J#!IOT:B*^G7@)YF0>`41X@5 M[NS!US\HW(@R)!;"Q9:'+Q>)ZN._SJ#HLS&XHGW]=+_)>=88.MJ^PC&+@LWI M0W7N>!L3==]\C`GKSI>YTPDVRED4`^ZYC30;=#3Y'%>IRV[Y2=DM/^R[T\== M&*5\-N?,^[JX%02).TCT.XGFUKH=R+&E\<0,AT.6\068@A1KB!6M0]Z+S'7N MFQS2(90?=OAM;?,P2O#V)$P36NKL<+/9/^YYN8_Q7;2)AG-;N@IU2ZI6L(X. M*A^L26![`H_X62/ MKW'Z%&UP-MSWI9`JWY!4RI).$KL3]#1A3Q!_(,V@_-XS5U252(S>>)<5$H4V M%4";TR'$68]+X6,D.-;%JER&RLC=VD/'91[G&,;5Y_R-. M\#<%";*JRQTHM_0Y)#3SZHVQUW]+%W5&8/7R,R:?!;<45 M435$*WJ"HK:D!(P[I:+:#TA`E7IP='%^?7%V>GQXSB']?HU2])N-]&M&/L.2.)5OT3\WKJ\0S0ZK!+:7T)G.(3]0\D MWN(T8[O1\A^4#C4)J+`C82(GXD^'YS^>7*/3<_K] MQ='??KHX.SZYNOX#.OG?OYS>_-I7RE>YNH2X*G\>&:Q-6VVN M3DC0>5AI1468?^WG?^";_/,7SQZPL[Y MTC8_Q>29CD,S^@P,].XF*ZY]61J#A'4.LDA6,RHFM?5@-@T]3`XO=S-O6J[L MD+7N1^="##$Y]&LEZ7F=<@JHR6;G'&+-YUS=R?,&\SOW/N`$WT4YSZ7"TC1^ M"#.\9=&$AA)^M:8Z8;\36^5KMK1E25XK[Q,T'2[*`_'?WGY0F$!Y^(QN"R-E M8B.>1?7U+3.$RNW,*$Q3=E<`W]GF-V2XP2R9`#K=>&-EMAV.')3/-[F<-9Q. M2C(IK]8UL=@5?Z65,F%8BU=M2RM4VUK,_3O+8YFD65\.S7QV"J";%J%+%MW> MKVAUM:(R:XWIU8J"6Q5OF(]%W:JHO%!1\RY%Z36*ZAL4K6O967076C:J8AI] MB^]6J/SV29C3K]_%A"')C!(H(PI+SN:/A%9=3K5"#K1AW)L=ZL0JSU.K M<-7)4*V>!A**2T&^D&G4FQ2'V3Y]X;,%/^/'6YSV<`=(E+]?*#$2Y?P?J%1C MT0T9%J%:+A]47Y:Y_Q^9Z5Y^+N.(KW]%O5A50CMJ.-'N-A79CO,MUIV"[V-@/70<"Y56]4ZL^N+RHR M*^^)#J6#=CJ#A?1"Y55#E&^SB_2!6-/_5->OK^L8A7"%1(17+3H!+>35#K<2 MRW+H"A5:%R(N"2SWGOB_P!IV=1>!O% M?#E0O!"GD"I_JE3*$H02NRY'/[`+"*209CT'OB-IE5N\R5<9-TI^8:VJ76)4 M%5W<2Q3:1`!M+H88Y_3]:7%C*"BA1UO0,4,:TU.29.#%A"<]Y8`__QS8(:A? M@"#BFH`YTNA`-.E;]L:4)G,-SQ57;S8I4]P%99U-=3E:X91)/,M9;%O,6>9TA MOVQ1LLW*3$GKDEIG&['TW+CL=!MY''^I:'?OEO@61,][N`QQH7VMJ'J7EYZ^ M_BVC"]D'5A^+OPEOXT&.).'#?AJ(\J'5JH78D]UZQ<"F?*6B)QK4?]/FCWWC M_9RAL!X(_/8D"1.X3+,4H:A&#T@\BQ)\2C_V%R3D`GU$M@3&HU)0H'\6KZR$ MCS5&U1XDB%4IMO'+)!`760J(A]5'3%ZX!-:U3@EMI35_1V"AS!Y@-@_'&3SL MLG;H'",U3=@A3-+!NK:M"QU\'RU3)N703<0A3[ZAD7##OJ[=G6H4FC:K9G;N ML#C@OY2S_6/J67;(SZ"B?8[46O?H'<8QGVMN?R4.6&9*Y8O15;($O9Z;"0*? MD6.(*0:&ZMLD3Q=RFZ0A,HA-O74)IZ??)J*)Q]E`Z2Q"F[ET@T<:T5M/5HB* M%XM<[=I93+2?`ZN2UF%*L/IL33Z&4?KW,-[C9OY2NN"G)5N^-H6L)3M!ZQ.T M%#K^($*J]0,F@K@,^ID?X%I"'A2]&BK0_6JS]_]R>^H/+'M^]7W_WIC^4I)Q0E*"\5 M%W2)`$B;'`.'S M2%5XL4A4")9F45Z-2%=:V/L-4A7.QS#I5X=0T\WY6JCBV M!9\&DE;=7[\0^)`>?)#J%<>^EC"^4NXWOH'/*#7+#C;T1G;+^"0JSJLTK%;%M,B>$I>IJP*["Q@U2#ZBFBX:[H M$WK>9:FL5&)6`;V&1*+1:2-`JQ-BQET'2N%D+%S6+;S0YT5?Y\N`BZSC88D7 MOULJV(4H9R3+6"_GB"2T-[.G!2U[-B3)/N`[DN)"CO:);.V;T;+T8/UM9G6>[F+_L\,Z`>4L3 M%*+HEEM%4?%7SNSZWDHP/_&(=T3W]S3,5HCNQHB9?_OG%7T<[B>:O=P+"CWK M.O:\8M+?%'-.C5O4^*VB4[FWM3"'.ONB2E.\5"MT\DR[+23=1DF8OA3;]E>( MC0FI=5HM,3-?E?F_PYP'ZOP>XYS/#O092>YOP18L_\A@^PTHC^2^[R423=)H[\.XHJNE2KE:KFG9Q>FZ(EO8&")BK>T M70[3UNR=[Z3%)@`AHVM0FK95IMPFHK:O96R'*](E0_OANA*B#7&5A,N=385- ME[R2F]?>V=32ZNV&6]"6IEY]R?8T#5\PL*>I$)9N:FK;6M#UV3VQ\\DRJ0NS:XK;*6,SP>WQOH]82^L.O(-8CN^A+'S5L)-I$;%9H]D+VA9' M9$M;E30W1X7Y[=7EM,"'D.IL\(KVKS=%QN=WZQ6B3#SX?'&A?1^U&AC#<:0; M9+PU1\9)`NX(E_LQQ\7;%B[^US[!Z-T!Q\3Z\\7$6W>8>#L1)MZYZA#)S9M# MX9WD4OO#/$^CVWU>96:A76+OIW=M\/'.'3[>>5^\O0F?3Y[9EC1<[E<3+K1* MI3J+H@(I)TL(`[N3G&F'/*GGY\6:U50ZVQR-B\=+F->65^=@#AI\]Z+IXH'" M<&I78G,ZK#A>&I+Z&`F39LF%[?4MGZ-7I83GZ18WB`%7&,9"QF_>Q_8=)Z(# MA8"$\'X<-T<*!3;=YFJ4F8<3,XJU6K?EE'./7W][<+!N9B!7Z$^K@X,#]E]U MEC#*NJN]U(H%^9S%(2 MXX&5/$SVJ(&)NN,-J`A206HA:,;KJ;;;B*UJA_%E&&U/DZ-P%^5A++QT34NV MNLP*EK5BC%8Y[!BC_XZ2E`IL9#+VO0JF1C51>^J)DBE88P9 M@N9CS!7.PRC!VVI;M)`JL%#Y/F1"5N2`/=NQ0FI;3@>)2E!]7^]`7PC\%15' M]%YS%_!BV0;IFCB8L5'8;/:/>YX!GQ^?8JU5BA_H`"AZ*C<^B1L(4[VJL=#7 MLVLXU'[8EBVG#8FA2Z!A,;(4M,3+W'`=A6IO9+G-YT'I-'&G!Z%`%E.DF2!S)6I`3]VI%/9EI.,K%&T!_0V7 MNIT5S#&G?-_R#:W"E'*`O:F0X6RM`/0P"A3K`A7%[9'LZ8+2$=I#1+)$,!XC M/I<'^'SL:9;M\?9XG](AQ27?F,%G:/FSBQT_R7#RC---E.'M8&ITI'Y[&YN9 MOHN-"B8>72Y+C'6NW.1@;#.H_F2YROFB!B*%G.]IV+&`ZN^'&%O'@MT2)J8& MFRG,R[&,W=:\E(<;VH]+B^OMBE-)/5J9J$@3E(I4G*>>'#J9)8FIU*U9CDJ) MF:!U(PMC\J9U0F)!^[Q5P`"36<(5I\IN.=2&\UW*O,V$QPF3H\H=NH"B+('J M"E7R*W[#:7G\]LL&IW;N53?H]-F#/-S^:U^>4KTADI48MBOF[@YO@"1S@P5$ MIU;KI49'5BV#@:-RN.R9NBT2%%!<>@K81C3,)0?]6)[@FQVR3J--7NW<0?LD M\IW@SC6VR:3`ZJ_(.G'0#G).R[R81'VR.4:EG"15G[NY1JGE&9+UF`)[_'YGBV57MP5!WHOFMVUD@0E8]7+5VBN;LDV4XX,C?4/, M'&4RJ+106*C5$QSE)FO:Q6-'?I_"F/4?/"=L'8TPXJ;6NV0WM=2.`>-*X2TR M'.-=BC<1[P?2SS%F'PZ3[>$C2?/H-]$`TT2E?*]Z*I:LUW$R04?-P"U$>A3C%FFRFTVWYM*<]7;H-6I89#=/*-DIP7F=D)ORO#;6/ M=J4#=/N"2'T33UA;7W%1_R++3NF`.A$P0)`-R@?H[AY[IT+BBHEAF]_P`BQ2H\4D%U_ZV^/NYB\8'R% M^1D;)3^TY:OU.+6\[>J*RH-+WN@Z`]=:M&S4/,K".$RCP56#(T-6-NJEN%$VK%="1GB=9+%N?#G@!9.Q=@.*4_HD?D'%:1?4 MJ+*T1\DV3+>>^WIVL",.4=!?71EAKKO<,KH\OOC@<*G0H@234($O)M:Z;!:= M:K?IT-5'U`!ZP3FJ*G8YN]'\$T:Z'NF+,=ZOO!=,Q[-9^X\Q^52GC>N1U5BO M?-D&>I9A1-N3RR&)J5,H6)C9"KBX7VZ;@X)8UE>7PMHFVK0U].N/J>E]F)3[ M'(Y(DI$XVH;E'HA+R@5:PK"(/1^C)$PV$1T25$67;29P:K-BN!N;MNQW48H) M.MDNRP4&#V=^@@]A%O%3P&T]SX'&*6[)A+#I!2@7YCO!RUUYET(X9[UXIR6: MA6NTE]^VQ4XVMZSQ%8ZV/<;)VF*3!Y@E/BZ->N[K+Y^FDK'` MNJ?1]'W]Q@C<$/OZ[-_3H6^E>WF'J?>9X>OP9AASQRZ1R^^0::Y39RUED7.V MT4*%VH*FPN8&M_06FGG0[;/I8E<21W59:0O,QOJ8MK,X.XZR34RR?8HE@^11 MNJW+N0UT'5S3K>UM@N9KC'_5#=YF]H*6"H\"'27_-W>;XX@XJ-[A;=[:9OKW M>AOZGQO0SAJT49Z=8GFM`#-JU!8SX)L?XI(V;3Z,^QV0E9?#*=LP#%UA1,U"`K[[F^Z'!?L ME>KM&R\7&,?=(DIU^Z45I'S&WX]AE/+]&H)+28PNT:6)#2[@I;/X-S)^FO[X"6_O.WOBE/,,#BS59S$L+%GO0!_M>Y)S&;:E M@;>DVUD/&@.HOP17VD"-$=][S^W129S#I+\-?;31[F9TR[+YI9##HQS6Y9B0 M/>L>?6H3$OHL<:YH6:22'NY8`JN\MO%UB2[NN@=$>1X`=O-'UAPAO0Q?H'WC M;HQ5+;VE,=M(9>7>Y>$1)R4!HY6]@_(L.K\G`77N7EA,/'*#33(%0GI!RIX7H$-M8KW[Z!GF5HT?8TP:C!U#<4 M-\QL!1UQWI,I%=`1Q>!]F:OG]'$71BD_C<42!?H-&N98(I;5W`T%VB;:K#?T M.R>8G?7?C;TZP_$:`G*K2[Z4=F\^"$OZV--CV/->&S9WAX]Q\>]IPG>\'K6W MNPXWW6BK-+MO-%3L-U$HG4RS'T?7K6)OA9Z9H))`48((WPU>;04/N93W/1;Z MZ"#C:V^PZ4*IW=M]H>EM)E"ZW.*C[=`%'HM-/P4@7U7"WS!L%B<5CCK'%+YL M;,IW!$T"SN6V&ZWTBT:-AT!/JP7IZ$W*V):GV=N2H>_Q!.[;:D@\:%46D]+7 M'#O:')94JPF/6R;TR3SP.R=X9VIS!%Z=X5:W]3G[_6%X5&/D`L0^FZ4?PRAA MTRX7"3OR>W'76KKM,49#LGQQH*0E7P';+J?@U6X@1JJT`R:`V#V#Y3'K:"'' MK'7JF!A71I=/@%*;04K;EI3)\.;;>_+T9HNC@BWT0Y\D]*M_'E*76^;V8QS> M]T`I?%9E>.X^&PG[00E<@%QF5`1IL6Q0?X78=Y[3#0MK@2A>7B^);UN,P5"B M.Q/HRG;B8Y1MPOB_<)B>)-OC,.^C0R56'3Z6BEF@4F;4%4`5]F58!=6"JG=3 M/$;L.:("B$EX/C&IJDJB_]I[1R`E&A7*88LS`?Z8;/@FBB(MM1CMH$RUAT`L M8X%SH457((>,RQ`NUPFJ1ZAXMA!HP_5&-%]S;\E<)%XA&K`U$YQ/$EK<%]EA M`\G3ZBJ8_E,+\/9LN8*MV*P,L"+IH/AR0=O!995"E&^R=PE+5[#"I%!_5C3^ M`\?QWQ+R*;FF`U*2X"W/I9X*L:F0[2!5*FN-6XEEMRB&G<"8AG0KA#.9U_]F M0JB2*K+8>\[1JU?1Q+`^1%R0J'69`=J>E2=_)_$^R+A$M`NJS:B^99%Z.Z)=U$MM#4KFLO>_17> ML=NQDWN637(O!C4LVL&V3-0:XF+#;I$.^H`!#ZA6N*^&F+4,*H26@']%#1.S MFA"Q0:S5)05D>59N<%(>T;'!/4E?A)002G28T).P)D#'GEO7^]LXVGR,23BX=E3VO(/9SG-KQ+:L MN<7KT#",UKY\A=7B>\0?+`&IHNHA&F]4A-*6:!>C`QNS(O0*WT=LNV:2GX>/ M?>A`(AV<]D6LH=HUZ!:M0MLP8`4J%6:;1X@]6P)L)15&]%ZP"+Q=Z2Y^19;F M[3C3+DH:QJ?)%C__#8N[!Q*9;E>Y+V/?1^Y:=-PY%AI7](H%.G5WN'B&^$-$ MGRX!RK)Z(YJO6=CS[8KWNKPB6_/"F3P^DH2GF^`'P+*+?9ZQJQ-I!UR,;0V% M+M!!!7O4`^8=4T#M2<$'E8&:'%RPR(RR0H4L:@DO@BLZ."!C:DK((D"W1RFE MEYF7+IL%U(_TF_X4BT(J[RY?#J0<+&#V;+I>PA2;5RUBBK2:95,H3TO("\65M4P%\@)@=Z1(@+ZI/(>@EKQZ"?4M%#/R!S9FA?T/-2M#>?M0#>/'(`::9(=.IH/OWAUP++%O_ODABJG0 M?7::G#QO<)9=W)V$:8*W5_@))_M^_6M*ES])*3T2A3H%=X%,`S\BM&JK!Y40 M'92B0@Q=W*%"$)62?H&M6_'$O':Z^%GK>%# MF"-,G;!KQA^P0#4M?&8(%QAF@8SMA[M]X0JX&&T6LM1T\]T?,A0E10GYC,5C MD3H;1=1MRPTBZ>`K^E/V<;%EG_M*2(["S4.$G]C/JTJ_I[V9G.7ZR+-OOSA* M20X,.>34\&20:U*]-2$5<"#3Q)\-I]ZRVW`*;'&R\#@>)9P?&;^=N.1`^H7& M\;>3@^YM!;KVNSNCG^B7U5?T?RR,9 M```/E`$`%0`<`&AW87DM,C`Q,3`V,S!?<')E+GAM;%54"0`#NDY`3KI.0$YU M>`L``00E#@``!#D!``#M75ES([F1?M\(_X>.]G.W6M.[L]L=TW90UYAAM:B0 M-/;Z::)4!,E:%PMT'9+H7[\`ZF`=.!*HH@!HYF5:PTHD,A,?$D`"2/STYY=M M_.X)I5F$DV_O3S]^>O\.)2%>1LGZV_LB^Q!D812]__.?_O`?/\51\L^O]#^/ M08;>D7))]O4EB[Z]W^3Y[NO)R?/S\\?GSQ]QNC[YX=.GTY/__7Y]'V[0-O@0 M)5D>)"%Z_X[0?\W8C]P]7-97P]WF0O@)4AI6-5^#X4FN(^G&#@CC? M/`?[[&.(MR7W"QP66Y3DLX2T7![E^WFRPNF6#0T`P0DS(MCIZ:1B+9B+0VU\AW9%&F[(^)X9B3/@,:;)MA'3*2/8/,<$G,F: M3+4B,\FD[(R%O"-F3XLP+U+"C?"]0S'MY.?$#&M$*YIO=T&4TFJO<68DN'85 MQLIO^QMM@+^@Y9JV34@^1;DA/C68&RM0>JR'X,5,Q$[Q<6[FC#B')?6FQ)4: M#UTB3B-ZR:PR")MY7DR7I=_> MZQ0ABT5J'%B1$UM&F&49:8SS(J48%F@MI:G4%-!8TXN.=W0A0_ZA0\(360?2 M"6-^'J3IGDPOV,2WIZ=6F4IO8)FN'=I];)9V;1*D85T%^;/3P881X8KB9,=< MT(=P$\5-WURE>*MJ.VRF=%O^K^^X5;S+\3L@:YR2@;O:*R"<5X@P*N-`$LV9 MVG$[6&2C\Y2SU8S.88EZCS&Z07EEB'X?`I#674E*ZBZ2-%0$`DC.L<+-#_[A MAJPD=D&TO'RAJS+$!XR4IC*C@,9=B$"4`F)#P*H"Q6?_0+$@4\BTHVX/$6*" MRG(\`G>QH%0'"`0>GPH%_^D?"EI!I(/7ZP%!2E,93T#C+AP@2@$1(6!5@>*_ M_`/%124L4:E46CC-`%!6MI12N@L3N()`L$@95I#YT3_(R`82F=/U9OB88.3@ M#QK_K=_8^>`@B06+:<4F^@84K.J[AH34,+#K@;._Z[S;%.]0FN]OXZ`\"4!6 MLSMJB)]3G&6"J(E>H69&#RMDS137*,@0C;7/M[L4/Y5A729<3WTU8:6RC-!: M9])L/*RA;[=/P2JBO4I6@;]=ZSS81<1Y1O\N=RF+'*7W>)4_DY;AH0I*WD3G M5.0>(4Q3=U.(R$^6>D;!`X"M$A5'IJ1 M>@1<#9TG]\ZLBM]8(,\HT&06V8-6Y>\*L;6;>(.34+41.Z09[L6V:;P!%41' M,PP)./N[$IP3$R3KZ#%&S0;2Y4L8%_3.\\\8+Y^C..XA2*=(LZ$+*>(-O@PL M8`8W6$7^+AD%"!/8T$.D3(J&08M[>!J@Q#%W3Y>[F>M16W.U&+,).68+WXF% M^G44/$8QN]DF/Z2M)JSWVR2$UD_2W@9[>EA'?H:63]0[/=LGLM8'``V#@;IU M>X*84/J(>^FI;,SR6ZE!^)Y$0E'/ZWD4CF-&K94.3KC<_#W"S0*E MRBF)@JH=CO9P.@+33@F._%`#Q,8R0F]P!=9VQ!D'.99./_D'IF&B-6&> M)!5ADQU)3&@S/4?9*$PZ7J8@"<4A-<>0PF+W4+8'AFC5[PTBKE6"CB$W?W>? M:()1(O&ZV7#*?3[Q_$"WG275GKK]; M)*>J]XI$5(XC!*:=#E"$'/W=);I#>1`E:%GG:N^$%*@-#"CB. M)&V==4`%8>[OZ;^'E.7NW@O')3%!94L>@>-X4>JD@P\>,X/])+=NJ+1`SI8B MG(<9:#+\&T06,F35.SSE8%)Z>%D+5MIQM(VSAM;XIUN3OWM;0T,H5Y#*E:/S M2%+JI`,6'K/?V,4G<)3!+(@C8U^O8SUR(4/+A3J*`W!MX:6H^ M>E],4$D--8/5\K!7_W0RL/HU^<%F_O=N^OS?D\$[$_@D#;-(F<1+-B_NOU7& MC86J"G'#H^)"CIB"29/-BGR#4YH826H"$3%7]2&QQ9O>6@TY"!@K].[?]894 M-HPC#ROQ-Z3,TVQ1Y/215WH[$0`R#K4$91UJSV$FUGQ*G'5J\?=Z0RL"#W3J M&B6&.QQ0=^XTZ/0M8`H\4$W^AL!;ZBF&40#E$&Q>#Z!PC2<`EW#H]##N/5!+ M/&Y"2$6P\G7$U-!Y,F#QQDH/;]=W]@-*S61;*ET*WIY*3>$1?-0:FJ*&RWGB M,+;#(26CM;)98`E:U43+)ZN!)=4#DW8?LTF)_Q/C8SLNY'E^$@502,@CX7?Z,.]XA=V_T9)<0CQS0_Z'(;)1%5E;[C M7KW'3\XORMBQ'.<$(]8$*=X"&"LUT^]1@M,HW]=6 M($-KETMY9N@[RC=X*?9`%FKN!#%>J6:WNX.M)M#H:J\HXC&2;=AXM;GR2V=D MG;4:W.U14/5?;NY3N8]GE6J:V..P,[^([\C:X0;EPE4#]UMENMXWE[$@4P., M@!Z3$9?FG7`0]>VS>M]%L!6@(JLSU0K)G%'P+,BB4*%=AT:@6D5C#>_*%L$P MO;K`%W%EB7;YW/P]YMA7Z"**BWQP^$=!)8!'0^450/BZF4.DX3?Q9H%;XPK0 M.8*'&#&_$;=[')EF_!U%ZPV!Q(S($ZS13;%]1.EB-3BI(QB'3(M73:!?W'E# M\<8SH[*:)K(]_ADC`8^S3[<7ZTI!N[=F[?Z.KP)%JT%!=3S2L+0'^C7,^*JIC>'Z=RXKOFV3]9USP"U=]7E!QJTRW%/ M64G+N>P83-4W/)LEK>!-':M=K,XW0;)&V3P9WE"W?\RV):=&ADJ-,L/;VT[F MK6SD>Z`O?HD4[GSL:U9]M*]":52:`0;*PKS@7> M!E'?JTMIZK@8G\:1J\W?$9TZ]=22D7`O,=_JZS&L6NR3@_)W\*@R8#@GZDI$7P>YK@ MB<$]-+Y)>N`^,T5:8`,X[U`:81H'3G/;)UID&;$?@A=!F%>S5/N)*TBIMW6, MV('6_"4AD]*89J4LUD:963A4INX?G]'=Y$UKG"*HG52/JP:[A_2(,F(?RKW)=G_ MQ26*EO]7E%=N:FN4MB%),R,@]G.W$C:/CNT"PD\W6B`SUE4EZ1E(4R M%46$KSOQBK@'(0-5%5B"<32(A+OU\A-3;YYE!5JV9S],8?9ML6/G^2Y?4!I& MV>`:CG'Y]GI;K[Q[Z!MK!`44#=A[')9OQOSL`0MV*.E%W]4*A3F](UY?>J,= MY`^CL$40)^L4G\3O$!,P+1^[&M]A\CPE$5YG0NR M=!)W*,3KA''A/??X6M5I=)AQU?G9DR8T\01=;)PT$V?8<:$)-2/M_`&<'V0W MR&!2!MDO$_[<\17MI1LLU\KU`&0NR?W@'P#E^SUF>Q.032`P9W_OB0'VB44[ MG.#-X1:#-V`HT$4'K+@H(+"=C'?'I!7/-W4[)ENLSH-L_`"$F'5U\XI#:W0:DXMRE^BDA#GNU_(9.<>=(D&)V%>?14/J[)-X$Y@\.& MJC:#M[5K_+H3.M/6TIJKZ-=S_&F+K34K71`D812CCGH/>%R_.V85O+7I9%7\ MGM_<9GCKJ+"9(CGZ,034SJSN;]JBMCK-^T;)FN[0],B5CJVA M]P]I1D1?U#']@0 M(X$HJ\?KU_8D?ET'D(IRH-'6##B^"2`@=Q;2!G82VH=[.N+ M-N7582(V04B^OXV#A#YV2P\^[S@CC'[!.@&V1D'7CC]`0(!'V`9TJ$$B!$NS MK5&Y@7L%7`UWT,&.[M23G%B05N=OK+=&W!5.B<8A0DOV,+;XX`*\0,]GR`HX MM`R_(U*E44CZ!T6!"I.3)ONC`',)![!"D#BZ]-M1"09041 M$2U6USA9/Z!T>X$>!PMR<('F)2IU`=<6X)#&Q@:V`"V\)967[UNI*_7W6/H= MVE7N28I"%5GS9HV(S%/$`?6>`F?BJKR?)=ZV%`L2WA4Y"45OE=*A\!15:FTG M<5R\6@RF=&YA"7[:EV,>X]/=$E[:I[NYO#Q%\I06G`+S(^4Q#]8Z#OJ6&X@8SC;\9Q-V\1;&R;*<"K4[GY06.O(O6C8\63G/>05N?O79@R MM_EB1=90FR!9HSMBG$5"#3!+V#X[/6'T%,2MULU91YQ$ZPA)ZV-2K MR-]QC:\1Z#$PDZ+U,T9:19U'Y0A+Z*%2KR*#4H7AU3., MGP59E"U6MRVNUE*)+])UD%3Y&@^9S\O$HVT!FUR.07Q(BBYZD'E*GO5%O&EX MVKNX.$;^BR@+8YP5*7H@:#N+A['?8[&?POI<]O:N!4X*3GQTT_W6G3-,,)7F\+]_LJS)UD%&':)TL@W2967/1-^CY(,YMBA/R9UBU M*!DNV2(V:Y*+,)J(--@NEIP#D=X&A/VX\>C!2QS/AH)YKE'%*1.M=9)FT&';:FV MWKAC.6S8,:W#*WCUII7``T[#K.ZV(YG9\WM0P<_:@HOFH!-QTS6JB)LUKS@1 MMO#4%NVZQG%2,J\X5CK/_6.3`1C9FQLV,AP:0^#Q`)2'&[9B2INWBOM2B1P1 MA%2LJPLN!-)86$O1;N>7\*_N#4OX>MYM+U`:/1%F],',YB(9F0W^!2W7W<,! M]I8C!PE)HQ1""96=?@).S=)D!">+"SMMJ86SFPE8F=O2!:6/D\MPI7@51RO97OJ.`:E;>KK75;1MI#J86+>0@I!5:Y*36?!1/+)$3 M`M%*U'7!C8!:#.OIVG4$LAIH3U=P]KPK=ZY`V@)U6PA!SY615,W*)['64]OB MB'JHE(:CE@L]4MH2&*93MP?R.-*>)^#D>8]C296*,"]2.D](EG4`9!.D:T2G M$//MCK@<.J:R9X/M75GGRJE,-*%=KKG4#BYG\1J_0D;URF`,"ZBEW%H)Z`," M3V*FKI,!2U$F"3"IW7/'1&^>14V`XQRS+2N4A#:#&Q*9E.$,H[+U23R]LO;. M)D+D%+DBL\(Z%G+!_9C!`(\T3]?Y:,G`3C=JUNVYZV$;/X=;L/;\#3U*FN\% M#H7_L;Y@T_MHS24\I"PHLV=7B$5=7TY4J20BLM:5!0V`@?IT^V27&>UT(B:^ M=Z[>DQX6MQ\/.RAQW$K7*3M[H5>HV:B#%;*X/]G>3&("WN`D;+\I)]ZOU"_* M,8NZJ,7]3*TFQZ-LTM_JA%1=[GKJ5.FY"Z$'-E*T04G&-CSH?J\U+\*\\P;' MQ*!9Z<-O<"Y:`\"(ZW?0%<0V9_E]\U/))/-Z$/EA)J\@MWCA"-1\6%OG_ETC M6375?%S!WO,>?AFD"5EBT#ND;#)N;P;>$T0T%U>0U;-R(9F]^_\]D42]6$DG M4-&%?JML'0S7KS=K%W!F=_7%'#WOG1DD[W\%>VY32Z@Z;3Y M@,;=1I>K`VSU`1/;3W]"F[UZ%/8JRL(@_@<*TLMD>1'D@UOY"K)Z0BPD<['] M@4HI(2#F8_LY0[W._W<4QW]-\'-RCX(,)VC)[FBF7">@H.TX`R&MBZ#040_H M'(3,;#^]I@>/O^&X(,JF^ZLH)LL]+BP$-!TX#&CK<[M,-I=5$[+_BM+R?M3A`$I.YB`:0<=+H@X&4[-Y\>,AB>S\E`M\8I?ZK( MI>C@H$?A;O/+5`&V>H^%[91W>HU]6SS&47@5XV`04!)][S1TY[N[S2Q6`]C( M'0;F64^M>/I#`FT6!NF=#XL.",R M+QD>XZ`_]G._5?;H?7.Q-67B*YNS5[AN3^<#?#4,;^O,G)P8KY2FUUE[-"ZV M,T0=`L` M`00E#@``!#D!``#M6EMSVC@4?M^9_0\:7K;[`(8DS3:9T`XAI&%*0Q;H7IXZ MPA:@J2VYDIS`O]\C^8*QJ6V@G>GL^"FR=,ZG3^?3E9R;=VO/1<]$2,I9M]%I MM1N(,)L[E"V[C4`VL;0I;;Q[^^LO-VMY+>T5\3!26"R)>L0>D3ZV2;>Q4LJ_ MMJS6BF!7K5[P1K9L[EEG[4ZG?7FN,5WB$:;NN?#NR`('KNHVO@;8I0M*G`8" M$DQ>KV6"]/+RTGHY;W&Q!)!VQ_KGXVAJ^HYM=2<5^@V-81QJXY,M_`++N0&/ M6XQ+L]UIGG=B)Y>R+SM\UG/AQHS.+=T\QY(DY'/V$?_.U=6595H34P"B!="4 M28693=+VCDH,-L0TO,-,\855C`W3554Z?N4+7A4`W4ZMM>Q M'A.R0";:UYI%MR&IY[LZE*9N)<@"*,!,:<:3Y+,O2`OXQ2:"NZ1`'-UL@8N$ MZ6R8C;8=QQ!8V#F4W&P`$.X3H2C,ONUDLK[;L&SL'CHL<+$#]Z<>E4,6AXX* M7"BC/_.@7#P_=%#@0MP?.QZ-,X,1(%WX-!E^<[LUA/J<2>Y2!ROBW&)7[U_3 M%2%*?F(X<*C2VSQUNHT*=@F/F,E6P;=P&+3;;=1$4UA]YDR!] MV>`.W?9&OVO*V34>>4F[O>+:F-Q?K!F3UA`#%9$41A450%WG#&& MI6_H%RW-,H=B5<]*UNAT!G\^#AY!T?$]&C\-)KW9$`SJU?I]]"Q9M@=YERE= MO'ZK*%VOY&.4'R_Z*\R61`[95''[RXJ[#KSC!E\#JC955G9%@&+]SZNN="U_ M_Z'W^'XP1<-'J!_W/SR,1W>#R?0W-/CSTW#V;[WZCUC]?2Q7]RY_J;J9[[$O M5OCBH+V\WYL^H/O1^.]Z+R]2\Q9+"F(\I48:RK:OH5B?RW`'OJ/2=KD,!($/ M@X+X`J5Q:A$R(DR(#2-T-T,I`^+T;)L'3%&VA*G.'"P<&4I2;E8FT%E.H!@3 MA:!HBXH2V%JOC%[3%5P38&H3I\\]GS"96C??:"M3YCRGC`%J&B24AJK5R*@Q M9%`D,[PFT3I)5Y3%_2(7]]`;&?*%H^YO*!+K,":1QD`%"::1:BHP4(\Z6,Z+_'S57H0([-66!_R,7>.V.M#_2 M`'6\<[ MFUBJ![.-17V@J!-3M^T&Z7YJ<7.O4\^CR3D#;T]]E27,3HZD(H,RT:YRHJ70 MC#P[>+4X^^[-$^('PE[!O5:F;LSIVA(9.NW]=V64PJA#GPT]=LEXL;TH1:'/ MUI:%/O_"UQ#Z@;\%J6.?WY-@E"MXP)F+L'Y>)'M1KJ%,@?P3?@K[4&F0T M&&#!8&.63T28S2(4(%=;%OW\,SV&0(`1[D-U[+./1FX'>F.`\W8`QZ/:#-F" M"R_UHTFA1;$F[:OP5(X0TD5`0R$<2N']C^6YL3)926'%;NZ2SERBGL^%0BR7 M.)?.1UMB[.\D:85)=R-N&[#=!*J]CA9QE8QKFENHUEHZ<9I'(9VBW*Q".ED? M73B9P)Z\M2H<4FY1^60FYC=:L3F82MHO_CB=3"`$7'B/8)-V3+Y.YD/6]NI@ M+HF3*9W,@6%JRX-);+W"XLDT)+4/)A'[Z,(Q!+)Y8E?A(<#($IO_"7Z#PXZ; M*\2.5U/C-#MGS<[EZ3S4P1S4,?WO!E7YXG`E8B=3^AY:I%-ZJ\3`N.BO9NRG M(W&N(W$"BPM+Z#S!B@2,M>[VHME^T^RT#Q,@EYY13J`]C"0NB]X"^N'XNM0RS:4WR_+7'87O`8C-4Q-,W,1A0,)=PYPST<-X+ M'OBQ*063!F*`CNQ MV[`%<:@*AVQN>F$LX>L_4$L!`AX#%`````@`-X@(/Z:*(Y9$8@``)[@%`!$` M&````````0```*2!`````&AW87DM,C`Q,3`V,S`N>&UL550%``.Z3D!.=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`-X@(/QF+@4AP#@``@;T``!4`&``` M`````0```*2!CV(``&AW87DM,C`Q,3`V,S!?8V%L+GAM;%54!0`#NDY`3G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`#>("#\4^X?4#`<``.Q$```5`!@` M``````$```"D@4YQ``!H=V%Y+3(P,3$P-C,P7V1E9BYX;6Q55`4``[I.0$YU M>`L``00E#@``!#D!``!02P$"'@,4````"``WB`@_QY/Y22```:'=A>2TR,#$Q,#8S,%]L86(N>&UL550%``.Z3D!. M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`-X@(/^,3G`7C&0``#Y0!`!4` M&````````0```*2!'ZX``&AW87DM,C`Q,3`V,S!?<')E+GAM;%54!0`#NDY` M3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`#>("#_C_LL^A08``$XQ```1 M`!@```````$```"D@5'(``!H=V%Y+3(P,3$P-C,P+GAS9%54!0`#NDY`3G5X C"P`!!"4.```$.0$``%!+!08`````!@`&`!H"```ASP`````` ` end XML 18 R1.htm IDEA: XBRL DOCUMENT v2.3.0.11

Document And Entity Information (USD $)
In Millions, except Share data
6 Months Ended

Jun. 30, 2011

Aug. 04, 2011

Jun. 30, 2010

Entity Registrant Name HEALTHWAYS, INC

Entity Central Index Key 0000704415

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Public Float $ 396.1

Entity Common Stock, Shares Outstanding 33,702,609

Document Fiscal Year Focus 2011

Document Fiscal Period Focus Q2

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2011

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12b
-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 20 R12.htm IDEA: XBRL DOCUMENT v2.3.0.11

Derivative Investments and Hedging Activities
6 Months Ended

Jun. 30, 2011

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Investments and Hedging Activities
(5)
Derivative Investments and Hedging Activities

We use derivative instruments to manage risks related to interest rates and foreign currencies.  We record all derivatives at estimated fair value as either assets or liabilities on the balance sheet and recognize the unrealized gains and losses in either the balance sheet or statement of operations, depending on whether the derivative is designated as a hedging instrument.  As permitted under our master netting arrangements, the fair value amounts of our derivative instruments are presented on a net basis by counterparty in the consolidated balance sheets.

Interest Rate

In order to reduce our exposure to interest rate fluctuations on our floating rate debt commitments, we maintain interest rate swap agreements with notional amounts of $335.0 million ($145.0 million of which will become effective in January 2012 and $30.0 million of which will become effective in January 2013) and termination dates ranging from December 30, 2011 to December 31, 2013.  These interest rate swap agreements effectively modify our exposure to interest rate risk by converting a portion of our floating rate debt to fixed obligations with interest rates ranging from 0.580% to 3.855%, thus reducing the impact of interest rate changes on future interest expense.  Under these agreements, we receive a variable rate of interest based on LIBOR, and we pay a fixed rate of interest.  We have designated these interest rate swap agreements as qualifying cash flow hedges.  We currently meet the hedge accounting criteria under U.S. GAAP in accounting for these interest rate swap agreements.

Foreign Currency

We enter into foreign currency options and/or forward contracts in order to minimize our earnings exposure to fluctuations in foreign currency exchange rates.  Our foreign currency exchange contracts do not qualify for hedge accounting treatment under U.S. GAAP.  We routinely monitor our foreign currency exposures to maximize the overall effectiveness of our foreign currency hedge positions.  We do not execute transactions or hold derivative financial instruments for trading or other purposes.

Fair Values of Derivative Instruments

The estimated gross fair values of derivative instruments at June 30, 2011 and December 31, 2010, excluding the impact of netting derivative assets and liabilities when a legally enforceable master netting agreement exists, were as follows:

June 30, 2011

December 31, 2010

(In $000s)

Foreign currency exchange contracts
Interest rate swap agreements

Foreign currency exchange contracts
Interest rate swap agreements

Assets:

  Derivatives not designated as hedging instruments:

     Other current assets

$98
$-

$136
$-

    Total assets $98 $- $136 $-

Liabilities:

  Derivatives not designated as hedging instruments:

     Accrued liabilities

$263
$-

$245
$-

  Derivatives designated as hedging instruments:

     Accrued liabilities

-
2,253

-
4,465

     Other long-term liabilities

-
3,746

-
2,593

Total liabilities

$263
$5,999

$245
$7,058

    See also Note 6.

Cash Flow Hedges

Derivative instruments that are designated and qualify as cash flow hedges are recorded at estimated fair value in the balance sheet, with the effective portion of the gains and losses being reported in accumulated other comprehensive income or loss (“accumulated OCI”).  Cash flow hedges for all periods presented consist solely of interest rate swap agreements.  Gains and losses on these interest rate swap agreements are reclassified to interest expense in the same period during which the hedged transaction affects earnings or the period in which all or a portion of the hedge becomes ineffective.  As of June 30, 2011, we expect to reclassify $3.9 million of net losses on interest rate swap agreements from accumulated OCI to interest expense within the next 12 months due to the scheduled payment of interest associated with our debt.

Gains and losses representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.  The following table shows the effect of our cash flow hedges on the consolidated balance sheet during the three and six months ended June 30, 2011 and June 30, 2010:

(In $000s)

Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)
For the Three Months Ended

Amount of Gain (Loss) Recognized in Accumulated OCI on Derivatives (Effective Portion)
For the Six Months Ended

Derivatives in Cash Flow Hedging Relationships

June 30, 2011

June 30, 2010

June 30, 2011

June 30, 2010

Interest rate swap agreements, gross of tax effect

$(235)

$(677)

$1,059

$(1,319)

During the three and six months ended June 30, 2011 and 2010, there were no gains or losses on cash flow hedges recognized in income resulting from hedge ineffectiveness.

Derivative Instruments Not Designated as Hedging Instruments

Our foreign currency exchange contracts require current period mark-to-market accounting, with any change in fair value being recorded each period in the consolidated statement of operations in selling, general and administrative expenses.  At June 30, 2011, we had forward contracts with notional amounts of $9.7 million to exchange foreign currencies, primarily the Australian dollar and Euro, that were entered into to hedge forecasted foreign net income (loss) and intercompany debt.

These forward contracts did not have a material effect on our consolidated statements of operations during the three or six months ended June 30, 2011 and 2010.

X

- Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708773-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80784-113994

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41635-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624258-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708775-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624177-113959

+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R17.htm IDEA: XBRL DOCUMENT v2.3.0.11

Share Repurchases
6 Months Ended

Jun. 30, 2011

Equity [Abstract]

Share Repurchases
(10)
Share Repurchases

The following table contains information for shares of our common stock that we repurchased during the second quarter of 2011:

Period

Total Number of Shares Purchased

Average Price Paid per Share

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs

Maximum Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs

April 1 through 30

178,614

$14.76

907,161

$49,000,274

May 1 through 31

18,443

$15.72

925,604

$48,710,350

June 1 through 30

176,161

$15.11

1,101,765

$46,048,557

Total

373,218

    All share repurchases were made pursuant to a share repurchase program authorized by the Company's Board of Directors and publicly announced on October 21, 2010, which allows for the repurchase of up to $60 million of our common stock from time to time in the open market or in privately negotiated transactions through October 19, 2012.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for an entity's treasury stock, including the average cost per share, carrying basis for each class of treasury stock, description of share repurchase program authorized by an entity's board of directors, the number of shares repurchased, the cost of the shares repurchased, the remaining maximum dollar value of shares available for repurchase under the program, the treatment of the purchase price in excess of the current market value, number of shares held for each class of treasury stock, and other information necessary to a fair presentation.

+ Details

Name: us-gaap_TreasuryStockTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.3.0.11

Basis of Presentation
6 Months Ended

Jun. 30, 2011

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation
(1)
Basis of Presentation

Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).  In our opinion, the accompanying consolidated financial statements of Healthways, Inc. (the “Company”) and its wholly-owned subsidiaries reflect all adjustments consisting of normal, recurring accruals necessary for a fair presentation.  We have reclassified certain items in prior periods to conform to current classifications.

We have omitted certain financial information that is normally included in financial statements prepared in accordance with U.S. GAAP but that is not required for interim reporting purposes. You should read the accompanying consolidated financial statements in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Name Statement of Position (SOP)
-Publisher AICPA
-Number 94-6
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4/FIN46(R)-8
-Paragraph 8, C1, C7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Name FASB Interpretation (FIN)
-Publisher FASB
-Number 46R
-Paragraph 4, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R14.htm IDEA: XBRL DOCUMENT v2.3.0.11

Long Term Debt
6 Months Ended

Jun. 30, 2011

Long Term Debt

Long Term Debt
(7)
Long-Term Debt

On March 30, 2010, we entered into the Fourth Amended and Restated Credit Agreement (the “Fourth Amended Credit Agreement”).  The Fourth Amended Credit Agreement provides us with a $55.0 million revolving credit facility from March 30, 2010 to December 1, 2011 (the “2011 Revolving Credit Facility”) and a $345.0 million revolving credit facility from March 30, 2010 to December 1, 2013 (the “2013 Revolving Credit Facility”), including a swingline sub facility of $20.0 million and a $75.0 million sub facility for letters of credit.  The Fourth Amended Credit Agreement also provides a continuation of the term loan facility provided pursuant to the Third Amended and Restated Credit Agreement, of which $191.0 million remained outstanding on June 30, 2011, and an uncommitted incremental accordion facility of $200.0 million.  As of June 30, 2011, availability under the 2011 Revolving Credit Facility and the 2013 Revolving Credit Facility totaled $245.1 million as calculated under the most restrictive covenant.

Revolving advances under the Fourth Amended Credit Agreement are drawn first under the 2013 Revolving Credit Facility, with any advances in excess of $345.0 million being drawn under the 2011 Revolving Credit Facility.  Revolving advances under the 2013 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 1.875% to 2.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.375% to 1.250%.  Revolving advances under the 2011 Revolving Credit Facility generally bear interest, at our option, at 1) LIBOR plus a spread of 0.875% to 1.750% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate, plus a spread of 0.000% to 0.250%.  Term loan borrowings bear interest, at our option, at 1) LIBOR plus 1.50% or 2) the greater of the federal funds rate plus 0.5%, or the prime rate.  See Note 5 for a description of our interest rate swap agreements.  The Fourth Amended Credit Agreement also provides for a fee ranging between 0.150% and 0.300% of the unused commitments under the 2011 Revolving Credit Facility and 0.275% and 0.425% of the unused commitments under the 2013 Revolving Credit Facility.  The Fourth Amended Credit Agreement is secured by guarantees from most of the Company's domestic subsidiaries and by security interests in substantially all of the Company's and such subsidiaries' assets.

We are required to repay outstanding revolving loans on the applicable commitment termination date, which is December 1, 2011 for the 2011 Revolving Credit Facility and December 1, 2013 for the 2013 Revolving Credit Facility. We are required to repay term loans in quarterly principal installments aggregating $0.5 million each, which commenced on March 31, 2007.  The entire unpaid principal balance of the term loans is due and payable at maturity on December 1, 2013.

The Fourth Amended Credit Agreement contains various financial covenants, which require us to maintain, as defined, ratios or levels of 1) total funded debt to EBITDA, 2) fixed charge coverage, and 3) net worth.  The Fourth Amended Credit Agreement also restricts the payment of dividends and limits the amount of repurchases of the Company's common stock.  As of June 30, 2011, we were in compliance with all of the covenant requirements of the Fourth Amended Credit Agreement.

As described in Note 5 above, as of June 30, 2011, we are a party to interest rate swap agreements for which we receive a variable rate of interest based on LIBOR and for which we pay a fixed rate of interest.

X

- Details

Name: us-gaap_LongTermDebtAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R19.htm IDEA: XBRL DOCUMENT v2.3.0.11

Comprehensive Income
6 Months Ended

Jun. 30, 2011

Stockholders' Equity Note [Abstract]

Comprehensive Income
(12)
Comprehensive Income

Comprehensive income, net of income taxes, was $5.9 million and $11.3 million for the three months ended June 30, 2011 and 2010, respectively, and $10.7 million and $20.3 million for the six months ended June 30, 2011 and 2010, respectively.

X

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R15.htm IDEA: XBRL DOCUMENT v2.3.0.11

Restructuring and Related Charges and Impairment Loss
6 Months Ended

Jun. 30, 2011

Restructuring and Related Activities [Abstract]

Restructuring and Related Charges and Impairment Loss
(8)
Restructuring and Related Charges

In November 2010, we began a restructuring of the Company primarily focused on aligning resources with current and emerging markets and consolidating operating capacity, which was largely completed by the end of fiscal 2010.  We do not expect to incur significant additional costs or adjustments related to this restructuring.  The change in accrued restructuring and related charges during the six months ended June 30, 2011 was as follows:

(In 000s)

Accrued restructuring and related charges at January 1, 2011
$
7,607

Additions

-

Payments

(4,448
)

Adjustments (1)

(734
)

Accrued restructuring and related charges at June 30, 2011
$
2,425

(1) Adjustments for the six months ended June 30, 2011 resulted primarily from a favorable adjustment to lease termination costs due to a sublease of certain unused office space.

X

- Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 146
-Paragraph 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 5
-Section P
-Subsection 3, 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=6394695&loc=d3e140864-122747

+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R13.htm IDEA: XBRL DOCUMENT v2.3.0.11

Fair Value Measurements
6 Months Ended

Jun. 30, 2011

Fair Value Disclosures [Abstract]

Fair Value Measurements
(6)
Fair Value Measurements

We account for certain assets and liabilities at fair value.  Fair value is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability.

Fair Value Hierarchy

The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. We categorize each of our fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are:

Level 1:  Quoted prices in active markets for identical assets or liabilities;

Level 2:  Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-based valuation techniques in which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and

Level 3:  Unobservable inputs that are supported by little or no market activity and typically reflect management's estimates of assumptions that market participants would use in pricing the asset or liability.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our assets and liabilities measured at fair value on a recurring basis at June 30, 2011 and December 31, 2010:

(In $000s)
June 30, 2011

Level 2

Gross Fair Value

Netting (1)

Net Fair Value

Assets:

Foreign currency exchange contracts

$
98

$
98

$
(45
)
$
53

Liabilities:

Foreign currency exchange contracts

$
263

$
263

$
(45
)
$
218

Interest rate swap agreements

5,999

5,999

-

5,999

(In $000s)
December 31, 2010

Level 2

Gross Fair Value

Netting (1)

Net Fair Value

Assets:

Foreign currency exchange contracts

$
136

$
136

$
(116
)
$
20

Liabilities:

Foreign currency exchange contracts

$
245

$
245

$
(116
)
$
129

Interest rate swap agreements

7,058

7,058

-

7,058

(1) This column reflects the impact of netting derivative assets and liabilities by counterparty when a legally enforceable master netting agreement exists.

The fair values of forward foreign currency exchange contracts are valued using broker quotations of similar assets or liabilities in active markets.  The fair values of interest rate swap agreements are primarily determined based on the present value of future cash flows using internal models and third-party pricing services with observable inputs, including interest rates, yield curves and applicable credit spreads.

Fair Value of Other Financial Instruments

In addition to foreign currency exchange contracts and interest rate swap agreements, the estimated fair values of which are disclosed above, the estimated fair value of each class of financial instruments at June 30, 2011 was as follows:

·
Cash and cash equivalents – The carrying amount of $1.0 million approximates fair value because of the short maturity of those instruments (less than three months).

·
Long-term debt –The estimated fair value of outstanding borrowings under our credit agreement is based on the average of the prices set by the issuing bank given current market conditions and is not necessarily indicative of the amount we could realize in a current market exchange. The estimated fair value and carrying amount of outstanding borrowings under the Fourth Amended Credit Agreement (see Note 7) at June 30, 2011 are $214.8 million and $222.6 million, respectively.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R6.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (USD $)
In Thousands

Total

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

Treasury Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Balance, December 31, 2010 at Dec. 31, 2010 $ 430,841 $ 0 $ 34 $ 232,524 $ 206,210 $ (4,494) $ (3,433)

Comprehensive income:

Net income 9,914 0 0 0 9,914 0 0

Net change in fair value of interest rate swaps, net of income axes of $416 643 0 0 0 0 0 643

Foreign currency translation adjustment 111 0 0 0 0 0 111

Total comprehensive income 10,668

Repurchases of common stock (9,456) 0 0 0 0 (9,456) 0

Exercise of stock options 3,736 0 0 3,736 0 0 0

Tax effect of stock options and restricted stock units (992) 0 0 (992) 0 0 0

Share-based employee compensation expense 4,528 0 0 4,528 0 0 0

Balance, June 30, 2011 at Jun. 30, 2011 $ 439,325 $ 0 $ 34 $ 239,796 $ 216,124 $ (13,950) $ (2,679)

X

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Tax benefit associated with any equity-based compensation plan other than an employee stock ownership plan (ESOP). The tax benefit results from the deduction by the entity on its tax return for an award of stock that exceeds the cumulative compensation cost for common stock or preferred stock recognized for financial reporting. Includes any resulting tax benefit that exceeds the previously recognized deferred tax asset (excess tax benefits).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 740
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6419406&loc=d3e23524-113945

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 62
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e540-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A5
-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 8, 9, 10, 11, 12, 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6508144

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e557-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity, net of tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 19, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 52
-Paragraph 13, 20, 31
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Change in accumulated gains and losses from derivative instrument designated and qualifying as the effective portion of cash flow hedges, net of tax effect. The after tax effect change includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 121
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value stock issued during the period as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 28 R9.htm IDEA: XBRL DOCUMENT v2.3.0.11

Recently Issued Accounting Standards
6 Months Ended

Jun. 30, 2011

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Recently Issued Accounting Standards
(2)
Recently Issued Accounting Standards

In May 2011, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2011-04, “Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”, an amendment to Accounting Standards Codification Topic 820, “Fair Value Measurements and Disclosures”.  These amendments provide a consistent definition of fair value and ensure that fair value measurements and disclosure requirements are consistent between U.S. GAAP and International Financial Reporting Standards. ASU No. 2011-04 is effective for interim and annual reporting periods beginning after December 15, 2011.  We do not expect the adoption of this amendment to have a material impact on our consolidated results of operations, financial position, cash flows, or notes to the consolidated financial statements.

In June 2011, the FASB issued ASU No. 2011-05, “Presentation of Comprehensive Income”.  This standard eliminates the current option to report other comprehensive income and its components in the statement of changes in stockholders' equity and requires an entity to present net income and other comprehensive income in one continuous statement or in two separate but consecutive statements.  ASU No. 2011-05 is effective for interim and annual reporting periods beginning after December 15, 2011.  We have not yet determined which presentation of comprehensive income we will elect but do not expect the adoption of this standard to have a material impact on our consolidated results of operations, statement of financial position, or cash flows.

X

- Definition

The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 11
-Section M

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB TOPIC 11.M)
-URI http://asc.fasb.org/extlink&oid=6369664&loc=d3e31137-122693

+ Details

Name: us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R10.htm IDEA: XBRL DOCUMENT v2.3.0.11

Share-Based Compensation
6 Months Ended

Jun. 30, 2011

Share-Based Compensation [Abstract]

Share-Based Compensation
(3)
Share-Based Compensation

We have several shareholder-approved stock incentive plans for employees and directors.  We currently have three types of share-based awards outstanding under these plans: stock options, restricted stock units, and restricted stock.  We believe that such awards align the interests of our employees and directors with those of our stockholders.

For the three and six months ended June 30, 2011, we recognized share-based compensation costs of $2.3 million and $4.5 million, respectively.  For the three and six months ended June 30, 2010, we recognized share-based compensation costs of $2.6 million and $5.6 million, respectively.

A summary of our stock options as of June 30, 2011 and changes during the six months then ended is presented below:

Weighted-

Average

Weighted-

Remaining

Aggregate

Shares

Average

Contractual

Intrinsic

Options

(000s)

Exercise Price

Term (years)

Value ($000s)

Outstanding at January 1, 2011

6,208

$
17.12

Granted

368

14.70

Exercised

(332
)

11.06

Forfeited or expired

(172
)

14.93

Outstanding at June 30, 2011

6,072

17.37

5.30

$ 14,598

Exercisable at June 30, 2011

3,576

19.64

3.14

$   7,407

The weighted-average grant-date fair value of options granted during the three and six months ended June 30, 2011 was $9.03 and $8.32, respectively.

The following table shows a summary of our restricted stock and restricted stock units (“nonvested shares”) as of June 30, 2011 as well as activity during the six months then ended:

Weighted-

Average

Shares

Grant Date

Nonvested Shares

(000s)

Fair Value

Nonvested at January 1, 2011

1,153

$
15.29

Granted

183

14.71

Vested

(180
)

16.44

Forfeited

(62
)

12.83

Nonvested at June 30, 2011

1,094

$
15.18

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 31 R18.htm IDEA: XBRL DOCUMENT v2.3.0.11

Sale of Investment
6 Months Ended

Jun. 30, 2011

Investments, All Other Investments [Abstract]

Sale of Investment
(11)
Sale of Investment

In January 2009, a private company in which we held preferred stock was acquired by a third party.  As part of this sale, we received two payments totaling $11.6 million in January and February 2009 and recorded a gain of $2.6 million during the first quarter of 2009.  During the second quarter of 2010, we recognized a gain of $1.2 million related to the receipt of a final escrow payment.

X

- Details

Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for investments and other noncurrent assets.

+ Details

Name: us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R11.htm IDEA: XBRL DOCUMENT v2.3.0.11

Income Taxes
6 Months Ended

Jun. 30, 2011

Income Tax Disclosure [Abstract]

Income Taxes
(4)
Income Taxes

Our effective tax rate increased to 43.7% and 43.8% for the three and six months ended June 30, 2011, compared to 37.8% and 39.2% for the three and six months ended June 30, 2010, respectively, primarily due to the favorable impact on the 2010 effective tax rate of an earn-out adjustment recorded during the three and six months ended June 30, 2010, as well an increase during the three and six months ended June 30, 2011 in the level of certain expenses related to international operations for which we currently are not able to recognize a tax benefit.

We file income tax returns in the U.S. federal jurisdiction and in various state and foreign jurisdictions.  Tax years remaining subject to examination in these jurisdictions include 2008 to present.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R5.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) (USD $)
In Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2011

Jun. 30, 2010

Jun. 30, 2011

Jun. 30, 2010

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Depreciation and amortization $ 8,970 $ 9,928 $ 17,994 $ 20,161

X

- Definition

Depreciation of property, plant and equipment directly related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(d))
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServicesDepreciationAndAmortization

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 34 R7.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands
6 Months Ended

Jun. 30, 2011

Jun. 30, 2010

Cash flows from operating activities:

Net income $ 9,914 $ 21,252

Adjustments to reconcile net income to net cash provided by operating activities, net of business acquisitions:

Depreciation and amortization 24,876 26,895

Amortization of deferred loan costs 954 869

Gain on sale of investment 0 (1,163)

Share-based employee compensation expense 4,528 5,591

Deferred income taxes (2,757) 1,908

Excess tax benefits from share-based payment arrangements (339) (806)

Decrease (increase) in accounts receivable, net 6,391 (11,782)

Decrease in other current assets 7,238 6,152

Increase (decrease) in accounts payable 2,084 (6,437)

Decrease in accrued salaries and benefits (12,421) (27,779)

Increase in other current liabilities 8,962 13,797

Other (458) (1,409)

Net cash flows provided by operating activities 48,972 27,088

Cash flows from investing activities:

Acquisition of property and equipment (21,664) (23,384)

Sale of investment 0 1,163

Change in restricted cash 469 0

Other (3,586) (2,814)

Net cash flows used in investing activities (24,781) (25,035)

Cash flows from financing activities:

Proceeds from issuance of long-term debt 203,147 417,450

Payments of long-term debt (223,198) (415,766)

Deferred loan costs 0 (3,166)

Excess tax benefits from share-based payment arrangements 339 806

Exercise of stock options 3,736 532

Repurchases of common stock (9,456) 0

Change in outstanding checks and other 611 (2,881)

Net cash flows used in financing activities (24,821) (3,025)

Effect of exchange rate changes on cash 521 (302)

Net decrease in cash and cash equivalents (109) (1,274)

Cash and cash equivalents, beginning of period 1,064 2,356

Cash and cash equivalents, end of period $ 955 $ 1,082

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The component of interest expense comprised of the periodic charge against earnings over the life of the financing arrangement to which such costs relate. Alternate captions include Noncash Interest Expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 8
-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reductions in the entity's income taxes that arise when compensation cost (from non-qualified share-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element represents the cash inflow reported in the enterprise's financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 00-15
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reductions in the entity's income taxes that arise when compensation cost (from non-qualified equity-based compensation) recognized on the entity's tax return exceeds compensation cost from equity-based compensation recognized in financial statements. This element reduces net cash provided by operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A96
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationOperatingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentAssets

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.

+ Details

Name: us-gaap_IncreaseDecreaseInOtherCurrentLiabilities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15, 16, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).

+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromInvestments

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash outflow or inflow from other investing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for loan origination associated cost which is usually collected through escrow.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfLoanCosts

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 17
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Investing Activities
-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18, 19, 20
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 20
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.3.0.11

Commitments and Contingencies
6 Months Ended

Jun. 30, 2011

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
(9)
Commitments and Contingencies

Shareholder Derivative Lawsuits

On June 27, 2008 and July 24, 2008, respectively, two shareholders filed putative derivative actions purportedly on behalf of the Company in the Chancery Court for the State of Tennessee, Twentieth Judicial District, Davidson County, against certain directors and officers of the Company, seeking damages and equitable and/or injunctive relief. These actions are based on allegations of individual violations of the Securities Exchange Act of 1934 and allegations that misleading statements were made and material information omitted from public communications regarding (i) the purported loss or restructuring of certain contracts with customers, (ii) the Company's participation in the Medicare Health Support (“MHS”) pilot program for the Centers for Medicare & Medicaid Services, and (iii) the Company's guidance for fiscal year 2008.  These lawsuits were consolidated and the plaintiffs filed a consolidated complaint on May 9, 2009.  On June 19, 2009, the defendants filed a motion to dismiss the consolidated complaint.  The Court granted the defendants' motion to dismiss on October 14, 2009. The plaintiffs filed a notice of appeal on November 12, 2009. The Tennessee Court of Appeals heard argument on the appeal on October 13, 2010 and affirmed the trial court's dismissal on March 14, 2011.

ERISA Lawsuits

On July 31, 2008, a purported class action alleging violations of the Employee Retirement Income Security Act (“ERISA”) was filed in the U.S. District Court for the Middle District of Tennessee, Nashville Division against the Company and certain of its directors and officers alleging breaches of fiduciary duties to participants in the Company's 401(k) plan.  An amended complaint was filed on September 29, 2008, naming as defendants the Company, the Board of Directors, certain officers, and members of the Investment Committee charged with administering the 401(k) plan, alleging that the defendants violated ERISA by failing to remove the Company stock fund from the 401(k) plan when it allegedly became an imprudent investment by (i) failing to disclose adequately the risks and results of the MHS pilot program to 401(k) plan participants, (ii) failing to seek independent advice as to whether to continue to permit the 401(k) plan to hold Company stock, and (iii) failing to closely monitor the Investment Committee and other 401(k) plan fiduciaries.   On August 6, 2009, the parties filed a stipulation of dismissal.  On February 1, 2010, a new named plaintiff filed another putative class action complaint in the United States District Court for the Middle District of Tennessee, Nashville Division, alleging ERISA violations in the administration of the Company's 401(k) plan.  The new complaint was identical to the original complaint, including the allegations and the requests for relief.  Defendants' answer to this complaint was filed on March 22, 2010.  On June 23, 2010, the parties reached an agreement in principle to settle this matter for $1.3 million.  The District Court gave preliminary approval of the settlement on December 1, 2010, and granted final approval following a fairness hearing held April 25, 2011.   Due to the Company's fiduciary liabilities insurance coverage, this settlement did not result in any charge to the Company.

Contract Dispute

We currently are involved in a contractual dispute with Blue Cross Blue Shield of Minnesota regarding fees paid to us as part of a former contractual relationship.  In 2010, we received a notice of arbitration under the terms of our agreement alleging a violation of certain contract provisions.  We believe we performed our services in compliance with the terms of our agreement and that the assertions made in the arbitration notice are without merit.  On August 3, 2011, we asserted numerous counterclaims against Blue Cross Blue Shield of Minnesota.  We are not able to reasonably estimate a range of potential losses, if any.

Outlook

We are also subject to other contractual disputes, claims and legal proceedings that arise from time to time in the ordinary course of our business. While we are unable to estimate a range of potential losses, we do not believe that any of the legal proceedings pending against us as of the date of this report will have a material adverse effect on our liquidity or financial condition.  As these matters are subject to inherent uncertainties, our view of these matters may change in the future.

Contractual Commitment

In May 2011, we entered into a ten-year applications and technology services outsourcing agreement with HP Enterprise Services, LLC (“HP”) that contains minimum fee requirements.  Total payments over the ten-year term must equal or exceed a minimum level of approximately $185 million; however, based on initial required service and equipment level assumptions, we estimate that the total payments will be approximately $380 million, $18.0 million of which will occur during the remainder of 2011, $100.9 million of which will occur during 2012 and 2013, $80.8 million of which will occur during 2014 and 2015, and the remaining $180.3 million of which will occur thereafter.  The agreement allows us to terminate all or a portion of the services after two years provided we pay certain termination fees which could be material to the Company.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R20.htm IDEA: XBRL DOCUMENT v2.3.0.11

Earnings Per Share
6 Months Ended

Jun. 30, 2011

Earnings Per Share

Earnings Per Share
(13)
Earnings Per Share

The following is a reconciliation of the numerator and denominator of basic and diluted earnings per share for the three and six months ended June 30, 2011 and 2010:

(In 000s, except per share data)

Three Months Ended
June 30,

Six Months Ended
June 30,

2011

2010

2011

2010

Numerator:

Net income - numerator for basic earnings per share

$
5,778

$
11,838

$
9,914

$
21,252

Denominator:

Shares used for basic earnings per share

33,942

34,117

33,957

34,037

Effect of dilutive securities outstanding:

Non-qualified stock options

510

456

417

493

Restricted stock units

338

360

337

398

Shares used for diluted earnings per share

34,790

34,933

34,711

34,928

Earnings per share:

Basic

$
0.17

$
0.35

$
0.29

$
0.62

Diluted

$
0.17

$
0.34

$
0.29

$
0.61

Dilutive securities outstanding not included in the computation of earnings per share because their effect is antidilutive:

Non-qualified stock options

3,746

3,935

4,191

3,601

      Restricted stock units

18

83

68

3

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R2.htm IDEA: XBRL DOCUMENT v2.3.0.11

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)
In Thousands

Jun. 30, 2011

Dec. 31, 2010

Current assets:

Cash and cash equivalents $ 955 $ 1,064

Accounts receivable, net 82,210 89,108

Prepaid expenses 10,393 12,577

Other current assets 2,802 3,064

Income taxes receivable 1,885 8,695

Deferred tax asset 13,657 11,272

Total current assets 111,902 125,780

Property and equipment:

Leasehold improvements 41,147 40,662

Computer equipment and related software 222,005 207,077

Furniture and office equipment 27,437 27,328

Capital projects in process 15,302 10,117

Property and equipment, gross 305,891 285,184

Less accumulated depreciation (172,860) (154,528)

Property and equipment, net 133,031 130,656

Other assets 12,888 14,733

Intangible assets, net 91,297 94,255

Goodwill, net 496,265 496,265

Total assets 845,383 861,689

Current liabilities:

Accounts payable 24,296 22,555

Accrued salaries and benefits 31,905 39,157

Accrued liabilities 29,896 31,532

Deferred revenue 6,275 5,931

Contract billings in excess of earned revenue 23,441 18,814

Current portion of long-term debt 4,178 3,935

Current portion of long-term liabilities 4,080 3,309

Total current liabilities 124,071 125,233

Long-term debt 223,200 243,425

Long-term deferred tax liability 24,621 23,050

Other long-term liabilities 34,166 39,140

Stockholders' equity:

Preferred stock, $.001 par value, 5,000,000 shares authorized, none outstanding 0 0

Common stock, $.001 par value, 120,000,000 shares authorized, 33,808,298 and 34,018,706 shares outstanding 34 34

Additional paid-in capital 239,796 232,524

Retained earnings 216,124 206,210

Treasury stock, at cost, 1,101,765 and 429,654 shares in treasury (13,950) (4,494)

Accumulated other comprehensive loss (2,679) (3,433)

Total stockholders' equity 439,325 430,841

Total liabilities and stockholders' equity $ 845,383 $ 861,689

X

- Definition

Liabilities representing performance-based fees billed on contracts that exceed the performance-based revenues earned to date by the entity based on the entity's inability to measure its performance or its performance results to date not achieving contractual targets.

+ Details

Name: hway_BillingsInExcessOfEarnedRevenue

Namespace Prefix: hway

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Subparagraph a
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a(1)
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 4
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3-4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 14
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14, 17, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.30(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Topic 210
-SubTopic 10
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
-Section S99
-Name Accounting Standards Codification
-Publisher FASB
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Concepts (CON)
-Number 6
-Paragraph 25
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 18
-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.18)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Section 45
-SubTopic 10
-Topic 210
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765
-Publisher FASB
-Name Accounting Standards Codification
-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 9
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The gross amount of capitalized computer software costs as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_CapitalizedComputerSoftwareGross

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7
-Footnote 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 30
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_ConstructionInProgressGross

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The current portion of the aggregate tax effects as of the balance sheet date of all future tax deductions arising from temporary differences between tax basis and generally accepted accounting principles basis recognition of assets, liabilities, revenues and expenses, which can only be deducted for tax purposes when permitted under enacted tax laws; after deducting the allocated valuation allowance, if any, to reduce such amount to net realizable value. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference. An unrecognized tax benefit that is directly related to a position taken in a tax year that results in a net operating loss carryforward is presented as a reduction of the related deferred tax asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31928-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42, 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the noncurrent portion of deferred tax liabilities, which result from applying the applicable tax rate to net taxable temporary differences pertaining to each jurisdiction to which the entity is obligated to pay income tax. A noncurrent taxable temporary difference is a difference between the tax basis and the carrying amount of a noncurrent asset or liability in the financial statements prepared in accordance with generally accepted accounting principles. In a classified statement of financial position, an enterprise separates deferred tax liabilities and assets into a current amount and a noncurrent amount. Deferred tax liabilities and assets are classified as current or noncurrent based on the classification of the related asset or liability for financial reporting. A deferred tax liability or asset that is not related to an asset or liability for financial reporting, including deferred tax assets related to carryforwards, are classified according to the expected reversal date of the temporary difference.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31958-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 41, 42
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e31931-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived, depreciable assets commonly used in offices and stores. Examples include desks, chairs, and store fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_FurnitureAndFixturesGross

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-Clause 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 68
-Subparagraph l
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 45
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141R
-Paragraph 72
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 5
-Subparagraph c

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 10
-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Section Appendix E
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.5(c))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_IncomeTaxesReceivable

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 42, 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16323-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived, depreciable assets that are an addition or improvement to assets held under lease arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6812-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_LeaseholdImprovementsGross

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 32
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.32)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 21
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total of the portions of the carrying amounts as of the balance sheet date of long-term debt, which may include notes payable, bonds payable, debentures, mortgage loans, and commercial paper, which are scheduled to be repaid within one year or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 19
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year (current maturities) or the normal operating cycle, if longer, and after deducting unamortized discount or premiums, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 22
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 8
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 17
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6904-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 20
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 6
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 24
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.28)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 02
-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 4
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Assets
-URI http://asc.fasb.org/extlink&oid=6509628

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6787-107765

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived physical assets used in the normal conduct of business and not intended for resale. This can include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentGrossAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 7
-Section 03
-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 12
-Paragraph 5
-Subparagraph b, c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.31(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A3
-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Technical Bulletin (FTB)
-Number 85-6
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 27 119 1 false 6 0 false 3 true false R1.htm 000990 - Document - Document And Entity Information Sheet http://.healthways.com/role/DocumentAndEntityInformation Document And Entity Information false false R2.htm 001000 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://.healthways.com/role/ConsolidatedBalanceSheetsUnaudited CONSOLIDATED BALANCE SHEETS (Unaudited) false false R3.htm 001010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://.healthways.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) false false R4.htm 002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://.healthways.com/role/ConsolidatedStatementsOfOperationsUnaudited CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) false false R5.htm 002010 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Sheet http://.healthways.com/role/ConsolidatedStatementsOfOperationsUnauditedParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) false false R6.htm 003000 - Statement - CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Sheet http://.healthways.com/role/ConsolidatedStatementOfChangesInStockholdersEquityUnaudited CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) false false R7.htm 004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://.healthways.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) false false R8.htm 006010 - Disclosure - Basis of Presentation Sheet http://.healthways.com/role/BasisOfPresentation Basis of Presentation false false R9.htm 006020 - Disclosure - Recently Issued Accounting Standards Sheet http://.healthways.com/role/RecentlyIssuedAccountingStandards Recently Issued Accounting Standards false false R10.htm 006030 - Disclosure - Share-Based Compensation Sheet http://.healthways.com/role/ShareBasedCompensation Share-Based Compensation false false R11.htm 006040 - Disclosure - Income Taxes Sheet http://.healthways.com/role/IncomeTaxes Income Taxes false false R12.htm 006050 - Disclosure - Derivative Investments and Hedging Activities Sheet http://.healthways.com/role/DerivativeInvestmentsAndHedgingActivities Derivative Investments and Hedging Activities false false R13.htm 006060 - Disclosure - Fair Value Measurements Sheet http://.healthways.com/role/FairValueMeasurements Fair Value Measurements false false R14.htm 006070 - Disclosure - Long Term Debt Sheet http://.healthways.com/role/LongTermDebt Long Term Debt false false R15.htm 006080 - Disclosure - Restructuring and Related Charges and Impairment Loss Sheet http://.healthways.com/role/RestructuringAndRelatedChargesAndImpairmentLoss Restructuring and Related Charges and Impairment Loss false false R16.htm 006090 - Disclosure - Commitments and Contingencies Sheet http://.healthways.com/role/CommitmentsAndContingencies Commitments and Contingencies false false R17.htm 006100 - Disclosure - Share Repurchases Sheet http://.healthways.com/role/ShareRepurchases Share Repurchases false false R18.htm 006110 - Disclosure - Sale of Investment Sheet http://.healthways.com/role/SaleOfInvestment Sale of Investment false false R19.htm 006120 - Disclosure - Comprehensive Income Sheet http://.healthways.com/role/ComprehensiveIncome Comprehensive Income false false R20.htm 006130 - Disclosure - Earnings Per Share Sheet http://.healthways.com/role/EarningsPerShare Earnings Per Share false false All Reports Book All Reports Process Flow-Through: 001000 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 001010 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Process Flow-Through: 002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Process Flow-Through: 002010 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (Parenthetical) Process Flow-Through: 004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) hway-20110630.xml hway-20110630.xsd hway-20110630_cal.xml hway-20110630_def.xml hway-20110630_lab.xml hway-20110630_pre.xml true true EXCEL 39 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3E-/3$E$051%1%]35$%414U%3E137T]&7T]0 M13$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K5])#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I7 M;W)K#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-H87)E7U)E<'5R8VAA#I%>&-E;%=O#I%>&-E;%=O M#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H M965T&-E;"!84"!O M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!);F9O&-E<'0@4VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M2!796QL+6MN;W=N(%-E87-O;F5D($ES'0^3F\\2!6;VQU;G1A'0^665S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E&5S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA"!A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$F5D+"!N;VYE M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D+"`S,RPX,#@L,CDX(&%N9"`S-"PP M,3@L-S`V('-H87)E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U M7S0Q.3)?.3'0O M:'1M;#L@8VAA'1087)T7V,U,#`R83%E7S@S-C5?-#$Y,E\Y-S)B7SDU,&0X,V-D861A9`T* M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]C-3`P,F$Q95\X,S8U7S0Q M.3)?.3'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA2P@:6YC;'5D960@ M8F5L;W"!E>'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0Y,#QS<&%N/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S(&]F("9N8G-P.R0T,38\+W1D/@T*("`@("`@("`\ M=&0@8VQA65E(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M<#XT+#4R.#QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!O<&5R871I;F<@86-T:79I=&EEF%T:6]N(&]F(&1E9F5R65E(&-O;7!E M;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XT+#4R.#QS<&%N/CPO&-E2!O<&5R871I;F<@86-T:79I=&EE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P M,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE M2UO=VYE9"!S=6)S:61I87)I97,@3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE2!I;F-L=61E9"!I;B!F:6YA;F-I86P@65A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!)'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!)3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R<^*#(I/"]F;VYT/CPO9&EV/CPO=&0^/'1D M(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0S,R4^/&1I=B!A M;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4W1A;F1A M6QE/3-$)V1I2`R,#$Q+"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A M;F1A'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE M2!T;R!P6QE/3-$)V1I3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA M'0^/&1I=CX\9&EV/CQT M86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$ M,3`P)2!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UEF4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE M/3-$)V1I3H@8FQO M8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G M:6XM6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^1F]R('1H M92!T:')E92!A;F0@F5D('-H87)E+6)A"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,"P@=V4@2X\ M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@=&5X M="UI;F1E;G0Z(#!P=#LG/CQB6QE/3-$)V1I2!O9B!O=7(@ M3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@ M+SX\+V1I=CX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I M;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0MF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1T;W`@=VED=&@],T0Y)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^079E3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0S)3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R<^5V5I9VAT960M/"]F;VYT/CPO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E/CQF;VYT('-T>6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V M86QI9VX],T1T;W`@=VED=&@],T0X)3X\9&EV(&%L:6=N/3-$8V5N=&5R('-T M>6QE/3-$)V1I6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^06=G6QE/3-$)V1I3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^4VAA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL M>3H@=&EM97,@;F5W(')O;6%N.R<^0V]N=')A8W1U86P\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R-24@F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE&5R8VES92!0F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1T;W`@=VED=&@],T0X)2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE M/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,33H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$,C4E/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@] M,T0S)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3$N,#8\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@8F=C;VQO3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,C4E/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*#$W,CPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24^/&1I=B!A;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0S)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F.64X('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#4E/CQD:78@86QI9VX],T1R:6=H="!S='EL M93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F M.64X('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@E/CQD:78@86QI9VX],T1R M:6=H="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE&5R8VES86)L92!A="!*=6YE(#,P+"`R M,#$Q/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS M1#(E/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#@E('-T>6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`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`[(#PO9F]N=#X\+W1D M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0S)3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@5&EM97,@3F5W(%)O;6%N.R<^5&AE('=E:6=H=&5D+6%V97)A M9V4@9W)A;G0M9&%T92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!D M=7)I;F<@=&AE('1H6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^5&AE(&9O;&QO M=VEN9R!T86)L92!S:&]W3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\ M+V1I=CX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<] M,T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V M86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^5V5I9VAT960M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1'1O M<"!W:61T:#TS1#$S)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W)3X\9&EV(&%L:6=N M/3-$8V5N=&5R('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q M-R4^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*#`P,',I M/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E M/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^1F%I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE'0M:6YD96YT.B`M,3AP=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,2PQ-3,\+V9O M;G0^/"]D:78^/"]T9#X\=&0@8F=C;VQO3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE'0M:6YD96YT.B`M M,3AP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3@S/"]F;VYT/CPO9&EV M/CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,30N-S$\+V9O;G0^/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3,E/CQF;VYT('-T>6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^ M/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-R4^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^*#$X,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A M;&EG;CTS1&QE9G0@8F=C;VQO3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`@=VED=&@],T0V)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE'0M:6YD96YT.B`M,3AP=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^*3PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3(N.#,\+V9O;G0^/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,3,E/CQF;VYT('-T>6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^ M/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-R4^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,2PP.30\+V9O M;G0^/"]D:78^/"]T9#X\=&0@8F=C;VQO3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\ M+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/&)R/CPO&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^ M/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)V9O;G0M6QE/3-$ M)V1I6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV M(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE"!R871E(&EN8W)E87-E9"!T;R`T,RXW)2!A;F0@-#,N M."4@9F]R('1H92!T:')E92!A;F0@2!D=64@=&\@=&AE(&9A=F]R86)L92!I;7!A M8W0@;VX@=&AE(#(P,3`@969F96-T:79E('1A>"!R871E(&]F(&%N(&5A"!M;VYT:',@96YD960@ M2G5N92`S,"P@,C`Q,2!I;B!T:&4@;&5V96P@;V8@8V5R=&%I;B!E>'!E;G-E MF4@82!T M87@@8F5N969I="X\+V9O;G0^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA'0M M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I"!R971U3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^*#4I/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0S.24^/&1I=B!A;&EG;CTS1&QE M9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^1&5R:79A=&EV92!);G9E6QE/3-$)V1IF4@=&AE('5N3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M6QE/3-$)V1I2`R,#$R(&%N9"`F M;F)S<#LD,S`N,"!M:6QL:6]N(&]F('=H:6-H('=I;&P@8F5C;VUE(&5F9F5C M=&EV92!I;B!*86YU87)Y(#(P,3,I(&%N9"!T97)M:6YA=&EO;B!D871E'!O6QE/3-$)V1I M6QE/3-$)V1I3H@8FQO M8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N M/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!4:6UE2!F;W(@:&5D9V4@ M86-C;W5N=&EN9R!T2!M;VYI=&]R(&]U3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$ M)V1I6QE/3-$)V1I M6QE.B!I M=&%L:6,[(&9O;G0M9F%M:6QY.B!4:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE M3H@8FQO8VL[('1E M>'0M:6YD96YT.B`P<'0[)SX\9&EV/CQT86)L92!C96QL<&%D9&EN9STS1#`@ M8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0S.24^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!C;VQS<&%N/3-$,B!V86QI9VX],T1M:61D;&4@=VED M=&@],T0Q-"4@F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^1F]R96EG;B!C M=7)R96YC>2!E>&-H86YG92!C;VYTF4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UEF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I6QE/3-$ M)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^07-S971S M.CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`@=VED M=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@] M,T0R)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$ M)V1I6QE/3-$)V1I M6QE.B!I M=&%L:6,[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X M)2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE#LG/CQD:78@86QI9VX],T1L969T M('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SXF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#L\+V9O;G0^3W1H97(@8W5R#LG/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1'1O<"!W:61T:#TS1#6QE/3-$)V)O"!S;VQI9#LG/CQD:78@ M86QI9VX],T1R:6=H="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN M+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)W!A9&1I;F3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB M#LG/CQF;VYT M('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!B9V-O;&]R/3-$=VAI=&4@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,24@#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@],T0R M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0T)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$)V1I M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T M;W`@=VED=&@],T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1M:61D;&4@=VED=&@] M,T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@ M;F5W(')O;6%N.R<^)B,Q-C`[)B,Q-C`[1&5R:79A=&EV97,@;F]T(&1E3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1M M:61D;&4@=VED=&@],T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG M;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1'1O<"!W:61T M:#TS1#3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0X)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[)B,Q-C`[1&5R:79A=&EV97,@ M9&5S:6=N871E9"!A3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG M;CTS1&QE9G0@8F=C;VQO6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1'1O M<"!W:61T:#TS1#6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,BPU.3,\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4^/&9O M;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED M=&@],T0X)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F.64X('9A;&EG;CTS M1&UI9&1L92!W:61T:#TS1#3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@],T0W M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)V1I6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^/&9O M;G0@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE M/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^1&5R:79A=&EV92!I;G-T'!E8W0@=&\@2`F;F)S M<#LD,RXY(&UI;&QI;VX@;V8@;F5T(&QO3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R M9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)V1IF4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO3H@ M8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T M>6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!C;VQS<&%N/3-$,R!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0R-"4@F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0R-"4@F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@] M,T0T)2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I#LG/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!S='EL93TS1"=P861D:6YG M+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,R4@F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F6QE M/3-$)V)O"!S;VQI9#LG/CQD:78@86QI M9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^2G5N92`S,"P@,C`Q,3PO9F]N=#X\+V1I=CX\+W1D/CQT M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T M=&]M.B!B;&%C:R`R<'@@6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^2G5N92`S,"P@ M,C`Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,R!V86QI9VX] M,T1T;W`@=VED=&@],T0W)2!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,G!X M.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)W!A9&1I;F#LG/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED M=&@],T0T)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N M.R<^/&9O;G0@3H@:6YL:6YE.R!T97AT+61E8V]R M871I;VXZ('5N9&5R;&EN93LG/D1E6QE/3-$)V1I3H@8FQO8VL[('1E>'0M:6YD96YT.B`P M<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4 M:6UE3H@8FQO8VL[('1E>'0M M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\+V1I=CX\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q M,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*#8I/"]F;VYT M/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T;W`@=VED M=&@],T0R,R4^/&1I=B!A;&EG;CTS1&QE9G0@3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT M+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^1F%I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE M/3-$)V1I3H@8FQO M8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G M:6XM6QE/3-$)V1I2!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z M(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SXF M(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@5&EM97,@3F5W(%)O;6%N.R<^1F%I6QE/3-$)V1IF4@96%C:"!O9B!O=7(@9F%I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P('=I9'1H M/3-$-S$E/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE2!O8G-E M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M2!L:71T;&4@;W(@;F\@;6%R M:V5T(&%C=&EV:71Y(&%N9"!T>7!I8V%L;'D@6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*$EN("9N M8G-P.R0P,#!S*3PO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL M93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[ M('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$ M)V1IF4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T M;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^1W)O3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O M"!S;VQI9#LG/CQD:78@3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I M=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@ M8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W M(')O;6%N.R<^3F5T=&EN9R`\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M6QE/3-$)V1I3H@8FQO8VL[('1E M>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV(&%L:6=N/3-$8V5N M=&5R('-T>6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^07-S971S.CPO M9F]N=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1T;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M'0M:6YD M96YT.B`M,3AP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A M;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$E/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I M6QE/3-$)V1I3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1M:61D;&4@=VED=&@],T0S-B4^ M/&1I=B!A;&EG;CTS1&IU3H@8FQO8VL[ M(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T M;W`@=VED=&@],T0U)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1M:61D;&4@=VED=&@] M,T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1M:61D;&4@=VED=&@],T0V)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I'0M:6YD96YT.B`M,3AP=#L@;6%R9VEN+7)I9VAT.B`P M<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`@=VED M=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F.64X('9A M;&EG;CTS1&UI9&1L92!W:61T:#TS1#8E/CQD:78@86QI9VX],T1R:6=H="!S M='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X M="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA6QE/3-$)V9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^ M*$EN("9N8G-P.R0P,#!S*3PO9F]N=#X\+V1I=CX\9&EV(&%L:6=N/3-$;&5F M="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@3H@8FQO8VL[('1E>'0M M:6YD96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^3&5V96P@,CPO9F]N M=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T M;W`@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)V)O"!S;VQI9#LG/CQD:78@3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SXF(S$V,#L\ M+V1I=CX\9&EV(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1M:61D;&4@=VED=&@],T0V)2!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#'0M=&]P.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*#$I M/"]F;VYT/CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F M9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S M;VQI9#LG/CQD:78@3H@8FQO8VL[('1E>'0M:6YD M96YT.B`P<'0[)SXF(S$V,#L\+V1I=CX\9&EV('-T>6QE/3-$)V1IF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I'0M:6YD96YT.B`M,3AP=#L@;6%R9VEN+7)I M9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`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`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$ M)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^,3,V/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&)G M8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E/CQF;VYT M('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/CQD:78@86QI9VX],T1R:6=H="!S='EL M93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI M;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB6QE/3-$ M)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG M;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#(E/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P=#L@ M;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0W)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I M6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^3&EA8FEL:71I97,Z/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&)G8V]L;W(],T0C96%F.64X('9A;&EG;CTS1'1O<"!W:61T:#TS M1#$E/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A M;&EG;CTS1&QE9G0@=F%L:6=N/3-$;6ED9&QE('=I9'1H/3-$,S8E/CQD:78@ M86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^1F]R M96EG;B!C=7)R96YC>2!E>&-H86YG92!C;VYT3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^,C0U/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/CQF;VYT('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3(Y/"]F;VYT/CPO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CQF;VYT M('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT M.B`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`P<'0[(&UA6QE M/3-$)V1I3H@8FQO8VL[ M('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$ M;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P M=#L@=&5X="UI;F1E;G0Z(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UAF4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!4:6UE6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&1I=B!S M='EL93TS1"=M87)G:6XM;&5F=#H@,'!T.R!T97AT+6EN9&5N=#H@,'!T.R!M M87)G:6XM6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!4:6UE6QE/3-$)V9O;G0M6QE/3-$)W=I9'1H.B`S-G!T.R<^/&1I=CX\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)VUA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE6UB;VPL('-E2!I;F1I8V%T:79E(&]F('1H92!A;6]U;G0@=V4@8V]U M;&0@2X\+V9O;G0^/"]D:78^/"]T9#X\+W1R M/CPO=&%B;&4^/"]D:78^/&1I=B!A;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E M:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM M97,@;F5W(')O;6%N.R<^*#3H@=&EM97,@;F5W(')O M;6%N.R<^3&]N9RU497)M($1E8G0\+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$=&]P('=I9'1H/3-$-3@E/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD M96YT.B`S-G!T.R!M87)G:6XM6QE/3-$ M)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^3VX@36%R8V@@,S`L(#(P,3`L('=E(&5N M=&5R960@:6YT;R!T:&4@1F]U2!P2!O9B`F;F)S<#LD,C`P+C`@;6EL;&EO;BXF(S$V M,#LF(S$V,#M!2!A;F0@=&AE M(#(P,3,@4F5V;VQV:6YG($-R961I="!&86-I;&ET>2!T;W1A;&5D("9N8G-P M.R0R-#4N,2!M:6QL:6]N(&%S(&-A;&-U;&%T960@=6YD97(@=&AE(&UO'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\ M+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE2=S(&%N9"!S=6-H('-U8G-I9&EA6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^5V4@87)E(')E<75I M2!T97)M(&QO86YS(&EN('%U87)T97)L>2!P6%B;&4@870@ M;6%T=7)I='D@;VX@1&5C96UB97(F(S$V,#LQ+"`R,#$S+CPO9F]N=#X\+V1I M=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT M.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I M3H@ M5&EM97,@3F5W(%)O;6%N.R<^5&AE($9O=7)T:"!!;65N9&5D($-R961I="!! M9W)E96UE;G0@8V]N=&%I;G,@=F%R:6]U3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\ M+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C M:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE2!T;R!I;G1E6QE/3-$)V1I3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H M=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@ M;F5W(')O;6%N.R<^*#@I/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$ M;&5F="!V86QI9VX],T1T;W`@=VED=&@],T0U-B4^/&1I=B!A;&EG;CTS1&QE M9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^4F5S=')U8W1U6QE/3-$)V1I2!P2P@=VAI8V@@=V%S(&QA3H@8FQO8VL[ M('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV/CQT86)L92!C M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED=&@] M,T0Q,B4^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1T;W`@=VED M=&@],T0Q,B4^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^-RPV M,#<\+V9O;G0^/"]D:78^/"]T9#X\=&0@8F=C;VQO3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1&UI M9&1L92!W:61T:#TS1#DE/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^/'1R M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q,B4@#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)W!A9&1I;F'0M:6YD96YT.B`M,3AP M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#!P=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$ M)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^06-C M6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,BPT M,C4\+V9O;G0^/"]D:78^/"]T9#X\=&0@8F=C;VQO6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-"4^ M/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1T;W`@=VED=&@],T0Q-"4^/&9O;G0@3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT M.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS M1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E M;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!4:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I M=CX\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US M:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*#DI M/"]F;VYT/CPO9&EV/CPO=&0^/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1T M;W`@=VED=&@],T0R."4^/&1I=B!A;&EG;CTS1&QE9G0@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^0V]M;6ET;65N=',@ M86YD($-O;G1I;F=E;F-I97,\+V9O;G0^/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$=&]P('=I9'1H/3-$-#6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT M.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I M6QE.B!I M=&%L:6,[(&9O;G0M9F%M:6QY.B!4:6UE'0M9&5C;W)A=&EO;CH@=6YD M97)L:6YE.R<^4VAA6QE/3-$)V1I2!#;W5R="!F;W(@=&AE(%-T871E(&]F(%1E;FYE&-H86YG92!!8W0@;V8@,3DS-"!A;F0@86QL96=A M=&EO;G,@=&AA="!M:7-L96%D:6YG('-T871E;65N=',@=V5R92!M861E(&%N M9"!M871E3H@8FQO8VL[(&UA'0M:6YD96YT.B`S M-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@ M3F5W(%)O;6%N.R<^/&9O;G0@3H@:6YL:6YE.R!T M97AT+61E8V]R871I;VXZ('5N9&5R;&EN93LG/D5225-!($QA=W-U:71S/"]F M;VYT/CPO9F]N=#X\+V1I=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^3VX@2G5L>2`S,2P@ M,C`P."P@82!P=7)P;W)T960@8VQA65E(%)E=&ER96UE;G0@26YC;VUE(%-E8W5R M:71Y($%C="`H)B,X,C(P.T5225-!)B,X,C(Q.RD@=V%S(&9I;&5D(&EN('1H M92!5+E,N($1I2!F86EL:6YG('1O(')E;6]V92!T:&4@0V]M<&%N>2!S=&]C:R!F=6YD(&9R M;VT@=&AE(#0P,2AK*2!P;&%N('=H96X@:70@86QL96=E9&QY(&)E8V%M92!A M;B!I;7!R=61E;G0@:6YV97-T;65N="!B>2`H:2D@9F%I;&EN9R!T;R!D:7-C M;&]S92!A9&5Q=6%T96QY('1H92!R:7-K2!C:&%R9V4@=&\@=&AE($-O;7!A;GDN/"]F;VYT/CPO9&EV M/CQD:78@3H@8FQO8VL[('1E>'0M:6YD96YT.B`P M<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S M-G!T.R!M87)G:6XM6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I6QE.B!I=&%L:6,[(&9O;G0M9F%M:6QY.B!4:6UE M'0M9&5C;W)A=&EO;CH@=6YD97)L:6YE.R<^3W5T;&]O:SPO9F]N=#X\ M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@=&5X M="UI;F1E;G0Z(#!P=#LG/CQB6QE/3-$)V1I2!O3H@8FQO8VL[('1E M>'0M:6YD96YT.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F M="!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@ M=&5X="UI;F1E;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M6QE/3-$)V1I6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^26X@36%Y(#(P,3$L M('=E(&5N=&5R960@:6YT;R!A('1E;BUY96%R(&%P<&QI8V%T:6]N2!S97)V:6-E6UE;G1S(&]V97(@=&AE('1E;BUY96%R('1E M&-E960@82!M:6YI;75M(&QE=F5L(&]F(&%P M<')O>&EM871E;'D@)FYB65A2X\ M+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B;&]C:SL@=&5X M="UI;F1E;G0Z(#!P=#LG/CQB7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA2!;06)S M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\6QE/3-$)V9O;G0M6QE/3-$)V1I6QE/3-$)V1I3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT M.B`P<'0[)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS M1"=D:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E M;G0Z(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!4:6UE6QE/3-$)V9O;G0M6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@ M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^ M4&5R:6]D/"]F;VYT/CPO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$E('-T>6QE/3-$)V)O"!S M;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X)2!S='EL93TS1"=B M;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0S)2!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R<'@@6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^5&]T86P@3G5M8F5R M(&]F(%-H87)E2!!;FYO M=6YC960@4&QA;G,@;W(@4')O9W)A;7,\+V9O;G0^/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^36%X:6UU;2!!<'!R M;WAI;6%T92!$;VQL87(@5F%L=64@;V8@4VAA6QE/3-$)V)O"!S;VQI9#LG/CQF;VYT M('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CPO='(^/'1R(&)G8V]L;W(],T0C9F9F9F9F/CQT9"!V86QI9VX],T1B M;W1T;VT@=VED=&@],T0Q-R4^/&9O;G0@3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,33H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`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`[(#PO9F]N=#X\ M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$U)3X\9&EV(&%L:6=N/3-$3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$U)3X\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0S)3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0T)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q-24^/&9O;G0@3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)V1I6QE/3-$)VQE='1EF5D(&)Y('1H92!#;VUP86YY)W,@ M0F]A2!A;FYO=6YC960@;VX@ M3V-T;V)E6QE/3-$)V1I3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q M.3)?.3'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3H@8FQO8VL[(&UA'0M:6YD M96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE M.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^*#$Q*3PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P M('=I9'1H/3-$,3@E/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[)SX\ M8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=D:7-P;&%Y M.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#,V<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!4:6UE2!A('1H:7)D('!A2`R,#`Y M(&%N9"!R96-O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX\9&EV/CQT86)L92!C96QL M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)2!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA M'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT M+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@ M=&EM97,@;F5W(')O;6%N.R<^0V]M<')E:&5N6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CPO='(^/"]T86)L93X\+V1I=CX\9&EV('-T>6QE/3-$)V1I3H@8FQO8VL[(&UA'0M:6YD96YT.B`S-G!T.R!M87)G:6XM6QE/3-$)V1I3H@5&EM97,@3F5W(%)O;6%N.R<^0V]M<')E M:&5N"!M;VYT:',@96YD960@2G5N M92`S,"P@,C`Q,2!A;F0@,C`Q,"P@6QE/3-$)V1I3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C-3`P,F$Q95\X,S8U7S0Q.3)?.3'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^*#$S*3PO9F]N=#X\+V1I=CX\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L M:6=N/3-$=&]P('=I9'1H/3-$,C4E/CQD:78@86QI9VX],T1L969T('-T>6QE M/3-$)V1I6QE/3-$ M)V1I3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[('1E>'0M:6YD96YT.B`P<'0[ M)SX\8G(@+SX\+V1I=CX\9&EV(&%L:6=N/3-$:G5S=&EF>2!S='EL93TS1"=D M:7-P;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z M(#,V<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!4:6UE"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2!A;F0@ M,C`Q,#H\+V9O;G0^/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!B;&]C M:SL@=&5X="UI;F1E;G0Z(#!P=#LG/CQB6QE/3-$)V9O;G0M6QE/3-$)W!A9&1I M;F3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@ M9F]N="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N M.R<^*$EN(#`P,',L(&5X8V5P="!P97(@#LG/CQF M;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!C;VQS<&%N/3-$-2!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q-R4@F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UEF4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE#LG/CQF;VYT('-T>6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!C;VQS<&%N/3-$-R!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q-R4@F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T.R!F M;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^2G5N92`S,"P\+V9O;G0^ M/"]D:78^/"]T9#X\=&0@8F=C;VQO#LG M/CQF;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,G!X.R<^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T-24^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@6QE/3-$)V1I6QE/3-$)V1I3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@ M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N M="US:7IE.B`Q,'!T.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^ M,C`Q,#PO9F]N=#X\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT M+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1C96YT97(@3H@8FQO8VL[(&UA'0M:6YD96YT.B`P M<'0[(&UA3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#L@9F]N="US:7IE.B`Q,'!T M.R!F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N.R<^,C`Q,#PO9F]N=#X\ M+V1I=CX\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0R)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@ M8FQO8VL[(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M#LG/CQF M;VYT('-T>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$)W!A9&1I;F'0M:6YD96YT.B`M,3AP M=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE#L@8F]R9&5R M+6)O='1O;3H@8FQA8VL@,G!X('-O;&ED.R<^/&1I=B!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)FYB6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3$L.#,X/"]F;VYT/CPO9&EV/CPO M=&0^/'1D(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)W!A9&1I;F#LG/CQF;VYT('-T M>6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE M/3-$)W!A9&1I;F6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V)O"!D;W5B;&4[ M)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE#LG/CQF;VYT('-T>6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!C M;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R)3X\9F]N="!S M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@8FQO8VL[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F M9F9F(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C M9F9F9F9F('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY M.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO M='(^/'1R/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1T;W`@=VED M=&@],T0U)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M'0M:6YD96YT.B`M,3AP=#L@;6%R9VEN+7)I9VAT.B`P<'0[ M)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O M;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B M9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@ M8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA M3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F M(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I'0M M:6YD96YT.B`M,3AP=#L@;6%R9VEN+7)I9VAT.B`P<'0[)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$ M)V)O"!S;VQI9#LG/CQF;VYT('-T>6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F.64X('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#@E('-T>6QE/3-$)V)O"!S;VQI9#LG/CQD:78@86QI9VX],T1R:6=H="!S='EL93TS1"=D:7-P M;&%Y.B!B;&]C:SL@;6%R9VEN+6QE9G0Z(#!P=#L@=&5X="UI;F1E;G0Z(#!P M=#L@;6%R9VEN+7)I9VAT.B`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`[(#PO9F]N M=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R<'@@ M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`T<'@@9&]U8FQE.R<^/&9O;G0@ M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V)O"!D;W5B M;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V)O"!D;W5B;&4[)SX\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I6QE/3-$ M)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N M/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V)O"!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CPO='(^ M/'1R/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1T;W`@=VED=&@] M,T0U)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0V)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^16%R;FEN9W,@<&5R('-H M87)E.CPO9F]N=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P M;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0W)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T M;VT@=VED=&@],T0V)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`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`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I M6QE/3-$)V1I6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[ M(&UA3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D M/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C9F9F9F9F('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT M.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q M-C`[(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@8F=C;VQO6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^1&EL=71E9#PO M9F]N=#X\+V1I=CX\+W1D/CQT9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX] M,T1B;W1T;VT@=VED=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I M;FQI;F4[(&9O;G0M6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV M(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V)O"!D;W5B;&4[ M)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[ M(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[ M(#PO9F]N=#X\+W1D/CQT9"!A;&EG;CTS1')I9VAT(&)G8V]L;W(],T0C96%F M.64X('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(E('-T>6QE/3-$)V)O"!D;W5B;&4[)SX\9&EV(&%L:6=N/3-$3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,"XV,3PO9F]N=#X\+V1I=CX\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1M:61D;&4@=VED=&@],T0R M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[ M(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N M=#X\+W1D/CPO='(^/'1R/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX] M,T1T;W`@=VED=&@],T0U)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI M;F4[(&9O;G0M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\ M+W1D/CQT9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M M3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!B9V-O;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I M3H@ M=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!B9V-O M;&]R/3-$(V9F9F9F9B!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3X\9F]N M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I6QE/3-$)V1I3H@8FQO M8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,RPY,S4\ M+V9O;G0^/"]D:78^/"]T9#X\=&0@8F=C;VQO3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE M/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT M9"!B9V-O;&]R/3-$(V5A9CEE."!V86QI9VX],T1B;W1T;VT@=VED=&@],T0R M)3X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M3H@8FQO8VL[(&UA'0M:6YD96YT.B`P<'0[(&UA3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE M6QE/3-$)V1I6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T M:6UE6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO M9F]N=#X\+W1D/CQT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-#4E/CQD:78@86QI9VX],T1L969T('-T>6QE/3-$)V1I6QE/3-$)V1I3H@ M:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@=&EM97,@;F5W(')O;6%N.R<^,3@\+V9O;G0^/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^/&9O;G0@3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M M9F%M:6QY.B!T:6UE6QE/3-$ M)V1I3H@=&EM97,@;F5W(')O;6%N.R<^)B,Q-C`[(#PO9F]N=#X\+W1D/CQT9"!A M;&EG;CTS1')I9VAT(&-O;'-P86X],T0S('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I6QE/3-$)V1I3H@:6YL M:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!T:6UE6QE/3-$)V1I3H@:6YL:6YE.R!F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B!T:6UE7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M M87,M;6EC'1087)T7V,U,#`R83%E7S@S-C5?-#$Y,E\Y-S)B7SDU,&0X +,V-D861A9"TM#0H` ` end

Document And Entity Information (USD $) In Millions, except Share data	6 Months Ended
	Jun. 30, 2011	Aug. 04, 2011	Jun. 30, 2010
Entity Registrant Name	HEALTHWAYS, INC
Entity Central Index Key	0000704415
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 396.1
Entity Common Stock, Shares Outstanding		33,702,609
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) (USD $) In Thousands	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, December 31, 2010 at Dec. 31, 2010	$ 430,841	$ 0	$ 34	$ 232,524	$ 206,210	$ (4,494)	$ (3,433)
Comprehensive income:
Net income	9,914	0	0	0	9,914	0	0
Net change in fair value of interest rate swaps, net of income axes of $416	643	0	0	0	0	0	643
Foreign currency translation adjustment	111	0	0	0	0	0	111
Total comprehensive income	10,668
Repurchases of common stock	(9,456)	0	0	0	0	(9,456)	0
Exercise of stock options	3,736	0	0	3,736	0	0	0
Tax effect of stock options and restricted stock units	(992)	0	0	(992)	0	0	0
Share-based employee compensation expense	4,528	0	0	4,528	0	0	0
Balance, June 30, 2011 at Jun. 30, 2011	$ 439,325	$ 0	$ 34	$ 239,796	$ 216,124	$ (13,950)	$ (2,679)

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities:
Net income	$ 9,914	$ 21,252
Adjustments to reconcile net income to net cash provided by operating activities, net of business acquisitions:
Depreciation and amortization	24,876	26,895
Amortization of deferred loan costs	954	869
Gain on sale of investment	0	(1,163)
Share-based employee compensation expense	4,528	5,591
Deferred income taxes	(2,757)	1,908
Excess tax benefits from share-based payment arrangements	(339)	(806)
Decrease (increase) in accounts receivable, net	6,391	(11,782)
Decrease in other current assets	7,238	6,152
Increase (decrease) in accounts payable	2,084	(6,437)
Decrease in accrued salaries and benefits	(12,421)	(27,779)
Increase in other current liabilities	8,962	13,797
Other	(458)	(1,409)
Net cash flows provided by operating activities	48,972	27,088
Cash flows from investing activities:
Acquisition of property and equipment	(21,664)	(23,384)
Sale of investment	0	1,163
Change in restricted cash	469	0
Other	(3,586)	(2,814)
Net cash flows used in investing activities	(24,781)	(25,035)
Cash flows from financing activities:
Proceeds from issuance of long-term debt	203,147	417,450
Payments of long-term debt	(223,198)	(415,766)
Deferred loan costs	0	(3,166)
Excess tax benefits from share-based payment arrangements	339	806
Exercise of stock options	3,736	532
Repurchases of common stock	(9,456)	0
Change in outstanding checks and other	611	(2,881)
Net cash flows used in financing activities	(24,821)	(3,025)
Effect of exchange rate changes on cash	521	(302)
Net decrease in cash and cash equivalents	(109)	(1,274)
Cash and cash equivalents, beginning of period	1,064	2,356
Cash and cash equivalents, end of period	$ 955	$ 1,082

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 955	$ 1,064
Accounts receivable, net	82,210	89,108
Prepaid expenses	10,393	12,577
Other current assets	2,802	3,064
Income taxes receivable	1,885	8,695
Deferred tax asset	13,657	11,272
Total current assets	111,902	125,780
Property and equipment:
Leasehold improvements	41,147	40,662
Computer equipment and related software	222,005	207,077
Furniture and office equipment	27,437	27,328
Capital projects in process	15,302	10,117
Property and equipment, gross	305,891	285,184
Less accumulated depreciation	(172,860)	(154,528)
Property and equipment, net	133,031	130,656
Other assets	12,888	14,733
Intangible assets, net	91,297	94,255
Goodwill, net	496,265	496,265
Total assets	845,383	861,689
Current liabilities:
Accounts payable	24,296	22,555
Accrued salaries and benefits	31,905	39,157
Accrued liabilities	29,896	31,532
Deferred revenue	6,275	5,931
Contract billings in excess of earned revenue	23,441	18,814
Current portion of long-term debt	4,178	3,935
Current portion of long-term liabilities	4,080	3,309
Total current liabilities	124,071	125,233
Long-term debt	223,200	243,425
Long-term deferred tax liability	24,621	23,050
Other long-term liabilities	34,166	39,140
Stockholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized, none outstanding	0	0
Common stock, $.001 par value, 120,000,000 shares authorized, 33,808,298 and 34,018,706 shares outstanding	34	34
Additional paid-in capital	239,796	232,524
Retained earnings	216,124	206,210
Treasury stock, at cost, 1,101,765 and 429,654 shares in treasury	(13,950)	(4,494)
Accumulated other comprehensive loss	(2,679)	(3,433)
Total stockholders' equity	439,325	430,841
Total liabilities and stockholders' equity	$ 845,383	$ 861,689